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Abstract 
 
The Hypobaric Decompression Sickness (DCS) Treatment Model links a decrease in computed 
bubble volume from increased pressure (P), increased oxygen (O2) partial pressure, and passage 
of time during treatment to the probability of symptom resolution [P(symptom resolution)]. The 
decrease in offending volume is realized in 2 stages: a) during compression via Boyle’s Law and 
b) during subsequent dissolution of the gas phase via the O2 window.  We established an 
empirical model for the P(symptom resolution) while accounting for multiple symptoms within 
subjects.  The data consisted of 154 cases of hypobaric DCS symptoms along with ancillary 
information from tests on 56 men and 18 women.  Our best estimated model is P(symptom 
resolution) = 1 / (1+exp(-(ln(P) – 1.510 + 0.795×AMB – 0.00308×Ts) / 0.478)), where P is 
pressure difference (psid), AMB = 1 if ambulation took place during part of the altitude 
exposure, otherwise AMB = 0; and where Ts is the elapsed time in mins from start of the altitude 
exposure to recognition of a DCS symptom.  To apply this model in future scenarios, values of 
P as inputs to the model would be calculated from the Tissue Bubble Dynamics Model based 
on the effective treatment pressure: P = P2 – P1 = P1×V1/V2 – P1, where V1 is the computed 
volume of a spherical bubble in a unit volume of tissue at low pressure P1 and V2 is computed 
volume after a change to a higher pressure P2.  If 100% ground level O2 (GLO) was breathed in 
place of air, then V2 continues to decrease through time at P2 at a faster rate.  This calculated 
value of P then represents the effective treatment pressure at any point in time.  Simulation of a 
“pain-only” symptom at 203 min into an ambulatory extravehicular activity (EVA) at 4.3 psia on 
Mars resulted in a P(symptom resolution) of 0.49 (0.36 to 0.62 95% confidence intervals) on 
immediate return to 8.2 psia in the Multi-Mission Space Exploration Vehicle.  The P(symptom 
resolution) increased to near certainty (0.99) after 2 hrs of GLO at 8.2 psia or with less certainty 
on immediate pressurization to 14.7 psia [0.90 (0.83 – 0.95)].  Given the low probability of DCS 
during EVA and the prompt treatment of a symptom with guidance from the model, it is likely 
that the symptom and gas phase will resolve with minimum resources and minimal impact on 
astronaut health, safety, and productivity.   
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Executive Summary 
 
 Decompression sickness (DCS) is an occupational hazard as long as extravehicular 
activity (EVA) is performed at suit pressure less than tissue inert gas tension.  Efforts to 
eliminate DCS in astronauts through engineering control of the habitat atmosphere to minimize 
atmospheric nitrogen partial pressure will reduce the probability of DCS [P(DCS)] and severity 
of symptoms related to evolved gas.  Prudent planning requires that DCS treatment resources be 
provided for Exploration Class missions where EVAs will be numerous, energetic, and a return 
to definitive medical care is not possible.   
 
Two statistical regression models are described that enable Mission Managers to quantify 
the P(DCS) associated with future EVAs and to quantify the probability of symptom resolution 
[P(symptom resolution)] given options for treatment.  A biophysical Tissue Bubble Dynamics 
Model that models bubble growth and dissolution is linked to the 2 probability regression 
models.  The regression models are quantitative descriptions of data collected during NASA-
funded research on DCS from 1983 to 2014, about 1000 altitude exposures that evaluated 
different denitrogenation protocols prior to simulated EVAs in hypobaric chambers. 
 
 A user of this “system” computes the P(DCS) and P(symptom resolution) given 
information about the denitrogenation (prebreathe) protocol, the suit pressure, the time to onset 
of a symptom during EVA, body mass index and age of the astronaut, and whether or not 
ambulation is present during the EVA.  The ambulation status is an important variable in the 
regressions, distinguishing between ambulation during EVA on a planetary surface or 
nonambulation during EVA in space.   
 
Effective treatment to achieve a high P(symptom resolution) is when treatment starts 
shortly after a symptom is recognized.  Effective treatment is through the application of pressure 
during repressurization of the suit to the habitat pressure, an increase in habitat pressure, 
additional pressurization of the suit above habitat pressure, and the use of 100% oxygen (O2) 
breathing to accelerate the natural process of bubble dissolution.  Combinations of both treatment 
pressure and 100% O2 breathing through time to achieve  0.75 P(symptom resolution) at the 
lower 95% confidence interval is proposed as a requirement to establish minimum treatment 
resources that assures a successful treatment outcome for Exploration Class EVAs.  Adjunctive 
pharmaceutical and supportive critical care therapy are also necessary, even given a low 
probability of serious DCS. 
 
Options for DCS treatment after Exploration Class EVAs must be based on evidence.  An 
evidence-based approach ultimately matches the most effective treatment to the anticipated risks.  
Providing medical treatment at remote locations is both costly and impacts the success of the 
mission, so it must be effective.  The “system” described in this communication meets the 
requirement of an evidence-based approach. 
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Diver, Aviator, and Astronaut DCS 
When a diver returns from a hyperbaric environment or an aviator or astronaut travels to a 
hypobaric environment, the amount of inert gas in excess of what can be held in solution at the new, 
lower pressure has the potential to come out of solution to form gas spaces that can displace or otherwise 
damage tissues.  Displacement of tissue by trapped gas spaces or disruption of metabolic function due to 
embolic obstruction of blood flow can cause a wide range of signs and symptoms.  The many signs and 
symptoms as a consequence of evolved gas and a review of treatment options for divers, aviators, and 
astronauts afflicted are summarized below and through several publications (Norfleet 2008, Stepanek & 
Webb 2008, Stepanek 2002, Krause & Pilmanis 2000, Ryles & Pilmanis 1996, Muehlberger et al. 2004, 
Conkin et al. 2003, Jersey et al. 2010, Moon & Gorman 2003).  
 
A fundamental axiom about decompression sickness (DCS) is that a transient gas supersaturation 
exists in a tissue region; the sum of all gas partial pressures in that region is greater than the ambient 
pressure opposing the release of the gas.  Expressed as an equation, supersaturation exists when ΔPss is 
positive: 
 
            n 
ΔPss = (Σ Pi - PB)          Eq. 1 
           i = 1 
 
where Pi is the dissolved gas tension of the ith gas of n species in the tissue and PB is the ambient 
pressure after depressurization.  The potential for bubble nucleation and rate of bubble growth are 
related to the magnitude of the time-dependent supersaturation. 
 
While gas supersaturation in the tissue is not in itself harmful, it is a thermodynamically unstable 
condition between the tissue and the surrounding environment. The difference between tissue gas 
tension and ambient pressure can be resolved with a phase transition, and some of the excess mass 
(moles) of gas in the form of bubbles may be accommodated by the tissue and cause no symptoms. 
However, when a gas space is formed due to partial or complete desaturation of a supersaturated tissue, 
there is a probability of DCS [P(DCS)] (Weathersby et al. 1984).  A necessary but insufficient condition 
for DCS is the formation of a gas phase in the tissue. The assumption that due to evolved gas, pain 
results from the deformation of tissue past a critical point may not account for symptoms other than 
pain-only DCS, but evolved gas is certainly the primary insult for all subsequent signs and symptoms. It 
is not the presence or even the volume of evolved gas in the tissue that is important in pain-only DCS; it 
is the pressure difference between the gas space and the tissue that is important. The pressure difference 
is termed “deformation pressure ()” by Nims 1951.  Reducing  is the key to effective symptom 
treatment in most cases.  For example, inflation of a pressure cuff around a joint is effective to resolve a 
symptom as compression of the gas phase through Boyle’s Law reduces the  between the gas phase and 
sensory nerves in the joint.  Resolving a symptom caused by prolonged ischemic damage due to a 
gaseous embolus would also benefit with the application of pressure so as to reestablish perfusion.  
Longer term recovery of ischemic-related injury would benefit with intervals of 100% oxygen (O2) 
breathing and appropriate pharmaceutical support – to reduce pain, inflammation, stabilize cell 
membranes, promote healing, etc. 
 
Preventing DCS is preferred to treating DCS.  However, treatment with pressure, O2, and time 
are effective when a symptom occurs.  Adjunctive pharmaceutical and emergency care interventions are 
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also needed in extreme cases.  One consistent observation about subjects at the NASA Johnson Space 
Center (JSC) is that pain-only DCS after significant denitrogenation, or prebreathe (PB), occurs 
predominately in the lower body, particularly with that part of the body associated in or around the 
patella of the knee (Ryles & Pilmanis 1996, Degner et al. 1965).  Subjects often reported fullness, 
awareness, or a frank pain when the leg was horizontally flexed with the body in a supine position. 
While standing or walking, this pain, fullness, or awareness would abate only to return when the leg was 
once again horizontally flexed.  Weight-induced compression temporarily counterbalanced or surpassed 
the offending deformation pressure, a condition present during EVA on a planetary surface but not 
during EVA in microgravity.  
 
Hyperbaric and Hypobaric DCS are Different 
 
Diver and aviator DCS have fundamental differences that suggest treatment strategies would be 
different.  Piccard 1941 reminds us that the same 5-to-1 pressure reduction ratio for a saturation diver 
and aviator does not result in the same evolved gas volume if there is not time in each case to reach 
equilibrium.  He depressurized 2 equal volumes of water, 1 was equilibrated at 5 atmospheres absolute 
(ATA) before a depressurization to 1 ATA and the other was equilibrated at 1 ATA before a 
depressurization to 0.2 ATA.  He observed that the 5-to-1 ATA depressurization for the saturation diver 
cases caused many small bubbles to quickly form in the water, producing a “milky cloud”.  In the 1-to-
0.2 ATA depressurization for the aviator case a few large bubbles formed at a much slower rate.  The 
total evolved volume was identical after both experiments came into equilibrium, but the time to reach 
the final evolved volume was shorter after the diver depressurization. 
 
Now take this simple system into living tissue.  Piccard knew that the evolved volume at 0.2 
ATA for the aviator or 1.0 ATA for the diver, expressed as N2 volume or total gas volume, would be 
identical after both depressurizations.  If the volume evolved is the critical variable, then both 
depressurizations would produce equally serious outcomes in a closed system.  A closed system means 
that blood does not transport N2 to or from the tissues.   However, living tissue is not a closed system.  In 
reality, the aviator breathes 100% O2 at 0.2 ATA to prevent anoxia.  The aviator has more time due to 
slower gas evolution for N2 to exit the lungs at a faster rate compared to the diver who is content to 
breathe air at 1.0 ATA.   
 
The rate at which a distribution of stable micronuclei transforms into growing bubbles is greater 
in the diver than the aviator.  The diver produces many small bubbles while the aviator produces fewer 
large bubbles.  The initial size distribution of micronuclei in the tissues is also different for the diver and 
aviator based on the absolute pressure profile that each experienced (Yount 1979, Tikuisis & Gerth 
2003).  Piccard suggested that differences in the probability of bubble formation due to the critical 
radius (rc) concept and the greater relative loss of N2 from the tissues of the aviator than from the diver 
accounts for the observed differences in outcome between the aviator and the diver.  
 
The historical concept of rc is that a bubble radius exists that would be in mechanical equilibrium 
with a given depressurization where it neither grows nor shrinks: rc = 2/(P2 – P1), where  is surface 
tension, and P2 and P1 are pressures where P2 – P1 > 0.  Tikuisis & Gerth 2003 summarizes 
contemporary thoughts about rc and the reality of heterogeneous nucleation.  Nuclei present in the tissue 
with radii greater than rc for a given depressurization would grow and those that have smaller radii 
would remain stable.  Surface tension, which is effective on very small bubbles, increases the bubble N2 
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partial pressure (PbubN2) to reduce the PtisN2 – PbubN2 difference, thus reducing diffusion of N2 into the 
bubble and slowing the initial bubble growth.  Piccard’s early experiment highlights the limits of the 
basic critical volume release hypothesis (Hennessy & Hempleman 1977) by introducing the complexities 
of bubble nucleation rate and bubble growth rate, and the reality of evolved gas in an open system.   
 
The composition of gases in the bubble of a diver is different than the aviator (Van Liew & 
Burkard 1995).  The constancy of metabolic gas tensions of CO2, O2, and H2O vapor, about 132 mmHg 
for venous blood, due to physiological controls dictates that the fraction of N2 in a bubble is much lower 
in the aviator than the diver.  So, taken in total, it is clear that a 5-to-1 pressure reduction has more 
consequences for the diver than the aviator.  During repressurization the aviator has less a burden of N2 
to transform back into the dissolved state than the diver.  Said another way, less repressurization is 
expected to resolve a symptom in the aviator than the diver.  A simple application of Boyle’s Law 
makes it clear that the aviator enjoys the same unit volume change on return to 1.0 ATA as the 
saturation diver on return to 5.0 ATA but the P for the aviator is only 0.8 ATA (1.0 – 0.2) compared to 
5.0 ATA (5.0 – 1.0) for the diver.  But for reasons described above the gas composition of the offending 
unit volume of evolved gas is different thus slowing the dissolution of the diver gas phase (see bubble 
model example in Fig. 24). 
 
Providing DCS treatment options and adjunctive therapy for Exploration Class missions must 
follow an evidence-based approach.  The approach needs to ultimately match the most effective 
treatment to the anticipated risks since providing proper medical treatment at remote locations is both 
costly and impacts the success of the mission (John-Baptiste et al. 2006, Rudge 1992, Krause & 
Pilmanis 2000, Dowell 1993, Dart & Butler 1998, and Butler et al. 2002).  
 
 
NASA Classification of DCS 
 
Different classification schemes for signs and symptoms of DCS are documented (Elliott 
& Moon 1993).  DCS symptom(s) at JSC are classified into Type I and Type II DCS, so it is 
necessary to define these categories since this terminology is used in various documents. 
Currently, the definitions for all evolved gas disorders reside in the Decompression Sickness 
Manual JPD 1800.3C.  The effectiveness of treatment based on symptom classification has been 
challenged (Francis & Smith 1991) resulting in a new consensus to treat the sign or symptom and 
not the category.  This symptom-based approach enables the Medical Officer (MO) to provide 
treatment options that are most effective instead of a one-size-fits-all approach.  
 
Type I DCS 
 
Symptoms of mild DCS (DCS Type I) involve joint pain, involvement of the peripheral 
nervous system, or simple skin bends. 
 
In Bends Test 1, a 4-point scale that was used primarily to categorize the intensity and 
performance impact of pain-only Type I DCS was developed by Waligora et al. 1984 as: 
 
 DCS Grade 1 – occasional, intermittent joint pain 
 DCS Grade 2 – steady but tolerable joint pain 
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 DCS Grade 3 – severe and steady joint pain; not incapacitating 
 DCS Grade 4 – severe joint pain with incapacitation of subject 
 
After Bends 1, the scale was modified when Waligora et al. 1984 developed a 7-point 
symptom scale for Bends Tests 2–11.  A pain scale above 3 was never achieved due to the test 
termination criteria in place for all testing at JSC.  The complete scale can be found in Waligora 
et al. 1984.  Definitions of the first 3 grades are: 
 
 DCS Grade 1 – Joint awareness: Reports of awareness or fullness of joints. Subject does not 
experience discomfort and may not be certain that the sensation felt is other than the normal 
feeling arising from fatigue. 
 DCS Grade 2 – Threshold of pain: Reports of discomfort, ache, or intermittent pain. The 
sensation does not interfere with activity.  The subject may liken this feeling to a transient 
pain or stiffness that occurs during warm-up exercises. 
 DCS Grade 3 – Pain: Reports of continuous pain rather than of ache or discomfort. Subject 
indicates that pain is just starting to interfere with activity.  Some favoring of affected limb is 
reported or noticed by observers. 
 
In Bends Test 11, the exposure was terminated at the diagnosis of DCS by the attending MO 
regardless of the degree of performance limitation or intensity of the Type I symptom(s).  For 
Bends 11 and all subsequent NASA-sponsored tests, the exposure was terminated at the 
diagnosis of DCS, or for any persistence symptom even if DCS could not be diagnosed.  The 
DCS case descriptions from JSC include the grade of the Type I symptom. 
 
Type II DCS 
 
Symptoms of DCS Type II involve the central nervous system (CNS), the cardiovascular 
system (circulatory collapse/shock), and the pulmonary system (the chokes).  A more complete 
discussion of symptoms that have been classified as Type II is in Conkin 2001.  Symptoms 
related to unusual presentation of headache and inappropriate fatigue are also included under 
Type II DCS. 
 
 Type II DCS symptoms are considered serious DCS.  This category includes, but is not 
limited to the following:  substernal disturbances (pulmonary chokes), involvement of the sensory, 
motor, and cognitive pathways of the brain and spinal cord, sudden collapse (neurocirculatory 
collapse), and even unexplained weakness.  Pulmonary chokes make up a substantial percentage 
of this category.  Signs and symptoms of serious DCS not specifically attributed to arterial gas 
embolism would also appear in this category.  Disturbances of the skin, such as rashes, mottling, 
paresthesia, and edema that appeared as the only sign or symptom were not considered as serious 
DCS in this analysis because there is no agreement on a classification of skin disturbances into 
either Type I or Type II DCS.  Disturbances involving the skin were often placed into a separate 
category.  Also, the 20 or so cases of death (Dixon 1992, Fryer 1969) in research and operational 
aviation settings since 1940 certainly qualify as more than serious DCS, and therefore are not 
included in this category.  Table I contains a sample of signs and symptoms that were classified as 
serious DCS in the 73 reports.  Adler 1964 provides an excellent description of serious DCS 
collected from the literature; also see Balldin et al. 2004. 
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Table I. Signs and Symptoms of Serious DCS. 
 
substernal disturbances auditory disturbances 
unproductive cough (chokes) tinitus 
dyspnea loss of hearing 
neurocirculatory collapse loss of balance 
disruption of motor, sensory,  
and cognitive pathways in brain  
and spinal cord 
generalized malaise  
(unexplained fatigue) 
paralysis diplopia 
ataxia nystagmus 
dysmetria distortion or blurring  
of vision 
dysphagia hemianopsia 
vertigo photophobia 
dizziness hyper or hypoesthesia 
numbness hyper or hypoalgesia 
aphasia hallucinations 
amnesia confusion 
altered mood depression 
manic behavior belligerence 
disorientation scotoma 
severe headache (migraine-like) nausea 
bladder disturbances loss of coordination 
paresis in arms or legs vomiting 
cardiovascular disturbances visual field disturbances 
syncope hypovolemic shock 
hypotension hyperkinesias 
dyskinesia pallor 
cold sweat  
  
 
Cutis Marmorata 
 
Cutis Marmorata (CM) is a sign of DCS that appears on the skin as a mottled pattern. 
 
 Placing a sign or symptom of hypobaric DCS into Type I or Type II DCS is artificial and 
causes problems if a sign or symptom does not conveniently fit into one category or the other.  
The problem becomes acute when categorizing CM from a hypobaric exposure into Type I or 
Type II DCS.  A categorization scheme only lends itself to quick and effective treatment 
strategies if it is specific.  However, CM does not lend itself to a specific category.  CM based on 
the best medical advice in 2002 was categorized as Type II DCS at JSC.  As a result, case 149-01 
in Appendix IV was classified as Type II DCS based only on the presence of CM.  Since the 
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current definitions of DCS at JSC assign CM to a category by itself, CM is no longer deemed 
Type I or Type II DCS. 
 
 CM was supposedly initiated by a disturbance within the CNS, or a whole-body systemic 
response linked to a large volume of evolved gas.  Therefore, a proper clinical response was 
initially to treat with the United States Navy (USN) Treatment Table (TT) V even when no other 
symptoms were present.  This aggressive treatment of CM resulted from an incomplete 
understanding of its pathophysiology and the observation that CM is often associated with 
serious Type II symptoms.  In essence, hyperbaric treatment was provided to affect a 
serious symptom not yet expressed.  More information about CM is found in Conkin et al. 2002. 
 
Arterial Gas Embolism (AGE)  
 
AGE is an evolved gas that produces the signs and the symptoms consistent with passage 
of that gas to the arterial circulation; i.e., severe neurological manifestations. 
 
We do not have a description of a diagnosed case of AGE.  However, AGE cannot be 
definitively discounted as being 1 of 6 descriptions of Type II DCS described in this report since 
the rapid return to site pressure resolved symptoms that could have otherwise been used to 
diagnose AGE.  Although information about patent foramen ovale (PFO) was collected from 
prospective and retrospective cases to better understand the risk of AGE, the results were 
inconclusive (Conkin et al. 2003). 
 
Air Diver Treatment Tables 
  
Several USN TTs are used to treat Type I, Type II DCS, and AGE using air or air and 
periods of 100% O2 breathing in military, science, and recreational divers.  There are also TTs 
for mixed-gas diving and saturation diving and many variations of TTs exist in other countries, 
again all for divers.  However, there is little incentive to systematically evaluate new treatment 
paradigms for aviators and astronauts since the USN has produced the current standard-of-care 
air and O2 TTs for divers (Davis 1979).   
 
USN HBO TT V and Extended TT VI 
  
Although symptoms of DCS were first identified in caisson workers, treatment protocols 
were not established until symptoms were routinely seen in divers.  The most widely used tables 
are USN TT V and VI.  These protocols include the use of 100% O2 so are points of departure 
for aviator and astronaut treatment modifications.  USN TT V is used for pain-only symptoms if 
symptoms resolve within 10 min at the maximum table depth of 60 fsw (2.8 ATA). This protocol 
takes a total time of 135 min to ascend from maximum depth.  Time is spent breathing 100% O2 
alternating with 5-min periods of air breathing to limit O2 toxicity (Stepanek 2002).  USN TT VI 
is used for symptoms of a serious nature, classified as Type II DCS, such as symptoms involving 
the CNS or cardiopulmonary systems, recurrence of previously treated DCS, or for a patient on 
Table V whose pain did not resolve within 10 min on 100% O2 at 60 fsw.  The maximum depth 
in Table VI is also 60 fsw.  However, the total treatment time is extended to 285 min and thus the 
patient can spend a longer duration at each ascending depth (Stepanek 2002).  
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Diving is an integral part of astronaut training, conducted at NASA’s Neutral Buoyancy 
Laboratory in Houston, Texas.  In support of astronaut training, this facility also has hypobaric 
and hyperbaric chamber capabilities.  The protocol currently used to treat a support diver or 
astronaut with DCS is USN TT V or VI, depending on the severity of the symptom.  Breathing 
100% O2 by mask, termed Ground Level Oxygen (GLO), by the patient is used while preparing 
for HBO treatment.  Regardless of hyperbaric or hypobaric induced DCS, the patient is treated 
with HBO since a chamber is readily available. 
 
USAF HBO TT V and Extended TT VI  
 
  Hyperbaric DCS experienced by divers and hypobaric DCS experienced by aviators have 
several differences, as described earlier.  The current procedure for treating aviators with DCS is 
based on the United States Air Force (USAF) guidelines that are modifications of the USN TT V 
and VI.  USAF TT V and VI incorporate modifications to the breathing schedule with additional 
air breathing to decrease the risk of O2 toxicity (Dart & Butler 1998).  Any HBO therapy requires 
costly resources, and thus plays a large limiting factor for aviators on missions distant from HBO 
chambers. It is therefore important to identify additional, lower resource, and cost effective ways 
for treating hypobaric DCS in select populations.  Dart & Butler 1998 suggested a more flexible 
treatment protocol for hypobaric induced DCS in low resource environments with the aggressive 
use of GLO and lower pressurization.  As an aviator at altitude descends to site pressure, they 
return to a pressure in which all initial N2 was dissolved in their tissues.  So decent to ground 
alone satisfies the pressure component of the DCS treatment model.  Additional treatment by 
breathing GLO incorporates all 3 DCS treatment components.   
 
Ground Level Oxygen 
 
GLO is an alternative to diver air or HBO TTs to treat aviators or astronauts.  Standard 
diver HBO TTs intersperse periods of breathing air with 100% O2 breathing to maximize bubble 
dissolution or are based only on air.  So all current hyperbaric treatment option must balance the 
reabsorption of a bubble through Boyle’s Law and the O2 window (defined later) with the 
potential adding N2 to the tissues since breathing HBO alone eventually causes pulmonary and 
CNS symptoms due to O2 toxicity.  Air breaks during diver or aviator DCS treatment add new N2 
to tissues, potentially working against otherwise effective treatment (Nikolaev 2013). 
 
Modest treatment pressures with 100% O2 to minimize O2 toxicity and to eliminate N2 
uptake into tissues are options if symptoms are mild and if treatment starts early.  The 
effectiveness of limited treatment resources to successfully treat hypobaric DCS at a remote 
location is contingent on early recognition and prompt treatment of a symptom during EVA. 
GLO is part of the USAF DCS treatment philosophy, particularly for Type I DCS.  Limited 
validation is documented for the use of only GLO for Type I DCS patients who immediately 
descend upon symptom recognition (Krause & Pilmanis 2000, Muehlerberger et al. 2004, Rudge 
1992).  Krause & Pilmanis 2000 provide a comprehensive review and data about GLO.  As 
expected, a large percentage of 728 exposures (97.2%) with Type I symptoms treated shortly 
after diagnosis had symptom resolution during descent while on 100% O2.  They remained on 
GLO for 2 hrs and only 10 (1.4%) had recurrent or delayed onset of symptoms.  Those 21 with 
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symptoms at site pressure (2.8%) had symptom resolution during 2 hrs of GLO and no recurrent 
or delayed onset of symptoms.  Unfortunately, there were no data where subjects with symptoms 
at site pressure were allowed to breathe air to compare outcomes with those that used GLO.  On 
balance, GLO allows for effective treatment of Type I DCS in remote locations where 
specialized equipment and medical training are not available without the onerous requirement to 
provide HBO resources. 
 
Evolving Treatment Option:  USAF TT VIII 
 
An attempt to lower the pressurization protocol is seen with USAF TT VIII, which was 
developed experimentally for hypobaric Type I DCS with onset of symptoms within 2 hrs of 
descent (Dart & Butler 1998, Butler et al. 2002). Table VIII uses a lower maximum 
pressurization of 33 fsw (2.0 ATA).  In a remote location, this is advantageous in that O2 toxicity 
and fire risk will be reduced, and fewer resources are needed.  Although Table VIII is rarely 
used, this was a first attempt to validate a new DCS treatment protocol that addressed the needs 
of working with limited resources, akin to treatment protocols needed when working in space. 
 
Current Astronaut Treatment 
 
A successful resolution of DCS symptoms in astronauts is conditional on early 
recognition and prompt treatment.  Early recognition is through education and training, such as 
the use of the current EVA Cuff Classification system (see Appendix I for details).  The DCS 
Treatment Flow (see Appendix II) assures prompt treatment and minimizes the time for return-
to-duty. An EVA Cuff Classification system is used to classify symptoms during EVA and 
define actions necessary to minimize symptoms attributed to DCS.  In brief, classes are 
categorized from 1 (mild pain) to 4 (serious symptoms).  Classes 2-4 require termination of EVA 
and return to airlock for repressurization.  With a suit pressure of 4.3 pounds per square inch 
absolute (psia) plus cabin pressure of 14.7 psia, the astronaut can pressurize to 19 psia just by 
returning to the ISS.  A simple DCS medical examination is used at periodic intervals by the 
Crew Medical Officer (CMO) throughout DCS treatment. The exam involves both in-suit and 
out-of-suit questions assessing neurologic function and vital signs.  If signs or symptoms of DCS 
persist upon return to ISS, then the ISS DCS Treatment Flow algorithms are used to treat the 
astronaut with additional pressure, O2, and time.  Details of this DCS treatment “system” for ISS 
EVAs are contained in MED EVAL DCS 31001 (rev. 6), 2012. 
 
A significant difference between astronauts and aviators is the availability of treatment 
resources. The majority of aviators who develop DCS at altitude must descent to site pressure 
and have access to HBO therapy provided by a trained medical staff.  However, an astronaut 
must work with the materials available on the ISS, with a CMO and telemedicine support to 
experts.  Currently it is not feasible or cost effective to transport a standard-of-care, dual-lock 
hyperbaric chamber to treat DCS in space.  Various feasibility studies and evaluations about a 
hyperbaric airlock were documented, but plans to build, transport to the ISS, and maintain the 
treatment facility were abandoned due to budget constraints and other operational conditions 
(Norfleet 1992, Barratt 1996, John-Baptiste et al. 2006). 100% O2 and a lower pressurization to 
treat DCS are available for current space exploration. These resources currently balance the low 
risk of DCS during EVA with effective treatment, minimal cost, and limited resources. 
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Bends Treatment Apparatus 
 
 In the rare instance that DCS symptoms are serious, do not resolve with 100% O2 at 19 
psi (4.3 psia suit + 14.7 psia cabin pressure) regardless of symptom classification, or first appear 
after the EVA, then the Bends Treatment Apparatus (BTA) is used (Snow 2000).  The BTA is a 
small mechanical device that allows pressurization of the space suit to 8.0 pounds per square 
inch delta (psid).  It has small mass and volume that is ideal for storage.  A suit pressure of 8.0 
psid plus the 14.7 psia ISS cabin pressure allows a total pressurization of 22.7 psia (1.54 ATA). 
The suit is unavailable for EVA after this application as a treatment vessel, until it is recertified. 
 
Adjunctive Pharmaceutical and Emergency Care Interventions 
 
 As adjunctive therapy, the medical kit aboard the ISS has 4 liters of normal saline.  The 
crewmember would first attempt to drink fluids orally but intravenous normal saline at 1 liter per 
hr can be administered.  In addition, limited quantities of dexamethasone and lidocaine are 
available.  The ISS is equipped with a respirator and automated external defibrillator for the most 
severe cases.  Under extreme conditions, a return to Earth is possible; if the astronaut is deemed 
fit enough for the rigors of reentry.   
 
Aspirin is currently used for prophylaxis. Crewmembers are instructed to take 1 tablet  
180 mg the night before an EVA and then again prior to suit donning.  Aspirin inhibits platelet 
aggregation that might occur on the surface of bubbles leading to activation of the coagulation 
cascade.  The medical kit for future exploration class missions where return to Earth is not 
possible may contain the following items to support DCS treatment: 
 
1. Isotonic fluid helps when a patient experiences loss of volume from transduction of 
plasma across damaged capillary walls (Stepanek & Webb 2008).  Replacing fluids will 
increase central blood volume, increase preload to the heart, and accelerate inert gas 
washout (Moon & Gorman 2003).  Currently there are 4 liters of normal saline on the 
ISS.  
2. Steroids may be useful for CNS edema but the evidence shows mixed results and requires 
additional research (Stepanek & Webb 2008). 
3. The use of heparin to prevent deep vein thrombosis is recommended in cases of 
neurologic DCS affecting the spinal cord that results in immobility (Stepanek & Webb 
2008). 
4. Lidocaine in the treatment of DCS as a neuroprotective agent has shown favorable results 
and investigation continues (Stepanek & Webb 2008). 
5. Intravenous perfluorocarbon emulsion, which is an efficient O2 and N2 carrier, combined 
with 100% O2 shows promising results to improve tissue oxygenation and N2 excretion 
(Stepanek & Webb 2008), but O2 toxicity is a concern (Moon & Gorman 2003).  
 
NASA DCS Data 
Data for the Hypobaric DCS Treatment Model, hereafter called “treatment model, and for 
the DCS and venous gas emboli (VGE) survival models described in this report come from the 
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NASA Hypobaric Decompression Sickness Database.  These data were assembled from 30 years 
of hypobaric chamber research from 5 laboratories on effective denitrogenation (prebreathe, PB) 
techniques from 47 protocols totaling 969 human exposures (786 male and 183 female).  
Subjects were volunteers, informed of all risks to participate, and could withdraw at any time 
without penalty.  All protocols were approved in advance by an Institutional Review Board at 
each test location.  Subjects were prescreened for health issues and eliminated if unable to pass a 
NASA-modified Class III Air Force Flight physical, or equivalent.  Subjects received 
instructions about DCS and other risks associated with hypobaric exposure, were trained on 
equipment and procedures, and understood their responsibility to report symptoms during and 
after the hypobaric exposure.  Test termination criteria were posted in the test area.  Mean age ± 
standard deviation (SD) for 969 exposures was 31.9 ± 7.7 years.   
 
Tests were performed in altitude chambers, often at 4.3 psia.  Subjects underwent either a 
no PB protocol or breathed 100% O2 by mask for some time prior to ascent.  All subjects 
breathed 100% O2 or O2-enriched air at altitude.  Exposure durations ranged from 3 to 24 hrs at 
ambient pressures of 4.3, 6.0, 6.5, 10.1, and 10.2 psia.  Prescribed moderate and repetitive 
physical activity with or without ambulation was also performed between 3 and 6 hrs of the 
exposure period.  In tests without ambulation, subjects were seated or semi-recumbent and 
physical activity consisted of primarily upper body exercise.  In general, subjects were removed 
from the altitude chamber through an airlock after a report of a DCS symptom thus permitting 
the test to continue with the remaining subjects.  An exception is that ambulatory subjects in 
some early protocols were allowed to continue until a symptom(s) interfered with performance 
of the prescribed exercise.     
 
Between 1 and 4 subjects participated in each test with multiple tests being run on each of 
47 PB protocols to characterize the DCS and VGE outcomes of the protocols.  The number of 
subjects participating in each protocol ranged from 3 to 56.  Noninvasive precordial monitoring 
for VGE in the pulmonary artery blood flow (venous blood) was performed for 4 min at about 15 
min intervals using various Doppler ultrasound bubble detectors (2.5 – 5.0 mHz) through the 
years.  A VGE grade between 0 and IV was assigned to each limb region after the subject 
sequentially and rhythmically flexed the limb about 3 times.  Other details about VGE 
monitoring are described elsewhere (Waligora et al. 1984, Conkin et al. 1996a).  Details of the 
DCS symptoms and VGE detected are provided as Appendix IV.  Details of the PB protocols are 
provided as Appendix V, and a summary of all protocols is provided as Appendix VI.     
 
The pressure at which the symptom resolved during the exposure, during repressurization 
to site pressure, or at site pressure was recorded.  There was no requirement during initial 
protocol testing to provide post-test GLO breathing.  However, 1 and then 2 hrs of GLO were 
eventually adopted to reduce the chance of post-test symptoms for those with symptoms that 
resolved during repressurization and for those with no symptoms but with VGE still present at 
the end of the hypobaric exposure.  Subjects with persistent or residual symptoms at site 
pressure, unusual symptoms during the test, or new or recurrent symptoms after being released 
from the study were treated by the MO as a minimum with 2.8 ATA HBO USN TT V.  
Currently, a subject with a mild Type I symptom with immediate repressurization where the 
symptom resolves during repressurization is provided a prophylactic USN TT V as an 
intervention to reduce the chance of recurrent or new symptoms.  
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There were 220 symptoms from 119 cases of DCS in 969 exposures.  The pressure at 
which these symptoms resolved was recorded for 195 symptoms, either at the test altitude, 
during the repressurization to site pressure, at site pressure, or during a 2.8 ATA HBO treatment.  
These 220 symptoms were entered into the NASA Hypobaric Decompression Sickness 
Treatment Database for analysis related to the treatment model.  Details about the symptom data 
are provided in Appendix III.  The difference between the pressure at which a symptom resolved 
(P2, psia) and the pressure at which the symptom occurred (P1, psia) is called the treatment 
pressure or P, in units of psid.   
   
P in Air Force DCS Data 
 
 Fig. 1 from Muehlberger et al. 2004 is very important to our understanding of hypobaric 
DCS symptom resolution.  The development of any probabilistic DCS treatment model must 
ultimately describe these data.  The NASA data used in our analysis is, in essence, a subset of the 
larger set of data used to create Fig. 1.  
 
 
Fig. 1 is based on 1,699 symptoms that resolved before, during, and following a 
repressurization to site pressure at Brooks Air Force Base (AFB).  66 symptoms resolved at the 
test altitude while 1,516 resolved during repressurization, however; 83 symptoms had no 
documented treatment pressure.  The curve shows the cumulative proportion of 1,499 symptoms 
with documented treatment pressures that resolved before or during repressurization out of 1,699 
total symptoms that all eventually resolved at site pressure.   
 
22 
 
A better estimate for symptoms that resolved before or during repressurization would be 
to remove the 83 symptoms that had no treatment pressure from the denominator, giving 1,616 
total symptoms with treatment pressures.  Therefore, the last point on the figure would be 92.7% 
(1,499/1,616) instead of 88.2% (1,499/1,699).    There were 117 symptoms that resolved at site 
pressure.  Adding these 117 symptoms that resolved at site pressure to the 1,499 with treatment 
pressures accounts for 100% of 1,616 symptoms that resolved and had a treatment pressure.  
Most subjects continued with 2 hr of GLO breathing even when a symptom resolved before, 
during, and following a repressurization to site pressure.  This treatment intervention likely 
helped to resolve symptoms still present at site pressure and likely reduced the incidence and 
severity of recurrent symptoms. 
 
Table II summarize Muehlberger’s data from 2,709 chamber exposures with 315 subjects 
that resulted in 1,699 individual symptoms that resolved at altitude, during repressurization, and 
at site pressure. 
 
 
Table II. Literature Data on Symptom Resolution. 
 
symptom 
category 
symptom resolution details treatment 
pressure 
data 
%  
of total 1,669 
A resolved at altitude 66 3.8 
B resolved on repressurization 1,433 84.3 
C resolved on repressurization 
but without documented 
treatment pressure 
83 4.9 
D resolved at site pressure 117 6.9 
 total symptoms resolved 1,699 100.0 
 
 
Muehlberger reported that all 1,699 symptoms resolved at altitude, during 
repressurization, or at site pressure.  Our experience is that some symptoms are persistent at site 
pressure.  Muehlberger did not provide detailed information on the prevalence of persistent or 
recurrent symptoms that needed additional treatment pressure.  He mentioned that of 117 
symptoms that resolved at site pressure that 112 were referred to HBO treatment (2.8 ATA) with 
no explanation.  Of the 1,433 symptoms that resolved during repressurization to site pressure, 52 
were referred to HBO treatment for various reasons, such as the symptom being serious 
(pulmonary) or recurring in nature.  For 93% of the 1,433 symptoms that resolved before 
reaching site pressure the subjects continued with 2 hr of GLO treatment at site pressure.  About 
56% (89 of 158) of symptoms in the NASA data were subsequently treated with a period of 
GLO, most often 1-hr.  Additional details not available from Muehlberger are available from the 
Air Force Research Laboratory Altitude Decompression Sickness Research Database archived at 
Wright-Patterson AFB (https://biodyn.istdayton.com/CBDN).  We summarize and analyze these 
1,699 symptoms later in this report.  
 
USAF Compared to NASA Data 
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 Fig. 2 shows results from a regression of 121 of 136 (88%) symptoms that resolved 
during repressurization to site pressure in our limited NASA data.  The additional 17 symptoms 
that resolved at site pressure plus the 121 that resolved during repressurization are the 
denominator for computing the cumulative proportion of symptoms that resolved just during 
repressurization.  Our 37 symptoms that resolved before repressurization are not considered here. 
After removing 66 symptoms that resolved at altitude the data from Muehlberger is comparable 
to the NASA data; 92.8% (1,516/1,633) of symptoms resolved during repressurization.   
 
 
 
 
Fig. 2.  Regression results of symptom resolution during repressurization.  121 of 138 symptoms 
resolved during repressurization to site pressure.  Seventeen symptoms resolved at site pressure.  
Regression model: P(symptom resolution) = 1 / (1+exp(-(ln(P) – 5.20) / 0.511)), plus 95% 
upper and lower CI, where P is pressure differential in units of mmHg.     
 
It is clear that the limited NASA data (121 of 138 symptoms) on symptom resolution 
during repressurization resembles 12-fold more data (1,516 of 1,633 symptoms) from the USAF, 
particularly when considering the 95% confidence limits (CLs) on Fig. 2.  An immediate return 
to site pressure following the onset of a DCS symptom from a wide variety of hypobaric 
exposure conditions has about a 90% probability of resolution.  Additional GLO is expected to 
resolve symptoms still present at site pressure, reduce recurrent symptoms, and in a small 
number of cases HBO treatment would be warranted.   
 
NASA Symptom Data 
 
The observation that 2 cumulative distributions of symptom resolution are similar from 
NASA and USAF sources given a wide variety of hypobaric exposures suggests that a common 
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underlying mechanism is present in the evolution and resolution of DCS symptoms.  Fig. 3 
shows the distribution of onset time for 216 symptoms in the NASA data.  The cumulative 
distribution of those data in Fig. 4 shows the expected S-shaped curve.  Compare this to the S-
shaped cumulative distribution of the P data in Fig. 5.  It is clear that an underlying mechanism 
links the onset time of a symptom and the P to resolve the symptom, even if the mechanism is 
not yet understood.  We show this linkage later as we develop the treatment model.   
 
 
 
 
Fig. 3. Histogram distribution of symptom onset times in 216 / 220 symptoms in 119 cases of 
DCS.  Distribution is skewed right with largest number of reports at about 120 min into the 
exposures. 
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Fig. 4. Empirical cumulative distribution [Fn(t)] of 216 symptom onset times in 119 cases of 
DCS.  Four symptoms had no onset times.  Onset (failure) times for the first symptom in 119 
cases of DCS were used in our survival analysis.  Note the S-shape of the cumulative 
distribution.  
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Fig. 5.  Cumulative proportion of 138 symptoms that resolved during repressurization and at site 
pressure.  Not included are 37 symptoms that resolved at the test altitude, before 
repressurization. 121 symptoms resolved during repressurization (88%) and 17 symptoms (12%) 
resolved at site pressure (between 14.5 and 14.7 psia).  20 symptoms that were persistent at site 
pressure and resolved during a 2.8 ATA HBO treatment are not included.  Note the S-shape is 
similar to the cumulative distribution of 216 symptom onset times in Fig. 4 
 
It seems that regardless of the decompression stress a few will report a symptom, early or 
late, that then resolves with a modest increase in pressure, regardless of the pressure at which the 
symptom appears.  This is seen as the upward inflection of the cumulative distributions to the 
right of the origin on Figs. 4 and 5.  A few subjects are particularly sensitive to the deformation 
pressure (see below) caused by evolved gas in a particular tissue and are equally responsive 
when deformation pressure is reduced with the application of pressure during repressurization. 
 
The prevalence of symptoms from the knees and ankles is fortuitous as it narrows a 
discussion to a particular anatomy and to a simple mechanical mechanism of symptom onset and 
resolution (Hills 1979).  In addition to S-shaped cumulative distributions for onset times and Ps 
for symptom resolution it seems that there would also be an S-shaped cumulative distribution of 
deformation pressure caused by evolved gas, which dictates onset times and Ps for symptom 
resolution.   
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Individual Perception of Pain 
 
The perception of pain is subject-specific in that each person has a threshold for 
perception of a noxious stimulus (Conkin et al. 1998), modified by many factors.  Eq. 2 shows 
that the subjective intensity (I) of a sensation is equal to the difference between the intensity of 
the stimulus (S) and a threshold stimulus (So) to a power (): 
 
I = k1 × (S - So)

,           Eq. 2 
 
where k1 relates the magnitude of the stimulus to the intensity of the sensation.  The same 
incremental increase of the stimulus has a greater influence on the intensity of the sensation 
when  is  1 and other relationships are possible when  is  to 1.  Stimulus is not time-
dependent in Eq. 2 and yet the rate and duration of the stimulus certainly influences the 
perceived intensity.  The sensation [(S - So)

] in our case is pain localized in or near a joint, 
purportedly caused by mechanical stimulation of sensory receptors (Hills 1979).  The stimulus is 
a constrained volume of gas that produces a pressure difference or deformation pressure () 
between the bubble and surrounding tissue.  Deformation pressure and evolved gas in living 
tissue are functionally linked even though the exact relationship must be complex (Srinivasan & 
Gerth 2013).  Eq. 3 defines  as equal to evolved gas in a volume of tissue:   
 
 = k2 × Vtot(a) / Vt,            Eq. 3  
 
where Vtot(a) / Vt is the volume of all gas released, expressed here at ambient pressure, per unit 
volume of tissue, and k2 is the bulk modulus of the tissue.  Values for bulk modulus between 2 
and 11 × 10
4
 dyne / cm
2
 are published for connective tissues and a value as high as 2.5 × 10
8
 
dyne / cm
2
 is documented for articular cartilage.  Deformation pressure as the stimulus for pain is 
directly related to the evolved volume of gas per unit volume of tissue in Eq. 3.   
 
 Many environmental and subject-specific factors dictate the actual Vtot(a) / Vt, some of 
which we attempt later to mathematically describe with the Tissue Bubble Dynamics Model 
(TBDM, Gernhardt 1991).  The location of the evolving or resolving gas phase influences  
through the particular properties of the tissue bulk modulus.  The perception of pain, its onset or 
resolution, is influenced by someone’s sensitivity, as dictated by the density and type of nerve 
fibers in the tissue that dictate the threshold and magnitude of response, as suggested in Eq. 4, 
the combination of Eqs. 2 and 3.   
 
I = k1 × ( - o)

,           Eq. 4 
 
This line of discussion may explain the similarities between cumulative distributions of symptom 
resolution with P in the NASA and USAF data irrespective of sample sizes.  There seems to be 
distributions of individual sensitivities and to deformation pressures caused by evolved gas in the 
knees and ankles.  This mechanistic framework would explain the particular and repeatable 
pattern of cumulative distribution for symptom resolution given the wide variety of hypobaric 
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conditions evaluated.  Subjects respond differently to deformation pressure – some sensitive to a 
small increase while others responsive only to a larger increase.  A probabilistic and not a 
deterministic process seems evident, both in the perception of a symptom and the resolution of a 
symptom.  Variability is manifested in a probabilistic outcome as evident in the cumulative 
distribution of symptom resolution during repressurization.  So both the likelihood and resolution 
of DCS are inherently probabilistic. 
 
Symptom Intensity and P(DCS) 
 
  It is observed that the greater the P(DCS) then the greater the symptom intensity.  The 
nonlinear relationship between group incidence [P(DCS)] and mean symptom intensity is seen in 
Fig. 6.  A conservative PB protocol results in a lower P(DCS) and is clearly associated with less 
symptom intensity.  It follows that an intensely painful symptom may require a greater P to 
resolve (see Fig. 8).  Conversely, less symptom intensity is expected to resolve with a modest 
P.   
 
 
 
Fig. 6.  Data from Allen et al. 1971.  Grade 1 is mild, intermittent pain, Grade 2 is tolerable, 
continuous pain, and Grade 3 is intolerable pain that cleared on descent.  If the P(DCS) is very 
low, then the intensity of pain is low and modest treatment intervention is expected to be 
effective.  
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Also, symptom intensity may be associated with symptom onset time, both of which 
could influence the P(symptom resolution).  Fig. 7 shows the few NASA data about maximum 
symptom intensity and symptom onset time.  Initial efforts to quantify a relationship between 
symptom intensity and onset time, P(DCS), and P(symptom resolution) for a given P are 
described in this report (see Overall Risk Model for Future Missions).   
 
    
Fig. 7.  128 symptoms with maximum symptom intensity associated with the symptom onset 
time.  Linear regression: symptom onset time = -6.4 × (x) + 156, where x is maximum symptom 
intensity, r2 = 0.033. 
 
Fig. 8 shows that the relationship between maximum symptom intensity available in 79 
of 138 symptoms and the P to resolve the symptom.  The relationship is not as strong as one 
might expect given the simple formulation of Eq. 4.  
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Fig. 8.  Maximum intensity score from 79 of 138 symptoms associated with the observed P 
during repressurization to site pressure.  When a range of intensity was reported, the mean 
intensity was used.  When intensity was reported as < 1, then 0.9 was used.  Linear regression: 
P = 0.234 × (x) + 3.44, where x is maximum symptom intensity, r2 = 0.032. 
 
Finally, Fig. 9 shows that the number of symptoms generally increases as the group 
incidence of DCS increases in 40 NASA protocols from 1982 to 2009.  The increase in symptom 
count is more than just the addition of one symptom for each new subject with DCS.  More 
symptoms per subject are reported as group incidence increases.  Several data points overlap, for 
example, there were 10 protocols with no DCS and no symptoms and are all represented by a 
single point at the origin.  Symbol size reflects sample number.  The regression line is weighted 
to reflect the sample number, a total sample of 820 altitude exposures.   
   
 
0 1 2 3 4 5 6 7 8 9 10
maximum symptom intensity
0
1
2
3
4
5
6
7
8
9
10
11
12
de
lta
P
 o
bs
er
ve
d 
(p
si
d)
31 
 
 
Fig. 9.  Number of 220 symptoms associated with group DCS incidence from 40 protocols.   
 
NASA Symptom Resolution Data 
 
Table III shows the number of 220 symptoms in 119 subjects with DCS parsed into 6 
symptom categories and the number of 195 symptoms associated with a treatment pressure.  The 
difference represents 25 symptoms that resolved but the treatment pressure was not recorded.  
About 17% of symptoms resolved at the test altitude compared to about 4% for Muehlberger et 
al. 2004.  Early testing at JSC allowed subjects to remain at 4.3 psia past the point of reporting a 
symptom, which was not the case in testing by the USAF.  Breathing 100% O2 at altitude is a 
treatment for a symptom and given enough time with a mild symptom 37 of 220 symptoms 
(17%) resolved before the start of repressurization.  The majority of symptoms (70%) resolved 
during repressurization and shortly after reaching site pressure, near 14.7 psia at 4 testing sites.  
Twenty symptoms (9%) that were persistent at site pressure resolved after a course of HBO 
treatment at 41 psia (2.8 ATA), either USN TT V or VI.  A clinical HBO treatment protocol was 
applied in totality regardless if the subject reported that the symptom resolved during any phase 
of treatment.   
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Table III. NASA Data on Symptom Resolution.  
symptom 
category 
symptom resolution 
details 
count % of 220 
symptoms 
treatment 
pressure 
data 
% of 195 
symptoms with 
pressure data  
A resolved at altitude 37 16.8 37 19.0 
B resolved on repressurization 137 62.2 121 62.0 
C resolved at site pressure 17 7.7 17 8.7 
D resolved after HBO for a 
persistent symptom at site 
pressure 
20 9.1 20 10.2 
E no treatment pressure 
information exits 
9 4.1 0 0 
 total 220 100.0 195 100 
F resolved but then 
reoccurred or was new and 
treated with HBO 
13 + + + 
+ Since repressurization resolved 13 cases, a treatment pressure already exists higher in the table even though a 
HBO treatment was later required. 
  
 
Fig. 10 makes the point that gender and a wide range of age are present in the symptom 
data.  Both gender and age are subsequently evaluated as explanatory variables in the treatment 
model.  Similar distributions for age are evident between men and women even though women 
just represented 21% of the 119 cases of DCS. 
 
 
33 
 
 
 
Fig. 10.  Histogram distribution of age in 119 men and women with DCS.   
 
 
Symptoms 
  
Figs. 11, 12, and 13 summarize the anatomical locations and attributes of 220 symptoms 
in our 119 cases of DCS.  Fig. 11 shows that the lower body (knees and ankles) dominates the 
location of symptoms, but evolved gas was not restricted just to the knees and ankles.  A greater 
percentage of 220 total symptoms were in the knees and ankles of subjects that ambulated (70%) 
compared to those that did not ambulate (50%), p = 0.004 from Pearson 2.  Other variables 
besides ambulation status were not controlled thus assumed equivalent in this summary 
comparison.  The symptom was often described as painful and constant in character (Fig. 12).  
Finally, conservative PB protocols and test termination criteria limited our experience with Type 
II DCS (Fig. 13).    
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Fig. 11.  Locations of 203 symptoms of Type I DCS.  Symptoms in toes or fingers were included 
in feet or hands.  One subject had skin symptoms (tingling) located in 7 body locations.
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Fig. 12.  Counts of 456 symptom attributes.  Seven of the 9 records for “tingling” symptom came 
from 1 subject.  The 2 symptoms of numbness were attributed to impaired circulation and not 
neurological in origin. 
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Fig. 13.  Type II DCS symptom attributes.  One of 3 headaches here was classified as Type I 
DCS.  Headache and a sensation of being hot during an otherwise unremarkable 4-hr test caused 
the symptom of “headache” to be classified as Type I DCS in a female.  However, the subject 
later reported with Type I symptoms and underwent HBO treatment.  Chest mottling (cutis 
marmorata) was initially classified as Type II DCS at JSC but now exists as its own category of 
DCS – not Type I or Type II.  It is shown on this graph in its historical context.  
 
P 
 
Figs. 14 and 15 demonstrate the challenge of describing P with available explanatory 
variables, either an individual variable or in combination with others in a multivariable linear 
regression.  Fig. 14 shows that the onset time of a symptom during the hypobaric exposure is not 
associated with the P needed to resolve the symptom.  A late report of a symptom did not 
require less treatment pressure just as an early report of a symptom did not require more 
treatment pressure in this analysis.  However, we show later that the onset time to report a 
symptom is useful to estimate the P(symptom resolution). 
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Fig. 14.  Relationship between the report of DCS symptoms and the P for symptom resolution 
during repressurization to site pressure.  The relationship is not impressive.  There is no 
correlation between subsequent Ps for symptom resolution and onset times in 134 symptoms, a 
Pearson correlation of only 0.07.  The near-horizontal slope indicates best fit linear regression.   
 
A delay to repressurization might be expected to increase the P to resolve the symptom.  
However, Fig. 15 shows this is not the case.  A persistent or residual symptom did not require a 
greater treatment pressure, as one might expect.  Other variables such as Tissue Ratio (TR, 
defined later), age, the Bubble Growth Index (BGI, defined later) at onset of a symptom, or BGI 
just prior to repressurization, alone or in combination, did not provide a satisfactory prediction of 
P.  So the effort to predict P with explanatory variables in a multivariable linear regression 
was abandoned in favor of a probabilistic approach where P is the independent and not the 
dependent variable.    
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Fig. 15.  Relationship between the duration of 134 symptoms and the P for symptom resolution 
during repressurization to site pressure.  There is no relationship, a Pearson correlation 
coefficient of only -0.09.  Symptom duration is defined as the difference between the elapsed 
time to the end of the exposure and the elapsed time when the symptom was reported.  The near-
horizontal slope indicates best fit linear regression.     
 
 
A range of Ps associated with symptom resolution defines the cumulative proportion of 
symptom resolution, as seen in Fig. 16.  The P data are the empirical representation of a 
cumulative distribution function (CDF) [Fn(P)].  
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Fig. 16.  Cumulative proportion of 138 symptoms that resolved at the given P during or shortly 
after repressurization to site pressure.     
 
Fig. 17 shows the totality of information available on P, 195 symptoms that resolved 
either during the hypobaric exposure (37 symptoms with P = 0), during repressurization to site 
pressure (121 symptoms), while at site pressure (17 symptoms), or during HBO treatment (20 
symptoms).  Thirty-seven symptoms (19%) resolved at the test altitude, before repressurization, 
121 symptoms (62%) resolved during repressurization, 17 symptoms (8.7%) resolved at site 
pressure (between 14.5 and 14.7 psia), and 20 symptoms (10.2%) were persistent at site pressure 
and resolved during a 2.8 ATA HBO treatment.  Not represented twice on the figure are 13 
symptoms that initially resolved prior to the subject being released from the test but reoccurred 
later, or were new symptoms, both of which initiated a 2.8 ATA HBO treatment.  Given the 
lengthy PB provided to NASA subjects, about 90% of 195 symptoms resolved over a P of 10.4 
psia with about 50% resolution over a P of just 3 psia.  
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Fig. 17.  Cumulative proportion of 195 symptoms that resolved at the given P, including 
symptoms that resolved at the test altitude.   
 
Our aim is to create a probabilistic model for symptom resolution given (conditional on) 
that a symptom is present just prior to repressurization.  Therefore, those 37 symptoms that 
spontaneously resolved during the hypobaric exposure are informative but not germane to our 
goal.  Since 100% O2 is breathed during EVA an evolved gas phase is simultaneously growing 
and resolving, the balance of the 2 processes at any given moment is the offending gas phase.  
Given enough time and the disposition to tolerate a symptom, the gas phase will eventually 
resolve along with the symptom.  We do not consider this approach as a prudent treatment option 
so the 37 symptoms that resolved without repressurization are excluded from the treatment 
model.  Resolved symptoms do not need a treatment intervention. 
 
Fig. 18 shows the cumulative proportion of 158 symptoms that resolved under a positive 
P.  Fig. 18 depicts the empirical mixture cumulative distribution function over all values of the 
covariates in the data set.  121 symptoms resolved during repressurization (76.5%), 17 symptoms 
(10.7%) resolved at site pressure (between 14.5 and 14.7 psia), and 20 symptoms (12.6%) were 
persistent at site pressure and resolved during a 2.8 ATA HBO treatment.  Also not represented 
on the figure are symptoms that reoccurred later, after the subject was released, or symptoms that 
were new, both of which initiated an HBO treatment. 
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Fig. 18.  Cumulative proportion of 158 symptoms that resolved at the given P, including 
symptoms that required HBO treatment.   
 
Those 121 symptoms that resolved during repressurization, which are similar to the 
Muehlberger et al. 2004 data in Fig. 1, and the 17 symptoms that resolved shortly after reaching 
site pressure are considered research-quality data since the subject reported when the symptom(s) 
cleared and the investigator documented the corresponding P.  The remaining 20 symptoms 
were persistent or residual at site pressure and compelled the MO to initiate an HBO treatment to 
resolve the symptom.  However, the Ps associated with HBO treatment are not considered 
research-quality data.  HBO treatment is a clinical intervention, not intended to further our 
detailed understanding of symptom resolution.  The HBO treatment was to 2.8 ATA, 
(approximately corresponding to P = 37 psid for exposures conducted at 4.3 psia), regardless of 
when the symptom resolved during pressurization to 2.8 ATA.  In other words, the subjects were 
not titrated to a P that resolved the symptom but underwent a standard-of-care HBO treatment 
originally designed to treat divers with DCS.  Thus, the 20 Ps associated with a standard HBO 
treatment are considered interval censored observations in the regression of the treatment model 
since we do not know the precise P that the symptom resolved. 
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HBO Treatment and Recurrent Symptoms 
 The treatment model does include the P for initial symptom resolution in those few with 
a recurrent symptom but does not include the P for HBO treatment for recurrent symptoms.  
Sufficient details are not available about symptoms that reoccurred after the subject was released 
from the test and that subsequently required HBO treatment.  Recurrent symptoms are those that 
resolved prior to the subject being released from the test by the MO but reoccurred hrs to days 
later.  Late symptoms are new symptoms that never appeared during the test but appeared hrs to 
days later and were treated with HBO.  Symptoms reported days after a hypobaric exposure are 
always suspect as being attributable to a persistent gas phase.  But these few cases were always 
treated with HBO and the subjects report improvement or complete relief, be it through a placebo 
effect or some real benefit from HBO.  The uncertainty and lack of details about recurrent and 
late symptoms prevent their inclusion in our treatment model.  Also, prophylactic HBO treatment 
pressure is not included in the treatment model.  There was no imminent reason to treat 
symptoms that resolved prior to or during GLO at site pressure with HBO.  However, the 
judgment of the MO in several cases was to treat a nonsymptomatic subject, primarily to reduce 
the chance of a recurrent symptom hrs or days later.  Not all symptoms classified as Type II DCS 
automatically received HBO treatment.  In several cases a prompt return to site pressure 
followed by GLO with the absence of symptoms at site pressure was sufficient treatment as 
deemed by the MO.   
 
Symptoms classified as Type I DCS that were persistent or residual in nature at site 
pressure did receive HBO treatment.  The treatment model does include HBO treatment pressure 
for 20 symptoms that were persistent at site pressure, which were referred to HBO treatment with 
or without prior GLO.  Persistent symptoms at site pressure referred for HBO treatment are 
classified as interval censored observations in our statistical analysis since the precise pressure at 
which the symptom resolved was not available; the only treatment pressure available was the 41 
psia (2.8 ATA) provided by a TT V or VI.  
 
Table IV lists all subjects that experienced an HBO treatment with summary information 
about the symptoms that precipitated the decision to treat with HBO.  There were 46 symptoms 
associated with 24 subjects that received HBO treatment; not all symptoms were present at the 
start of HBO treatment.  In several cases a prophylactic HBO treatment was provided for 
symptoms that resolved and were not present at the start of the HBO treatment.  Only 9 subjects 
had symptoms that were persistent at site pressure.  It is notable that of the 20 symptoms that 
persisted at site pressure that 9 symptoms were from 2 subjects: D980714C and D030327A (see 
Appendix III for details).  The lack of information from case descriptions about some symptoms, 
either the same recurrent symptom or a new symptom, prevented their inclusion in the treatment 
model.    
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Table IV. NASA Hyperbaric Oxygen Treatments. 
 
subject ID persistent 
symptom(s) 
at site 
pressure 
symptom(s) 
resolved 
prior to or 
at site 
pressure 
new or 
recurrent 
symptom(s) 
hrs to days 
later 
one 
symptom 
as Type 
II 
HBO 
treatment 
table 
HBO used 
in DCS 
treatment 
model 
34-01 0 1 1 0 V 0 
34-02 0 1 at site 1 0 V 0 
121-01 1 0 0 1 VI 1 
138-01 0 1 1 0 V 0 
133-02 0 1 1 0 V 0 
149-01 1 0 0 1 V 1 
136-01 0 1 1 0 VI 0 
182-01 1 0 0 1 V 1 
D980113C 0 1 0 0 V* 0 
D980120B 0 1 1 0 VI** 0 
D980203B 0 1 1 0 VI** 0 
D980210A unknown unknown 1 0 VI** 0 
D980303B 1 0 0 0 VI 1 
D980714C 1 0 0 1 VI 1 
H990615B 0 1 1 0 V** 0 
D030327A 1 0 0 1 VI 1 
D030825B 1 0 0 0 V 1 
D031009B 0 1 0 0 V* 0 
D031106B 1 0 0 0 V 1 
D040817B 1 0 0 0 V 1 
D040831A 0 1 0 0 V* 0 
D040915A 0 1 0 0 V* 0 
D070515A 0 1 0 0 V* 0 
D070821A 0 1 0 0 V* 0 
*Prophylactic HBO treatment – no post-exposure symptom to treat.  
**New symptom(s) post-test was not first reported during test. 
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P(symptom resolution) 
 
The P(symptom resolution) during repressurization was modeled as an interval-censored 
log-logistic function of pressure difference (P as psid) for symptom resolution and other 
explanatory variables while accounting for multiple symptoms (dependency) within subjects 
using STATA version 13 software (StataCorp 2013).  In our case, all symptoms resolved at a 
particular P.  However, subjects were not titrated to a P that resolved 20 symptoms during 
HBO treatment, so those Ps are considered interval censored observations in all subsequent 
regressions.  We accounted for multiple symptoms in some subjects (dependency) by 
incorporating robust standard error calculations in the treatment models (Royall 1986). 
 
A brief description of the regression model starts with the log-logistic survival function 
S(x): 
 
S(x) = 1 - [ 1 / ( 1 + exp (-))],        Eq. 5 
      
where  = [ln(x) - 2] / 1 and x is P in our application.  With Eq. 5 as P increases the 
probability of unsuccessful treatment decreases. 
  
 The distribution is specified with 2 parameters and generalized to include the effects of 
covariates (explanatory variables) on P.  The generalized log-logistic is called an accelerated 
model where the logarithm of P is a linear function of the covariates:   
 
 = [ln(P) - 2 - x1 × x1 - ... - xn × xn ] / 1.                                       Eq. 6   
  
Our preference to graph the log-logistic function is as the CDF F(x): 
 
F(P;z) = 1 – S(P;z) = 1 / ( 1 + exp (-(ln(P) – 2 - x1 × x1 - ... - xn × xn) / 1)), Eq. 7 
 
where F(P;z) indicates the accelerated log-logistic model and now as P increases the 
probability of successful treatment increases, our P(symptom resolution). 
 
 We start our evolution to the final treatment model by first understanding the contribution 
of the limited HBO treatment information.  Fig. 19 shows the results of adding the 20 censored 
HBO treatment data to 138 symptoms that resolved during repressurization and shortly after 
reaching site pressure in a regression with just P (univariate).  The regression curve predicts 
almost complete symptom resolution at a P of 37 psid, which is our experience.  All symptoms 
resolved during HBO treatment at  41 psia.  The regression primarily reflect the contribution 
from ambulatory males: 90 symptoms from ambulatory and 33 from nonambulatory males 
compared to 12 from ambulatory and 23 from nonambulatory females.   
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Fig. 19.  P(symptom resolution) based on 158 symptoms that resolved at a P between 0 and 
37.1 psid.  P(symptom resolution) = 1 / (1 + exp(-(ln(P) – 1.411) / 0.524)), plus 95% upper and 
lower CL that assumes independence among symptoms. 
 
An alternative regression is to just select the 138 symptoms that resolved during 
repressurization and shortly after reaching site pressure as the basis of the treatment model, then 
extrapolated to a P(symptom resolution) when P is > 11 psid.  Fig. 20 shows the regression 
results from data seen in Fig. 16 with the regression curve extrapolated to a P of 40 psid.  Note 
that the extrapolated curve shows that symptom resolution at 40 psid is near 100% certainty, 
without considering the lower 95% CL.  Also, the P(symptom resolution) is near 0.93 at site 
pressure, which reflects the reality that not all symptoms promptly resolve on repressurization to 
site pressure.   
 
On balance, the regression results in Fig. 20 accord with our experience more so than in 
Fig. 19, given no explanatory variables in the regression.  An extrapolation from 10.4 psid to 
about 40 psid provides an estimate of the additional P needed to resolve a symptom that does 
not promptly resolve at site pressure.  As before, the regression primarily reflect the contribution 
from ambulatory males: 87 symptoms from ambulatory and 23 from nonambulatory males 
compared to 12 from ambulatory and 16 from nonambulatory females.   
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Fig. 20.  P(symptom resolution) based on 138 symptoms that resolved at a P between 0 and 
10.4 psid.  P(symptom resolution) = 1 / (1 + exp(-(ln(P) – 1.239) / 0.457)), plus 95% upper and 
lower CL that assumes independence among symptoms.   
 
We decided to keep the censored Ps from HBO treatment in the treatment model and 
included explanatory variables that improved the treatment model.  This approach eliminates the 
uncertainty (false certainty) of extrapolating the treatment model into a significant range of 
HBO.  Even the 20 censored HBO symptoms provide some information to the treatment model, 
making it more conservative [lower P(symptom resolution)] at Ps > 11 psid.  The final form of 
the treatment model is described after first providing a necessary description of how effective 
treatment P is computed from the TBDM, a related discussion about the O2 window, a brief 
description of the TBDM, and descriptions of DCS and VGE survival models for all NASA data 
to date.  The background information is needed to properly interpret the P(symptom resolution) 
from the final treatment model. 
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Computing Effective Treatment Pressure 
 
 Eq. 8 is Boyle’s Law for an isothermal system with fixed amount of ideal gas (closed 
system).   
 
P1×V1 = P2×V2,          Eq. 8 
 
where V1 is dry-gas volume at pressure P1 and V2 is dry-gas volume at pressure P2.  The ratio of 
V1 to V2 is equivalent to the ratio of P2 to P1.  An initial unit volume of dry gas (V1) is reduced 
by half when initial pressure (P1) doubled.  Eq. 9 is Eq. 8 solved for P.  The pressure difference 
(P) in this example is 1 unit.  An increase of 1 P unit results in 50% reduction in initial ideal 
gas volume.  
 
P2 – P1 = P = V1/V2 × P1 – P1.        Eq. 9 
 
 
The volume of a sphere is: 
 
V =  ସଷ ߨݎଷ.            Eq. 10 
 
 
The TBDM accounts for the time-dependent change in the mass of N2 during 
compression and during the final reabsorption of the bubble.  In the TBDM, the radius per unit 
volume of tissue that a spherical bubble achieves through time was computed for a particular PB 
protocol, ascent rate, exposure duration, and repressurization condition.  Radii at the time of 
repressurization and at the time the symptom was resolved were converted to respective gas 
volumes through Eq. 10.  Volumes in the TBDM were expressed at body temperature (37°C), 
ambient pressure, and dry-gas conditions (BTPD).  Boyle’s Law dominates the volume change 
during any short repressurization due to the limited diffusion of N2 and metabolic gases out of 
the bubble in a short period of time.  The very small loss of N2 during a short repressurization to 
site pressure as well as the continued loss of N2 in a bubble driven by the magnitude of the O2 
window, and other factors that influence bubble N2 partial pressure (PbubN2) contribute to the 
final volume reduction through time.  The reduction in volume is the treatment potential for a 
DCS symptom.  Our underlying assumption is that given the reduced volume, the computed P 
from Eq. 9 is the effective treatment pressure at any point in time since the TBDM is time-
dependent. 
 
The observed P to resolve a symptom must be very close to the computed P with Eq. 9 
since the TBDM incorporates Boyle’s Law for ideal gas.  Fig. 21 shows the observed P to 
resolve 138 symptoms during repressurization and at site pressure on the x-axis and the 
computed P on the y-axis applying Eq. 9 to the initial and final BGIs from the TBDM.  BGI is a 
unitless index of bubble growth, defined as the ratio of bubble radius at some time t, usually the 
beginning of a repressurization, to an initial stabilized micronuclei radius of 3 microns (m).  
BGI was first converted back to bubble radius as BGI × 3 at a point in each record where 
repressurization commenced and where the symptom resolved during the repressurization.  Both 
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radii were then converted to volumes through Eq. 10, and to the computed P through Eq. 9.  
Computed volumes for 20 symptoms from 9 subjects that needed HBO are not included on Fig. 
21.  The details to compute volume with the TBDM were unavailable, such as time at site 
pressure prior to HBO, breathing gas composition prior to HBO, and time during HBO treatment 
for symptom resolution.  The agreement between observed P and computed ideal gas P from 
Boyle’s Law on Fig. 21 is evident in the linear regression result:  P computed = 1.0016 × P 
observed – 0.324, with r2 = 0.977.     
 
All 138 data should fall on the identity line if only Boyle’s Law was represented.  Slight 
deviations from the identity line are expected since the computed volume at symptom resolution 
is from a time-dependent open system and Eq. 9 applies to a closed system.  It is enough to 
conclude from Fig. 21 that Boyle’s Law for ideal gas applied to the TBDM over the short 
repressurization times is the dominant factor to account for symptom resolution. 
 
 
 
   
Fig. 21.  Observed P to resolve 138 symptoms compared to the computed P based on Eq. 9.   
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A change in ambient pressure is transmitted equally through all tissues; living tissue is in 
equilibrium with the prevailing hydrostatic pressure.  Therefore, a volume of wet-gas in the 
tissue is subject to change with a change in ambient pressure.  An important distinction between 
dry and wet gas is made in the application of Boyle’s Law.  All natural or accidental voids in the 
body at 37°C are in equilibrium with water vapor partial pressure of 47 mmHg.  Water is a liquid 
at body temperature and water vapor is a dispersed liquid phase.  In contrast to other gases in a 
bubble, saturated water vapor at one temperature will condense out of the gas phase at a lower 
temperature.  The maximum partial pressure of water in a saturated wet gas is equal to the vapor 
pressure of water at 37°C.  Because water vapor partial pressure is constant at a given 
temperature regardless of pressure, it is subtracted from total pressure when applying Boyle’s 
Law to wet gas.  The noncompressibility of water vapor causes wet gas to respond differently to 
pressure changes than dry gas (Stepanek 2002).   
 
Eq. 11 is Boyle’s Law with reference to wet gas: 
 
P1 – pH2O × V1 = P2 – pH2O × V2.        Eq. 11 
 
Solving Eq. 11 for P2 – P1, the P associated with a volume change of wet gas, yields Eq. 12: 
 
P2 – P1 = P = V1/V2 × (P1 – pH2O) + pH2O - P1.      Eq. 12 
 
 
We converted all V1 and V2 pairs from BTPD to BTPS by multiplying BTPD volumes by 
the ratio PB / (PB – pH20) to apply Eq. 12.  Fig. 22 shows the same data as in Fig. 21 except the 
computed P was from Eq. 12 after dry gas volumes from the TBDM were corrected for wet 
gas.  So V1 becomes the volume of a spherical bubble under BTPS conditions in a unit volume of 
tissue at low pressure PB = P1, V2 is volume under BTPS conditions after a change to a higher 
pressure PB = P2, and pH2O at 37°C is 0.909 psia.  Now the ratio of V1 to V2 is not equivalent to 
the ratio of P2 – pH2O to P1 – pH2O.  Given the same change in pressure there is a slightly 
greater volume expansion during a depressurization and a slightly greater volume compression 
during repressurization when compared to the ideal gas application of Boyle’s Law.  The results 
are essentially identical in Fig 22 as in Fig 21, as evident in the linear regression result:  P 
computed = 0.999 × P observed – 0. 28, with r2 = 0.980.   
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Fig. 22.  Observed P to resolve 138 symptoms compared to the computed P based on Eq. 12. 
 
As long as Eq. 9 is used in conjunction with V1 and V2 outputs from the TBDM, then it is 
valid to create a predictive model for symptom resolution based on effective Boyle’s Law acting 
on ideal gas volumes.  The dr/dt equation includes radius on the right side of the equation so the 
actual radius of the changing bubble impacts the dr/dt.  Therefore, the subsequent decrease in V2 
from the loss of N2 after the repressurization event in a smaller bubble is different if ideal gas 
volume is used in place of corrected wet-gas volume.  Smaller bubbles derive 2 benefits from a 
highly curved surface: a) the surface force along with the smaller radius of curvature results in a 
greater internal pressure due to surface tension thus increasing partial pressures of all gases 
within the bubble so increases the outward diffusion and b) the curved surface results in a greater 
divergence of the gas flux lines and therefore a more rapid drop in partial pressure with 
increasing distance from the surface, raising the partial pressure difference and the rate of gas 
efflux.  
 
Other bubble-tissue model systems (Van Liew & Hlastala 1969, Van Liew & Burkard 
1995, Srinivasan et al. 2003, Gerth & Vann 1997, Tikuisis et al. 1994, Nikolaev 2013, and 
Srinivasan & Gerth 2013) can be used to compute the effective Boyle’s Law change using Eq. 9 
or 12 if the TBDM is not available to a user of the treatment model.  This is because the P data 
0 1 2 3 4 5 6 7 8 9 10 11 12
deltaP observed (psid)
0
1
2
3
4
5
6
7
8
9
10
11
12
de
lta
P
 c
om
pu
te
d 
(B
TP
S
)
51 
 
on symptom resolution is independent of the bubble-tissue model system to compute an effective 
Boyle’s Law change through time.  The user computes the effective Boyle’s Law P for any 
bubble-tissue model and takes the result to a statistical regression of empirical data that relates 
the observed P to the P(symptom resolution).  The treatment model links a decrease in 
computed bubble volume to the P(symptom resolution).  The decrease in volume is realized in 2 
stages: a) during compression due to Boyle’s Law and b) during subsequent dissolution of the 
gas phase by the O2 window.  The computed P is the effective treatment pressure at any point 
in time.       
 
Fig. 23 is an example of Eq. 11 applied to instantaneous volume reduction in an astronaut 
and diver seeking relief from a symptom.  The figure shows the reduction in a unit volume of 
wet gas with the application of sea level pressure (1 ATA) to gas at 0.29 ATA from an astronaut 
and application of HBO pressure (2.8 ATA) to gas at 1.0 ATA from a diver.  The 
noncompressibility of water vapor causes wet gas to respond differently to pressure changes than 
dry gas.  For example, a unit volume of dry gas taken from 760 mmHg to 140 mmHg (40,000 ft 
altitude) would experience a 5.4-fold volume expansion using Eq. 8, and visa versa.  Application 
of Boyle’s Law with reference to wet gas requires that 0.0618 ATA (47 mmHg) water vapor 
pressure be removed from the initial and final pressures, yielding a 7.6-fold volume expansion 
using Eq. 11, and visa versa.  A unit volume of wet gas taken as 100% in the aviator would 
decrease to 24% on repressurization from 0.29 ATA to 1.0 ATA after removing 0.0618 ATA 
water vapor pressure from the initial and final pressures.  The diver experiences a reduction to 
34% of the unit volume on repressurization from 1.0 ATA to 2.8 ATA.  So in this example there 
is an advantage in the hypobaric case compared to the hyperbaric case when considering volume 
decrease during repressurization.  A more extensive analysis with the same conclusion was 
reached by Dart & Butler 1998 (their Fig. 3), based on a dry-gas application (Eq. 8) of Boyle’s 
Law. 
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Fig. 23.  Comparison of astronaut and diver repressurizations.  An astronaut enjoys a slight 
advantage from Boyle’s Law compression of an offending gas phase at 0.29 ATA while 
returning to 1 ATA compared to a diver given an HBO treatment for the same gas phase at 2.8 
ATA.          
 
A second example highlights the significant gas volume reduction with small P when 
the gas phase is present at a low absolute ambient pressure.  We compare the unit volume 
reduction in an astronaut that returns to the ISS at 14.7 psia while still pressurized at 4.3 psid in 
the spacesuit to the equivalent depth that a diver needs to achieve for the same unit volume 
reduction.  The wet-gas reduction using Eq. 11 for the astronaut is from 1.0 ml to 0.18 ml at 19.0 
psia while the diver must pressurize to 74.5 psia for the same volume reduction, a pressurization 
equivalent to treatment at 134 fsw.  
 
Boyle’s Law is a major factor but not the only factor to consider for effective DCS 
treatment.  Due to the presence of a constant metabolic gas partial pressure, the N2 partial 
pressure of astronaut and diver bubbles is different.  The reabsorption of the bubbles during the 
application of pressure while breathing 100% O2 is dictated by the N2 partial pressure gradient 
between the bubbles and mixed venous blood N2 tension, a reflection of tissue N2 tension.  It 
could be that the N2 gradient is greater for the astronaut relative to the diver since the astronaut 
breathes 100% O2 for several hrs as DCS evolves compared to the diver who was breathing air 
during and after the dive. 
 
 Fig. 24 demonstrates the combination of Boyle’s Law and the removal of N2 from a 
bubble-tissue open system to resolve a symptom as modeled by the TBDM.  The first curve from 
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left is after a 60 min PB in an astronaut exposed to 4.3 psia (0.29 ATA) with return to 14.7 psia, 
second curve is a saturation diver with return to 41.1 psia (2.8 ATA) after exposure to14.7 psia, 
and the third curve is after a 300 min PB in an astronaut exposed to 4.3 psia with return to 14.7 
psia (5 min for all pressure transitions).   
 
 
 
 
Fig. 24.  Examples of bubble growth and dissolution using the TBDM.  Three examples 
demonstrate the resolution of a 14 unit BGI given a Boyle’s Law decrease in bubble volume with 
applied treatment pressure and the bubble-to-tissue N2 gradient as computed with the TBDM.  
 
The elapsed time from the start of decreased pressure (time 0) to bubble resolution is 
shorter in the astronaut cases (207 and 216 min), dependent on the PB time, compared to the 
saturation diver (236 min).  The difference is due to a slight Boyle’s Law advantage during the 
return to site pressure (14.7 psia for astronaut and 41.1 psia for saturation diver) combined with a 
greater bubble-to-tissue N2 gradient for the astronaut with the longer PB compared to the 
saturation diver.   
 
A tentative conclusion based on 3 examples and multiple assumptions in the TBDM is 
that the time is shorter to resolve a theoretical bubble for an astronaut treated with 100% O2 at 1 
ATA compared to a saturation diver treated with 100% O2 at 2.8 ATA (his saturation pressure, 
and the treatment pressure for the USN TT V).  One other complication for the diver is the high 
pO2 during treatment, a level that is reduced during air breaks to prevent CNS or pulmonary O2 
toxicity.  This complexity was not included in the simulation and is not a complexity that the 
astronaut must face since 100% O2 at 1 ATA is tolerable for several hrs. 
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O2 Window and Bubble Dissolution 
 
A volume of any gas introduced into living tissue eventually dissipates.  An 
understanding about the absorption mechanism is necessary to ultimately understand the 
resolution of a DCS symptom.  The following discussion is based on a clear description of the O2 
window by Van Liew et al. 1993 (also Van Liew et al. 1995), and is required reading for those 
responsible for DCS treatment. 
 
The sum of gas tensions in mixed venous blood under steady state sea level (1 ATA 
breathing air) conditions is not equal to the sum of alveolar gas partial pressures (PAx).  Alveolar 
gas partial pressures at sea level are 40 mmHg for CO2, 103 mmHg for O2, 570 mmHg for N2 
(including 1% Argon in breathing air as N2), and 47 mmHg for H2O, summing to 760 mmHg.  
Mixed venous blood tensions, a reflection of whole-body tissue tensions (Ptisx), are 45 mmHg for 
CO2, 40 mmHg for O2, 570 mmHg for N2, and 47 mmHg for H2O, summing to 702 mmHg.  The 
difference of 58 mmHg is termed inherent unsaturation, partial pressure vacancy, or most 
commonly the O2 window.  Eq. 13 defines the O2 window (Pw) as: 
 
Pw = PB – (PtisN2 + PtisO2 + PtisCO2 + pH2O).        Eq. 13 
 
Gas partial pressures in bubbles (Pbubx) approach equilibrium with gas tensions in tissues 
where PtisO2 and PtisCO2 are constant due to metabolic control over tissue gas exchange and rapid 
diffusion occurring across the bubble-tissue boundary.  The total of all gas partial pressures, 
including pH2O of 47 mmHg at 37°C, in a bubble must sum to the ambient pressure (PB) or an 
even higher bubble pressure (Pbub) that includes PB in accordance with Dalton’s Law of Partial 
Pressure.  Therefore, PbubN2 is eventually larger than PtisN2 in living tissues resulting in diffusion 
of N2 from bubble to tissue.  The O2 window in this application is the PbubN2 – PtisN2 gradient.     
 
Eq. 14 defines the partial pressure of N2 in a bubble as: 
 
PbubN2 = PB - PtisO2 - PtisCO2 - pH2O.         Eq. 14 
 
In the example above at sea level, a gas phase introduced into the body, from a plebe of 
gas injected under the skin, a pneumothorax from alveolar rupture, mediastinal emphysema from 
rupture of the trachea, or even evolved gas from inert gas supersaturation will all be absorbed 
through time as a consequence of the O2 window.  The magnitude of the O2 window is not 
constant for all tissues at all times but depends on particular moment-to-moment metabolic and 
blood flow conditions in the tissue surrounding a gas phase.  It is smaller, for example, in muscle 
tissue at rest relative to brain tissue owing to the high metabolic demands of neural tissue.  Under 
steady state conditions PAN2 = PtisN2 so a quantifiable pN2 gradient exists between PbubN2 and 
and PAN2.  However, when a bubble is present in a tissue compartment with a long half-time, 
such as the theoretical 360 min half-time compartment used here, PAN2 can change abruptly 
when breathing 100% O2 while the PtisN2 decreases slowly in response.  Under this non-steady 
state condition, the exact O2 window is less certain and is approximated by the PbubN2 - PtisN2 
gradient, as is done in the TBDM.  Therefore, breathing 100% O2 or O2-enriched gas reduces 
PtisN2 through denitrogenation and increases PbubN2 through the O2 window.  In particular, this 
overall process limits bubble growth during EVA while breathing 100% O2 and accelerates 
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bubble dissolution during repressurization and subsequent symptom treatment by maximizing the 
PbubN2 - PtisN2 gradient. 
 
Other factors besides the O2 window modify PbubN2, especially when a bubble becomes 
very small.  For example, the effects of surface tension and tissue elasticity increases Pbub above 
PB.  Also, PtisN2 eventually equilibrates with PAN2 so that the PbubN2 - PtisN2 gradient constantly 
changes through time until the bubble is absorbed.  Substituting steady state tissue gas tension 
values above into Eq.14 results in a PbubN2 of 628 mmHg.  PtisN2 was 570 mmHg, so an O2 
window of 58 mmHg (PbubN2 – PAN2) in this example is the concentration gradient by which 
diffusion of N2 from the gas volume to the lungs.  A PbubN2 – PtisN2 gradient for only N2 was 
described in this simplified description, but during this steady state dissolution of the gas phase a 
small outward diffusive gradient also exists for O2 and CO2.  These gradients are related through 
the reciprocals of blood solubility × diffusivity of each gas.  The result is about a 3-mmHg 
gradient for O2 and a 1-mmHg gradient for CO2 for a bubble in venous blood (Hlastala & Berger 
2001). 
 
Table V provides details about how PW and normalized PW (PWnorm) are computed in 6 
cases, all examples about DCS treatment associated with the MMESV.  The reasons for these 
details are to demonstrate the importance of PW and PWnorm to resolve a gas phase and to 
demonstrate that PW is part of the TBDM.  
 
 Cases 1 through 6 in Table V are summarized as follows: 
 
1. Steady state treatment at 8.6 psia (14,000 ft) on air (adapted to hypoxia through chronic 
increase in ventilation) where PtisN2 = PAN2. 
2. Steady state treatment at 8.2 psia (15,500 ft) on 34% O2 where PtisN2 = PAN2. 
3. 2-hrs with 95% O2 treatment at 8.2 psia (15,500 ft) where PtisN2  PAN2, and 3 PtisN2s are used 
in place of PAN2. 
4. 35% O2 treatment at 14.7 psia where PtisN2  PAN2, and 3 PtisN2s are used in place of PAN2. 
5. 95% O2 treatment at 14.7 psia until BGI = 1 where PtisN2  PAN2, and 3 PtisN2s are used in 
place of PAN2. 
6. 95% O2 treatment at 22.9 psia until BGI = 1 where PtisN2  PAN2, and 3 PtisN2s are used in 
place of PAN2.   
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Table V. Estimated O2 Windows Related to MMSEV DCS Treatment. 
 
variable case 
1 
case 
2 
case 
3 
case 
4 
case 
5 
case 
6 
notes 
PB 
(mmHg) 
altitude 
(ft) 
447 
14,000 
422 
15,500 
422 
15,500
760 
0 
760 
0 
1184 
-- 
ambient pressure
FIO2 0.21 0.34 0.95 0.35 0.95 0.95 
PAO2 
(mmHg) 
42 81 316 203 637 1040 from alveolar gas equation, 
equilibrium condition
PACO2 
(mmHg) 
35 40 40 40 40 40 
PAH2O 47 47 47 47 47 47 partial pressure of 
water vapor (BTPS) 
PAN2 323 254 19 470 36 57 PAN2 = PtisN2, equilibrium 
condition, argon included as N2
       
O2physoln 
(ml/dl) 
0.13 0.25 0.98 0.63 2.0 3.2 vol% is ml (STPD)/dl, plasma 
content 0.0031 vol% / mmHg 
PAO2
CaO2Hb 
(ml/dl) 
16.2 19.2 20.0 19.9 20.0 20.0 blood content from blood-gas 
model!
CaO2 
(ml/dl) 
16.3 19.5 21.0 20.6 22.0 23.2 blood content from O2physoln + 
CaO2Hb
CaCO2 
(ml/dl) 
46.0 47.6 47.4 47.4 47.4 47.4 blood content from blood-gas 
model
CVO2 
(ml/dl) 
11.3 14.5 15.9 15.6 70.0 18.2 blood content from blood-gas 
model
CVCO2 
(ml/dl) 
50.0 51.6 51.4 51.4 51.4 51.4 blood content from blood-gas 
model
PVO2 
(mmHg) 
28.0 37.6 43.5 41.7 49.0 49.0 blood partial pressure from 
blood-gas model, mixed PVO2  
PtisO2
PVCO2 
(mmHg) 
39.8 45.4 45.9 45.7 46.7 46.7 blood partial pressure from 
blood-gas model, mixed PVCO2 
 PtisCO2
       
PtisN2 
(mmHg) 
323 254 19* 470* 36* 57* equilibrium case where no N2 is 
lost during EVA, PtisN2 = PAN2 
PtisN2(1) 
(mmHg) 
294 225 200 350 200 200 first option where some N2 is lost 
during EVA in cases 1 and 2 and 
is lost even more with O2 
treatment in cases 3, 5 and 6 but 
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is added during pressure 
treatment at 14.7 psia in case 4, 
PtisN2  PAN2 so PtisN2 in place of 
PAN2
PtisN2(2) 
(mmHg) 
269 200 175 300 175 175 second option where some N2 is 
lost during EVA in cases 1 and 2 
and is lost even more with O2 
treatment in cases 3, 5 and 6 but 
is added during pressure 
treatment at 14.7 psia in case 4, 
PtisN2 ≠ PAN2 so PtisN2 in place 
of PAN2
PtisN2(3) 
(mmHg) 
244 175 150 250 150 150 third option where some N2 is 
lost during EVA in cases 1 and 2 
and is lost even more with O2 
treatment in cases 3, 5 and 6 but 
is added during pressure 
treatment at 14.7 psia in case 4, 
PtisN2  PAN2 so PtisN2 in place of 
PAN2
       
PbubN2 
(mmHg) 
332 292 286 625 617 1041 equilibrium case, PbubN2 = PB - 
PtisO2 - PtisCO2 - PH2O
       
PW 
(mmHg) 
9 38 267* 155* 587* 984* equilibrium case, PW = PAO2 + 
PACO2 – PtisO2 – PtisCO2, 
or Pw = PbubN2 – PAN2,
or Pw = PB – (PtisN2 + PtisO2 + 
PtisCO2 + PH2O)
PW(1) 
(mmHg) 
38 67 85 275 417 841 first option 
PW(2) 
(mmHg) 
63 92 110 325 442 866 second option 
PW(3) 
(mmHg) 
88 117 135 375 467 891 third option 
       
PWnorm  0.03 0.13 0.93* 0.25* 0.95* 0.94* equilibrium case, PWnorm = PW / 
PbubN2, or
PWnorm = (PbubN2 – PAN2) / PbubN2
PWnorm(1)  0.11 0.23 0.29 0.44 0.68 0.80 first option where PtisN2  PAN2 
so PtisN2 in place of PAN2 
PWnorm(2)  0.19 0.36 0.38 0.52 0.71 0.83 second option where PtisN2  
PAN2 so PtisN2 in place of PAN2 
PWnorm(3)  0.26 0.46 0.47 0.60 0.75 0.85 third option where PtisN2  PAN2 
so PtisN2 in place of PAN2 
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BGI 
resolution!!  
 800# 411 307 167 149 103 
 
RER = 0.85 else 1.0 when 100% O2 is breathed, tissue with arteriovenous O2 difference of 5 vol% (O2 extraction), 
Qs/Qt = 2%, Qt = 5 l/min, VO2 = 250 ml/min, VA/Q = 1, Hb = 15 g/dl, and HbP50 = 26 mmHg.   
! Olszowka & Farhi 1968. 
!! time (min) from start of treatment pressure (after repressurization from 4.3 psia) with BGI = 28 to reach BGI = 1 
after 2-hr of 95% O2 treatment in the suit in case 3 and until BGI = 1 in cases 5 and 6.   
*these cases are not reasonable because PtisN2  PAN2 since an O2 (case 3) or pressure (case 4) or both (cases 5,6) 
treatment is underway. 
# BGI reduced to 13.2 after 828 min but regrew while at 8.6 psia conditions. 
 
 
Besides computed Pw under 4 conditions: PW, PW(1), PW(2), and PW(3) for the 4 conditions 
of PtisN2: equilibrium PtisN2, and non-equilibrium cases, PtisN2(1), PtisN2(2), and PtisN2(3), it is also 
important to include the 4 computed normalized O2 windows, PWnorm:   PWnorm, PWnorm(1), 
PWnorm(2), and PWnorm(3).  The normalized O2 window is defined in Eq. 15. 
 
 PWnorm = Pw / PbubN2 = (PbubN2 – PAN2) / PbubN2.        Eq. 15  
 
When breathing air, the normalized O2 window is comparatively low, indicating that 
change of bubble size due to the O2 window in air-breathing persons at altitude would be slower 
than in air-breathing persons at normal or hyperbaric pressures.  This difference is because 
partial pressures of O2 for both arterial and venous blood are on the steep part of the O2-Hb 
dissociation curve so there is a small pO2 difference between the two.  But when a person 
breathes 100% O2 long enough that PAN2 and PtisN2 are zero, the normalized O2 window equals 
1.0 for a bubble that contains N2.  This condition sets the maximum rate for absorption of a 
bubble.  When the arteriovenous difference is small, the O2 window is as much as 50 times 
greater when breathing 100% O2 than with air.  
 
 The left column in Table V shows the environmental conditions for the 6 treatment 
simulations with the associated alveolar gas partial pressures, the O2 and CO2 content and 
resulting O2 and CO2 tensions in the arterial and venous blood and several N2 tensions in the 
tissue (PtisN2); N2 tension either in equilibrium with PAN2 or not in equilibrium and estimated.  
The PtisN2 for cases 3 through 6 are shown as if they are in equilibrium with PAN2, but in reality 
this could not be true.  Cases 3 through 6 include treatment options where O2-enriched breathing 
gas or the application of pressure or both are part of the simulation and therefore PAN2 ≠ PtisN2.  
In order to advance the discussion about the O2 window and bubble reabsorption to include 
realistic scenarios one must focus on the pN2 gradient from PbubN2 to PtisN2 since PtisN2 will not 
instantaneously reflect changes in PAN2 during treatment interventions.  PtisN2(1), PtisN2(2), and 
PtisN2(3), are reasonable deviations from equilibrium tissue N2 tension due to conditions expected 
to change PtisN2 and therefore change the PbubN2 - PtisN2 gradient.  Note that over a range of FIO2 
from 0.21 to 0.95 under various environmental conditions that PVO2 and PVCO2 remain low and 
relatively constant, contributing to a high PbubN2.    
 
The lower part of Table V shows the results, the computed PbubN2 based on Eq. 14, PW 
based on Eq. 13, PWnorm based on Eq. 15, and finally the resolution time for a BGI of 28 units in 
the TBDM given some of the information from the Table V.  As expected, the fastest resolution 
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time for the simulated bubble was with case 6; PW was 984 mmHg with PWnorm at 0.94 compared 
to PW of 58 mmHg with PWnorm of 0.09 to resolve a plebe of gas at 1 ATA introduced into tissue 
in a person breathing air.  However, these values are for the unrealistic case where PAN2 = PtisN2 
since treatment protocols are being simulated and PtisN2 would not instantaneously equal PAN2 
under pressure and O2 treatment interventions.  A better evaluation of Pw and PWnorm for the 6 
cases is to consider a range of potential PtisN2 for each case.  The best statistical association 
between PWnorm and BGI resolution time when PtisN2 ≠ PAN2 is when the PtisN2(1) estimates were 
used. 
 
Fig. 25 shows the relationship between BGI resolution time from 28.2 to 1.0 units and 
PWnorm(1) where PtisN2(1) was used in place of PAN2.  There is a relationship between an 
independent assessment of PWnorm(1), where PWnorm(1) = (PbubN2 - PtisN2(1)) / PbubN2, and an 
independent assessment of BGI resolution time.  The relationship appears nonlinear, as expected 
since N2 kinetics in the bubble-tissue system is described with an exponential and surface tension 
in a spherical bubble dramatically increases PbubN2 as radius approaches zero.  The conclusion is 
that the O2 window and other variables that define the PbubN2 - PtisN2 gradient are accounted for 
in the TBDM, although not to the detail described by Van Liew et al. (1993,1995).  A summed 
mixed venous blood gas tension of 132 mmHg for O2, CO2, and H2O and an instantaneous 
equilibration of metabolic gases (Pmet) between tissue and bubble are simplifications used in the 
TBDM, and are sufficiently precise for our narrow application. 
 
 
 
 
Fig. 25.  Relationship between PWnorm(1) and BGI dissolution time.  The greatest potential and 
rate of BGI reabsorption is during a simulation of treatment case 6, breathing 95% O2 at 22.9 
psia.   
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Tissue Bubble Dynamics Model Details 
 
Whether a bubble grows or dissolves depends on the sum of the flux of all gases in the 
bubble, each of which diffuse independently.  The TBDM (Gernhardt 1991) is a biophysical 
model of bubble growth and resolution in tissue as defined by Eq. 16:  
 
ୢ௥
ୢ௧ ൌ
ିഀವ೓ ቀ௉ಳି௩௧ା
మം
ೝ ା
ర
యగ௥యெି௉౪ି௉ౣ౛౪ቁା
ೝೡ
య
௉ಳି௩௧ାరംయೝା
ఴ
యగ௥యெ
 ,     Eq. 16 
   
where r is the bubble radius (cm), t is time (sec), α is Ostwald N2 solubility (0.0125 
cm3gas /cm3tissue for water at 37°C), D is the diffusion coefficient (2.0×10-8cm2/sec for water), h is 
bubble film thickness (3.0×10-4 cm), PB is initial ambient pressure (dyne/cm2), v is ascent or 
descent rate (dyne/cm2×t),  is surface tension (30 dyne/cm), M is tissue modulus of elasticity, 
the ratio of bulk modulus (H) of 2.5×108 dyne/cm2 to articular cartilage volume (H/cm3tissue = M, 
dyne/cm2×cm3) times bubble volume  ସଷ ߨݎଷ to compute a deformation pressure (dyne/cm2), Pt is 
total tissue tension of all inert gases (dyne/cm2) in the general model but is specifically tissue N2 
tension (PtisN2) in this application, and Pmet are metabolic gas (O2+CO2+H20) tensions (1.76×105 
dyne/cm2, or 132 mmHg).  Eq. 16 is a first order non-linear differential equation; however, it has 
no closed-form solution and must be solved numerically with the aid of a computer. 
 
 
Denitrogenation 
 
The TBDM accommodates multiple half-time compartments to reflect the varying rates 
at which different body tissues take up and eliminate inert gases during and following a dive.  
However, in this application we use the same 360 min half-time compartment for tissue N2 
uptake and elimination for all PB conditions that do not include exercise during prebrerathe.  
Aviators and astronauts are initially in an environment that is in equilibrium with atmospheric 
pN2 so any PB procedure first eliminates N2 from well-perfused tissues.  Denitrogenation 
protocols used or tested by NASA are conservative so this leaves only tissues that retain N2 as 
possible sources of DCS symptoms, discounting embolic insult.  Therefore, in our modeling of 
DCS risk, computed PtisN2 is an essential component of decompression dose, whether manifested 
as a simple TR (Conkin et al. 1996, Conkin et al. 1996a, Conkin 1998, Conkin et al. 1998) or as 
a BGI (Abercromby et al. 2014) calculated in the TBDM.  TR is defined as the ratio of computed 
PtisN2 to PB at the start of the altitude exposure.  BGI based on Eq. 16 is the ratio of final bubble 
radius to an initial pre-formed micronuclei radius of 3 m.  The BGI for a decompression 
exposure is calculated over the duration of the exposure with peak BGI as a measure of 
decompression dose. 
 
Initial equilibrium tissue N2 tension PtisN2(0) is taken as ambient pN2, 11.6 psia (1 psi = 
6.8947 × 104 dyne/cm2) at 1 ATA.  The 1% contribution of argon in normal air is treated as if it 
were N2.  A PB protocol often takes place over a long interval of time during which a resting 
subject breathes 100% O2 by mask.  However, these protocols can also be complex; for example 
when the total PB time T is divided into m smaller intervals (0, t1), (t1, t2), . . .,(tm‐1, T=tm), with 
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varying amounts of exercise performed during some of the intervals to accelerate 
denitrogenation. 
 
Eq. 17 describes the change in PtisN2 when there is a change in ambient pN2 from Pa,i-1 to 
a new level Pa,i over the i-th time interval ti.= (ti‐1, ti). 
 
P୲୧ୱNଶሺiሻ ൌ 	 ௔ܲ,௜ିଵ ൅ ൫ ௔ܲ௜ െ ௔ܲ,௜ିଵ൯ሺ1 െ ݁ି௞೔୼௧೔ሻ ൅ ݏ௜Δݐ௜ െ ௦೔௞೔ ሺ1 െ ݁
ି௞೔୼௧೔ሻ	,      Eq. 17 
 
where PtisN2(i) is the new value of PtisN2 and the average rate of change (si) of pN2 in the 
breathing gas mixture is ((Pai – Pa, i-1) /ti.).  The rate constant ki varies with exercise and is 
expressed as a function of normalized O2 consumption ሶܸைమ௜	expressed as ml O2(STPD)×kg-1×min-1: 
 
݇௜ ൌ ௘
 ሶܸ ܱ2݅	
ହଵଽ.ଷ଻,            Eq. 18 
 
where  is assumed equal to 0.03 based on a previous analysis of exercise prebreathe (Conkin et 
al. 2004).  For example, in PBs that contain intervals of rest and exercise the resting O2 
consumption is 3.5 ml O2×kg-1×min-1, then ݇௜ is 0.00213 and when the O2 consumption during a 
brief bout of exercise is 35 ml O2×kg-1×min-1, then ݇௜ is 0.00550.  In PBs that contain no 
exercise the total PB time T consists of only one interval (m = 1) and O2 consumption is 
negligible.  In this case, Eq. 18 is evaluated with ሶܸைమ= 0 and yields k = 1/519.37 = 0.00192.  This 
value corresponds to a 360 min half-time through the relation t1/2 = ln(2)/k.  Changes in pN2 occur 
either through a change in ambient pressure while breathing any constant O2 – N2 mixture or an 
O2 – N2 mixture that changes in time while at a constant pressure.  In most of our applications 
100% O2 is breathed by mask during the PB, depressurization, while at altitude, and during 
repressurization.  In this case ambient pN2 abruptly decreases to zero (Pai = si = 0, for i > 0) in all 
phases of the PB, so Eq. 17 reduces to P୲୧ୱNଶሺiሻ ൌ 	 ௔ܲ଴ െ ௔ܲ଴ሺ1 െ ݁ି௞೔୼௧೔ሻ.  
 
Eq. 17 is used to calculate PtisN2 and then a decompression dose as TR at the start of the 
altitude exposure and BGI at any time during or after the altitude exposure, for example, during 
repressurization and during subsequent GLO as part of a DCS treatment protocol.  Additional 
details about quantifying the time course of denitrogenation during PB protocols with exercise 
are found in (Conkin et al. 2004). 
 
Fig. 26 demonstrates the range of BGI response to 6 treatment simulations in the 
MMSEV.  Decompression sickness occurs 480 min after initial depressurization in the astronaut.  
There is a 5 min delay to begin a 2 min repressurization to 8.2 psia.  The delay allows BGI to 
increase to 28.2.  If the symptom resolved during the repressurization to 8.2 psia, then breathing 
35% O2 in the MMSEV would require 411 min to resolve the BGI to 1 (curve not shown).  But if 
the astronaut repressurizes to 8.2 psia and breathes 95% O2 after a suit purge, then it would 
require 275 min from start of O2 treatment in the MMSEV at 8.2 psia to reach a BGI of 1 (solid 
baseline curve).  
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Fig. 26.  Six simulated treatment cases in the MMSEV.  DCS is reported in all 6 cases after BGI 
reaches 28.0 at 4.3 psia (horizontal line).   
 
The 5 dashed curves in Fig. 26 are alternative options:  
 
a) return to suitport and treat with 95% O2 for 2-hrs if symptom cleared on repress (307 min to 
resolve from BGI of 28.2 to 1 from return to 8.2 psia),  
 
b) return to suitport, treat with 95% O2 for 2-hrs if symptom cleared on repress, then repress to 
14.7 psia and breathe 35% O2 to accelerate bubble reabsorption (217 min to resolve from BGI of 
28.2 to 1 from return to 8.2 psia),  
 
c) return to 14.7 psia and breathe 35% O2 if symptom did not clear on repress (167 min to 
resolve from BGI of 28.2 to 1 from return to 14.7 psia, comparable to ISS case with 176 min to 
resolve bubble in suit at 19.0 psia with 95% O2),  
 
d) return to 14.7 psia and breathe 95% O2 in suit for 2-hrs (unpressurized) if symptom did not 
clear on repress (149 min to resolve from BGI of 28.2 to 1 from return to 14.7 psia), and  
 
e) return to 14.7 psia and breathe 95% O2 in suit pressurized to 8.2 psia (total 22.9 psia) for an 
“emergency” Type II case (103 min to resolve from BGI of 28.2 to 1 from return to 22.9 psia). 
 
 
DCS Survival Model 
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A DCS survival model based on symptom onset times and right censored times that 
relates the probability of DCS at a particular time [P(DCS)t] during the EVA is helpful when 
developing a treatment strategy, for additional perspective about the potential effectiveness of 
treatment.  Our survival model expresses the probability P(T<t) of the DCS onset time T being 
less than a particular time t at altitude for environmental conditions associated with a simulated 
EVA.  The BGI through EVA time often increases and the likelihood of DCS increases since it 
takes time to grow a bubble sufficiently to illicit a symptom.  Therefore, it logically follows that 
lower P(DCS)t is associated with a smaller BGI and a smaller BGI is associated with lower 
symptom intensity.  A low-probability case of DCS is still a case of DCS but fundamentally 
means those few with DCS have smaller BGI through time and lower symptom intensity.  
Conversely, a high-probability case of DCS is still a case of DCS but fundamentally means those 
many with DCS have larger BGI through time and higher symptom intensity.  There is a linkage 
between group incidence and intensity of symptoms; the larger the group incidence (or 
probability), then the greater the mean symptom intensity (Allen et al. 1971, Conkin et al. 1998).  
The above assertion is strengthened if a high-probability case that causes early onset (failure) of 
DCS is associated with a large BGI at the time of DCS and if a low-probability case that causes 
late onset of DCS is associated with small BGI or with a BGI as large as in the high-probability 
case just at a longer elapsed time.  Our empirical data confirms the above assertion by showing 
that greater treatment pressure (during repressurization to site pressure) is needed for a high-
probability case of DCS associated with larger BGI.  Simple BGI, a single spherical bubble 
expanding or contracting in a unit volume of elastic tissue, as the only explanation for DCS 
incidence, type of symptom, onset time, symptom intensity, and symptom resolution is 
unreasonable in mechanistic terms.  So the best to achieve is a pragmatic and utilitarian 
concordance between BGI and all aspects of DCS.      
 
Log-logistic Accelerated Survival Model for DCS with BGI 
 
The general techniques of survival analysis and optimization through maximum 
likelihood are described elsewhere (Cox & Oakes 1984, Lee 1992).  We have used the right-
censored log-logistic survival model in other applications to estimate the P(DCS)t since the 
hazard function [h(t)] is non-monotone, meaning that instantaneous failure rate increases to a 
maximum and then decreases during the altitude exposure.  This is the pattern for the rate of 
DCS observed through time (Conkin 1998, Conkin et al. 1996).  Estimation was made using the 
Survival Module in SYSTAT version 13 software (Steinberg et al. 2009).  The program 
minimizes the difference between the predicted outcome from the model and the observed 
dichotomous DCS outcome by making small, systematic adjustments to the parameters in the 
model.  The optimization process continued until the absolute value of the summed log 
likelihood (LL) number was minimized.     
 
Fig. 27 is the empirical representation of the CDF [Fn(t)] for 119 DCS cases out of 969 
total exposures.  The mean survival time was 1.97 ± 1.07 hrs SD.  The median survival time was 
1.75 hrs and ranged from 0.28 to 5.40 hrs.  The range of time in 969 exposures was 2.0 to 24.0 
hrs with mean of 5.4 ± 4.2 hrs SD.    
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Fig. 27.  Cumulative proportion of DCS increases as exposure time increases in 47 protocols that 
totaled 969 altitude exposures.    
 
 
Eq. 19 is the CDF form of the log-logistic survival model used to describe the failure and 
right censored times in the data used to create Fig. 27.  Eq. 19 is expanded (accelerated) to 
include BGI for the planned exposure duration as the only explanatory variable. 
 
F(t;z) = P(DCS T < t) = 1 / (1+exp(-(ln(t) – 9.34 + 0.0560×BGI) / 0.914)),   Eq. 19 
 
where F(t;z) is the CDF for the accelerated log-logistic survival model, P(DCS T < t) is the 
probability that survival time T for DCS is  t, that DCS will be observed in the interval between 
0 and t (0 < T < t), t is in mins from start of exposure at PB, 9.347 is a fitted β2 coefficient, 0.0560 
is a coefficient for BGI for the planned exposure duration, and 0.914 is the β1 coefficient in the 
log-logistic survival model.   
 
The sample size for this regression was 968 exposures in 47 unique protocols with 119 
total cases of DCS.  For points of reference, we calculate the LL number for the constant-only 
model (null model) and, at the other extreme, the saturated (discontinuous) model, wherein the 
predicted values of P(DCS) exactly match the observed DCS incidence in each of the 47 
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protocols.  Our accelerated (continuous) model had a LL between the extremes of the null and 
discontinuous models.  The null model LL of -556 compared to the continuous model LL of -518 
and to the discontinuous model LL of -296 gauges the goodness-of-fit of the continuous model 
(Eq. 18).  The difference in LL between the 2-parameter null model (-556) and the 3-parameter 
continuous model (-518) was significant at p < 0.01 from the Likelihood Ratio Test (Lee 1998), 
so an additional explanatory variable improved the regression.  
 
 Fig. 28 shows the increase in P(DCS) during an EVA that extends to 6 hrs given the BGI 
at a particular time.  The PB and EVA conditions dictate the change in BGI as defined by the 
TBDM and Eq. 19 estimates the P(DCS) at a particular time for the specific BGI at that time.  
 
 
 
 
Fig. 28.  Survival analysis results with BGI as only explanatory variable for DCS failure time.  
P(DCS) as a function of time and maximum BGI in steps of 5 BGI units.  A BGI of 40 at 60 min 
has a P(DCS) of about 4% but at 360 min the P(DCS) is about 21%.   
 
 
Fig. 29 shows the same model results as in Fig. 30 except the x-axis is BGI. 
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Fig. 29.  P(DCS) as a function of time and maximum BGI in steps of 5 BGI units.  A BGI of 40 
at 1.0 hr has a P(DCS) of about 4% but at 6.0 hrs the P(DCS) is about 21%. 
 
Accelerated DCS Survival model 
 
 Variables other than BGI dictate the P(DCS).  Eq. 20 includes explanatory variables in 
addition to BGI that statistically improved the survival model.  Table VI provides details about 
the regression. 
 
F(t;z) = P(DCS T< t) = 1 / (1+exp(-(ln(t) – 14.32 + 0.0132×BGI +  
4.097×TR + 0.0241×AGE + 1.267×AMB – 0.0642×BMI) / 0.745))   Eq. 20 
 
where t is in mins from start of exposure at PB, 14.32 is a fitted β2 coefficient, 0.0132 is a 
coefficient for BGI for the planned exposure duration, 4.097 is a coefficient for TR at start of 
altitude exposure, 0.0241 is a coefficient for AGE (in years), 1.267 is a coefficient for AMB, 
0.0642 is a coefficient for BMI computed as mass in kg divided by height in m2, and 0.745 is the 
β1 coefficient in the log-logistic survival model.  When AMB is “1”, the subject ambulated 
before and during the altitude exposure and when “0” the subject did not ambulate.   
 
The LL for the null model was again -556 compared to the continuous model (Eq. 20) of 
-476 and compared to the discontinuous model of -296.  The difference in LL between the 2-
parameter null model (-556) and the 7-parameter continuous model (-476) was again significant 
at p < 0.01 from the Likelihood Ratio Test. 
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Table VI. Regression Details about DCS Survival Model. 
 
parameter estimate  
± 95% CL 
standard 
error 
z-score p-value 
B1 0.745 
0.622 to 0.867 
0.0626 11.89 <0.001 
B2 14.321 
11.95 to 16.68 
1.206 8.47 <0.001 
TR -4.097 
-5.13 to -3.05 
0.531 -7.71 <0.001 
BGI -0.0132 
-0.027 to 0.000 
0.00707 -1.87 0.0615 
AGE -0.0241 
-0.042 to -0.005 
0.00961 -2.50 0.0122 
AMB -1.267 
-1.66 to -0.87 
0.2007 -6.31 <0.001 
BMI 0.0642 
0.008 to 0.120 
0.0285 2.24 0.0245 
 
 
Table VII shows a comparison of the computed P(DCS) with Eq. 20 to the observed 
incidence of DCS in 8 large-sample protocols.  The regression results are based on 968 
exposures where 119 subjects reported DCS.  Mean values for the required explanatory variables 
are included in the table.  Overall, the predicted P(DCS) is similar to the observed incidence, 
certainly if the 95% CLs are considered. 
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Table VII. Observed and Predicted DCS in Selected Large-Sample Protocols. 
 
3a.  4-hr resting PB, 30-min ascent to 4.3 psia, ambulation plus EVA exercise during 6-hr exposure. 
3b. 1-hr PB before ascent to 10.2 psia for 12 hrs breathing 26.5% O2, then 40 min PB before 25-min ascent to 4.3 
psia for 6-hr EVA exercise that included ambulation.  
8a.  No PB with 3.2-min ascent to 6.5 psia for 3-hr EVA exercise that included ambulation. 
*PB included prescribed exercise; all others were resting during PB. 
 
Accelerated VGE Survival Model 
 An EVA is successful if there were no symptoms that compromised the goals of the EVA 
or compromised the health of the astronaut.  It is not uncommon for a symptom-free 
decompression to still be associated with detectable VGE (Conkin et al. 1996).  In small 
numbers a healthy lung is able to tolerate the embolic load, but if possible the magnitude and 
frequency of pulmonary embolic insult should be minimized.  To that end, a survival model for 
VGE onset is provided to assess the P(VGE) associated with EVA.   
 
Fig. 30 is the empirical cumulative distribution [Fn(t)] for 345 VGE cases out of 842 total 
exposures.  The mean survival (failure) time was 1.47 ± 1.00 hrs SD.  The range of time in 842 
exposures was 2.0 to 6.0 hrs with mean of 4.0 ± 1.1 hrs SD.    
 
 
Test PB 
(psia) 
time 
(min) 
n gender 
% 
male 
mean 
age 
mean 
TR 
mean 
BGI 
mean 
BMI 
amb DCS 
(%) 
P(DCS)t ± CL 
3a 4.3 360 28 100 31.0 1.604 41.9 24.97 1 21.4 0.23 (0.18-0.29) 
3b 4.3 360 35 100 30.1 1.675 45.2 24.87 1 22.8 0.31 (0.25-0.39) 
8a 6.5 180 40 72.5 32.4 1.777 25.6 24.17 1 17.5 0.20 (0.15-0.27) 
Phase  
I 
4.3 240 49 71.4 29.4 1.869 41.7* 24.15 0 18.3 0.12 (0.09-0.16) 
Phase  
II 
4.3 240 50 76.0 32.2 1.854 40.8* 24.70 0 0 0.11 (0.08-0.15) 
Phase  
IV 
4.3 240 65 76.9 30.4 1.899 42.8* 24.70 0 12.3 0.14 (0.10-0.19) 
Phase  
V-3 
4.3 240 50 78.0 36.9 1.858 41.3* 25.14 0 14.0 0.13 (0.10-0.18) 
Phase  
V-5 
4.3 240 49 77.5 32.1 1.730 36.3* 24.56 0 4.1 0.06 (0.04-0.08) 
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Fig. 30.  Cumulative proportion of VGE increases as exposure time increases in 40 protocols that 
totaled 842 altitude exposures.    
 
As with the DCS survival data we also provide an analysis of the VGE survival data in 
Fig. 30.  Those that develop PB procedures and plan operational EVA events can use Eq. 21 to 
estimate the probability that a particular EVA scenario will result in VGE.  Table VIII provides 
details about the regression.  Eq. 21 is the best-fit CDF form of the log-logistic accelerated 
survival model for interval-censored VGE. 
 
F(t;z) = P(VGE T< t) = 1 / (1+exp(-(ln(t) – 14.11 + 3.667×TR +  
0.0349×AGE + 1.155×AMB + 0.548×GENDER) / 0.954))     Eq. 21 
 
where t is in mins from start of exposure at PB, 14.11 is a fitted β2 coefficient, 3.667 is a 
coefficient for TR at start of altitude exposure, 0.0349 is a coefficient for AGE (in years), 1.156 
is a coefficient for AMB, 0.548 is a coefficient for GENDER, and 0.954 is the β1 coefficient in 
the log-logistic survival model.  When AMB is “1”, the subject ambulated before and during the 
altitude exposure and when “0” the subject did not ambulate, GENDER is “1” for male and “0” 
for female.   
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The sample size was 841 exposures in 40 unique protocols with 334 total cases of VGE.  
The null model LL of -1406 compared to the continuous model LL of -1336 and to the 
discontinuous model LL of -508 are used to gauge the goodness-of-fit of the continuous model 
(Eq. 21).  The difference in LL between the 2-parameter null model (-1406) and the 6-parameter 
continuous model (-1336) was significant at p < 0.01 from the Likelihood Ratio Test, so the 
additional explanatory variables improved the regression.  
 
Table VIII. Regression Details about VGE Survival Model. 
 
parameter Estimate 
± 95% CL 
standard 
error 
z-score p-value 
B1 0.954 
0.86 to 1.04 
0.0454 20.991 <0.001 
B2 14.110 
12.47 to 15.74 
0.834 12.003 <0.001 
TR -3.667 
-4.45 to -2.87 
0.404 -9.080 <0.001 
AMB -1.155 
-1.47 to -0.83 
0.163 -7.089 <0.001 
AGE -0.0349 
-0.051 to -0.018 
0.00829 -4.209 <0.001 
GENDER -0.548 
-0.897 to -0.198 
0.178 -3.073 0.00211 
 
 
Table IX shows a comparison of the computed P(VGE) with Eq. 21 to the observed 
incidence of VGE in 8 large-sample protocols.  The regression results are based on 842 
exposures where 345 subjects had VGE.  Mean values for the required explanatory variables are 
included in the table.  Overall, the predicted P(VGE) is similar to the observed incidence, 
certainly if the 95% CLs are considered. 
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Table IX. Observed and Predicted VGE in Selected Large-Sample Protocols. 
 
3a.  4-hr resting PB, 30-min ascent to 4.3 psia, ambulation plus EVA exercise during 6-hr exposure. 
3b. 1-hr PB before ascent to 10.2 psia for 12 hrs breathing 26.5% O2, then 40 min PB before 25-min ascent to 4.3 
psia for 6-hr EVA exercise that included ambulation.  
8a.  No PB with 3.2-min ascent to 6.5 psia for 3-hr EVA exercise that included ambulation. 
*PB included prescribed exercise; all others were resting during PB. 
 
Test PB 
(psia) 
time 
(min) 
n gender 
% 
male 
mean 
age 
mean 
TR 
mean 
BGI 
mean 
BMI 
amb VGE 
(%) 
P(VGE)t ± CL 
3a 4.3 360 28 100 31.0 1.604 41.9 24.97 1 46.4 0.61 (0.56-0.66) 
3b 4.3 360 35 100 30.1 1.675 45.2 24.87 1 57.1 0.67 (0.62-0.72) 
8a 6.5 180 40 72.5 32.4 1.777 25.6 24.17 1 50.0 0.57 (0.51-0.63) 
Phase  
I 
4.3 240 49 71.4 29.4 1.869 41.7* 24.15 0 49.0 0.41 (0.35-0.46) 
Phase  
II 
4.3 240 50 76.0 32.2 1.854 40.8* 24.70 0 30.0 0.42 (0.37-0.48) 
Phase  
IV 
4.3 240 65 76.9 30.4 1.899 42.8* 24.70 0 40.0 0.45 (0.40-0.51) 
Phase  
V-3 
4.3 240 50 78.0 36.9 1.858 41.3* 25.14 0 50.0 0.47 (0.42-0.53) 
Phase  
V-5 
4.3 240 49 77.5 32.1 1.730 36.3* 24.56 0 29.1 0.31 (0.27-0.36) 
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Table X shows the P(DCS) and P(VGE) from the log-logistic survival models, both with 
95% CLs, as a function of EVA time given a simulation where TR was 1.22 (no PB) at the start 
of an EVA after living in the MMSEV at 8.2 psia with 34% O2 breathing atmosphere.  The 
computed BGI at 1, 2, 4, 6, and 8 hrs from start of ascent to 4.3 psia was 3.3, 8.4, 17.5, 24.0, and 
28.0 using the TBDM  The astronaut is a 35 yo male with BMI of 25 that ambulated as part of a 
surface EVA. 
 
Table X. P(DCS) and P(VGE) for MMSEV 
 
EVA Time 
(min) 
P(DCS) 95% CL P(VGE) 95% CL 
60 0.002 0.001 – 0.005 0.061 0.042 – 0.088 
120 0.006 0.003 – 0.011 0.118 0.084 – 0.164 
240 0.016 0.009 – 0.028 0.216 0.159 – 0.287 
360 0.029 0.017 – 0.052 0.300 0.224 – 0.380 
480 0.045 0.026 – 0.080 0.364 0.280 – 0.456 
 
 
 The P(DCS) is very low, even after an 8-hr EVA.  However, the upper 95% CL for the 
P(VGE) is near 0.50 in this simulation.  A mission planner might decide to divide the EVA task 
into 2 shorter EVAs of 4-hrs to reduce the P(VGE) or recommend that a reasonable interval of 
in-suit PB be performed before the start of a long EVA, just to minimize the risk of circulating 
VGE.  
 
 
Hypobaric DCS Treatment Model 
  
The following analysis shows the final form of the Hypobaric DCS Treatment Model.  
Figs. 19 and 20 earlier in this report showed the regression results based only on observed P for 
the maximum available data: 158 symptoms that included 20 that definitively resolved during 
HBO treatment (Fig. 19) and 138 symptoms that excluded the 20 from the analysis (Fig. 20).  
The 95% CLs for both regressions assumed independence among the symptoms, so the CLs are 
different than they would be if significant dependency among the symptoms is present. 
  
Fig. 31 shows a comparison of the 95% CLs with (solid) and without (dashed) 
dependency among the 158 symptom data, without regard to other explanatory variables.  The 
difference is notable, but not dramatic. 
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Fig. 31.  Comparisons of the P(symptom resolution) based on 158 symptoms that resolved at a 
P between 0 and 37.1 psid.  P(symptom resolution) = 1 / (1 + exp(-(ln(P) – 1.411) / 0.524)), 
plus 95% upper and lower CLs as solid curves that account for dependency among symptoms 
and dashed curves that assumes independence among symptoms.   
 
Table XI shows regression results from SYSTAT version 13 software (Steinberg et al. 
2009) for the treatment model that includes P, elapsed time (min) at PB to onset of symptom 
(Ts), and ambulation state as explanatory variables, based on 154 symptoms where all 
explanatory variables were available and where dependency among symptoms is not considered.  
The 2-parameter null model returned a LL of -359 compared to the 4-parameter accelerated 
(continuous) model (Eq. 22) of -345.  The difference in LL was significant at p < 0.01 from the 
Likelihood Ratio Test.  Maximum symptom intensity was a significant explanatory variable in 
these data along with Ts and ambulation state.  However, it was only available for 87 of the 154 
symptoms and so not considered further.  Maximum symptom intensity was also significant in a 
model from the combined NASA and USAF data (see Table XVII), but was available for only 
1,361 of the 1,707 symptoms.  
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Table XI. Regression Details about Symptom Resolution Model  
(no Dependency) 
 
parameter estimate 
± 95% CL 
standard 
error 
z-score p-value 
B1 0.478 
0.54 to 0.41 
0.0326 14.66 <0.001 
B2 1.510 
1.24 to 2.12 
0.172 8.74 <0.001 
AMB -0.795 
-1.08 to -0.50 
0.148 -5.35 <0.001 
Ts  
(min)  
0.00308 
0.0009 to 0.0052 
0.0011 2.77 0.005 
 
 
Table XII shows results from the same regression but dependency among symptoms is 
considered using STATA version 13 software (StataCorp 2013).  We used information about 
154 symptoms to fit the model.  In particular, 56 men (mean age and BMI ± SD of 33.2 ± 8.2 
and 24.2 ± 2.2) reported 119 symptoms and 18 women (mean age and BMI ± SD of 34.1 ± 8.0 
and 22.0 ± 2.1) reported 35 symptoms.  Note that the estimates for the 4 coefficients are identical 
but the standard errors are slightly larger when dependency is considered.  A larger standard 
error creates wider CLs.  Assessing goodness-of-fit of Eq. 22 was through the Wald statistic in 
place of the Likelihood Ratio Test since there is no assumption of independence among 
symptoms.  The computed 2 was 13.99 and with 2 degrees of freedom the p-value was <0.001, 
so the 2 explanatory variables improved the regression. 
 
Table XII. Regression Details about Symptom Resolution Model 
(Dependency) 
 
parameter estimate 
± 95% CL 
standard 
error* 
z-score p-value 
B1 0.478 
0.41 to 1.79 
0.077 9.48† <0.001† 
B2 1.510 
1.06 to 1.95 
0.227 6.65 <0.001 
AMB -0.795 
-1.28 to -0.304 
0.250 -3.17 0.002 
Ts  
(min)  
0.00308 
0.0010 to 0.0052 
0.00107 2.87 0.004 
 
*adjusted for dependency among 154 symptoms. 
†B1 is constrained to be positive so its sampling distribution is skewed right, giving a standard error that is 
not entirely meaningful.  It is better to use the standard error for ln(B1) to get confidence limits for ln(B1), 
and then exponentiate to get confidence limits for B1.  For similar reasons, a z-score and p-value for H0: B1 
= 0, do not make sense, since by definition B1 > 0.  Values are provided based on ln(B1). 
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The regression equation to estimate the P(symptom resolution) is: 
 
P(symptom resolution) = 1 / (1+exp(-(ln(P) – 1.510 + 0.795×AMB –  
0.00308×Ts) / 0.478)),           Eq. 22 
 
where P is a real or computed input, AMB = 1 if ambulation took place during part of the 
altitude exposure, otherwise AMB = 0; and where Ts is the elapsed time at PB in min to onset of 
a DCS symptom.  We consider Eq. 22 as a model since one source of P input comes from the 
TBDM even though Eq. 22 is simply a statistical regression equation optimized to empirical 
data.  
 
Fig. 32 shows 4 curves from Eq. 22 for an ambulatory exposure where the subject reports 
a symptom at 60, 120, 180, or 240 min into the exposure.  As the time to report a symptom 
increases the P(symptom resolution) at a particular P decreases. 
 
 
Fig. 32.  P(symptom resolution) for the ambulatory condition.  The subject reports a symptom at 
a) 60 min, b) 120 min, c) 180 min, or d) 240 min into the exposure.     
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Fig. 33 shows 4 curves from Eq. 22 for a nonambulatory exposure where the subject 
reports a symptom at 60, 120, 180, or 240 min into the exposure.  As the time to report a 
symptom increases the P(symptom resolution) at a particular P decreases.  Also, the 
P(symptom resolution) is lower for the nonambulatory compared to the ambulatory condition at 
a given symptom onset time at a particular P. 
 
 
Fig. 33.  P(symptom resolution) for the nonambulatory condition.  The subject reports a 
symptom at a) 60 min, b) 120 min, c) 180 min, or d) 240 min into the exposure.     
 
We have no mechanistic explanation why the P(symptom resolution) for a given P and 
Ts is so much lower for the nonambulatory condition compared to the ambulatory condition.  
However, a comparison of data in Table XIII does suggest why the regression performs as it 
does.    
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Table XIII.  Comparison of Ambulatory and Nonambulatory Symptom Data 
 
data ambulatory (n=100 symptoms) nonambulatory (n=54 symptoms) 
source historical testing (1983-1998) PRP testing (1999-2009) plus 
historical AGRO testing 
DCS cases 78 41 
global DCS% 13% (78 / 591 exposures) 11% (41 / 378 exposures) 
mean symptom time 142 ± 68 min 116 ± 41 min 
Type I symptoms 93% (93 / 100 symptoms) 83% (45 / 54 symptoms) 
Type II symptoms 7% (7 / 100 symptoms) 17% (9 / 54 symptoms) 
GLO after symptom 38% (38 / 100 symptoms) 89% (48 / 54 symptoms) 
HBO after symptom 3% (3 / 100 symptoms) 31% (17 / 54 symptoms) 
PRP – Prebreathe Reduction Program where exercise during PB was used to accelerate denitrogenation. 
 
The global DCS incidence is about the same between the ambulatory (13%) and 
nonambulatory (11%) conditions, suggesting that the overall decompression stress is about 
equivalent between the conditions.  However, of the 20 symptoms that were persistent or residual 
at site pressure, thus requiring subsequent HBO treatment, 17 were reported by 7 subjects tested 
in the nonambulatory condition, whereas only 3 were reported by 2 subjects that were 
ambulatory.  Considering that almost 2/3 of these symptoms (100/154) arose from testing of 
ambulatory subjects, it appears that symptoms arising from the nonambulatory condition would 
require greater P for resolution. 
 
Fig. 34 shows the P(symptom resolution) for Ts = 120 min in the ambulatory (upper 
curve) and the nonambulatory (lower curve) condition.  The 95% CLs, not accounting for 
dependency among the symptoms, show a greater range for the nonambulatory condition. 
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Fig. 34.  Simulation with ambulatory (upper curve) and nonambulatory (lower curve) subject 
without accounting for dependency among symptoms, where Ts = 120 min.  The figure 
demonstrates the range of the 95% CLs without accounting for dependency among symptoms. 
 
 
Finally, Fig. 35 shows the P(symptom resolution) for Ts = 120 min in the ambulatory 
(upper curve) and the nonambulatory (lower curve) condition.  The 95% CLs, accounting for 
dependency among the symptoms, show a greater range for the nonambulatory condition when 
compared to the ambulatory condition and larger when compared to Fig. 34. 
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Fig. 35.  Simulation with ambulatory (upper curve) and nonambulatory (lower curve) subject 
accounting for dependency among symptoms, where Ts = 120 min.  The figure demonstrates the 
range of the 95% CLs after accounting for dependency among symptoms.   
 
 
Simulations to Estimate P(symptom resolution) 
 
Two simulations show the application of the treatment model (Eq. 22).  Fig. 36 shows the 
time course of BGI growth and resolution calculated from Eq. 16 for a hypothetical treatment 
situation, in which a 120-min resting PB at 14.7 psia and a 6-min ascent to 4.3 psia on 100% O2 
has reduced and continues to reduce PtisN2 (Eq. 17) through time.  Pain occurs in an ankle at Ts = 
60 min after the beginning of the ambulatory exposure (66 min from the start of ascent) with 
BGI = 15.0.  A 30-min delay before repressurization then causes the BGI to increase to B1 = 
21.8.  Finally, the BGI reduces to B2a = 14.8 during a 15-min repressurization to 14.7 psia and 
continues to decrease to B2b = 11.2 during one hour of GLO breathing at 14.7 psia. 
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Fig. 36.  Simulation of BGI growth at 4.3 psia and dissolution at 14.7 psia given a short PB with 
Ts =  60 min and 66 min from start of ascent. 
 
 
In this example, the values of P needed to reduce the BGI from B1 to B2a, or from B1 to 
B2b may be obtained from Eq. 9 where V1 is the volume of a spherical bubble with radius R1 = 3 
ൈ B1  m at the time just before repressurization interacting with a unit volume of tissue during 
the exposure at low pressure (P1 = 4.3 psia), and V2 is the new volume of a bubble with radius 
R2a = 3 ൈ BGIC m after a change to a higher pressure (P2 = 14.7 psia) at the end of the 
repressurization, or with radius R2b = 3 ൈ B2b m at the end of the subsequent GLO breathing.  
Thus before repressurization, V1 =  
ସ
ଷ ߨܴଵଷ = 1,176,964.8 m3.  Subsequently, V2 =  
ସ
ଷ ߨܴଶ௔ଷ  = 
370,255.0 m 3 at the end of repressurization or V2 =  ସଷ ߨܴଶ௕ଷ  m 3= 159,167.1 m 3 after the 1-hr 
GLO treatment.  Thus using Eq. 9 with P1 = 4.3 psia, the value of P needed to reduce the BGI 
from B1 to B2a (21.8 to 14.8) would be 9.37 psid and to reduce it from B1 all the way to B2b = 11.2 
with repressurization followed by a 1-hr period of GLO would require a higher P to 27.5 psid.  
Substituting these values of P into Eq. 22 with AMB = 1 and Ts = 60 min, we obtained 
P(symptom resolution) = 0.94 (0.86 to 0.97) following the repressurization step to sea level and 
P(symptom resolution) = 0.99 (0.98 to 0.998) at the conclusion of the GLO breathing, at an 
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estimated total treatment time of 75 min.  Ninety-five percent confidence limits shown in 
parentheses reflect the sampling uncertainty of the fitted model. 
 
A consideration about this result is the potential linkage between the P(DCS)t and the 
P(symptom resolution).  An example of computing P(DCS)t builds on the example we developed 
with Fig. 36 to compute the 2 P(symptom resolution)s.  The computed P(DCS)t is additional 
information to potentially supplement the interpretation of P(symptom resolution) (see 
Discussion).  The P(DCS)t is 0.32 (0.17 to 0.52), taken from Eq. 20 where time is 60 min from 
the start of the exposure at 4.3 psia to report the symptom, BGI is 21.8 at the start of 
repressurization, TR is 2.11 at the start of the exposure at 4.3 psia since 126 min of breathing 
100% O2 has reduced the computed PtisN2 (Eq. 17) to 9.10 psia using 0 ml×kg-1×min-1 for O2 
consumption since the PB had no exercise, AGE is 45 years, BMI is 25, and ambulation status is 
1.  The person in this example reports a symptom of DCS even though the P(DCS)t at the time of 
the report is < 0.50, taking the upper 95% CL.  The rather high estimate of 0.32 suggests that the 
symptom onset time might be shorter and the intensity of the symptom might be greater than if 
the estimate were closer to 0.05, especially since there is a 30 min delay to start of 
repressurization.  So the high P(symptom resolution) of 0.94 on return to sea level likely resolves 
the symptom.  But the subject would probably benefit from the additional 60 min of GLO before 
accepting that the symptom is adequately treated.   
 
Overall Risk Model for Future Missions 
 
Dr. Feiveson had the insight to combine the models for P(DCS)t and P(SR) to calculate a 
measure of risk incurred by only having enough capability for applying P up to a specified 
value of P for a future mission.  From Eq. 20, let G(t; x) = P(T < t) given a vector of predictors 
x, consisting of observed values of BGI, TR, AMB, BMI, and AGE.  Also let g(t; x)  = ߲ܩሺݐ; ࢞ሻ/
߲ݐ be the corresponding probability density of time to DCS given x.  Note also that the model for 
P(SR) is conditional on that DCS has occurred at some time Ts.  In terms of Eq. 22 with Ts = t, 
and yi equal to some fixed treatment pressure differential p0, one can re-express P(SR) as F(p0; 
t, x ), where x is the same vector of predictors as used in the model for DCS time of occurrence.  
(Some of the components of x might have zero coefficients in one of the 2 models.)  Considering 
all possible values of t, these 2 models can then be combined to give the probability that a 
subject with observed predictors x develops DCS that cannot be resolved with some fixed 
treatment pressure differential p0. 
  
ܳሺ࢞ሻ ൌ ׬݃ሺݐ; 	࢞ሻሾ1 െ ܨሺ݌0; 	ݐ, ࢞	ሻሿ݀ݐ       Eq. 23 
 
By taking into account likely values of x that might occur during EVA’s, NASA mission 
planners could use Q(x) as a measure of risk incurred by not carrying a capability for Ps greater 
than p0. 
 
Building on the example illustrated with Fig. 36, we used both the model for P(SR) and 
the model for P(DCS)t to evaluate the corresponding risk of not having enough P capability on 
a future mission.  More specifically, we used Eq. 23 to calculate the probability Q of having DCS 
occur and fail to respond to treatment given a maximum P capability (max P) on a future 
mission involving a 45-year old astronaut with BMI = 25 undergoing ambulation during an EVA 
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under conditions where TR = 2.11 at start of exposure and the BGI = 21.8 at start of 
repressurization (as detailed above).  Fig. 37 shows the risk (Q) as a function of max P.  In 
particular, if such a future mission did not have a HBO capability and EVA’s were conducted at 
4.3 psia, then max P would then be equal to 10.4 (14.7 – 4.3) psid.  From Fig. 37, it can be seen 
that the incurred risk of a non-treatable DCS event would then be quantified by Q = 0.162 
(16.2%).  The conclusion is that a capability for repressurization beyond 14.7 psi and the 
judicious use of 100% O2 are considerations in the design of future exploration missions. 
 
 
 
 
Fig. 37.  Application of Eq. 23 given a future hypothetical EVA similar to the example shown 
and described by Fig. 36.  There is a 0.16 probability that an astronaut will incur DCS and not 
have symptom resolution given the details of the exposure and immediate recompression to 14.7 
psia from 4.3 psia, a P of 10.4 psid.  
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Finally, Fig. 38 shows 2 simulations about an EVA from the MMSEV: a) with a 15 min 
in-suit PB at 8.2 psia breathing 85% O2 (dashed curve), and b) no PB at all (solid curve).  In the 
first simulation with PB the computed TR is 1.19.  A symptom of DCS occurs 220 min from start 
of ascent (203 min or 3.4 hrs from start of EVA) with a BGI of 15.1.  A 20 minute delay to start 
of repress allowed BGI to increase to 16.4.  The astronaut returns to 8.2 psia with a BGI of 13.3.  
A 2 hr period of GLO with 85% O2 continues in the suit that reduces the BGI to 7.0. 
 
 
 
 
Fig. 38.  Realistic simulation scenario of an EVA from the MMSEV.  Solid line is the BGI given 
no PB prior to a 17 min depressurization to 4.3 psia from 8.2 psia while dashed line is after a 15 
min PB with 85% O2 prior to a 17 min depressurization.  Repressurization is in 2 min back to the 
MMSEV operating pressure of 8.2 psia.  The BGI continues to slowly resolve in both cases as 
the astronaut breathes 85% O2 in the suit for 2 hrs and then 34% O2 in the habitat until BGI 
returns to 1.  
 
 
As before, the BGI at time of repressurization is converted to V1 and V2 after the 
repressurization back to 8.2 psia and V2 after 2 hrs of GLO.  The P(symptom resolution) for the 
case of an ambulatory astronaut reporting a symptom 203 min into the EVA with a computed 
3.76 psid is 0.49 (0.46 to 0.53) following the repressurization step to 8.2 psia.  The P(symptom 
resolution) is 1.0 for the case of a computed 51.0 psid at the conclusion of the GLO.  In this 
example, the P(DCS)t is 0.015 (0.007 to 0.029), computed from Eq. 20.  It is very unlikely that 
these conditions would result in a symptom.  But if a symptom does occur, then it is reasonable 
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to anticipate a mild symptom.  A brief 20 min delay to repressurization assures the offending gas 
phase does not intensify the symptom.  However, even the rapid 2-min return to 8.2 psia has a 
low P(symptom resolution) so additional time in the suit breathing 85% O2 is warranted.  The O2 
window and other factors that increase PbubN2 maximize the dissolution of the offending gas 
phase such that the symptom is expected to resolve during the course of the GLO treatment.    
 
In the second simulation without PB the computed TR is 1.22.  As in the first simulation 
a symptom also appears 220 min from start of ascent with a BGI of 16.2.  A 20 minute delay to 
start of repress allowed BGI to increase to 17.5.  The astronaut returns to 8.2 psia, with a BGI of 
14.2.  The P(symptom resolution) for the case of an ambulatory astronaut reporting a symptom 
203 min into the EVA with a computed 3.75 psid is essentially the same as before [0.49 (0.36 to 
0.62)] following the repressurization step to 8.2 psia.  Instead of 2 hrs of GLO in the suit at 8.2 
psia the astronaut is pressurized to 14.7 psia and the BGI after a 6-min repressurization is 11.4.  
The computed P for the BGI that decreased from 17.5 to 11.4 is 11.2 psid, with a P(symptom 
resolution) of 0.90 (0.83 to 0.95).  It is likely that the symptom will resolve during or shortly 
after a pressurization to 14.7 psia, without GLO at 14.7 psia if O2 resources are limited.  But in 
this case, additional GLO at 14.7 psia seems warranted.   
 
Time to Resolve Gas Phase 
 
 Previous examples showed the minimum treatment conditions to resolve a symptom.  
However, variability in response to the treatment conditions is expected as reflected in the CLs.  
There is a rationale to continue GLO past the point of symptom resolution, to minimize recurrent 
or late symptoms.  In effect, prolonged GLO is treating an asymptomatic gas phase for the sake 
of completeness, given that 100% O2 is readily available.  But what guidance can the TBDM 
offer about the duration of time to provide GLO? 
 
Fig. 39 demonstrates the benefit of a large initial Boyle’s Law compression combined 
with the accelerated reabsorption of the gas phase with 100% O2 under 2 conditions where the 
astronaut returns to her saturation pressure, either 14.7 psia or 8.2 psia.  The figure shows a 
comparison of BGI resolution time after returning to saturation pressure at 14.7 psia (curves to 
left) or 8.2 psia (curves to right), with (dashed curve) and without (solid curve) 2-hrs of 100% O2 
breathing once at saturation pressure.  Breathing 100% O2 at 8.2 psia shortens the resolution time 
by 109 min compared to the 57 min by breathing 100% O2 at 14.7 psia.  The conclusions are 
specific to this 1 simulation given a spherical bubble with radius of 84 m (a BGI of 28.0) since 
the size reduction due to the initial and important Boyle’s Law compression is a function of 
bubble volume which changes as r3.  It would be incorrect to generalize these results to any other 
situation. 
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Fig. 39.  Comparison of 2 repressurizations.  The time to reduce BGI to 1 is greater for the 8.2 
psia condition (right curves) relative to the 14.7 psia condition (left curves), with (298 vs 192 
min) or without (407 vs 249 min) 2-hrs of 100% O2 treatment.   
 
The 2 curves on the left show the increase in BGI to 28.0 after a 4-hr PB and 30 min 
depress to 4.3 psia.  The astronaut complains of a DCS symptom during the EVA and is 
recompressed in 15 min to 14.7 psia where BGI decreases initially to 18.4 at 225 min from start 
of depress.  If the astronaut breathes air at 14.7 psia, then the time to resolve BGI to 1 is 249 min 
but if he first breathes 2-hrs of 100% O2 as DCS treatment, then the time to resolve BGI to 1 is 
192 min.  Details about the 2 left curves are: a) left solid curve, 14.7 psia air saturation, PB 4 hrs 
with 95% O2, depress to 4.3 psia in 30 min, EVA until BGI = 28.0 with 95% O2, repress to 14.7 
psia in 15 min, and hold while breathing air until BGI = 1, b) left dashed curve, 14.7 psia air 
saturation, PB 4 hrs with 95% O2, depress to 4.3 psia in 30 min, EVA until BGI = 28.0 with 95% 
O2, repress to 14.7 psia in 15 min,  hold at 14.7 psia while breathing 100% O2 for 2-hrs, and hold 
while breathing air until BGI = 1. 
 
The 2 curves on the right show the increase in BGI to 28.0 after a 17 min depress to 4.3 
psia once saturated with N2 at 8.2 psia while breathing 34% O2.  The astronaut complains of a 
DCS symptom much later into the EVA and is recompressed in 5 min to 8.2 psia where BGI 
decreases initially to 22.5 at 485 min from start of depress.  If the astronaut breathes 34% O2 at 
8.2 psia, then the time to resolve BGI to 1 is 407 min but if he first breathes 2-hrs of 100% O2 as 
DCS treatment, then the time to resolve BGI to 1 is 298 min.  Details about the 2 right curves 
are: a) right solid curve, 8.2 psia and 34% O2 saturation, purge to 85% O2, depress to 6.0 psia in 
1 min, hold at 6.0 psia for 15 min, depress to 4.3 psia in 1 min, EVA until the balance of 8 hrs is 
complete with 85% O2 – BGI grew to 28.0, repress to 8.2 psia in 5 min, and hold while breathing 
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34% O2 until BGI = 1, b) right dashed curve, 8.2 psia and 34% O2 saturation, purge to 85% O2, 
depress to 6.0 psia in 1 min, hold at 6.0 psia for 15 min, depress to 4.3 psia in 1 min, EVA until 
the balance of 8 hrs is complete with 85% O2 – BGI grew to 28.0, repress to 8.2 psia in 5 min, 
hold at 8.2 psia while breathing 100% O2 for 2-hrs, and hold while breathing 34% O2 until BGI = 
1. 
 
 Finally, Fig. 40 shows 4 options to resolve a bubble given exposure to treatment 
pressures from 8.2 to 14.0 psia and the use of 100% O2 by mask to accelerate bubble dissolution.  
The figure shows BGI dissolution times after returning to saturation pressure at 8.2 psia where 
DCS is reported after BGI reaches 28.0 at 4.3 psia (horizontal line).  DCS occurs 480 min after 
initial depressurization in the astronaut.  There is a 5 min delay to begin a 2 min repressurization 
to 8.2 psia.  The delay allows BGI to increase to 28.2.  The astronaut repressurizes to 8.2 psia 
and breathes 95% O2 after a suit purge until BGI is 1, the solid baseline curve on right.  It 
required 275 min from start of O2 treatment in the MMSEV at 8.2 psia to reach a BGI of 1.  The 
dashed curves are alternative options where after breathing 95% O2 for 2-hrs in the suit the 
astronaut exits the suit and dons a mask with 100% O2 as the MMSEV cabin pressure is 
increased to 10.0 psia, or 12.0 psia, or 14.0 psia.  The elapsed time from start of in-suit O2 
treatment to a BGI of 1 is 244 min for exposure to 10.0 psia, 225 min for exposure to 12.0 psia, 
and 214 min for exposure to 14.0 psia.     
      
  
 
 
Fig. 40.  Four simulated treatment cases in the MMSEV.   
 
Recovery time at 8.2 psia with 34% O2 and not 100% O2 and pressure is a reasonable 
treatment strategy in the case where a symptom clears on repressurization to 8.2 psia.  In other 
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words, intervening with long periods of 100% O2 and pressures above 8.2 psia are only 
marginally effective at resolving this simulated bubble.  100% O2 breathing by mask presents 
complicated procedures and is potentially wasteful of limited resources since exhaled O2 may 
exceed a 35% upper O2 concentration limit in the MMSEV atmosphere.  Breathing 34% O2 at 
8.2 psia after a 2-hr in-suit period with 95% O2 resolves the BGI to 1.0 after about 320 min 
compared to 214 min for the best-case scenario of in-suit O2 for 2-hrs plus 100% O2 on a mask 
while at 14.0 psia in the MMSEV. 
 
Validation of Hypobaric DCS Treatment Model 
 
Data available from 2013 – 14 testing of the NASA Micronuclei Research Project at 
Duke University were assembled as an independent source to validate the treatment model 
(Pollock et al. 2014).  Table XIV shows details about the DCS symptoms, observed P at 
symptom resolution, P(symptom resolution) from the treatment model based on computed P 
from the TBDM at symptom resolution and once the subject reached site pressure. 
 
Table XIV. Validation Data for Hypobaric DCS Treatment Model. 
 
subject  
ID 
location symptom 
onset 
time 
(min) 
observed P 
at symptom 
resolution 
(psid) 
computed 
P at 
symptom 
resolution 
(psid) 
P(symptom 
resolution) ± 
95% CL at 
resolution  
computed 
P at site 
pressure 
(psid) 
P(symptom 
resolution) ± 
95% CL at site 
pressure 
D130827A* lt knee 60(1) 4.16 3.55 0.68 (0.51-0.81) 9.96 0.95 (0.88-0.98) 
D130827A* lt ankle 60(1) 4.16 3.55 0.68 (0.51-0.81) 9.96 0.95 (0.88-0.98) 
D130904A* lt knee 62(2) 4.30 3.06 0.61 (0.43-0.76) 9.83 0.94 (0.87-0.98) 
D130904B* lt knee 112(3) 5.81 5.31 0.78 (0.65-0.87) 10.37 0.93 (0.86-0.97) 
D131112B* rt ankle 145(4) 3.66 3.46 0.55 (0.41-0.66) 10.20 0.92 (0.84-0.96) 
 
Note:  Subjects ambulated before and during exposure to 4.3 psia. 
*Subject received a prophylactic USN TT V treatment; no symptom was present at site pressure and unknown GLO 
time prior to HBO treatment. 
(1) Time from ascent to start of repressurization was 112 min; 30 min ascent and 82 min at 4.3 psia,  
repressurization from 4.3 psia to site pressure was 7 min. 
(2) Time from ascent to start of repressurization was 114 min; 30 min ascent and 84 min at 4.3 psia,  
repressurization from 4.3 psia to site pressure was 19 min. 
(3) Time from ascent to start of repressurization was 148 min; 30 min ascent and 118 min at 4.3 psia, 
repressurization from 4.3 psia to site pressure was 10 min. 
(4) Time from ascent to start of repressurization was 189 min; 30 min ascent and 159 min at 4.3 psia, 
repressurization from 4.3 psia to site pressure was 5 min. 
 
 
All 5 mild Type I symptoms in 4 subjects resolved with a mean computed P(symptom 
resolution) of  0.66 ± 0.08 SD.  At site pressure the mean P(symptom resolution) increased to 
0.94 ± 0.01 SD prior to prophylactic USN TT V treatment.  An undefined period of GLO 
preceded the treatment.  These favorable outcomes are attributed, in part, to significant 
denitrogenation prior to the exposure and prompt repressurization within 30 min of symptom 
recognition, conditions that would be present in future EVAs. 
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 An astronaut returning to the MMSEV with a P of 3.7 psid and P(symptom resolution) 
of 0.49 from the examples in Fig. 38 may not have prompt relief of the symptom, according to 
the validation data.  Additional GLO at 8.2 psia, a return to a higher cabin pressure, either in the 
suit or outside the suit, or a combination of additional treatment pressure and GLO would be 
necessary to resolve the symptom, according to the treatment model.   
 
Combined NASA and USAF Data on Symptom Resolution 
 
Additional symptom data were obtained from the Air Force Research Laboratory Altitude 
Decompression Sickness Research Database archived at Wright-Patterson AFB.  These data 
were previously evaluated by Muehlberger et al. 2004.  These data resemble the limited NASA 
treatment data since the cumulative proportion of symptoms that resolved for a given P (his 
Fig. 1) resembles our data (see Fig. 5) and is about 12 times the amount of the NASA data.  
Table XV summarizes the combined NASA and USAF data on symptom resolution.  We take 
the opportunity here to evaluate additional explanatory variables to describe the P(symptom 
resolution) in the larger combined data.    
 
Table XV. Combined NASA and USAF Data on Symptom Resolution. 
 
symptom 
category 
symptom resolution 
details 
NASA 
treatment 
pressure 
data 
USAF 
treatment 
pressure 
data 
combined 
treatment 
pressure 
data 
%  
of total 
1,919 
A resolved at altitude 37 65 102 5.3 
B resolved on 
repressurization 
121 1,431 1,552 80.8 
C resolved on 
repressurization but 
without documented 
treatment pressure 
25 83 108 5.6 
D resolved at site pressure 17 58 75 3.9 
E resolved with HBO 20 62 82 4.3 
 total symptoms resolved 220 1,699 1,919 100.0 
 
 
Fig. 41 shows the cumulative proportion of 1,709 symptoms from combined NASA and 
USAF sources that resolved at the given P, including 75 symptoms that resolved at site 
pressures between 14.4 and 14.7 psia and 82 symptoms that required 2.8 ATA (41.1 psia) HBO 
treatment (TT V or VI) for persistent or residual symptoms at site pressure.  The 1,709 symptoms 
are from 372 subjects (299 men and 73 women) with mean age of 30.5 years ± 6.6 SD.  About 
95% of all symptoms resolved on return to site pressure over a range of exposure pressures at 
symptom onset from 2.7 to 9.0 psia.    
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Fig. 41.  Cumulative proportion of 1,709 symptoms from NASA and USAF that resolved at the 
given P, the empirical CDF [Fn(P)]. 
 
Fig. 42 shows the P(symptom resolution) and 95% CLs that account for dependency 
among the symptoms.  The inner solid curves are 95% CLs that assume independence amount 
symptoms while the outer dashed curves account for dependency among the symptoms.  The 
differences are small but notable in this large sample of data.   
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Fig. 42.  P(symptom resolution) based on 1,709 symptoms from USAF and NASA that resolved 
at a P between 0 and 37.9 psid.  Dashed 95% CLs account for dependency among the 
symptoms while the solid 95% CLs do not.  P(symptom resolution) = 1 / (1 + exp(-(ln(P) – 
1.0473) / 0.448)). 
 
 Several explanatory variables common to both the NASA and USAF symptom data 
allowed us to fully evaluate them in the combined data.  Explanatory variables found significant 
to include in various regressions include:  
 
a) P1:  the pressure (psia) at which a symptom appears,  
b) AMB:  the ambulation status for the tested protocol (ambulation = 1 and nonambulation 
= 0) even though the nonambulation state only represented 5% (83/1,709) of the 
symptoms that resolved during repressurization to site pressure or during HBO treatment, 
c) GENDER:  male=1 and female=0,  
d) TYPE DCS:  Type I=1 and Type II=0. A symptom was designated as Type I (pain-only 
or skin manifestations) or Type II (serious).  Type I included joint pain, nondermatomal 
pins and needles tingling, pruritus (skin itching), hot and cold sensations, urticaria, 
edema, muscle pain, and muscle spasm.  Type II includes fatigue, dizziness, blurred 
vision, Cutis Marmorata (CM), light headedness, abnormal reflex, cold sweat, cough, 
headache, dyspnea, hyperesthesia, substernal distress, numbness, nausea, paresthesia 
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associated with dermatomal distribution, and impaired coordination.  The presence of 
CM by itself or in conjunction with other symptoms was designated as Type II since this 
was our historical convention.  This convention no longer applies when CM appears in 
isolation from other symptoms.  This assemblage of signs and symptoms is not all-
inclusive and is how they were categorized for analysis in the combined NASA and 
USAF sources.  
e) AGE:  age of the person in years, and 
f) MAXINTEN:  the maximum intensity of the symptom on a 1-10 scale. 
 
Table XVI shows the regression results for all explanatory variables useful to the 
treatment model. 
 
Table XVI. Regression Details about Symptom Resolution Model in 
Combined NASA and USAF Data (n=1,707) 
 
parameters estimate 
± 95% CL 
standard 
error* 
z-score p-value 
B1 0.425 
0.40 to 0.45 
0.031 -27.46† <0.001† 
B2 2.091 
1.60 to 2.57 
0.247 8.44 <0.001 
AMB -0.461 
-0.75 to -0.16 
0.151 -3.05 0.002 
GENDER -0.201 
-0.35 to -0.05 
0.077 -2.59 0.01 
TYPE DCS -0.772 
-0.98 to -0.56 
0.107 -7.18 <0.001 
AGE 0.0092 
-0.001 to 0.020 
0.0055 1.68 0.092 
 
*adjusted for dependency among 1,707 symptoms. 
†B1 is constrained to be positive so its sampling distribution is skewed right, giving a standard error that is 
not entirely meaningful.  It is better to use the standard error for ln(B1) to get confidence limits for ln(B1), 
and then exponentiate to get confidence limits for B1.  For similar reasons, a z-score and p-value for H0: B1 
= 0, do not make sense, since by definition B1 > 0.  Values are provided based on ln(B1). 
 
The time to symptom onset (Ts) at P1 was not significance enough to include in the USAF 
data or in the combined NASA and USAF data.  However, Ts was significant in just the NASA 
data (see Table XII).  The final treatment model with 4 explanatory variables in a large set of 
data (n=1,707 symptoms) is:  
 
P(symptom resolution) = 1 / (1+exp(-(ln(P) – 2.091 + 0.461×AMB + 0.201×GENDER + 
0.772×TYPE DCS – 0.0092×AGE) / 0.425)),        Eq. 24 
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where P is a real or computed input from a bubble model and the other explanatory variables 
are as described above.  We consider Eq. 24 as a general model, suitable for any aviation or even 
EVA application. 
Fig. 43 shows a best-case and a worst-case simulation result based on Eq. 24 where 
combinations of explanatory variables either increase or decrease the P(symptom resolution) for 
a given P.  A person would require greater P if older, if gender is female with a Type II 
symptom, and if the person is nonambulatory.  The difference in P(symptom resolution) for a 
given P is dramatic, indicating that certain combinations of explanatory variables significantly 
influence the likelihood of symptom resolution. 
 
 
 
Fig. 43.  P(symptom resolution) based on 1,707 symptoms that included 82 HBO treatments for 
symptoms at site pressure.  Upper curve simulates a best-case combination of explanatory 
variables:  ambulatory 30 year old male subject with Type I symptom.  Lower curve simulates a 
worst-case combination of explanatory variables:  nonambulatory 50 year old female subject 
with Type II symptom. 
 
 An additional explanatory variable was available, but not available for all symptoms.  
Including the maximum intensity of the symptom, on a 1 to 10 scale, reduced the sample size 
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from 1,707 to 1,361 symptoms.  For completeness, we provide the regression results with 
maximum intensity as a significant explanatory variable.  We accept that including information 
about symptom intensity has the consequence of reducing the number of symptoms to evaluate.  
Several explanatory variables in Table XVI remained significant, even in the smaller set of data 
that included maximum symptom intensity.  Table XVII shows the regression results after 
including maximum symptom intensity as an explanatory variable.    
 
Table XVII. Regression Details about Symptom Resolution Model in 
Combined NASA and USAF Data (n=1,361) 
 
parameters estimate 
± 95% CL 
standard 
error* 
z-score p-value 
B1 0.395 
0.37 to 0.42 
0.325 -28.5† <0.001† 
B2 1.905 
1.30 to 2.50 
0.306 6.21 <0.001 
AMB -0.569 
-0.90 to -0.23 
0.173 -3.28 0.001 
P1 -0.0628 
-0.115 to -0.009 
0.027 -2.29 0.022 
GENDER -0.158 
-0.31 to -0.0003 
0.080 -1.96 0.049 
TYPE DCS -0.418 
-0.69 to -0.14 
0.142 -2.94 0.003 
AGE 0.0083 
-0.002 to 0.018 
0.005 1.56 0.120 
MAXINTEN 0.055 
0.027 to 0.083 
0.014 3.83 <0.001 
 
*adjusted for dependency among 1,361 symptoms. 
†B1 is constrained to be positive so its sampling distribution is skewed right, giving a standard error that is 
not entirely meaningful.  It is better to use the standard error for ln(B1) to get confidence limits for ln(B1), 
and then exponentiate to get confidence limits for B1.  For similar reasons, a z-score and p-value for H0: B1 
= 0, do not make sense, since by definition B1 > 0.  Values are provided based on ln(B1). 
  
 
P1 was significant enough to include in the combined NASA and USAF data that also 
included maximum symptom intensity as an explanatory variable.  Age was retained in both 
models above because it significantly correlated with both gender and ambulation status 
(Somer’s D correlation) even when p-value was > 0.05.  The treatment model with 6 explanatory 
variables in a smaller set of data (n=1,361 symptoms) is:  
 
P(symptom resolution) = 1 / (1+exp(-(ln(P) – 1.905 + 0.569×AMB + 0.0628×P1 + 
0.158×GENDER + 0.418×TYPE DCS – 0.0083×AGE – MAXINTEN×0.055) / 0.395)),   Eq. 25 
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where P is a real or computed input from a bubble model and the other explanatory variables 
are as described above.  Eq. 25 would be considered if a proper assessment of symptom intensity 
was available. 
Fig. 44 shows a best-case and a worst-case simulation result based on Eq. 25 where 
combination of explanatory variables either increase or decrease the P(symptom resolution) for a 
given P.  As in Fig. 43, a person would require greater P if older, if gender is female with a 
Type II symptom, if the person is nonambulatory, and now if symptom intensity is high.  In 
addition, a slightly greater P is required if the symptom originates at a lower P1. 
 
 
 
Fig. 44.  P(symptom resolution) based on 1,361 symptoms that included 36 HBO treatments for 
symptoms at site pressure.  Upper curve simulates a best-case combination of explanatory 
variables:  ambulatory 30 year old male subject with Type I symptom at 6.0 psia with symptom 
intensity of 2/10.  Lower curve simulates a worst-case combination of explanatory variables:  
nonambulatory 50 year old female subject with Type II symptom at 4.0 psia with a reported 
symptom intensity of 8/10. 
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The addition of P1, the pressure (psia) at symptom onset, as an explanatory variable 
significantly improved this regression.  The P(symptom resolution) increases for a given P as 
P1 increases.  The relationship in the combined NASA and USAF data between P1 and the 
P(symptom resolution) was not present in just the NASA data.  The dominant exposure pressure 
in the NASA hypobaric chamber tests was 4.3 psia, being the operating pressure of the space 
suit, while the USAF tested over a range of exposure pressures for various Air Force 
applications.  There is a small but statistically significant relationship between P1 and the 
P(symptom resolution) for a given P in the combined NASA and USAF data (n=1,361 
symptoms).  Figure 45 is an example using Eq. 25 to evaluate a simulation.  The upper curve is 
for P1 = 6.5 psia and the lower curve is for P1 = 3.5.  A lower P1 is associated with a lower 
P(symptom resolution) for a given P.  In both simulations a 30 year old ambulatory male 
reports a Type I DCS symptom with intensity of 5/10.   
 
 
 
Fig. 45.  P(symptom resolution) for a given P is associated with the pressure at the onset of a 
symptom (P1).   
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Treatment Model Validation - combined NASA and USAF data 
 
Cross-validation is an analytical process to assess how the results of a statistical analysis 
generalize to an independent set of data.  The goal here was to validate the predictability of the 
6-parameter treatment model described earlier (Eq. 24) now optimized to a set of training data by 
assessing how well the model describes an independent set of validation data. 
 
The 1,707 symptom records were first partitioned into complementary subsets, the 
training and validation sets.  If all symptom records were independent, then simply selecting 
every other record would produce 2 complementary subsets of equal samples.  However, many 
subjects had more than one symptom prior to repressurization.  The approach to create 
complementary subsets was to select every other subject that contributed to the 1,707 symptom 
records.  As a result, no subject with multiple symptoms had symptoms in both subsets.  The 
resulting training set had 876 symptom records and the validation set had 831 symptom records.   
 
Visual Validation 
 
With dichotomous data you routinely have successful and unsuccessful outcomes.  A 
model optimized to dichotomous data then computes the probability of the outcome, usually 
given one or more explanatory variables.  An analysis of predicted versus observed outcome 
within the training set is the basis to assess goodness-of-fit.  But in cross-validation, the 
optimized model from the training set is used to predict the outcomes in the validation set.  In 
our case all treatment outcomes were successful in that all subjects had relief of their 
symptom(s), relief across a range of P.  Our approach was to compute probabilities given 4 
explanatory variables in the training set and then graph the P(symptom resolution) and the 
empirical CDF of symptom resolution [the Fn(P)] against the P in the training set.  Then 
compute the P(symptom resolution) for all data in the validation set using the treatment model 
optimized from the training set and graph the P(symptom resolution) and the Fn(P) against the 
P in the validation set.  A comparison of the 2 graphs plus an evaluation of observed Fn(P) 
minus predicted P(symptom resolution) across the range of P are means to validate the 
treatment model optimized to the training set. 
  
Figure 46 shows the computed P(symptom resolution) for the Ps in the training set as 
X-symbols based on the 6-parameter treatment model optimized to the training set.  The 4 
explanatory variables and the Ps for symptom relief for all 876 records create a pattern similar 
to the empirical CDF, seen as O-symbols, over the same range of P (also see Fig. 41).  A point 
below or above the Fn(P) is from combinations of explanatory variables that reduced or 
increased the P(symptom resolution) more so than the P for symptom resolution would suggest.  
The observed values from the Fn(P) from 876 training records were subtracted from the 
predicted values [P(symptom resolution)] computed from the 6-paratemeter treatment model for 
each P and plotted in Fig. 47.  The circles above a horizontal line at 0 on the y-axis are results 
below the empirical Fn(P) on Fig. 46.  The circles above the horizontal 0-line are from results 
above the empirical Fn(P) on Fig. 46.  The mean ± SD for the difference between observed and 
predicted was -0.0048 ± 0.101 for the 6-parameter treatment model optimized to the training set.   
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Fig. 46.  The P(symptom resolution) with X-symbol compared to the empirical CDF [Fn(P)] of 
876 symptoms with O-symbol from the training set that resolved at the given P.   
 
0 4 8 12 16 20 24 28 32 36 40
deltaP (psid)
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
P(
sy
m
pt
om
s 
re
so
lu
tio
n)
98 
 
   
Fig. 47.  Difference between observed empirical CDF [Fn(P)] minus predicted P(symptom 
resolution) over the range of P from the 6-paratement treatment model optimized to 876 
symptoms in the training set.   
 
 
In contrast, Fig. 48 shows the P(symptom resolution) based on the treatment model 
optimized to the training set but then applied to the validation set.  The model from the training 
set was evaluated for the Ps and the 4 explanatory variables in the validation set.  The 4 
explanatory variables and the Ps for symptom relief for all 831 records create a pattern similar 
to the empirical CDF, seen as O-symbols, over the same range of P.  The observed values from 
the Fn(P) from 831 training records was subtracted from the predicted values [P(symptom 
resolution)] computed from the 6-paratemeter treatment model for each P and plotted in Fig. 
49.  The mean ± SD for the difference between observed and predicted was -0.017 ± 0.116 for 
the 6-parameter treatment model optimized to the training set but applied to the validation set. 
 
The close visual concordance of the computed P(symptom resolution) between both sets 
of data with a treatment model only optimized to the training set is a validation of the treatment 
model.  We have high confidence that the treatment model from the combined set of data (n = 
1,707, Eq. 24) is valid to compute the P(symptom resolution) in future scenarios when the 
required explanatory variables are available. 
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Fig. 48.  The P(symptom resolution) with X-symbol compared to the empirical CDF [Fn(P)] of 
831 symptoms with O-symbol from the validation set that resolved at the given P.   
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Fig. 49.  Difference between observed empirical CDF [Fn(P)] minus predicted P(symptom 
resolution) over the range of P from the 6-paratement treatment model applied to 831 
symptoms in the validation set.   
 
 
Discussion 
 
The Hypobaric DCS Treatment Model links a decrease in computed bubble volume from 
increased P, increased O2 partial pressure, and passage of time during treatment to the 
P(symptom resolution).  The decrease in offending volume is realized in 2 stages: a) during 
compression via Boyle’s Law and b) during subsequent dissolution of the gas phase via the O2 
window.  The computed P from the TBDM for a specific EVA scenario is the effective 
treatment pressure at any point in time.   
 
The additional step of computing P with Eq. 9 given V from the TBDM may seem 
redundant.  In either case, the predictive models would be equivalent.  However, those 
responsible for DCS treatment are accustomed to treating symptoms based on the application of 
pressure (P) and the use of 100% O2 through time.  Basing the treatment model on P and not 
on V is consistent with how physicians treat symptoms.  P, after all, was based on the V of a 
single gas bubble in a theoretical 360 min half-time tissue compartment.  Muehlberger et al. 
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2004 shows cumulative fraction of symptom resolution as a function of P.  Without knowing 
the details of those exposures, it is not possible to compute a V through the TBDM.  However, 
a computed P for a particular simulated exposure from the TBDM, or any other bubble model, 
links the simulation result to our empirical P data and other published P data.   
 
Decompression sickness during Exploration Class EVAs is unlikely since a conservative 
PB protocol will be used by the astronauts, yet we cannot say with certainty that DCS will never 
occur during such EVAs.  Therefore, the events of developing and subsequently resolving a DCS 
symptom must be treated probabilistically in mission planning.  With this in mind, our survival 
and treatment models can be used to estimate Q (Eq. 23), the probability of a DCS symptom 
occurring and not resolving under treatment at maximum designed P capability.  If the risk 
(quantified by the value of Q) is unacceptably high, then an alternative treatment option is 
evaluated that combines the max P with a period of 100% O2 breathing to raise the effective 
treatment pressure to a level such that Q is acceptable.   
 
The effort to develop Eq. 23 was motivated by discussions about the link between 
P(DCS)t and P(symptom resolution), both being aspects of the same process.  There is a 
probability of response and a probability of recovery.  The details and magnitude of the response 
necessarily dictate the details and magnitude of the recovery.  Knowing something about the 
P(DCS)t means knowing something about the P(symptom resolution), and visa versa.  We 
suppose that the P(DCS)t is linked to the intensity of a symptom (Allen et al. 1971 (Fig. 6), 
Conkin et al. 1998) that, in turn, is linked to the onset time of a symptom (Fig. 7), which we 
showed here is linked to the P(symptom resolution).  A high-probability case of DCS is still a 
case of DCS but fundamentally means those many with DCS may have higher symptom intensity 
with shorter onset times.  Conversely, a low-probability case of DCS is still a case of DCS but 
fundamentally means those few with DCS may have lower symptom intensity with longer onset 
times.  Eq. 23 (see Overall Risk Model for Future Missions) is the first effort to combine all we 
know about a hypobaric exposure and response to treatment to compute a single P(DCS without 
resolution).  The objective is to plan the EVA and treatment resources to minimize the P(DCS 
without resolution).   
 
We have proposed a method for calculating the effective treatment pressure using a 
model (TBDM) of bubble growth that assumes the behavior of a single bubble in a unit volume 
of tissue is representative of an aggregate of thousands of bubbles in a larger volume of tissue 
since hydrostatic pressure is transmitted equally throughout the body during treatment.  In 
particular, under this assumption, a change in one bubble would be similar to that in all bubbles 
regardless of where in the body a symptom originates.  This assumption is certainly suspect 
considering that different symptoms can originate from different tissues through mechanical 
deformation or ischemia, or both.  Furthermore, the final dissolution of a gas phase by the O2 
window is specific to the local perfusion and metabolic conditions in the tissue, in our case a 
theoretical 360 half-time compartment.  Other models of bubble-tissue systems (Srinivasan & 
Gerth 2013, Nikolaev 2013) can be used to compute effective treatment pressure.  Whether these 
models account for single or multiple bubbles, use 30 or 50 dyne / cm for surface tension, with or 
without a term for deformation pressure, whether they account for the O2 window in a simple or 
complex fashion, or other details about diffusion of gases through a boundary layer, we suspect 
(future work) that the differences in computed P between different models would be small.  The 
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differences in these bubble models seem minor while the fundamental physics of bubble growth 
and resolution seem similar in all model systems, especially in the light of the considerable 
individual variation in propensity for DCS.  For these reasons, we would expect that 
the difference in computed effective treatment pressures between different models for identical 
treatment scenarios would be small, maybe no more than ± 0.5 psid.  A difference in P(SR) given 
small differences in P is acceptable in an operational context.  Future work would be needed to 
verify our suspicion through collaboration with others with bubble models that differ from the 
TBDM.  Technically, any biophysical model about a single spherical bubble expanding or 
contracting in a unit volume of tissue as the only explanation for DCS incidence, type of 
symptom, onset time, symptom intensity, and symptom resolution would be unrealistic in 
mechanistic terms.  Nevertheless, we feel the TBDM as implemented here in combination with 
the log-logistic models for P(SR) and P(DCS)t provides a pragmatic and utilitarian means for 
taking the possibility of DCS into account when planning future space missions. 
 
The Hypobaric DCS Treatment Model applies to astronauts that are protected from DCS 
through an effective PB protocol.  Astronauts will also be educated about the early recognition 
and prompt treatment of symptoms.  Eq. 22, specific to our discussion about astronauts, is: 
P(symptom resolution) = 1 / (1+exp(-(ln(P) – 1.510 + 0.795×AMB – 0.00308×Ts) / 0.478)), 
where P (psid) is known or computed from the TBDM, AMB = 1 if ambulation takes place 
during the EVA, otherwise AMB = 0; and where Ts is the elapsed time in min from start of the 
EVA to recognition of a DCS symptom.  Ambulation on a planetary surface certainly contributes 
to symptoms in the lower body and to the P(symptom resolution) given a particular P and Ts.  
EVAs in space would not have the ambulation component.  For reasons not mechanistically 
apparent, our analysis shows that the nonambulation case would require additional treatment 
resources to resolve a symptom.  Values of P as inputs to the model are calculated from the 
TBDM based on the effective treatment pressure: P = P2 – P1 = P1×V1/V2 – P1, where V1 is the 
computed volume of a spherical bubble in a unit volume of tissue at low pressure P1 and V2 is 
computed volume after a change to a higher pressure P2.  If 100% GLO was breathed in place of 
air or O2-enriched air, then V2 continues to decrease through time at P2 at a faster rate.  This 
calculated value of P then represents the effective treatment pressure at any point in time.  Time 
is not explicit in the treatment model.  However, the time to achieve a particular P is available 
from the TBDM and is the best estimate at this time for the time of P(symptom resolution).   
 
An example here highlights treatment considerations leading to a final treatment strategy.  
A simulation of a Type I symptom at 203 min into an ambulatory EVA at 4.3 psia on Mars 
results in a P(symptom resolution) of 0.49 on immediate return to 8.2 psia in the MMSEV.  The 
95% CLs are 0.36 to 0.62.  The P(symptom resolution) increases to near certainty (0.99) after 2 
hrs of GLO at 8.2 psia or with less certainty on immediate repressurization to 14.7 psia [0.90 
(0.83 – 0.95)].  Treatment options, constrained by limited resources at a remote location, are 
considered to maximize a successful treatment outcome.  In this example, combinations of 
pressure, O2, and time to achieve  0.75 P(symptom resolution) at the lower 95% CL is accepted 
as a working balance between resource allocation and a successful treatment outcome.  A 
Mission Manager must balance the availability of resources to either pressurize the MMSEV 
from 8.2 to 14.7 psia or to proceed with GLO in the suit while at 8.2 psia, or some other 
combination of habitat and suit pressurization and the availability of an O2-enriched breathing 
gas.  The treatment model becomes a decision tool on how to proceed to resolve a symptom 
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while minimizing treatment resources.  Given the low probability of DCS during EVA and the 
prompt treatment of a symptom with guidance from the model it is likely that the symptom and 
gas phase will resolve with minimum resources and minimal impact to astronaut health, safety, 
and productivity.   
 
Our confidence in the treatment model is based on limited validation with data from 
recent testing of the NASA Micronuclei Research Project at Duke University, from published 
data from Muehlberger et al. 2004, and from our cross-validation analysis of combined NASA 
and USAF data.  However, model validation about the benefit of GLO to resolve a symptom was 
not possible since MOs responsible for subject safety initiated HBO treatments for persistent 
symptoms rather than monitor the course of GLO treatment. We have no data about symptom 
resolution for the case where repressurization was stopped for an extended period at less than site 
pressure, and found only one report (Krause & Pilmanis 2000) with limited information on the 
effectiveness of GLO to treat hypobaric DCS.  The contribution to the computed effective 
treatment pressure from Eq. 9 beyond Boyle’s Law compression is through a bubble model that 
quantifies a decrease in bubble volume once the repressurization step is over.  Therefore, the 
untested hypothesis is that the combination of Boyle’s Law from initial (P1) to final (P2) pressure 
and continued bubble dissolution at P2 is indeed the effective treatment pressure over the interval 
dictated by the TBDM.  An answer to this hypothesis plus rigorous model validation awaits new 
data.  Subjects must be willing to be monitored under various treatment scenarios, for example 
with different values P2 over extended periods, with and without GLO.  Those charged with 
subject safety must allow careful monitoring of alternative treatment options, to accumulate 
these results for model validation.  
 
We consider Eq. 22 as the best specific guidance to estimate the P(symptom resolution) 
for astronauts since the 154 symptoms are from PB protocols specifically tested to support EVAs 
at 4.3 psia.  However, Eq. 24 (from 1,707 symptoms) and Eq. 24 (from1,361 symptoms) from 
the combined NASA and USAF data are important additional guidance.  Eq. 22 just requires Ts 
and ambulation status plus an actual P or computed P from the TBDM, with an assumption 
that P1 is 4.3 psia.  Eqs. 24 and 25 require additional information about the astronaut (gender, 
age) and about the symptom (P1, symptom classification, and symptom intensity) in addition to 
the ambulation status plus an actual P or computed P from the TBDM.  The example used 
earlier highlights differences in P(symptom resolution) when Eq. 22 is compared to Eq. 25.  An 
unclassified symptom appears at 203 min into an ambulatory EVA at 4.3 psia on Mars.  There is 
a 20-min delay on the return to 8.2 psia in the MMSEV, and the resulting P(symptom resolution) 
is 0.49 from Eq. 22.  Had Ts been the same at 203 min into the EVA but the symptom was 
specifically classified as Type I DCS pain in a knee with an intensity of 5 on a 1 to 10 scale in a 
female astronaut 40 years of age, then for the same computed P of 3.76 psid from the TBDM 
the P(symptom resolution) is 0.54.  The estimates are similar, especially when overlapping CLs 
are considered.  Now consider a male astronaut 50 years of age with substernal discomfort 
classified as Type II DCS with intensity of 8 on a 1 to 10 scale, and all else equal as above.  The 
P(symptom resolution) in this cases decreases to 0.24, which would be assessed with Eq. 22 as 
0.49.  Clearly, additional treatment intervention, such as treatment pressure greater than 8.2 psia 
or a period of 100% GLO, should be considered based on Eq. 25.  Eqs. 24 and 25 are available to 
supplement Eq. 22, especially when detailed information about the symptom is available.   
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Finally, regardless if a treatment option is more or less effective, the passage of time 
almost always improves the outcome.  Any residual symptom after a treatment will eventually 
resolve since metabolizing tissues reabsorb a gas phase.  Michael Collins on Gemini X and again 
on Apollo 11 retrospectively reported a pain in his left knee consistent with Type I DCS 
(Hawkins & Zieglschmid 1975).  He described the onset of pain shortly upon orbital insertion 
after the capsule depressurized to 5 psia with 100% O2, with pain eventually resolving.  Our data 
also shows that about 17% of symptoms (see Table III and Fig. 17) resolved at the test altitude if 
subjects continued past the point of initial symptom recognition.  In astronauts protected through 
prior denitrogenation, breathing 100% O2 during EVA is treatment for DCS given that the 
symptom is tolerable for the time it takes to reduce the gas phase.  There is a competition for N2 
molecules during EVA, either N2 diffuses into a bubble or it diffuses into the alveolar space.  
This competition is clearly evident when measuring the lag, response, and recovery phase of 
VGE transported through the pulmonary artery (Conkin et al. 1996a).  Treating a symptom by 
ignoring the symptom is not a treatment option that we endorse, but highlights the reality that 
most cases of hypobaric DCS are self-limiting when preceded with some denitrogenation and the 
use of 100% O2 to prevent anoxia during the hypobaric exposure. A future variable pressure 
EVA suit will afford the opportunity to initiate rapid treatment thus enabling the time to plan and 
execute definitive treatment.  
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Appendix I:  ISS Aeromedical Flight Rule B13-259 
 
B13-259 Decompression sickness response and treatment [rC] [E] 
[J]  ®[062603-6027 ]  ®[ED          ]  
 
A. DEORBIT REQUIREMENTS:  ®[101499-7038 ]   ®[082301-4745]   ®[092607-8602B] 
1. FOR ALL LEVELS OF DCS WHICH RESOLVE WITH TREATMENT, 
THERE IS NO REQUIREMENT FOR EMERGENCY DEORBIT. 
If symptoms resolve with treatment, there is a low risk of recurring symptoms and injury to the 
crewmember.  Therefore, the risk of an emergency return is not warranted.  However, based on specific 
symptoms and response to treatment, Surgeon may request the affected crewmember be returned to 
Earth before the normal end of mission. 
2. FOR ALL CUFF CLASS 1 SYMPTOMS, OR CUFF CLASS 2 AND 3 
SYMPTOMS WHICH RESOLVE WITH TREATMENT, THERE IS NO 
REQUIREMENT FOR ANY EARLY MISSION TERMINATION. 
3. EARLY DEORBIT WILL GENERALLY NOT BE CONSIDERED FOR 
UNRESOLVED NON-CUFF CLASS 4 SYMPTOMS UNLESS MEDICAL 
JUDGMENT DEEMS THE SYMPTOMS ARE PROGRESSING AND/OR 
ENDANGER CREW HEALTH AND SAFETY. 
98.6 percent or more of non‐Cuff Class 4 symptoms resolve with ground level O2, so we would 
expect them to resolve with our on‐orbit treatments.  Additionally, we have data and experience 
that clearly suggest the suit creates residual symptoms, pain, and paresthesia that are consistent 
with non‐Cuff Class 4 DCS.  Also, data indicates there is no long term injury associated with 
unresolved non‐Cuff Class 4 symptoms.  ®[082301-4745  ]   ®[092607-8602B]  
This Rule Continued on Next Page 
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B13-259 Decompression sickness response and treatment 
[rC] [E] [J]  (Continued) 
B. FOR UNRESOLVED CUFF CLASS 4 SYMPTOMS, ALL ATTEMPTS WILL BE 
MADE TO TREAT USING THE ON-ORBIT PROTOCOLS. REPEAT TREATMENTS 
WILL BE PERFORMED UNTIL THERE IS NO FURTHER MEDICAL 
IMPROVEMENT. ®[101499-7038 ]   ®[092607-8602B] 
Return of a crewmember with severe Type II DCS is most likely not survivable on the Soyuz because 
adequate medical support cannot be provided. 
®[101499-7038 ]  
C. THE CAPABILITY OF THE AFFECTED CREWMEMBER TO RETURN TO DUTY 
AND TO EVA AFTER TREATMENT WILL BE DETERMINED BY THE SURGEON 
CONSISTENT WITH NASA JSC DECOMPRESSION SICKNESS PROCEDURES 
AND GUIDELINES, JPG 1800.2B. 
D. THE SUIT WILL REMAIN IN THE PRESS MODE OR AT BTA TREATMENT 
PRESSURE AS SUPPORTED BY SUIT CONSUMABLES.  THE BTA CAN BE 
INSTALLED TO PROVIDE THE MAXIMUM PRESSURE IN THE SUIT FOR 
TREATMENT.  ®[082301-4745  ] 
The BTA can now be installed without depressurizing the suit.  The use of the BTA will pressurize the 
affected crewmember to 6 or 8 psi above ambient.  Using the BTA to press the suit to 8 psi over ambient 
renders the suit unusable for subsequent EVA’s due to a need for recertification of the suit seals.   
®[101499-7038 ]   ®[082301-4745  ]   ®[092607-8602B]  
This Rule Continued on Next Page 
113 
 
B13-259 Decompression sickness response and treatment 
[rC] [E] [J]  (Continued) 
E. THE STATION PRESSURE WILL REMAIN AT 14.7 PSIA FOR DCS 
TREATMENT.  FOR CUFF CLASS 2, 3, AND 4 SYMPTOMS, THE 
AFFECTED CREWMEMBER WILL NOT BE EXPOSED TO A REDUCED 
STATION PRESSURE FOR AT LEAST 72 HRS AFTER DCS TREATMENT 
UNLESS REQUIRED FOR EMERGENCY RETURN, CONSUMABLES 
MANAGEMENT, OR OXYGEN CONSTRAINTS.  ®[101499-7038 ]   ®[092607-8602B] 
In all cases, the most effective immediate treatment is repressurization.  The total pressure reached at 
station pressure with the suit in PRESS mode suffices for Cuff Class 2 and 3 symptoms. 
Due to the severity of Cuff Class 4 symptoms, additional total pressure is desirable. ISS total pressure 
can only be increased as high as 15.15 psi.  The additional treatment resulting from the 0.45 psi 
increase does not warrant the additional operational complexity required for the pressure increase.  
Therefore, the ISS treatment does not include a cabin pressure increase above 14.7 psi. The application 
of the BTA on the EMU will provide increased total pressure. 
To prevent recurring symptoms, the affected crewmember will not be exposed to station pressure 
reductions for at least 72 hrs.  Surgeon may require a longer period based on specific symptoms and 
response to treatment. 
DOCUMENTATION:  NSTS 16007 LCC Rev G (ECL‐05), DCS Risk Definition and Contingency Plan Review, 
April 1998; NASA JSC Decompression Sickness Procedures and Guidelines, JPG 1800.3; OMI V1217 Test 
Data. 
Arthur, D.C. and Margulies, R.A.  The Pathophysiology, Presentation, and Triage of Altitude‐Related 
Decompression Sickness Associated with Hyperbaric Chamber Operation.  Aviat. Space Environ. Med. 
48:489‐494, May 1982.  ®[082301-4745  ]  
Wade Frost presented to the Systems Safety Review Panel, “Review of the Revised On‐orbit Bends 
Treatment Procedure,” May 23, 2001. 
Conkin, J.  EVA‐IPT response to ACTION about barotrauma risk with rapid decompression of EMU with 
BTA attached.  February 2, 2001. 
Reference Rule {B17‐3}, OXYGEN PARTIAL PRESSURE MANAGEMENT.   ®[101499-7038 ]   ®[082301-4745  ]   
®[062603-6027 ]   ®[092607-8602B]  
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Appendix II:  ISS Decompression Sickness Treatment Flow 
 
Note:  The ISS DCS treatment flow is necessarily specific to the hardware and resources on the 
ISS.  However, elements of the ISS DCS treatment flow are common to any treatment scenario 
so provides a template for future applications.  Future Exploration Class missions will also have 
prepared treatment flows, aided in design by the DCS Treatment Model.  The treatment model 
could also be integrated into real-time treatment schemes to add flexibility in treatment paths.  
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Appendix III:  Decompression Sickness Treatment Database 
Headings 
  
Note: This database is a quantitative summary of more detailed information contained in 119 
case descriptions of DCS, available as Appendix IV.  
 
Definition of Column Headings 
1. Id:  Subject identification number.  Those with a dash “-“ extension show the 
number of times a JSC subject participated in a DCS test.  Those with letters designate 
Duke (D), Hermann Hospital (H), or the Defense Research and Development Canada – 
Toronto (C) as the location of the DCS test.  These ID numbers reflect the year of test 
(first two digits), the month of test (next two digits), and day of test (last two digits).  
Final letter designates the exercise cot used by the subject, as many as four cots (A, B, 
C, and D). 
2. Depend: Number to indicate “dependence” in these data related to subject ID that 
identifies multiple symptoms per subject.  The same number repeated identifies the 
same subject with multiple symptoms. 
3. Runnumb: A run number discriminator of a different test protocol when DEPEND is 
otherwise equivalent.  For example, a DEPEND number of 21 appears six times.  DCS 
symptoms were reported six times in subject 21 during three different protocols: two 
symptoms in the first protocol (RUNNUMB = 1), two in a second protocol 
(RUNNUMB = 2), and two in a third protocol (RUNNUMB = 3).  No subject had 
symptoms reported in four or more protocols.  DEPEND and RUNNUMB are details 
needed to statistically evaluate dependency in the symptom data, else one must assume 
independence in the symptom data during statistical analysis. 
4. Ht:  Height in cm 
5. Ht1:  Height in cm per symptom 
6. Wt:  Weight in kg 
7. Wt1:  Weight in kg per symptom 
8. BMI:  Body Mass Index, computed from kg / meter height2 
9. BMI1: Body Mass Index, computed from kg / meter height2 per symptom       
10. Age:  Age in years 
11. Age1: Age in years per symptom 
12. Gender: 1=male, 0=female 
13. Gender1: Gender per symptom.  1=male, 0=female 
14. Bodyloc: Gross anatomical region where a symptom was located. 1=upper body, 
0=lower body. 
15. Ambul: Ambulation before and during altitude exposure. 1=yes, 0=no 
16. Ambul1: Ambulation before and during altitude exposure per symptom. 1=yes, 
0=no 
17. Test:  Test identification code indicating a unique test procedure. 
18. ALTTIME: Time in hrs for the duration of the planned exposure. 
19. P1:  Specific altitude test pressure with psia unit, either 4.3, 6.5, 6.0, or 10.1. 
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20. TR360: Ratio of computed tissue N2 pressure in 360 half-time compartment to P1, 
or PB for any general ambient pressure, for resting prebreathe condition only.  This 
calculation assumes 0 ml/kg/min O2 consumption, resulting in a 360 min half-time rate 
constant in denitrogenation equation that contains a  term.   
21. TRCOMBINED: Ratio of computed tissue N2 pressure in half-time compartment to P1 
for resting prebreathe condition (3.5 ml/kg/min) when combined with half-time 
compartments that varied due to exercise prebreathe in denitrogenation equation that 
contains a  term. 
22. Infile: Prebreathe data input file to Tissue Bubble Dynamics Model. 
23. BGI360: Ratio of final computed bubble growth index to initial 3 micron 
micronuclei radius for the planned elapsed time at P1 – for scheduled end of test so 
BGI360 also applies to those without DCS.  Mass balance and metabolic gas were 
included along with computed tissue N2 pressure in 360 min half-time compartment for 
resting prebreathe condition and when half-time compartment was variable due to 
exercise prebreathe.   
24. Location: Reported anatomical location of a DCS symptom or in some cases a brief 
description of a symptom or DCS sign. 
25.  Symcount: Numerical sequence of reported symptoms. 
26. Time1…10: Best assessment of elapsed time in minutes from the start of the test at 
altitude to the recollection or report of a DCS symptom. 
27. BGI1…10: BGI360 associated with time of subsequent reported symptom.  The 
appropriate BGI360 is after elapsed time from the start of test to report of symptom 
plus the time of ascent. 
28. Scale1…10: A 0 to 10 symptom intensity scale provided by the test subject.  When a 
range of intensity was reported, the mean intensity was used.  When intensity was 
reported as < 1, then 0.9 was used.  No entry associated with an elapsed time means 
that the subject did not report  symptom intensity. 
29. Maxinten: Maximum reported symptom intensity. When a range of intensity was 
reported, the mean intensity was used.  When intensity was reported as < 1, then 0.9 
was used.   
30. Extp2: Extended time at P1.  1=yes, 0=no.  Certain exposures, by design or 
accident, continued for an extended time after a symptom was reported.  Information 
about the evolution of a symptom is only possible if Extp2 = 1. 
31. Rlfp2: Symptom was completely resolved at the test altitude P1 before 
repressurization began.  1=yes, 0=no. 
32. Rpstime: Elapsed time in minutes from start of test to start of repressurization from 
P1. 
33. RpstimeBGI: BGI360 at the time of repressurization – reflects actual time for the 
subject with a symptom.  RpstimeBGI may not equal bgi360 in all cases. 
34. Symdeltm:Difference in time (minutes) at P1 between Rpstime – time1, being the time 
exposed to the symptom prior to repressurization. 
35. Rlfp3: Symptom was completely resolved during the repressurization interval 
(about 5 to 15 minutes).  1=yes, 0=no. 
36. Rlfpres3: Pressure in psia unit during repressurization from P1 where symptom 
resolved or the pressure of the test altitude if symptom resolved at P1 before start of 
repressurization.  Test altitude was either 4.3, 6.5, 6.0, or 10.1 psia in one case. 
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37. Rlfpres3BGI: BGI360 at time where symptom resolved during repressurization. 
38. Rlfp4: Symptom was completely resolved at site pressure. 1 = yes, 0 = other. 
39. Rlfpres4BGI: BGI360 at time where symptom resolved at site pressure. 
40. Rlfpres5BGI: BGI360 at time where symptom resolved during repressurization plus 
BGI360 at time where symptom resolved at site pressure (Rlfpres3BGI and 
Rlfpres4BGI).  
41. P2:  Either Rlfpres3 or site pressure when symptom resolved at site pressure. 
42. Deltap: Difference in pressure (mmHg unit, 1 psi = 57.1 mmHg) between Rlfpres3 
- P1, and site pressure – P1 when Posttest = 1. 
43. Volindex: Computed deltaP from Boyle’s Law: (P1 * 4/3(RPSTIMEBGI*3)3) / 
(4/3(RLFPRES5BGI*3)3) – P1, used to confirm that Boyle’s Law is the dominant 
factor to decrease BGI during the recompression step.  Also can compute the “effective 
Boyle’s Law” change by following BGI reabsorption through time, either during GLO 
period or while breathing air.  Computed volindex is close to observed deltap. 	 ൌ
3.14159 
44. Glo:  Ground Level Oxygen (1 to 2 hrs) was continued as a treatment for 
symptoms that resolved at P1, during the repressurization from P1, or at site pressure, 
and if symptoms were still present at site pressure.  1=yes, 0=no. 
45. Posttest: A symptom that resolved before subject was released but later reoccurred 
is designated with a 1 (9 subjects with 13 symptoms), a symptom that persisted after 
return to site pressure is designated as a 2 (9 subjects with 20 symptoms), and a 0 
indicates no posttest symptom information. 
46. Hbo:  Hyperbaric Oxygen Treatment, either USN Treatment Table V or VI, that 
was required to resolve a persistent symptom at site pressure, a recurrent symptom, or 
even prophylactically when there was no symptom to treat.  1=yes, 0=no. 
47. Rlfhbo: Symptom was relieved during HBO treatment. 1=yes, 0=no.  An 
indication of 0 means that HBO was provided but there was no symptom to resolve or 
the symptom did not resolve and was diagnosed as no DCS. 
48. Dcstype: Symptom was designated as (1) for Type I pain-only or skin 
manifestations or (0) for Type II serious.  The presence of Cutis Marmorata (CM) by 
itself or in conjunction with other symptoms was designated as Type II since this was 
our historical convention.  This convention no longer applies when CM appears in 
isolation from other symptoms.  Type I includes joint pain, non-dermatomal pins and 
needles tingling, pruritus (skin itching), hot and cold sensations, urticaria, edema, 
muscle pain, and muscle spasm, while Type II includes fatigue, dizziness, blurred 
vision, CM, light headedness, abnormal reflex, cold sweat, cough, headache, dyspnea, 
hyperesthesia, substernal distress, numbness, nausea, paresthesia associated with 
dermatomal distribution, and impaired coordination.  This list is not all-inclusive and is 
how symptoms were described in the combined NASA and USAF sources. 
49. Loc:  Same information as in column labeled “Location”. 
50. Pain:  Symptom attribute where “pain” described symptom. 
51. Ache: Symptom described as an ache.  
52. Sharp: Symptom described as a sharp or stabbing sensation. 
53. Slight: Symptom described as a slight sensation. 
54. Mild: Symptom described as a mild sensation. 
55. Dull:  Symptom described as a dull sensation. 
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56. Deep: Symptom described as deep in location. 
57. Superfsl: Symptom described as superficial in location. 
58. Discomf: Symptom described as a discomfort, a twinge, cramp, soreness, or even 
twitching. 
59. Awareness: Symptom described as an awareness sensation. 
60. Stiff:  Symptom associated with stiffness, an inability to completely extend a 
limb. 
61. Full:  Symptom described as a fullness sensation. 
62. Weakness: Affected location felt weak or fatigued, like weakness in a limb. 
63. Numb: Numbness or cool sensation, associated with poor circulation. 
64. Other: Symptom other than those attributed to musculoskeletal pain-only,      
often classified as Type II DCS symptoms. 
65. Const: Symptom that was constant in nature. 
66. Throb: Symptom associated with a throbbing sensation. 
67. Interm: Symptom that was intermittent or transient in nature. 
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Appendix IV:  Case Descriptions of  
Hypobaric Decompression Sickness 
 
Note:  The following case descriptions are the basis for the NASA Hypobaric Decompression 
Sickness Treatment Database.  Quantitative information extracted from these descriptions 
allowed for the calculation of Bubble Growth Index (BGI) at various times along the symptom 
history, including BGI at symptom resolution during repressurization.  Readers that need these 
details are directed to our repository for these data (NASA Life Science Data Archive, 
http://lsda.jsc.nasa.gov).           
 
Bends 1a: DCS Assigned at JSC 
 
1. Summary: ID# 21-01, 34-year-old male, maximum Grade 3, first VGE at 46 minutes, first 
report at 44 minutes, study done on n = 11, independent sample statistical design. 
 
Procedure 1. A technical problem with the airlock lid delayed decompression such that total 
PB time was extended from 3.5 to 4.0 hrs for this subject, with all else the same as described 
under Procedure 1 in Appendix V. 
 
Narrative: At 44 minutes, subject reported pain on top of right foot. Did not report initial 
pain score on the 1–10 scale since this scale was not yet implemented. At 118 minutes, he 
reported pain in right knee in addition to that in right foot. First VGE detected at 46 minutes, 
Grade 0 from left arm, Grade 0 from left leg, Grade 2 from right arm, and Grade 2 from right leg. 
Next VGE detected at 62 minutes, Grade 1 in left leg, Grade 1 in right arm and Grade 3 in right 
leg. Last VGE record at 112 minutes with Grade 0 from left arm, Grade 2 from left leg, Grade 2 
from right arm, and Grade 3 from right leg. The MO decided to remove subject from the test, 
and repressurization began 131 minutes into the test. Symptoms in right foot and right knee 
resolved during descent at 5.9 psia. 
 
Diagnosis: Grade 3 Type I DCS 
Treatment: None, just observation at the JSC Clinic with follow-up consultation. 
 
2. Summary: ID# 25-01, 32-year-old male, maximum Grade 4, first VGE at 27 minutes, first 
report at 49 minutes, study done on n = 11, independent sample statistical design. 
 
Procedure 1 
 
Narrative: At 49 minutes, subject reported pain in left foot. Did not report initial pain score on 
the 1–10 scale since this scale was not yet implemented. At 76 and 116 minutes, subject reported 
pain in left heel. First VGE detected at 27 minutes, Grade 0 from left arm, Grade 2 from left leg, 
Grade 3 from right arm, and Grade 2 from right leg. Last VGE record at 109 minutes with Grade 
2 from left arm, Grade 4 from left leg, Grade 3 from right arm, and Grade 4 from right leg. The 
MO decided to remove subject from the test. Subject last reported at 124 minutes that he had 
continuous pain in left foot and left heel. Symptoms in left foot and left heel resolved during 
descent at 8.0 psia. 
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Diagnosis: Grade 3 Type I DCS 
Treatment: None, just observation at the JSC Clinic with follow-up consultation. 
 
3. Summary: ID# 26-01, 27-year-old male, maximum Grade 1, first VGE at 59 minutes, first 
report at 75 minutes, study done on n = 11, independent sample statistical design. 
 
Procedure 1 
 
Narrative: At 75 minutes, subject reported pain in left knee. Did not report initial pain score 
on the 1–10 scale since this scale was not yet implemented. First VGE detected at 59 minutes, 
Grade 0 from left arm, Grade 1 from left leg, Grade 0 from right arm, and Grade 0 from right leg. 
Last VGE record at 67 minutes with Grade 0 from left arm, Grade 1 from left leg, Grade 0 from 
right arm, and Grade 0 from right leg. The MO decided to end the test for this subject. Shortly 
after this decision was made, the second chamber mate (27-01) reported discomfort in right 
knee. Recompression of subject began 86 minutes from the start of the test. Symptoms in 
left knee resolved during descent at 6.0 psia. 
 
Diagnosis: Grade 2 Type I DCS 
Treatment: None, just observation at the JSC Clinic with follow-up consultation. 
 
4. Summary: ID# 27-01, 39-year-old male, maximum Grade 2, first VGE at 47 minutes, first 
report at 76 minutes a symptom he noticed moments earlier, study done on n = 11, independent 
sample statistical design. 
 
Procedure 1 
 
Narrative: At 76 minutes, subject reported discomfort in right knee. Did not report initial pain 
score on the 1–10 scale since this scale was not yet implemented. Subject noticed discomfort at 
previous Doppler monitoring station. The exercise protocol was disrupted during the removal of 
a chamber mate (26-01) at 86 minutes due to pain in left knee. At 102 minutes, the logbook still 
indicated pain in right leg, specifically the right knee and right ankle. First VGE detected at 47 
minutes, Grade 0 from left arm, Grade 0 from left leg, Grade 0 from right arm, and Grade 1 
from right leg. Last VGE record at 102 minutes with Grade 0 from left arm, Grade 1 from 
left leg, Grade 0 from right arm, and Grade 3 from right leg. The MO decided to end the 
test. Repressurization was started about 102 minutes into the test. Symptoms resolved 
in right leg during descent at 7.2 psia. 
 
Diagnosis: Grade 3 Type I DCS 
Treatment: None, just observation at the JSC Clinic with follow-up consultation. 
 
Bends 1b: DCS Assigned at JSC 
 
5. Summary: ID# 12-01, 29-year-old male, maximum Grade 4, first VGE at 62 minutes, first 
report at 77 minutes, study done on n = 13, independent sample statistical design. 
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Procedure 2 
 
Narrative: At 77 minutes, subject reported pain in right knee. Did not report initial pain score 
on the 1–10 scale since this scale was not yet implemented. First VGE detected at 62 minutes, 
Grade 0 from left arm, Grade 0 from left leg, Grade 0 from right arm, and Grade 3 from right leg. 
Last VGE record at 79 minutes with Grade 0 from left arm, Grade 0 from left leg, Grade 4 from 
right arm, and Grade 4 from right leg. The exercise activities were interrupted while his chamber 
mate was removed for pain symptoms in the knees (11-01). The MO decided to abort this test 
earlier than the planned after 3 hrs. Initiated repressurization at 81 minutes. Symptoms in 
right knee resolved during descent at 5.0 psia. 
 
Diagnosis: Grade 3 Type I DCS 
Treatment: None, just observation at the JSC Clinic with follow-up consultation. 
 
6. Summary: ID# 11-01, 45-year-old male, maximum Grade 4, first VGE at 6 minutes, first 
report at 28 minutes a symptom he noticed earlier, study done on n = 13, independent sample 
statistical design. 
 
Procedure 2 
 
Narrative: At 28 minutes, subject reported pain in right knee and left knee. Did not report 
initial pain score on the 1–10 scale since this scale was not yet implemented. First VGE detected 
at 6 minutes, Grade 3 from left arm, Grade 4 from left leg, Grade 4 from right arm, and Grade 4 
from right leg. Last VGE record at 23 minutes with Grade 3 from left arm, Grade 4 from left leg, 
Grade 4 from right arm, and Grade 4 from right leg. The MO decided to remove subject from the 
test; after 42 minutes, repressurization began. Symptoms resolved during descent in right knee at 
5.27 psia and in left knee at 8.69 psia. During debrief, subject mentioned that he felt sensations 
in the knees long before he reported the symptoms, and that he felt a sharp pain while getting 
into the airlock for recompression. Pain at that time was a constant deep ache. 
 
Diagnosis: Grade 3 Type I DCS 
Treatment: None, just observation at the JSC Clinic with follow-up consultation. 
 
7. Summary: ID# 2-01, 36-year-old male, maximum Grade 3, first VGE at 57 minutes, first 
report at 64 minutes a symptom he noticed moments earlier, study done on n = 13, independent 
sample statistical design. 
 
Procedure 2 
 
Narrative: At 64 minutes, subject reported pain in left knee. Did not report initial pain score 
on the 1–10 scale since this scale was not yet implemented. First VGE detected at 57 minutes, 
Grade 0 from left arm, Grade 3 from left leg, Grade 0 from right arm, and Grade 2 from right leg. 
This was also the last VGE monitoring period. Since the DT had also reported pain and fullness 
in the left knee at 44 minutes, the MO terminated the 3-hr test early. Initiated repressurization at 
66 minutes. Both subject’s and DT’s symptoms in left knee resolved during descent at 12.0 psia. 
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Diagnosis: Grade 2 Type I DCS 
Treatment: None, just observation at the JSC Clinic with follow-up consultation. 
 
Bends Prevention Test Summary 7/22/82 (from PI) 
 
Decompression to 10.2 psi was completed 7/21/82 at 06:15. 27% O2 was reached in the ETA and 12 hr period at 
10.2 psi was begun. The lock observer began his prebreathe at 03:30 and remained on O2 until 6:45, a period of 3 hrs 
and 15 minutes. At 07:26 the 12 hr period was completed and O2 breathing was begun. At 8:06 the 40 minutes O2 
breathing was completed. At 08:12 decompression to 4.3 psi was begun. Decompression to 4.3 psi was completed at 
08:19. The first exercise cycle began at 08:20 and was completed at 08:34. The DT and both subjects showed no 
bubbles and no symptoms. Between 08:34 and 08:37 Grade 3 bubbles were detected after movement of the DTs left 
leg and Grade 1 bubbles were detected after movement of the right leg and right arm. The DT had no symptoms. 
Between 08:39 and 08:47 both subjects were monitored. No bubbles were detected and no symptoms were reported. 
At 08:47 to 08:52 the DT was monitored and Grade 3 bubbles were detected after movement of the left leg and 
Grade 2 bubbles after movement of the right leg. Between 08:54 and 09:03 subjects 1 or 2 were monitored. No 
bubbles were detected real time and no symptoms were reported. Posttest tape review indicates a possible Grade 1 
bubble after movement of subject 2 left leg. Between 09:03 and 09:09 the DT was monitored. Grade 2 bubbles were 
detected without limb movement. Grade 3 bubbles were detected after movement of the left arm and right leg. Grade 
4 bubbles were detected after movement of the left leg and right arm. At 9:07 the DT reported slight transitory pain 
in the left knee. Between 9:09 and 9:12 subject 1 was monitored and real time Grade 1 was detected after movement 
of the right leg. Posttest review of the tape indicated this was an artifact, not a bubble. There were no symptoms. The 
DT was monitored from 9:12 to 9:15. Grade 3 bubbles were detected after movement of the left arm and right leg. 
Grade 4 bubbles were detected after movement of the left leg and right arm. Symptoms were reported to be about 
the same as before, but not definite. Between 9:16 and 9:18 subject 2 was monitored and Grade 3 bubbles were 
detected after movement of the left leg and Grade 2 bubbles after movement of the right leg. Subject had not 
reported symptoms. At 09:18 to 09:22 the DT was monitored and Grade 3 bubbles were detected without movement. 
With movement, strong Grade 4 bubbles with heavy showers were measured. The DT then reported fullness in the 
left knee, like a sprain. Subject 2 then (09:23) reported mild pain in the left knee that had started during his last 
exercise period (09:16 to 09:18). At 09:25 the decision was made by the MO to terminate the test. At 09:34, at 12 
psi, both subject #2 and the DT reported symptoms gone. At 09:36 subject #2 was monitored and no bubbles were 
detected. At 09:38 the DT was monitored and Grade 3 bubbles were detected after movement of the left leg. At 9:40 
the ETA reached 14.7 psi. At 9:51 the DT was monitored again and no bubbles were detected at 09:55. Subject #2 
and the DT were taken to the clinic for surveillance. 
 
Bends 1c: DCS Assigned at JSC 
 
8. Summary: ID# 20-01, 34-year-old male, maximum Grade 4, first VGE at 19 minutes, first 
report at 76 minutes, study done on n = 12, independent sample statistical design. 
 
Procedure 3. Same as Procedure 3 except subject spent 4 minutes flexing hip and knee joints 
by rhythmically stepping in place once every 10 seconds, instead of stepping on an 18.4-cm step 
once every 10 seconds for 4 minutes. 
 
Narrative: At 76 minutes, subject reported discomfort in right knee. Did not report initial 
pain score on the 1–10 scale since this scale was not yet implemented. First VGE detected at 
19 minutes, Grade 0 from left arm, Grade 0 from left leg, Grade 2 from right arm, and Grade 2 
from right leg. Last VGE record at 68 minutes with Grade 3 from left arm, Grade 3 from left leg, 
Grade 4 from right arm, and Grade 4 from right leg. The MO decided to remove subject from 
the test. At 96 minutes, discomfort in right knee had gone before subject entered the airlock, 
but returned when he stepped into the airlock and was present prior to repressurization. 
Symptoms in right knee resolved during descent at 8.30 psia. 
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Diagnosis: Grade 3 Type I DCS 
Treatment: None, just observation at the JSC Clinic with follow-up consultation. 
 
9. Summary: ID# 19-01, 37-year-old male, maximum Grade 4, first VGE at 25 minutes, first 
report at 78 minutes, study done on n = 12, independent sample statistical design. 
 
Procedure 3 
 
Narrative: At 78 minutes, subject reported a short pain in right knee that went away 
while stepping. Did not report initial pain score on the 1–10 scale since this scale was not yet 
implemented. At 104 minutes, subject reported slight discomfort in right knee; level remained 
constant. First VGE detected at 25 minutes, Grade 0 from left arm, Grade 0 from left leg, Grade 
3 from right arm, and Grade 0 from right leg. Last VGE record at 109 minutes with Grade 2 from 
left arm, Grade 4 from left leg, Grade 4 from right arm, and Grade 4 from right leg. At 116 min-
utes subject, reported intermittent discomfort or low-level pain or awareness in right knee. The 
MO decided to abort the 3-hr test after 120 minutes of exposure after subject’s chamber mate 
also developed symptoms in right knee (18-01). Symptoms in right knee resolved during descent 
at 7.3 psia. 
 
Diagnosis: Grade 2 Type I DCS 
Treatment: None, just observation at the JSC Clinic with follow-up consultation. 
 
10. Summary: ID# 18-01, 33-year-old male, maximum Grade 4, first VGE at 69 minutes, first 
report at 104 minutes, study done on n = 12, independent sample statistical design. 
 
Procedure 3 
 
Narrative: At 104 minutes, subject reported slight discomfort in right knee. At 116 minutes, 
he reported intermittent discomfort or low-level pain awareness in right knee. Did not report 
initial pain score on the 1–10 scale since this scale was not yet implemented. Grade 4 VGE were 
detected 87 minutes into the test after flexing right leg, and again at 101 minutes when right leg 
or left leg was flexed. First VGE detected at 69 minutes, Grade 0 from left arm, Grade 0 from 
left leg, Grade 0 from right arm, and Grade 1 from right leg. Last VGE record at 101 minutes 
with Grade 1 from left arm, Grade 2 from left leg, Grade 4 from right arm, and Grade 4 from 
right leg. The MO decided to abort the 3-hr test after 120 minutes of exposure after subject’s 
chamber mate also developed symptoms in right knee (19-01). Symptoms in right knee resolved 
during descent at 7.3 psia. 
 
Diagnosis: Grade 2 Type I DCS 
Treatment: None, just observation at the JSC Clinic with follow-up consultation. 
 
11. Summary: ID# 15-01, 28-year-old male, maximum Grade 4, first VGE at 37 minutes, first 
report after the end of the test during debrief, estimated at 166 minutes into the test, study done 
on n = 12, independent sample statistical design. 
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Procedure 3 
 
Narrative: During debrief, subject mentioned that he felt some pain during the last round of 
exercise at about 166 minutes in his right ankle, and that there was a sharp pain below both knee 
caps just prior to descent. Did not report initial pain score on the 1–10 scale since this scale was 
not yet implemented. First VGE detected at 37 minutes, Grade 0 from left arm, Grade 0 from left 
leg, Grade 0 from right arm, and Grade 1 from right leg. Last VGE record at 181 minutes with 
Grade 0 from left arm, Grade 3 from left leg, Grade 2 from right arm, and Grade 3 from right 
leg. Symptoms in both knees and right ankle resolved during descent at 12.2 psia, as esti-
mated from the posttest comments. 
 
Diagnosis: Grade 2 Type I DCS 
Treatment: None, just self-monitoring most likely with follow-up consultation. 
 
Bends 1d: DCS Assigned at JSC 
 
12. Summary: ID# 11-02, 45-year-old male, maximum Grade 4, first VGE at 34 minutes, first 
report after the end of the test during debrief, estimated at 50 minutes into the test, study done on 
n = 3, independent sample statistical design. 
 
Procedure 4 
 
Narrative: During debrief, subject mentioned that after 3rd or 4th exercise period he felt 
something in his knees. This would have been about 50 minutes into the test. Did not report 
initial pain score on the 1–10 scale since this scale was not yet implemented. He said that the 
sensations in his knees did go away on return to site pressure. He compared symptoms in left 
and right shins, and intermittent pain in the knees as a different type of pain to that he had ex-
perienced on a previous exposure (11-01), 2 days earlier. It was a much milder pain than before. 
First VGE detected at 34 minutes, Grade 1 from left arm, Grade 3 from left leg, Grade 0 from 
right arm, and Grade 3 from right leg. Last VGE record at 177 minutes with Grade 3 from left 
arm, Grade 4 from left leg, Grade 4 from right arm, and Grade 4 from right leg. Symptoms in 
both knees and shins resolved during descent at site pressure, as revealed during debriefing. 
 
Diagnosis: Grade 2 Type I DCS 
Treatment: None, just self-monitoring most likely with follow-up consultation. 
 
13. Summary: ID# 10-02, 44-year-old male, maximum Grade 4, first VGE at 62 minutes, first 
report after the end of the test during debrief, estimated at 60 minutes into the test, study done on 
n = 3, independent sample statistical design. 
 
Procedure 4 
 
Narrative: During debrief, subject mentioned that after about 60 minutes into the test he 
experienced a symptom in right leg. Symptom was clear during the last hr of the 3-hr test. Did 
not report initial pain score on the 1–10 scale since this scale was not yet implemented. First 
VGE detected at 62 minutes, Grade 0 from left arm, Grade 1 from left leg, Grade 1 from right 
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arm, and Grade 2 from right leg. Last VGE record at 174 minutes with Grade 0 from left arm, 
Grade 1 from left leg, Grade 3 from right arm, and Grade 4 from right leg. There were no 
symptoms prior to descent; symptoms resolved at the test altitude of 4.3 psia. 
 
Diagnosis: Grade 2 Type I DCS 
Treatment: None, self-monitoring most likely with follow-up consultation. 
 
Bends 2a: DCS Assigned at JSC 
 
14. Summary: ID# 37-02, 26-year-old male, maximum Grade 4, first VGE at 55 minutes, first 
report at 59 minutes, study done on n = 23, independent sample statistical design. 
 
Procedure 5 
 
Narrative: At 59 minutes, subject reported momentary pain in right knee; pain was gone at 1st-hr 
questioning. Reported initial pain score of 1 on a 1–10 scale. At 106 minutes, subject reported an 
occasional twinge in right knee. At 218 minutes, subject reported continuing twinges in right 
knee; level remained constant at 1. The exercise protocol was briefly interrupted as his chamber 
mate (21-02) was returned to site pressure at 177 minutes for pain in left knee and left ankle. 
First VGE detected at 55 minutes, Grade 0 from left arm, Grade 3 from left leg, Grade 0 from 
right arm, and Grade 3 from right leg. Last VGE record at 176 minutes with Grade 0 from left 
arm, Grade 0 from left leg, Grade 0 from right arm, and Grade 4 from right leg. The 4-hr test was 
completed. Logbook indicated that subject was clear of symptoms in right knee on the way to 
site pressure. During debrief, subject indicated mild right knee pain for most of the test and an 
itch on right thigh for about half an hr during test. Pain diminished with descent, but rash mark 
still remained at location of itch. Subject mentioned that there was still very slight discomfort in 
right knee. 
 
Diagnosis: Grade 2 Type I DCS, CM cannot be ruled out 
Treatment: None, medical observation provided for 12 hrs with follow-up consultation. 
 
15. Summary: ID# 35-02, 43-year-old male, maximum Grade 4, first VGE at 116 minutes, first 
report at 116 minutes a symptom he noticed moments earlier, study done on n = 23, independent 
sample statistical design. 
 
Procedure 5 
 
Narrative: At 116 minutes, subject reported pain in arch of right foot. Reported initial pain 
score of 4 on a 1–10 scale. He noticed symptom earlier, just before going to the Doppler mon-
itoring station. At 177 minutes, the level decreased to 3–4; and by 243 minutes, subject reported 
pain in both knees, the level had decreased to 2. His chamber mate (38-03) reported discomfort 
in left knee at 221 minutes. First VGE detected at 116 minutes, Grade 0 from left arm, Grade 0 
from left leg, Grade 0 from right arm, and Grade 2 from right leg. Last VGE record at 196 min-
utes with Grade 0 from left arm, Grade 0 from left leg, Grade 3 from right arm, and Grade 4 
from right leg. Symptoms in both knees, arch of right foot, and right ankle resolved during 
descent at 8.81 psia. During debrief, subject mentioned that pain in arch of right foot moved 
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up into right ankle, and it felt like a strain in the joint. He favored right knee at first, but was able 
to do the assigned exercise. Pain then spread to right knee. Intensity of the pain decreased with 
time. It was mentioned that pain in the knee (or knees) decreased when he was in the reclined 
position, and decreased when he bent his knee (or knees). 
 
Diagnosis: Grade 2 Type I DCS 
Treatment: None, medical observation provided most likely for 12 hrs with follow-up 
consultation. 
 
16. Summary: ID# 21-02, 34-year-old male, maximum Grade 4, first VGE at 105 minutes, first 
report at 76 minutes, study done on n = 23, independent sample statistical design. 
 
Procedure 5 
 
Narrative: At 76 minutes, subject reported pain in left ankle. Reported initial pain score of 1 
on a 1–10 scale. At 117 minutes, subject reports dull ache in left knee; level remained constant at 
1, but increased to a pain score of 7 at 148 minutes with pain reported in left knee and left ankle, 
with pain blending together. His chamber mate (37-02) had reported a momentary pain in right 
knee at 59 minutes. First VGE detected at 105 minutes, Grade 0 from left arm, Grade 4 from left 
leg, Grade 0 from right arm, and Grade 3 from right leg. Last VGE record at 122 minutes with 
Grade 0 from left arm, Grade 3 from left leg, Grade 0 from right arm, and Grade 2 from right leg. 
The MO decided to remove subject from the test. At 166 minutes, subject reported continuous 
pain in left knee and left ankle, but pain score had reduced to 3. Repressurization was started 
177 minutes into the 4-hr test. Symptoms in left ankle and left knee resolved during 
descent at 7.1 psia. 
 
Diagnosis: Grade 3 Type I DCS 
Treatment: None, medical observation provided for 12 hrs with follow-up consultation. 
 
17. Summary: ID# 34-01, 30-year-old male, maximum Grade 4, first VGE at 77 minutes, first 
report of a symptom was after the test, and estimated to be 42 minutes into the test, study done 
on n = 23, independent sample statistical design. 
 
Procedure 5. Same as Procedure 5 except the PB was extended by 10 minutes because a lock 
valve was open and interfered with nominal ETA pump down. 
 
Narrative: Subject did not report symptoms during test. During debrief, subject mentioned a 
dull pain in right knee at about 42 minutes, also a twinge in left knee for which no time was doc-
umented. Subject did not report initial pain score on the 1–10 scale. At 119 minutes, pain score 
increased to 5; and by 228 minutes, pain score decreased to 2, for right knee. At 139 minutes, 
subject had Grade 4 VGE during all limb movements. First VGE detected at 77 minutes, Grade 0 
from left arm, Grade 0 from left leg, Grade 2 from right arm, and Grade 0 from right leg. Last 
VGE record at 218 minutes with Grade 0 from left arm, Grade 3 from left leg, Grade 1 from 
right arm, and Grade 2 from right leg. Prior to return to site pressure, at 4 hrs he still had 
symptoms in left knee and right knee because he said pain had resolved during return to site 
pressure. Symptoms in both knees resolved at 7.34 psia during descent, based on debrief 
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estimate. It is unclear from the logbook if subject still had awareness in both knees at site 
pressure. Within 2 hrs of the conclusion of test, subject reported pain in both knees. 
 
Diagnosis: Grade 2 Type I DCS 
Treatment: USN HBO TT V for reoccurrence of symptoms. Pain was relieved on the 
compression. Medical observation provided for 12 hrs with follow-up consultation. 
 
18. Summary: ID# 5-02, 29-year-old male, maximum Grade 4, first VGE at 104 minutes, first 
report at 160 minutes, study done on n = 23, independent sample statistical design. 
 
Procedure 5 
 
Narrative: At 160 minutes, subject reported some pain and discomfort in right knee and 
right foot. Reported initial pain score of 7 on a 1–10 scale. He described pain in right foot as 
a muscle cramp, and pain in right knee as sharp when standing. Right knee pain was localized 
outside the joint. It went to a pain score of 2 when standing on the floor at rest, but increased to a 
7 when walking from station to station. At 177 minutes, level remained constant at 7; and at 223 
minutes, level was still constant at 7. First VGE detected at 104 minutes, Grade 0 from left arm, 
Grade 0 from left leg, Grade 0 from right arm, and Grade 2 from right leg. Last VGE record at 
222 minutes with Grade 0 from left arm, Grade 0 from left leg, Grade 0 from right arm, and 
Grade 4 from right leg. Symptoms in right knee and right foot resolved during descent at 
9.35 psia. During debrief, it appeared that subject had a tendency to favor right knee, but 
this did not interfere with his exercise activities. Pain in right foot was localized in the 
arch or instep, where he sometimes gets cramps. 
 
Diagnosis: Grade 2 Type I DCS 
Treatment: None, medical observation provided most likely for 12 hrs with follow-up 
consultation. 
 
19. Summary: ID# 32-01, 29-year-old male, maximum Grade 4, first VGE at 18 minutes, first 
report at debrief, but no indication of when during the test the symptoms first appeared, study 
done on n = 23, independent sample statistical design. 
 
Procedure 5 
 
Narrative: Subject did not report symptoms during test. During debrief, subject indicated 
very mild pain, more like stiffness in right knee and right foot, but no time was documented. Did 
not report initial pain score on the 1–10 scale. He mentioned that there was no pain at all during 
4th-hr questioning, but that stiffness (unclear if this is for right knee, right foot, or both) went 
away on recompression to site pressure. This was his first indication that his symptoms might be 
related to decompression to 4.3 psia. First VGE detected at 18 minutes, Grade 0 from left arm, 
Grade 0 from left leg, Grade 0 from right arm, and Grade 3 from right leg. Last VGE record at 
230 minutes with Grade 0 from left arm, Grade 0 from left leg, Grade 0 from right arm, and 
Grade 3 from right leg. Symptoms resolved during descent, but exact altitude was not noted. 
Symptoms from right foot and right knee were gone at site pressure. 
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Diagnosis: Grade 1 Type I DCS 
Treatment: Not clear if HBO was provided in this case, but there would be a follow-up 
consultation. 
 
20. Summary: ID# 38-03, 33-year-old male, maximum Grade 3, first VGE at 216 minutes, first 
report at 221 minutes, study done on n = 23, independent sample statistical design. 
 
Procedure 5 
 
Narrative: At 221 minutes, subject reported discomfort, but not pain, in left knee along the 
lateral aspect. Reported initial pain score of less than 1 on a 1–10 scale. At 243 minutes, subject 
reported that pain scale was 1. His chamber mate (35-02) reported a pain in arch of the right foot 
at 116 minutes. First VGE detected at 216 minutes, Grade 0 from left arm, Grade 3 from left leg, 
Grade 1 from right arm, and Grade 0 from right leg. Last VGE record at 232 minutes with Grade 
0 from left arm, Grade 3 from left leg, Grade 0 from right arm, and Grade 0 from right leg. There 
were no symptoms prior to descent; symptoms resolved at the test altitude of 4.3 psia. During 
debrief, subject mentioned that symptom in left knee was an awareness. 
 
Diagnosis: Grade 1 Type I DCS 
Treatment: None, just self-monitoring most likely with follow-up consultation. 
 
Bends 2b: DCS Assigned at JSC 
 
21. Summary: ID# 35-03, 43-year-old male, maximum Grade 4, first VGE at 34 minutes, first 
report at 17 minutes, study done on n = 22, independent sample statistical design. 
 
Procedure 6 
 
Narrative: At 17 minutes, subject reported deep pain in left knee. Reported initial pain score of 
7 on a 1–10 scale. He reported that this symptom was similar to one he experienced in right foot 
and right knee on a previous test (35-02) where symptoms were present at about 116 minutes. At 
34 minutes and 60 minutes, level remained constant at 7, but did not interfere with his activities. 
Pain score intensity decreased to 3 at 81 minutes and 110 minutes. During 3rd-hr questioning, 
subject reported that pain score increased to 6–7, left leg seemed weaker, and pain occupied the 
entire left knee. At 201 minutes, subject reported again that left leg seemed to be getting weak, 
on a pain scale of 9, but felt he could get through the last hr. At 4th-hr questioning, subject 
reported there was no change in left knee symptoms from the last report; a pain score of 9 at 240 
minutes. First VGE detected at 34 minutes, Grade 0 from left arm, Grade 4 from left leg, Grade 1 
from right arm, and Grade 2 from right leg. Last VGE record at 228 minutes with Grade 0 from 
left arm, Grade 0 from left leg, Grade 0 from right arm, and Grade 0 from right leg. Symptoms 
improved during descent but did not clear completely at site pressure. During debrief, subject 
mentioned that left knee was not hurting, and strength had returned to left leg. Pain score 
was about 1 initially at site pressure; 16 minutes after the start of repressurization to site pres-
sure, all symptoms were gone. He said that lying down made pain in his left knee worse to the 
point where he sat up during any rest period and after Doppler monitoring. During the greatest 
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discomfort, at a pain score of 9, he had trouble walking. Finally, pain in left knee noticeably 
lessened at about 10.5 psia. 
 
Diagnosis: Grade 3 Type I DCS 
Treatment: None, medical observation provided most likely for 12 hrs with follow-up 
consultation. 
 
22. Summary: ID# 34-02, 31-year-old male, maximum Grade 4, first VGE at 69 minutes, first 
report at 236 minutes a symptom he noticed at 206 minutes, study done on n = 22, independent 
sample statistical design. 
 
Procedure 6 
 
Narrative: At 236 minutes, subject reported minor aches and pains in right knee and left 
knee, with right knee symptoms more noticeable. Reported initial pain score of 2 on a 1–10 
scale. Symptoms had started about 30 minutes earlier (206 minutes) and were localized beneath 
the patella of both knees. His chamber mate (31-03) had reported symptoms in right arm at 180 
minutes. First VGE detected at 69 minutes, Grade 0 from left arm, Grade 3 from left leg, Grade 1 
from right arm, and Grade 2 from right leg. Last VGE record at 233 minutes with Grade 3 from 
left arm, Grade 4 from left leg, Grade 4 from right arm, and Grade 4 from right leg. Logbook did 
not indicate if symptoms in both knees improved during repressurization to site pressure. During 
debrief, subject mentioned that his knees felt better, but there was still some residual awareness 
like what you would experience after a good run. Subject had a previous chamber test (34-01) 
where symptoms were present but reported after the test. Debrief notes for this test indicated he 
had a reoccurrence of symptoms in his knees and was treated 1.0–1.5 hrs after debrief. 
 
Diagnosis: Grade 2 Type I DCS 
Treatment: USN HBO TT V for reoccurrence of symptoms. Symptoms disappeared at the 60-
foot level on treatment, plus a follow-up consultation.  Note: It is unclear from the available 
information if persistent symptoms in the knees at site pressure were the reason for the HBO 
treatment or if a reoccurrence of symptoms after the subject was released from the test prompted 
the HBO treatment.  There is an indication that that the symptoms had finally resolved at site 
pressure.  For purposes of post-test analysis the symptoms are classified as having cleared at 
site pressure to an extent that the subject was released from the test, but that within 1.0-1.5 hrs 
after the debrief the symptoms reoccurred to such an extent to prompt an HBO treatment 
(08/22/13).  
 
23. Summary: ID# 31-03, 31-year-old male, maximum Grade 1, first VGE at 144 minutes, first 
report at 180 minutes, study done on n = 22, independent sample statistical design. 
 
Procedure 6 
 
Narrative: At 180 minutes, subject reported right arm felt different than left arm, meaning 
symptom was in right arm. Reported initial pain score of 1 on a 1–10 scale, as determined from 
debrief comments. At 207 and 236 minutes, level remained constant at 1. His chamber mate (34-
02) had reported symptoms in right knee and left knee at 236 minutes. First VGE detected at 144 
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minutes, Grade 0 from left arm, Grade 1 from left leg, Grade 0 from right arm, and Grade 0 from 
right leg. Last VGE record at 236 minutes with Grade 0 from left arm, Grade 0 from left leg, 
Grade 0 from right arm, and Grade 0 from right leg. During 4th-hr questioning, subject 
mentioned that he had a cramp in left foot, but attributed problem to his shoes; cramp was 
improved when he took his shoes off. Symptoms in right arm resolved during descent at 5.45 
psia. During debrief, there was some question if symptom in right arm had gone before the re-
pressurization, or if it cleared on the way to 25,000 feet (5.45 psia). Location of symptom was 
in forearm of right arm, and was not exercise related in that the feeling was not exacerbated 
during arm exercise and the symptoms were very intermittent. 
 
Diagnosis: Grade 1 Type I DCS 
Treatment: None, medical observation provided most likely for 12 hrs with follow-up 
consultation. 
 
24. Summary: ID# 3-03, 29-year-old male, maximum Grade 4, first VGE at 76 minutes, first 
report at 175 minutes, study done on n = 22, independent sample statistical design. 
 
Procedure 6 
 
Narrative: At 175 minutes, subject reported no aches or pains, but felt a heaviness in his legs, 
like blood pooling. Reported initial pain score of 1 on a 1–10 scale. At 209 minutes, he was more 
specific in that lower right leg felt like it had poor circulation; no particular area hurt. Assigned a 
pain score of 2 to right heel; classified symptom as an awareness. Massaging right leg and right 
foot seemed to make them feel better. Right heel and top front of right shin had diffuse sensa-
tions. Right knee was also reported to have an awareness or fullness, like poor circulation, at this 
time. At 4th-hr questioning, subject reported the same numbness, toes cold like you experience 
with lack of circulation. Still had an awareness of symptoms that were accentuated by right leg 
movements. He assigned pain score of 2 for his symptoms at 241 minutes. First VGE detected at 
76 minutes, Grade 0 from left arm, Grade 0 from left leg, Grade 1 from right arm, and Grade 2 
from right leg. Last VGE record at 236 minutes with Grade 1 from left arm, Grade 2 from left 
leg, Grade 2 from right arm, and Grade 4 from right leg. Symptoms of cold right foot and numb-
ness resolved during descent at approximately 6.75 psia. During debrief, subject mentioned that 
symptoms during this test were like symptoms on his first 10.2-psia test (test designation 1b, 3-
01), but no DCS was diagnosed during that test. This was 3rd time subject had participated in a 
chamber test, and the 1st time he reported symptoms. He mentioned that ball of right foot had 
cramped. Symptoms were described as diffuse, moving around right leg. Also mentioned that 
he was fatigued toward the end of the test. 
 
Diagnosis: Grade 1 Type I DCS 
Treatment: None, medical observation provided most likely for 12 hrs with follow-up 
consultation. 
 
25. Summary: ID# 21-03, 34-year-old male, maximum Grade 4, first VGE at 37 minutes, first 
report at 160 minutes, study done on n = 22, independent sample statistical design. 
 
Procedure 6 
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Narrative: At 160 minutes, subject reported pain, ache, and some stabbing in left shoulder. 
Reported initial pain score of 2 on a 1–10 scale. For completeness, he also reported a slight ache 
in one of his teeth when the test at 4.3 psia first began. At 3rd-hr questioning, he said pain in left 
shoulder was gone, but was at a pain score of 1 on the last exercise activity. At about 210 
minutes, subject reported a stabbing type of pain had appeared in left ankle during last exercise 
activity; gave this a pain score of 2 at about 201 minutes. Pain in left ankle had decreased to a 
pain score of 1–2 at 239 minutes. First VGE detected at 37 minutes, Grade 3 from left arm, 
Grade 0 from left leg, Grade 0 from right arm, and Grade 0 from right leg. Last VGE record 
at 240 minutes with Grade 3 from left arm, Grade 3 from left leg, Grade 0 from right arm, and 
Grade 0 from right leg. Symptoms in left ankle resolved during descent at 5.45 psia. Subject 
had 2 previous tests (21-01 and 21-02) where symptoms were present. 
 
Diagnosis: Grade 2 Type I DCS 
Treatment: None, medical observation provided most likely for 12 hrs with follow-up 
consultation. 
 
26. Summary: ID# 18-02, 33-year-old male, maximum Grade 4, first VGE at 1 minutes, first 
report at 65 minutes, study done on n = 22, independent sample statistical design. 
 
Procedure 6 
 
Narrative: At 65 minutes, subject reported discomfort and pain in right knee. Reported 
initial pain score of 1 on a 1–10 scale. At 103 minutes, level increased to 2–3. Grade 1 VGE 
were detected 1 minute into the test after flexing right leg. Grade 4 VGE were detected at 17 
minutes after flexing right leg. Grade 4 VGE were detected from all limbs at 52 minutes and at 
92 minutes. Subject in a previous test (18-01) reported discomfort in right knee at 104 minutes. 
Last VGE record at 92 minutes with Grade 4 from left arm, Grade 4 from left leg, Grade 4 from 
right arm, and Grade 4 from right leg. At 103 minutes, subject reported sudden onset of fatigue 
and cold sweat. At the same time, red and white mottling or marbling appeared on chest. Skin 
mottling was diagnosed 103 minutes into the exposure. Accumulation and rapid onset of signs 
and symptoms initiated removal of subject through a smaller transfer airlock at 115 minutes. 
Pain in right knee and feeling of fatigue cleared at 7.2 psia. Mottling disappeared in 10 min-
utes at site pressure on 100% O2. During debrief, subject mentioned that fatigue was very 
significant and he felt it would interfere with his ability to perform the exercise protocol. 
 
Diagnosis: Type II DCS (at this time, CM by itself was also classified as Type II DCS at JSC) 
Treatment: Two-hr GLO. Subject was held in a horizontal position while on 100% O2 for 2 hrs 
and was under medical observation in a hyperbaric chamber overnight. There were no further 
symptoms or indication of neurological deficit during follow-up consultation. 
 
A 33-year-old male, 62.6 kg, 167 cm, with 15% computed body fat and 22.4 BMI [body mass index], participated 
in an altitude exposure at JSC. Subject had one previous altitude exposure as a research subject to evaluate the 
effectiveness of a staged decompression protocol to prevent DCS during extravehicular activity from the Space 
Shuttle.  A brief description of the first test is warranted. Subject ascended to 10.2 psia in about 2 minutes, and the 
chamber atmosphere was enriched to 26.5% O2. There was minimal physical activity, including sleep, during the 
12 hr exposure. A 90 minutes O2 PB with a 4 minutes ascent preceded a 3 hr exposure to 4.3 psia. Exercise stressed 
the lower body since 4 minutes were spent flexing the ankle, knee, and hip joints by rhythmically stepping onto an 
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18.4-cm step once every 10 seconds. This was followed by 4 minutes of flexing the wrist, elbow, and shoulder joints 
by rhythmically lifting a 1.36 kg weight alternately every 5 seconds from left to right hand. Finally, there was a 4 
minutes period of rest and a 4 minutes period of bubble monitoring with subject asked to flex each limb in turn 
while in a supine position. Bubble monitoring was provided by a DT trained to detect the blood flow signal in the 
pulmonary artery, at the precordial position, using an ultrasound Doppler bubble detector. Subject ambulated to the 
2 exercise stations within the chamber. Grade IV VGE were detected 87 minutes into the test after flexing the right 
leg, and again at 101 minutes when the right or left leg was flexed. Subject reported pain in the right knee at 116 
minutes, and the test was aborted at 118 minutes for an unrelated reason. The pain in the right knee cleared at 7.3 
psia during the repressurization to site pressure. Several changes were made to the staged decompression protocol, 
and subject was willing to participate again. Five months later subject again ascended to 10.2 psia in about 5 
minutes, and the chamber atmosphere was once again enriched to 26.5% O2. There was minimal physical activity, 
including sleep, during the 12 hr exposure. A 40 minutes O2 PB with a 25 minutes ascent preceded a 4 hr exposure 
to 4.3 psia. Exercise stressed the upper body since 4 minutes were spent flexing the wrist, elbow, and shoulder joints 
while rhythmically rotating the wheel of a bicycle ergometer against a set resistance from a standing position, 4 
minutes torquing fixed bolts with either the left or right hand from a standing position, and 4 minutes of 
rhythmically pulling against a set resistance from a seated position. Additional details about the exercises are avail-
able. Finally, there was a 4 minutes period of rest and a 4 minutes period of bubble monitoring with the subject 
asked to flex each limb in turn while in a supine position. Subject ambulated to the three exercise stations within the 
chamber. Grade I VGE were detected 1 minutes into the test after flexing the right leg. Grade IV VGE were detected 
at 17 minutes after flexing the right leg. Grade IV VGE were detected from all limbs at 52 minutes and at 92 min-
utes. Subject reported pain in the right knee after 57 minutes. At 103 minutes subject reported sudden onset of fa-
tigue, and cold sweat. At the same time, red and white mottling or marbling appeared on the chest. Skin mottling 
was diagnosed 103 minutes into the exposure. The accumulation and rapid onset of signs and symptoms initiated the 
removal of subject through a smaller transfer airlock at 115 minutes. Pain and feeling of fatigue cleared at 7.2 psia. 
Mottling disappeared in 10 minutes at site pressure on 100% O2. Subject was held in a horizontal position while on 
100% O2 for 2 hr and was under medical observation in a hyperbaric chamber overnight. There were no further 
symptoms or indication of neurological deficit. 
 
Bends 3a: DCS Assigned at JSC 
 
27. Summary: ID# 42-02, 28-year-old male, maximum Grade 4, first VGE at 34 minutes, first 
report at 356 minutes a symptom he first noticed at about 294 minutes, study done on n = 28, 
independent sample statistical design. 
 
Procedure 7 
 
Narrative: At 356 minutes, during 6th-hr questioning, subject reported minor ache in right knee. 
Reported initial pain score of 4 on a 1–10 scale that went to a pain score of 2, but this was for 
symptom he experienced earlier in the test. Symptom was present on the cot at the Doppler 
monitoring station. He noticed this symptom about 2.5 exercise rotations earlier, or at about 294 
minutes. His chamber mate (44-02) had reported symptom at 68 minutes of very mild discomfort 
in the right knee. First VGE detected at 34 minutes, Grade 0 from left arm, Grade 0 from left leg, 
Grade 0 from right arm, and Grade 3 from right leg. Last VGE record at 356 minutes with Grade 
1 from left arm, Grade 0 from left leg, Grade 2 from right arm, and Grade 2 from right leg. At 
continuation of 6th-hr questioning, subject reported ache in right knee was not present at that 
time. There were no symptoms prior to descent; symptoms resolved at the test altitude of 4.3 
psia. During debrief at site pressure, subject mentioned pain in right knee was continuous for 
about 20 minutes; initially a sharp clear pain for about 30 seconds, then went from a pain score 
of 4–5 to about 1–2, and was worse when standing and exercising at the arm ergometer. 
 
Diagnosis: Grade 2 Type I DCS 
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Treatment: None, medical observation provided most likely for 12 hrs with follow-up 
consultation. 
 
28. Summary: ID# 47-01, 26-year-old male, maximum Grade 4, first VGE at 4 minutes, first 
report at 60 minutes a symptom he noticed at 50 minutes, study done on n = 28, independent 
sample statistical design. 
 
Procedure 7 
 
Narrative: At 60 minutes, during 1st-hr questioning, subject reported pain that came and went in 
left knee and was worse when lying down. Reported initial pain score of 4 on a 1–10 scale. He 
recalled that symptom was noticed about 10 minutes earlier, and did not interfere with his 
exercise activities. Pain score remained constant at 4 during 2nd-hr questioning, and again a pain 
score of 4 at 179 minutes. During 3rd-hr questioning, pain was described as intermittent and 
noticed in left knee while he was lying down with movement of the limb and ankle during the 
Doppler monitoring. At 4th-hr questioning, subject reported no change in left knee pain, but now 
both ankles had a continuous pain; no pain score was given for ankles. Left knee had a pain score 
of 1 at this time. At 5th-hr questioning, subject reported no further pain in left knee, just a bit of 
mild continuous stiffness in ankles. At 6th-hr questioning, pain in ankles was still present. First 
VGE detected at 4 minutes, Grade 0 from left arm, Grade 4 from left leg, Grade 0 from right 
arm, and Grade 2 from right leg. Last VGE record at 355 minutes with Grade 0 from left arm, 
Grade 0 from left leg, Grade 0 from right arm, and Grade 2 from right leg. Symptoms in ankles 
resolved during descent at 6.33 psia on the way to site pressure. 
 
Diagnosis: Grade 2 Type I DCS 
Treatment: None, medical observation provided most likely for 12 hrs with follow-up 
consultation. 
 
29. Summary: ID# 46-01, 50-year-old male, maximum Grade 4, first VGE at 76 minutes, first 
report at 303 minutes a symptom he noticed at 120 minutes, study done on n = 28, independent 
sample statistical design. 
 
Procedure 7 
 
Narrative: At 303 minutes, during 5th-hr questioning, subject reported a little bit of pain in right 
knee. Reported initial pain score of 1–2 on a 1–10 scale. He first felt something in right knee at 
about 120 minutes, but feeling went away. It was back now and was continuous, but got better 
when he walked. His chamber mate (13-04) had reported symptom in the left knee at 205 
minutes. First VGE detected at 76 minutes, Grade 2 from left arm, Grade 0 from left leg, Grade 0 
from right arm, and Grade 0 from right leg. Last VGE record at 355 minutes with Grade 0 from 
left arm, Grade 3 from left leg, Grade 0 from right arm, and Grade 2 from right leg. At 6th-hr 
questioning, subject reported right knee discomfort was same as before, and left ankle pain had 
gone. This was first indication that there was a symptom in left ankle. Symptoms in right knee 
resolved during descent at 5.66 psia. During debrief at site pressure, subject said he did not re-
port initial sensations in right ankle and right knee until they reoccurred later in the test. The 
logbook mentions there was a very clear remission of right knee symptoms during repressuriza-
140 
 
tion to site pressure. This description is inconsistent, however, since left ankle symptom men-
tioned at 6th-hr questioning was not mentioned during debrief, and right ankle symptom 
mentioned during debrief was never mentioned (documented) during test. What seems 
clear is that an ankle along with the right knee had symptoms. 
 
Diagnosis: Grade 2 Type I DCS 
Treatment: None, medical observation provided most likely for 12 hrs with follow-up 
consultation. 
 
30. Summary: ID# 44-02, 36-year-old male, maximum Grade 4, first VGE at 42 minutes, first 
report at 68 minutes a symptom he noticed moments before, study done on n = 28, independent 
sample statistical design. 
 
Procedure 7 
 
Narrative: At 68 minutes, subject reported very mild discomfort in right knee. Reported initial 
pain score of 1 on a 1–10 scale. For completeness, subject reported tingling sensations in thighs 
at 29 minutes. At 1st-hr questioning, subject mentioned symptoms in right knee had been present 
for the last couple of minutes, and were a continuous mild discomfort. There was no tingling in 
thighs at this time, and he suspected symptom was due to being warm. Pain score remained 
constant at 1 at 105, 119, and 165 minutes. Pain score only increased to 2 after 180 minutes. At 
108 minutes, subject reported that pain was better localized, and was pain rather than discomfort 
on the right side of right patella. At 120 minutes, pain was reported to be a little less than it had 
been at previous report at 108 minutes, and was less painful compared to his previous exposure 
(44-01). At 125 minutes, pain score was 2 while straightening right leg during Doppler monitor-
ing. At 3rd-hr questioning, reported that right ankle discomfort was gone from that noticed at 2nd 
hr. This was first indication in the logbook that he had a symptom in right ankle. Right knee pain 
was unchanged from 2nd hr. Left knee also has general discomfort, noticed about 15 minutes 
earlier, now at a pain score less than 1. Symptoms did not interfere with the exercise protocol. 
Pain score decreased back to 1 at 238, 289, 297, 327, and 359 minutes. First VGE detected at 42 
minutes, Grade 0 from left arm, Grade 2 from left leg, Grade 0 from right arm, and Grade 1 from 
right leg. Last VGE record at 364 minutes with Grade 0 from left arm, Grade 2 from left leg, 
Grade 0 from right arm, and Grade 3 from right leg. At 4th-hr questioning, right knee pain was 
less, left knee discomfort was almost gone, with joints aggravated with movement but not 
noticeable when motionless. At 291 minutes, there was still discomfort in left knee, also pain in 
shin about one inch below left knee. Right knee still had pain when joint was moved, but no pain 
when joint was motionless. At 299 minutes, there was no discomfort in right knee, but some 
present in left knee; gave pain score of 1 for the shin just below left knee. At 326 minutes, 
subject reported that discomfort in right knee had returned; pain score of 1. At 6th-hr questioning, 
there was no discomfort in either ankle, but both knees still had same level of discomfort with an 
occasional sharp pain. His chamber mate (42-02) had also reported symptoms in right knee at 
6th-hr questioning. Symptoms in both knees resolved during descent at 12.3 psia on the way to 
site pressure. 
 
Diagnosis: Grade 2 Type I DCS 
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Treatment: None, medical observation provided most likely for 12 hrs with follow-up 
consultation. 
 
31. Summary: ID# 61-03, 29-year-old male, maximum Grade 4, first VGE at 41 minutes, first 
report at 83 minutes a symptom he noticed at 78 minutes, study done on n = 28, independent 
sample statistical design. 
 
Procedure 7 
 
Narrative: At 83 minutes, subject reported constant ache in joint, dull ache in left knee. 
Reported initial pain score of 2 on a 1–10 scale. He first noticed this symptom at 78 minutes, 
during last set of exercise activities, but did not interfere with his exercise activities. Pain score 
reported to increase to 3 by 2nd-hr questioning, at 128 minutes,; subject reported that flexing left 
knee at the Doppler monitoring station made dull ache worse. At 3rd-hr questioning, subject 
reported pain in left knee was at same level as before, a pain score of 3, but now left foot had a 
cramp symptom between toes and ankle. Symptom was described as “sharp;” a pain score of 2. 
At 220 minutes, subject reported an increase in pain score to 5 in left knee with trouble flexing 
the knee as required at the Doppler monitoring station. Symptom was described as still a dull 
ache, with no problems to continue the test or to walk to each exercise station. At 4th-hr ques-
tioning, subject reported a worse feeling in left ankle and left knee; a pain score of 6. He said that 
he preferred to put weight on his right leg, and that he limped a little. Pain was noticeable when 
he rotated the left ankle. MO decided to remove subject from the test. Initiated repressurization 
at 268 minutes. First VGE detected at 41 minutes, Grade 0 from left arm, Grade 3 from left leg, 
Grade 0 from right arm, and Grade 0 from right leg. Last VGE record at 253 minutes with Grade 
0 from left arm, Grade 4 from left leg, Grade 2 from right arm, and Grade 2 from right leg. 
Symptoms in left knee and left ankle almost completely resolved during descent at 9.36 psia. 
During debrief at site pressure, subject mentioned that improvement in symptoms during re-
pressurization was dramatic. Pain in left knee was localized beneath the patella and was at 
its worst at 4th-hr questioning. 
 
Diagnosis: Grade 3 Type I DCS 
Treatment: None, medical observation provided most likely for 12 hrs with follow-up 
consultation. 
 
32. Summary: ID# 13-04, 36-year-old male, maximum Grade 4, first VGE at 88 minutes, first 
report at 205 minutes a symptom he noticed at 180 minutes, study done on n = 28, independent 
sample statistical design. 
 
Procedure 7 
 
Narrative: At 205 minutes, subject reported constant, uncomfortable pain in left knee. 
Reported initial pain score of 3–4 on a 1–10 scale. He first noticed symptom at 3rd-hr 
questioning, but did not report it at that time. Symptom was noticed when he was lying on 
his back during a previous rest period. At 4th-hr questioning, subject reported pain in left knee 
was perhaps a little less than previously reported, was not worse with movement, and did not 
interfere with his exercise activities. At 242 minutes, the score decreased to 3. At 302 minutes 
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during 5th-hr questioning, subject reported left knee pain was about gone and not continuous. His 
chamber mate (46-01) had reported a symptom in right knee during 5th-hr questioning. First VGE 
detected at 88 minutes, Grade 0 from left arm, Grade 0 from left leg, Grade 0 from right arm, and 
Grade 1 from right leg. Last VGE record at 347 minutes with Grade 0 from left arm, Grade 3 
from left leg, Grade 2 from right arm, and Grade 0 from right leg. At 6th-hr questioning, subject 
reported that pain in left knee was now gone, and had been absent since last report at 5th-hr 
questioning. Symptoms resolved while at the test altitude of 4.3 psia prior to the repressurization 
to site pressure. 
 
Diagnosis: Grade 2 Type I DCS 
Treatment: None, subject was advised to stay in the quarantine trailer for 12 hrs of medical 
observation, but did not stay. Follow-up consultation the next day was done. 
 
Bends 3b: DCS Assigned at JSC 
 
33. Summary: ID# 63-01, 23-year-old male, maximum Grade 4, first VGE at 24 minutes, first 
report at 120 minutes a symptom he noticed at 90 minutes, study done on n = 35, independent 
sample statistical design. 
 
Procedure 8 
 
Narrative: At 120 minutes, subject reported intermittent stiffness in right ankle. Reported 
initial pain score of 1 on a 1–10 scale. He noticed symptoms about 30 minutes earlier. Pain score 
remained constant at 1 at 89 minutes, and decreased to 0 at 178 minutes; there was no stiffness in 
right ankle at the 3rd- to 6th-hr questioning. First VGE detected at 24 minutes, Grade 0 from left 
arm, Grade 0 from left leg, Grade 0 from right arm, and Grade 1 from right leg. Last VGE record 
at 350 minutes with Grade 0 from left arm, Grade 0 from left leg, Grade 0 from right arm, and 
Grade 0 from right leg. There were no symptoms prior to descent; symptoms resolved at the test 
altitude of 4.3 psia. Repressurization was back to 10.2 psia. 
 
Diagnosis: Grade 1 Type I DCS 
Treatment: None, just self-monitoring most likely with follow-up consultation. 
 
34. Summary: ID# 60-01, 23-year-old male, maximum Grade 4, first VGE at 134 minutes, 
first report at 180 minutes a symptom he noticed about 160 to 165 minutes earlier. Symptoms 
reported at 300 minutes, but noticed at 297 minutes, are likely to be DCS-related, study done on 
n = 35, independent sample statistical design. 
 
Procedure 8 
 
Narrative: At 180 minutes, during 3rd-hr questioning, subject reported slight tingling in 
right wrist. Reported initial pain score of 1 on a 1–10 scale. He noticed pain about 160 to 165 
minutes earlier, and it lasted a few minutes while pulling on the Pull Station exercise. Pain score 
remained constant at 1 at 180 minutes, then decreased to a pain score of 0 at 239 minutes, during 
4th-hr questioning. At 5th-hr questioning, subject reported a stiff right ankle, not a soreness, that 
he had first noticed at the last exercise. He gave right ankle a pain score of 2 at 300 minutes. First 
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VGE detected at 134 minutes, Grade 0 from left arm, Grade 0 from left leg, Grade 0 from right 
arm, and Grade 2 from right leg. Last VGE record at 350 minutes with Grade 0 from left arm, 
Grade 0 from left leg, Grade 0 from right arm, and Grade 3 from right leg. At 6th-hr questioning, 
subject reported a slight constant pain in right ankle, a little less noticeable than at 5th-hr 
questioning. There was no further report about right wrist. Symptoms in right ankle resolved 
during descent at 5.3 psia on the way to 10.2 psia. During debrief while at 10.2 psi,a subject 
mentioned that symptoms were best characterized as a constant awareness, not a pain. 
 
Diagnosis: Grade 1 Type I DCS 
Treatment: None, just self-monitoring most likely with follow-up consultation. 
 
35. Summary: ID# 51-01, 26-year-old male, maximum Grade 0, first report at 240 minutes, 
study done on n = 35, independent sample statistical design. 
 
Procedure 8 
 
Narrative: At 240 minutes, during 4th-hr questioning, subject reported a little fatigue in left arm 
but no pain. Did not report initial pain score on the 1–10 scale. At 5th-hr questioning, he still 
report some fatigue in left arm and assigned a 2–3 pain score. At 352 minutes, gave a final report 
of fatigue in left arm bicep. Subject had no VGE during the test. Last VGE record at 341 minutes 
with Grade 0 from left arm, Grade 0 from left leg, Grade 0 from right arm, and Grade 0 from 
right leg. Symptoms of fatigue in left arm resolved during descent at 7.4 psia on the way to 10.2 
psia. During debrief while at 10.2 psia, subject said that feeling of fatigue was worse in 4th-hr 
questioning than toward 6th-hr questioning, but cleared up on repressurization to site pressure. 
There were never any numbness or pins-and-needles sensations. 
 
Diagnosis: Grade 1 Type I DCS 
Treatment: None, just self-monitoring most likely with follow-up consultation. 
 
36. Summary: ID# 47-02, 26-year-old male, maximum Grade 4, first VGE at 39 minutes, first 
report at 123 minutes a symptom he noticed at 113 minutes, study done on n = 35, independent 
sample statistical design. 
 
Procedure 8 
 
Narrative: At 123 minutes, subject reported ache in left knee. Reported initial pain score of 1 
on a 1–10 scale. He noticed pain 10 minutes earlier at 113 minutes at the Doppler monitoring 
station. There was no ache while standing. Pain score remained constant a 1 at 184, 241, 300, 
and 360 minutes. At 2nd-hr questioning, subject reported left knee felt as though it had to be 
“popped” and had a dull pain. At 4th-, 5th-, and 6th-hr questioning, subject reported no change in 
symptoms in left knee. Pain was only noticeable at the Doppler monitoring station and only 
when lifting left leg. First VGE detected at 39 minutes, Grade 0 from left arm, Grade 3 from left 
leg, Grade 0 from right arm, and Grade 0 from right leg. Last VGE record at 358 minutes with 
Grade 0 from left arm, Grade 1 from left leg, Grade 0 from right arm, and Grade 0 from right leg. 
Symptoms in left knee resolved during descent at 5.7 psia on the way to 10.2 psia. During de-
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brief while at 10.2 psia, subject mentioned that pain, which was more like a discomfort, was 
less than he experienced in a previous test (47-01) where he also reported pain in left knee. 
 
Diagnosis: Grade 2 Type I DCS 
Treatment: None, just self-monitoring most likely with follow-up consultation. 
 
37. Summary: ID# 8-04, 28-year-old male, maximum Grade 4, first VGE at 133 minutes, 
first report at 169 minutes a symptom he had at 164 minutes, study done on n = 35, independent 
sample statistical design. 
 
Procedure 8 
 
Narrative: At 169 minutes, subject reported constant pain in right knee and right ankle. 
Reported initial pain score of 1 on a 1–10 scale. He reported that symptom was present 5 minutes 
earlier. At 3rd-hr questioning, reported no change in symptoms from right knee and right ankle. 
At 180 minutes, level was constant at 1; and at 208 minutes, level increased to 2, and was worse 
while moving left leg at the Doppler monitoring station. At 4th-hr questioning, pain score for 
right knee was 1, no mention of was made of right ankle, and a new symptom was reported in 
left knee at a pain score of 1. At 5th- and 6th-hr questioning, a pain score of 1 was given for right 
knee, right ankle, and left knee. His chamber mates (27-05 and 62-02) had also reported 
symptoms during this test. First VGE detected at 133 minutes, Grade 0 from left arm, Grade 0 
from left leg, Grade 0 from right arm, and Grade 2 from right leg. Last VGE record at 351 min-
utes with Grade 0 from left arm, Grade 3 from left leg, Grade 1 from right arm, and Grade 2 
from right leg. Symptoms in both knees and right ankle resolved during descent at 9.0 psia 
on the way to 10.2 psia. 
 
Diagnosis: Grade 2 Type I DCS 
Treatment: None, just self-monitoring most likely with follow-up consultation. 
 
38. Summary: ID# 27-05, 40-year-old male, maximum Grade 4, first VGE at 256 minutes, first 
report at 334 minutes a symptom he noticed at 324 minutes, study done on n = 35, independent 
sample statistical design. 
 
Procedure 8 
 
Narrative: At 334 minutes, subject reported mild pain in right knee. Reported initial pain score 
of 1 on a 1–10 scale. He reported that symptom was present at 324 minutes. At 6th-hr question-
ing, subject reported mild sensation in right knee, mostly present at the Doppler monitoring sta-
tion when right leg was moved horizontally, and also noticed the sensation occasionally at other 
stations. His chamber mates (8-04 and 62-02) had also reported symptoms during this test. This 
subject had reported a symptom in the right knee at 76 minutes in a previous test (27-01). First 
VGE detected at 256 minutes, Grade 0 from left arm, Grade 0 from left leg, Grade 0 from right 
arm, and Grade 2 from right leg. Last VGE record at 348 minutes with Grade 1 from left arm, 
Grade 1 from left leg, Grade 1 from right arm, and Grade 4 from right leg. Symptoms resolved 
prior to descent, while at the test altitude of 4.3 psia. Repressurization was back to 10.2 psia. 
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Diagnosis: Grade 1 Type I DCS 
Treatment: None, just self-monitoring most likely with follow-up consultation. 
 
39. Summary: ID# 44-01, 36-year-old male, maximum Grade 4, first VGE at 107 minutes, 
first report at 225 minutes a symptom he noticed at about 221 minutes, study done on n = 35, 
independent sample statistical design. 
 
Procedure 8 
 
Narrative: At 225 minutes, subject reported pain around the front in right ankle. Reported 
initial pain score of 8–9 on a 1–10 scale for a few seconds, and 3–4 for about 45 seconds; but 
at this time pain was gone. Pain score fluctuated during remainder of test. He first noticed right 
ankle symptom moments before, at about the time of last Doppler measurement at 221 minutes. 
For completeness, subject had initially reported tiredness in right wrist at 1st-hr questioning, and 
tiredness in right forearm at 2nd-hr questioning, with no tiredness in right wrist. At 3rd-hr 
questioning, he reported tiredness in right wrist, along back of right wrist, and in right forearm. 
At this time (180 minutes), he mentioned a momentary sharp pain on back of right wrist. At 4th-
hr questioning, he reported that right ankle had no symptoms, but there was general tiredness in 
right knee at a pain score of 2. Pain was localized in front of right knee, below patella, but did 
not interfere with performance of the exercises. At 255 minutes, subject reported pain in right 
knee at a pain score of 2–3. At 268 minutes, subject reported right wrist and right knee hurt when 
he walked in the chamber but did not hurt when he stood still. At 273 minutes, there was no pain 
while motionless on the Doppler monitoring cot, but there was a noticeable discomfort in right 
knee and right ankle when right leg was moved from a horizontal position. He volunteered a pain 
score of 4. At 5th-hr questioning, pain in right knee was still present and given a pain score of 4 
when walking; it did not interfere with walking. Pain was localized about 2 inches below patella. 
At 331 minute, subject reported slight discomfort in right knee and right ankle while sitting, a 
mild pain in these locations while walking, and overall less pain than previous reports. At 6th-hr 
questioning, subject reported no sharp pain anymore in right knee or right ankle, and not made 
worse by movement now; a pain score of 1 by inference. First VGE detected at 107 minutes, 
Grade 0 from left arm, Grade 0 from left leg, Grade 0 from right arm, and Grade 2 from right leg. 
Last VGE record at 369 minutes with Grade 0 from left arm, Grade 0 from left leg, Grade 1 from 
right arm, and Grade 2 from right leg. Symptoms in right knee and right ankle resolved during 
descent at 10.3 psia on the way to 10.2 psia. 
 
Diagnosis: Grade 2 Type I DCS 
Treatment: None, just self-monitoring most likely with follow-up consultation. 
 
40. Summary: ID# 62-02, 32-year-old male, maximum Grade 1, first VGE at 103 minutes, first 
report at 120 minutes a symptom he noticed at 105 minutes, study done on n = 35, independent 
sample statistical design. 
 
Procedure 8 
 
Narrative: At 120 minutes, during 2nd-hr questioning, subject reported fullness in left knee. 
Reported initial pain score of 1 - 2 on a 1–10 scale. He noticed symptom earlier at 105 minutes. 
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At 3rd-hr questioning, subject reported that left knee was better now; no pain score reported. At 
4th-, 5th- and 6th-hr questioning, there were no problem with left knee. His chamber mates (8-04 
and 27-05) had also reported symptoms during test. First VGE detected at 103 minutes, Grade 0 
from left arm, Grade 1 from left leg, Grade 0 from right arm, and Grade 0 from right leg. Last 
VGE record at 343 minutes with Grade 0 from left arm, Grade 0 from left leg, Grade 0 from 
right arm, and Grade 0 from right leg. VGE grade never exceeded 1, but was detected from left 
leg. There were no symptoms prior to descent; symptoms resolved at the test altitude of 4.3 
psia. Repressurization was back to 10.2 psia. 
 
Diagnosis: Grade 1 Type I DCS 
Treatment: None, just self-monitoring most likely with follow-up consultation. 
 
Bends 3c: DCS Assigned at JSC 
 
41. Summary: ID# 44-03, 36-year-old male, maximum Grade 2, first VGE at 77 minutes, first 
report at 105 minutes, study done on n = 14, independent sample statistical design. 
 
Procedure 9 
 
Narrative: At 105 minutes, subject reported discomfort in right ankle. At 2nd-hr question-
ing, subject reported steady discomfort in right ankle at initial pain score of less than 1 on a 1–
10 scale. Pain score increased to 2 at 145 minutes; transient right hip discomfort had gone away. 
Pain score in right ankle then decreased to 1 at 157 and 178 minutes. At 4th-hr questioning, he 
reported a barely perceptible discomfort in right knee, right ankle had a continuous discomfort. 
Subject had reported pain symptoms in right ankle at 225 minutes during a previous exposure 
(44-01). First VGE detected at 77 minutes, Grade 0 from left arm, Grade 0 from left leg, Grade 1 
from right arm, and Grade 0 from right leg. Last VGE record at 355 minutes with Grade 0 from 
left arm, Grade 0 from left leg, Grade 0 from right arm, and Grade 0 from right leg. At 5th-hr 
questioning, subject reported discomfort in right ankle had increased to a pain score of 2 when 
ankle was rotated, but discomfort did not interfere with his exercise activities. At 6th-hr 
questioning, pain score for right ankle had decreased to 1. Symptoms in right ankle re-
solved during descent to site pressure at 9.5 psia. 
 
Diagnosis: Grade 2 Type I DCS 
Treatment: None, medical observation provided most likely for 12 hrs with follow-up 
consultation. 
 
42. Summary: ID# 48-03, 36-year-old male, maximum Grade 3, first VGE at 172 minutes, first 
report at 300 minutes a symptom he noticed at 296 minutes, study done on n = 14, independent 
sample statistical design. 
 
Procedure 9 
 
Narrative: At 300 minutes, during 5th-hr questioning, subject reported a dull aching pain in right 
knee. He noticed symptom at about 296 minutes while at the Doppler monitoring station. 
Reported initial pain score of 3–4 on a 1–10 scale, based on his recollection of first symptom. 
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Now at 300 minutes, pain score decreased to 1. Right knee was more of a problem whenever he 
put weight on it. At 6th-hr questioning, he reported that right knee pain had been gone since 
shortly after 5th-hr questioning. His exposure to 4.3 psia the previous day (48-02) produced 
a symptom in right shoulder after the 5th hr at 4.3 psia. First VGE detected at 172 minutes, Grade 
0 from left arm, Grade 0 from left leg, Grade 0 from right arm, and Grade 2 from right leg. Last 
VGE record at 352 minutes with Grade 0 from left arm, Grade 0 from left leg, Grade 0 from 
right arm, and Grade 0 from right leg. There were no symptoms prior to descent; symptoms re-
solved at the test altitude of 4.3 psia. During debrief at site pressure, subject mentioned that 
pain in right knee was localized below the patella and was intermittent. He also mentioned 
a little ill-defined pain in his right shoulder. 
 
Diagnosis: Grade 2 Type I DCS 
Treatment: None, medical observation provided most likely for 12 hrs with follow-up 
consultation. 
 
43. Summary: ID# 10-07, 45-year-old male, maximum Grade 3, first VGE at 221 minutes, first 
report at 203 minutes a symptom he noticed at 201 minutes, study done on n = 14, independent 
sample statistical design. 
 
Procedure 9 
 
Narrative: At 203 minutes, subject reported intermittent pain in left ankle. Reported initial pain 
score of 2–3 on a 1–10 scale. He noticed symptom at last exercise station, at about 201 minutes. 
At 4th-hr questioning, he reported pain in left ankle at a decreased pain score of 2; pain was 
associated with movement of ankle joint, was worse if he rose on tiptoes, and was least when 
sitting with weight off his feet. At 5th-hr questioning, left ankle discomfort was intermittent and 
subsided to a pain score of 1. At 6th-hr questioning, left ankle discomfort was still intermittent 
and subsided to a pain score of less than 1. First VGE detected at 221 minutes, Grade 0 from left 
arm, Grade 2 from left leg, Grade 0 from right arm, and Grade 0 from right leg. Last VGE record 
at 349 minutes with Grade 0 from left arm, Grade 0 from left leg, Grade 0 from right arm, and 
Grade 0 from right leg. Symptoms in left ankle resolved during descent at 6.3 psia. During 
debrief at site pressure, subject mentioned pain in left ankle was directly on the ankle, and on 
both sides. 
 
Diagnosis: Grade 2 Type I DCS 
Treatment: None, medical observation provided most likely for 12 hrs with follow-up 
consultation. 
 
Bends 3d: DCS Assigned at JSC 
 
44. Summary: ID# 60-03, 23-year-old male, maximum Grade 4, first VGE at 105 minutes, first 
report at 239 minutes, study done on n = 12, independent sample statistical design. 
 
Procedure 10 
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Narrative: Subject had reported symptoms at 1 hr in left shoulder and left elbow the day before 
while at 4.3 psia. PI was not convinced that these were symptoms of DCS. During the morning 
prior to 2nd test to 4.3 psia, subject reported to PI that he had no aches or pains in the shoulder 
while at 10.2 psia for the evening. But when he awoke, he had a slight numbness in a leg that 
lasted 10 minutes until he moved around. The logbook was not clear which leg had a slight 
numbness. Subject was clear to perform the test. At 239 minutes, subject reported slight 
discomfort in left shoulder. Reported initial pain score of 3 on a 1–10 scale while exercising the 
limb; score decreased to 1 when not exercising the limb. Subject reported that pain was similar to 
that he experienced during the previous test, 1 day earlier. At 5th-hr questioning, subject still 
reported slight pain in left shoulder, with a pain score of 1. At 335 minutes, subject reported 
slight stiffness in right ankle that he noticed moments before while walking between exercise 
stations. He assigned it a pain score of 1–2. At 6th-hr questioning, subject reported slight pain in 
left shoulder, at a pain score of 3 with right ankle assigned a score of 4. Subject had previously 
reported (60-01) a symptom in right ankle at 5th-hr questioning of the test, but this was in a test 
that was conducted about 2 weeks earlier. First VGE detected at 105 minutes, Grade 0 from left 
arm, Grade 0 from left leg, Grade 0 from right arm, and Grade 3 from right leg. Last VGE record 
at 353 minutes with Grade 0 from left arm, Grade 0 from left leg, Grade 0 from right arm, and 
Grade 2 from right leg. Symptoms in right ankle resolved during descent at 9.5 psia, and 
symptoms in left shoulder were reported to feel better at 13 psia. During debrief at site pressure, 
the PI was not as clear that subject’s left shoulder was a DCS problem, but was clear that right 
ankle pain was a clear DCS problem. 
 
Diagnosis: Grade 2 Type I DCS 
Treatment: None, medical observation provided most likely for 12 hrs with follow-up 
consultation. 
 
45. Summary: ID# 42-05, 28-year-old male, maximum Grade 2, first VGE at 149 minutes, first 
report at 241 a symptom he noticed at 216 minutes, study done on n = 12, independent sample 
statistical design. 
 
Procedure 10 
 
Narrative: Subject had no reported aches or pains during exposure to 4.3 psia the previous 
day. At 241 minutes, during 4th-hr questioning, subject reported ache in right ankle. Reported 
initial pain score of 3 on a 1–10 scale. He had first noticed symptom 25 minutes earlier; but ache 
did not interfere with exercise activities. First VGE detected at 149 minutes, Grade 0 from left 
arm, Grade 0 from left leg, Grade 1 from right arm, and Grade 2 from right leg. Last VGE record 
at 347 minutes with Grade 0 from left arm, Grade 0 from left leg, Grade 0 from right arm, and 
Grade 0 from right leg. At 5th-hr questioning, subject reported pain in right ankle had subsided to 
a pain score of 2, but was still a continuous pain. It felt worse when putting his weight on right 
ankle. He felt 2 distinct pains in right ankle while lying down: one on top of the ankle and one 
under the ankle. Pain on top of the ankle was worse when lying down. At 6th-hr questioning, 
subject reported pain in right ankle only hurt when he put weight on it, but still about a pain 
score of 2 when weight was put on it. Symptoms in right ankle resolved during descent at 
7.3 psia. During debrief at site pressure, subject localized right ankle pain to the muscle 
or tendons around the joint, and not to pain within the joint. 
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Diagnosis: Grade 2 Type I DCS 
Treatment: None, medical observation provided most likely for 12 hrs with follow-up 
consultation. 
 
Bends 4a: DCS Assigned at JSC 
 
46. Summary: ID# 64-01, 29-year-old male, maximum Grade 4, first VGE at 16 minutes, first 
report at 60 minutes a symptom he noticed at 24 minutes, study done on n = 12, independent 
sample statistical design. 
 
Procedure 11 
 
Narrative: At 1st-hr questioning, subject reported that about 35 minutes earlier (24 minutes 
elapsed time) he experienced a slight dull ache in left elbow. At this time while at the Doppler 
monitoring station, he noticed a transient twinge in left knee and persistent twinge in right knee. 
Reported initial pain score of 1 on a 1–10 scale for left elbow and left knee, and a score of 3 for 
right knee. None of the 3 symptoms interfered with exercise activities. Pain score decreased to 1 
at 119 minutes, and then decreased to 0 at 176 minutes. At 2nd-hr questioning, subject reported 
no noticeable aches or pain sensations at all from right knee, but characterized symptoms in left 
elbow and left knee as a very slight awareness. First VGE detected at 16 minutes, Grade 3 from 
left arm, Grade 3 from left leg, Grade 0 from right arm, and Grade 2 from right leg. Last VGE 
record at 162 minutes with Grade 2 from left arm, Grade 4 from left leg, Grade 1 from right arm, 
and Grade 4 from right leg. At 3rd-hr questioning, there were no symptoms to report, and the 
chamber was recompressed to 10.2 psia for a lunch break prior to second decompression of the 
day back to 4.3 psia. There were no symptoms prior to descent to 10.2 psia; symptoms resolved 
at the test altitude of 4.3 psia. Just after arriving at 10.2 psia for a lunch break, a Doppler reading 
was taken and subject had no VGE. Subject had no VGE on the second 3-hr exposure to 4.3 psia 
after the lunch break. 
 
Diagnosis: Grade 2 Type I DCS 
Treatment: None, just self-monitoring most likely with follow-up consultation. 
 
Bends 5a: DCS Assigned at JSC 
 
47. Summary: ID# 91-01, 51-year-old female, maximum Grade 4, first VGE at 128 minutes, 
first report at 180 minutes a symptom she noticed at 165 minutes, study done on n = 38, inde-
pendent sample statistical design.  
 
Procedure 12 
 
Narrative: At 180 minutes, subject reported that right ankle hurt a little. Did not report initial 
pain score on the 1–10 scale. Ache was first noticed at the Doppler monitoring station, as a little 
twinge that came and went. Symptom did not interfere with exercise activities by 3rd hr. She 
mentioned that symptom had appeared about 15 minutes earlier (165 minutes); her only other 
report, at 2nd-hr questioning, was a transient cramp in her left side during previous exercise 
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activity. At 180, 240, 300, and 360 minutes, level remained constant at 1. At 4th-hr questioning, 
she reported there was still an intermittent twinge in her right ankle, no better or worse than 
before, and a little more pronounced when she lay down at the Doppler monitoring station. At 
the 5th-hr questioning, she reported that right ankle still felt funny when rotating the joint. At 6th-
hr questioning, she reported a slight discomfort in right ankle, but not as bad as previous reports. 
First VGE detected at 128 minutes, Grade 0 from left arm, Grade 0 from left leg, Grade 0 from 
right arm, and Grade 3 from right leg. Last VGE record at 344 minutes with Grade 0 from left 
arm, Grade 0 from left leg, Grade 0 from right arm, and Grade 1 from right leg. Subject had a 
right ear block during descent that diverted from detailed monitoring of any change in symptoms 
in right ankle. There were no symptoms in right ankle at site pressure. During debrief, she men-
tioned that mild pain had bothered her for about 2 hrs, but gradually became a very mild 
sensation by the end of the test. 
 
Diagnosis: Grade 1 Type I DCS 
Treatment: None, just self-monitoring most likely with follow-up consultation. 
 
48. Summary: ID# 92-01, 45-year-old female, maximum Grade 3, first VGE at 277 minutes, 
first report at 300 minutes a symptom she noticed at 292 minutes, study done on n = 38, inde-
pendent sample statistical design. 
 
Procedure 12 
 
Narrative: At 300 minutes, during 5th-hr questioning, subject reported that right arm had 
experienced a hurtful sensation, in both the right wrist and right upper arm. Did not report initial 
pain score on the 1–10 scale. She noticed symptoms at about 292 minutes while at the previous 
Doppler monitoring station. At 300 minutes, symptom in right arm was all but gone. Feeling was 
slight in right wrist, arm, and upper arm. At 312 minutes, she felt a sensation in right arm while 
she was on the cot used for Doppler monitoring. Bubbles were not detected with confidence until 
312 minutes into the test. There were Grade 2 and 3 VGE from the left and right leg with a single 
Grade 1 VGE from the right arm at 312 minutes. She reported no symptoms at 328 minutes or at 
360 minutes. First VGE detected at 277 minutes, Grade 0 from left arm, Grade 2 from left leg, 
Grade 0 from right arm, and Grade 0 from right leg. Last VGE record at 348 minutes with Grade 
0 from left arm, Grade 0 from left leg, Grade 0 from right arm, and Grade 0 from right leg. There 
were no symptoms prior to descent; symptoms resolved at the test altitude of 4.3 psia. During 
debrief, she mentioned that there was pain also in her right shoulder, and all symptoms in the 
right arm had appeared during the Doppler monitoring period just prior to and just after the 4th hr 
of the test. 
 
Diagnosis: Grade 2 Type I DCS 
Treatment: None, just self-monitoring most likely with follow-up consultation. 
 
49. Summary: ID# 96-01, 27-year-old male, maximum Grade 4, first VGE at 39 minutes, first 
report at 60 minutes a symptom he noticed minutes earlier, study done on n = 38, independent 
sample statistical design. 
 
Procedure 12 
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Narrative: At 60 minutes, subject reported pain in left ankle. Did not report initial pain score 
on the 1–10 scale. He reported that pain was first noticed during the previous Doppler monitor-
ing, and ached only when the joint was rotated. At 80 minutes, he reported that pain had spread 
to left knee and felt “like when you need to pop a knuckle,” but it did not interfere with exercise 
activities. At 2nd-hr questioning, subject reported that left ankle pain was only noticeable when 
moving the joint, and left knee pain had not changed in intensity or character since the last report 
at 80 minutes. At 3rd-hr questioning, the left ankle felt okay, but there was still pain in the left 
knee especially during the Doppler monitoring. He reported a new pain in the right ankle, which 
appeared about 30 minutes earlier. Pain score remained constant at 1 at 80, 120, 150, 180, 199, 
219, and 240 minutes, but increased to 9–10 at 300 and 360 minutes. At 219 minutes, subject 
reported that right knee pain was noticeable while just quietly sitting, but still not severe enough 
to interfere with exercise activities. At 4th-hr questioning, pain in left ankle was the same, a de-
crease of pain in the left knee, right ankle, and right knee. At 5th-hr questioning, subject reported 
that left knee, left ankle, right knee, and right ankle were the same as before. However, at this 
time subject volunteered a pain score of 9–10, but the logbook does not specify the location for 
these scores. At 6th-hr questioning, subject reported left leg had less intense pain than right leg. 
First VGE detected at 39 minutes, Grade 0 from left arm, Grade 2 from left leg, Grade 2 from 
right arm, and Grade 0 from right leg. Last VGE record at 356 minutes with Grade 0 from left 
arm, Grade 1 from left leg, Grade 0 from right arm, and Grade 3 from right leg. Symptoms in 
both legs (knees and ankles) resolved during descent at 5.0 psia at the same time. During debrief, 
subject volunteered that left ankle had become sore on movement about 30 minutes into the test, 
and pain had spread to left knee after about 10–15 minutes. Pain had intensified over the next hr. 
Then about 3 hrs into the test, the right ankle and right knee followed the same pattern 
of symptom onset. There were periods where symptoms were more noticeable, especially dur-
ing the Doppler monitoring periods or when getting up from a seated or lying position. 
 
Diagnosis: Grade 2 Type I DCS 
Treatment: None, just self-monitoring most likely with follow-up consultation. 
 
50. Summary: ID# 97-01, 36-year-old female, maximum Grade 4, first VGE at 91 minutes, first 
report at 112 minutes a symptom she noticed at 104 minutes, study done on n = 38, independent 
sample statistical design. 
 
Procedure 12 
 
Narrative: At 112 minutes, subject reported dull ache in right knee. Reported initial pain 
score of 1 on a 1–10 scale. Subject reported that she first noticed ache at about 104 minutes after 
completing the Doppler monitoring, and it did not interfere with her exercise activity. Pain score 
increased to 2 at 120 and 132 minutes, and then increased to 4–5 at 149 minutes followed by a 
decrease to 3 at 180 minutes. At 120 minutes, during 2nd-hr questioning, she said that ache in 
right knee was just a little worse than before. It was a continuous ache that did not interfere with 
her performance. At 132 minutes, subject reported that right knee was getting tender to walk on, 
and she needed to limp to get to the different exercise stations. At 144 minutes, subject reported 
a dull sensation in right hip that felt like the sensation she first had in right knee, but at a lower 
intensity than was in right knee at that time. At 149 minutes, subject reported that right ankle was 
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now hurting, but she was still able to walk from station to station. At 3rd-hr questioning, she 
reported that an ache was still present in right knee and right ankle, but pain in right hip was not 
as bad as before. A pain score of 2.5 was provided, but it was unclear if this was for one or all 
the locations. An earlier report at 155 minutes of pain in the left ankle of the DT had increased, 
and the DT’s right ankle had become involved at 192 minutes. At 194 minutes both knees, and 
especially the right knee, of the DT became painful enough to cause the early termination of the 
test. First VGE for subject was detected at 91 minutes, Grade 0 from left arm, Grade 0 from left 
leg, Grade 0 from right arm, and Grade 2 from right leg. Last VGE record at 176 minutes with 
Grade 0 from left arm, Grade 0 from left leg, Grade 2 from right arm, and Grade 3 from right leg. 
Symptoms in right knee, right ankle, and right hip for subject resolved dramatically during 
descent at 5.9 psia. During debrief, subject mentioned that pain in right ankle went from a 
pain score of 6 to a pain score of about 2 toward the end of the test. 
 
Diagnosis: Grade 2 Type I DCS 
Treatment: None, just self-monitoring most likely with follow-up consultation. 
 
Bends 6: DCS Assigned at JSC 
 
51. Summary: ID# 109-01, 31-year-old male, maximum Grade 3, first VGE at 98 minutes, first 
report at 182 minutes a symptom he noticed at 152 minutes, study done on n = 29, independent 
sample statistical design. 
 
Procedure 13 
 
Narrative: At 182 minutes, at the 3rd-hr questioning, subject reported a dull pain localized in the 
belly of left bicep, but no joint pain. Did not report initial pain score on the 1–10 scale. During 
debrief, he mentioned that symptom had appeared about 30 minutes earlier. At 4th-hr 
questioning, subject reported that he still had a dull continuous pain in his left arm. At 180, 240, 
300, and 360 minutes, the pain score remained constant at 1. At 240 minutes, subject reported 
there was still a dull pain in left arm. At 300 minutes, pain was receding; by 360 minutes, there 
was still some pain in left arm. At 6th-hr questioning, he also volunteered that he experienced 
a slight ache in right ankle when he walked on right leg. But ache was gone when he sat quietly 
(he later recalled that he had symptoms in right ankle while resting just prior to repressurization). 
First VGE detected at 98 minutes, Grade 0 from left arm, Grade 0 from left leg, Grade 0 from 
right arm, and Grade 1 from right leg. Last VGE record at 356 minutes with Grade 0 from left 
arm, Grade 0 from left leg, Grade 0 from right arm, and Grade 0 from right leg. Symptoms in 
left arm and right ankle did not clear during descent, but were resolved at site pressure. During 
debrief, he reported that he first noticed pain in left arm as a dull sensation about 30 minutes be-
fore reporting it. This dull pain was in the tricep muscle (bicep was mentioned in another section 
of the logbook, but it appears to have been in the tricep), and was a continuous pain. Subject was 
asked to turn the ergometer at site pressure and to walk about to see if any symptoms were pres-
ent in the right ankle or left arm. Subject reported that the symptoms were amazingly diminished, 
and no pain was present in any limb by the end of debrief. Subject was contacted 48 hr later by 
the PI. Subject mentioned that he had twisted his right ankle 4 or 5 times in the past 4 or 5 years, 
and that he did recall having symptoms in his right ankle just prior to repressurization to site 
pressure at the end of the 6-hr test. 
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Diagnosis: Grade 1 Type I DCS 
Treatment: None, just self-monitoring most likely with follow-up consultation. 
 
Bends 7a (high exercise): DCS Assigned at JSC 
 
52. Summary: ID# 123-01, 28-year-old male, maximum Grade 4, first VGE at 61 minutes, first 
report at 90 minutes, study done on n = 11, crossover dependent sample statistical design. 
 
Procedure 14 
 
Narrative: At 90 minutes, subject reported a cramp in lower right leg (calf). Did not report 
initial pain score on a 1–10 scale. Still had cramp at 94 minutes, but did not have it during prac-
tice exercise at site pressure. There was no pain score report at 121, 161, or 172 minutes into the 
test. At 100 minutes, the cramp had diminished. At 120 minutes, he reported a slight headache in 
frontal area and pain in bell of muscle of right calf; the pain was present most of the time now. 
At 127 minutes, the PI noted that what started out as a cramp was now a mild throbbing that had 
diminished in discomfort. At 164 minutes, he reported pain in right knee, shooting and throb-
bing, “pretty good jab of pain.” When he had right knee up, it hurt; when it was extended, the 
pain diminished. Pain was in back of, in front of, and all around knee, but did not interfere with 
performance. First VGE detected at 61 minutes, Grade 0 from left arm, Grade 4 from left leg, 
Grade 1 from right arm, and Grade 4 from right leg. Last VGE record at 161 minutes with Grade 
0 from left arm, Grade 3 from left leg, Grade 0 from right arm, and Grade 3 from right leg. At 
172 minutes, subject reported dizziness and sudden onset of “wobbly” and then blurred vision. 
Test was immediately aborted. Symptoms were clearing within 2 minutes of repressurization to 
site pressure. Vision cleared at 10.1 psia, headache cleared at 10.9 psia, and knee pain resolved 
just prior to return to site pressure (13.7 to 14.7 psia). At debrief, he described last symptom 
as dizziness associated with at first a “wobbly” vision that he found hard to describe, then a 
blurring of vision. There were no signs of posttest neurological deficit. 
 
Diagnosis: Type II DCS with Grade 3 Type I DCS  
Treatment: Two-hr GLO, 12-hr medical observation, then released from study with follow-up 
consultation. Subject did have a PFO, with positive indication at rest. Dr. Meehan made 
additional opthalamic observations with a fundus camera immediately after the return to site 
pressure, but comments in the logbook were illegible. 
 
53. Summary: ID# 121-01, 30-year-old male, maximum Grade 4, first VGE at 49 minutes, first 
report at 75 minutes, study done on n = 11, crossover dependent sample statistical design. 
 
Procedure 14 
 
Narrative: At 75 minutes, subject reported continuous pain in left-hand ring finger, at joint 
just behind fingernail. Did not report initial pain score on the 1–10 scale. At 83 minutes and 96 
minutes, pain in left-hand ring finger was almost gone. By 102 minutes, there was no pain in left-
hand ring finger. Pain score was not reported at 155 or 160 minutes into test. At 159 minutes, he 
reported pain in right knee, just below the patella. Subject reported that he noticed the sharp pain 
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about 30 seconds before reporting it. It was determined that although it caused repeated pain 
on the row machine, this did not interfere with performance. First VGE detected at 49 minutes, 
Grade 0 from left arm, Grade 1 from left leg, Grade 0 from right arm, and Grade 0 from right leg. 
Last VGE record at 164 minutes with Grade 2 from left arm, Grade 2 from left leg, Grade 2 from 
right arm, and Grade 4 from right leg. At 172 minutes, he reported pain behind right eye; a throb-
bing headache localized behind right eye felt like a sinus headache. Test was aborted, and recom-
pression to site pressure began approximately 8 minutes from the report of pain behind the right 
eye. Headache was diminishing with increased ambient pressure; knee pain was greatly reduced 
but still some awareness at site pressure. Ophthalmologic examination at site pressure revealed 
some sheathing of vessels and some change in the ground. While waiting for the chamber to be 
readied, the headache did not resolve and may have increased its focal area and intensity. Both 
headache and residual knee pain were resolved during the treatment. Ophthalmologic signs 
decreased during treatment. At no time did subject have visual symptoms. 
 
Diagnosis: Type II DCS and Grade 2 Type I DCS 
Treatment: One-hr GLO prior to USN HBO TT VI, medical observation for 12 hrs with follow-
up consultation over the next several days. A final ophthalmologic exam was negative. Did not 
have a detectable PFO.  
 
Test Director’s / Principal Investigator’s Special Report on Bends VII Test 11 
 
Eleventh test of the Bends VII Test Series was conducted on 1/13/89. The test subjects are designated at Subject #1 
(122-02), who was conducting the low metabolic rate profile and Test Subject #2 (121-01), who was conducting the 
high metabolic rate profile. The DT was JC, the Test Director was JW, the Test Investigator was Dr. KV and the test 
Surgeon was Dr. PS. Each of the test subjects had already completed one of the paired tests called for in the test 
series plan. Venous bubbles had been detected on both subjects during their previous run. Test subject #1 had exper-
ienced no symptoms during his prior high metabolic rate run. Test subject #2 had experienced simple limb bends in 
his left knee in the conduct of his low metabolic rate test. This symptom was judged to be Grade 2 limb bends and 
did not result in an early termination of that test. The symptom was resolved upon return to site pressure at the end 
of the test. Subject was observed for 12 hrs and released without further symptoms. The test series protocol called 
for each of the test subjects to have a fundus camera measurement after one of their 2 test runs. Subject #1 had not 
had the measurement on his previous run and so was scheduled to have it on this run. Subject #2 had this measure-
ment on his previous run and was not scheduled to have the measurement on this run. 
 
The test was begun with the start of ascent to 10,000 feet at 9:21. The start of ascent to 21,000 feet, the test altitude, 
was at 9:24. The test altitude, 21,000 feet was reached at 9:28 and the elapsed time clock was started at 0:00 at this 
same time. At this time subjects were asked the baseline question about any pain or discomfort. Subject #2 stated 
that he had measles shot about four days ago and that his right deltoid was a little sore. He reported that he had no 
other aches or pains. Subject #1 reported no ache or pain. 
 
Subjects then began their test exercises that they were to sustain for the three hrs and 16 minutes of the planned test 
duration. After 1 hr, in response to questioning, subject #1 reported everything was fine except for a dry mouth. 
Subject #2 reported he had no aches or pains other than the right shoulder where the soreness was less noticeable 
than originally. At an elapsed time of 1 hr and 15 minutes, subject #2 reported pain in the left fourth finger, left hand 
next to the little finger. This was a continuous pain in the knuckle, first joint right behind the fingernail. This pain 
was not interfering with performance and the test continued. At an elapsed time of 1 hr and 23 minutes crewman #2 
reported that the pain in the finger was almost gone. At an elapsed time of 1 hr and 24 minutes subject #l reported a 
sharp momentary pain in the right elbow that was then continuous at a lower level that did not interfere with 
performance. At an elapsed time of 1 hr and 36 minutes both subjects were questioned about their symptoms. 
Subject #2 reported that his finger pain was much better, almost gone. Subject #1 reported that his elbow was still a 
little painful but not like it was on the rowing machine, where he first reported the symptom. At an elapsed time of 1 
hr and 42 minutes subject #2 was questioned and said he had no pain in his finger. At an elapsed time of 1 hr and 46 
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minutes Subject #1 reported that the pain in the elbow was just about cleared up. This was immediately after 
working on the rowing machine where the symptom was first reported. At about this time there was an error in the 
exercise routine that resulted in subject #2 working at the peak exercise rate of 2,000 Btu/hr for 20 minutes rather 
than the planned 16 minutes. So four additional minutes of the subsequent work rate, which should have been at the 
1440 Btu / hr rate, was at 2,000 Btu/hr. 
 
At the end of the second hr, after all the high exercise in the high exercise protocol was completed, in response to 
the hrly questions, Subject #1 stated that his right shoulder and his right elbow were a little sore, but nothing like at 
the time it first appeared on the rowing machine. This was the first time subject had mentioned his shoulder. He was 
asked about this and replied that when he first described the elbow pain, the shoulder did not hurt and now it does 
but that it could be due to his body position during the Doppler monitoring (on his left side) which is very 
uncomfortable. The sensations are separate and distinct, and they are continuous. They did not interfere with 
performance. Subject #2 reported no symptoms. He was asked about his finger and reported that the previous 
pain in the finger was completely gone. 
 
The test was continued into the third hr according to protocol. In chamber blood draws were done in the first 30 
minutes of this hr so there is some reduction in the work activity during this period. At an elapsed time of 2 hr and 
39 minutes Subject #2 reported that he had a pain originating right below the kneecap of the right knee and that he 
stated having sharp pains thereafter. He had this pain for about 30 seconds before contacting us. The subject was 
stopped in his exercise sequence while he was being questioned. The Investigator and the Surgeon asked subject 
questions to determine if the symptoms were Grade 2 or Grade 3 symptoms interfering with performance. Subject 
said that he could continue without much trouble but with some pain. At this point the scheduled rowing activity 
was completed and subject was asked to move to the next station, which was the Doppler station he did so without 
limping. It was determined that the symptoms were Grade 2, and the test was continued. At an elapsed time of 2 hr 
and 52 minutes Subject #2 reported pain behind the right eye. Subject was seated and questioned by the test 
Surgeon. He reported a throbbing headache behind the eye, more specifically behind the right eye. At one point he 
said it feels like a sinus headache. At 3 hr elapsed time the test was aborted. At that time subject #1 reported no pain 
anywhere even when he moved his right elbow and shoulder. Subject #2 had some pain in the right knee but only 
when he moves it around. He still had the headache. During repress to site pressure at 10,000 feet subject #2 
reported no change in symptoms. At 5,000 feet he reported that the headache was dispersing, not as bad. At site 
pressure subject #2 reported that he felt pretty good, still some headache, leg pain none, hardly at all. Ophthal-
mologic examination revealed some sheathing around major vessels and some change in color of the ground. The 
decision was made to treat with a table 6 treatment. Subject #2 was held in the altitude chamber on O2 until the 
hyperbaric chamber was ready. Altitude chamber reached site pressure at an elapsed time of 3 hr and 4 minutes, a 
clock time of about 12:28. At 12:37 a posttest Doppler on subject #2 showed he still had some bubbles on movement 
of the right leg. Subject was transported to the hyperbaric chamber at 1:34 and treatment was started at about 1:42. 
Details of the treatment are reported in the outside MO report of the treatment. Subject had both CNS and limb 
bends symptoms at the beginning of the treatment and the symptoms disappeared during the 60-feet portion of the 
treatment table. The ophthalmologic signs also decreased during the treatment. All signs and symptoms were gone 
at the completion of the treatment. Fundus camera photographs of the eyes were taken that evening. Subject was 
observed for the next 12 hrs without incident and follow-up was continued for the next several days. A visual field 
mapping procedure is scheduled with a local ophthalmologist on 1/24/89. At no time has subject had any visual 
symptoms, and has no residual symptoms of any kind. 
 
54. Summary: ID# 120-01, 23-year-old male, maximum Grade 4, first VGE at 81 minutes, first 
report at 78 minutes, study done on n = 11, crossover dependent sample statistical design. 
 
Procedure 14 
 
Narrative: At 78 minutes, subject reported slight pain under patella of left knee. Reported 
initial pain score of 1 on a 1–10 scale. At 93 minutes, subject reported that pain had increased to 
a 2–3, and was constant. At 103 minutes, pain was described as located in the front and back of 
left knee, was constant, and had a pain score of 3. At 2nd-hr questioning, subject reported that 
pain in left knee was spreading down left leg, and that both wrists had a pain score of 1 on 
156 
 
flexing the wrists. At 145 minutes, subject reported that left knee pain had somewhat subsided. 
At 3rd-hr questioning, subject reported no pain in the wrists, and left knee pain was still at a pain 
score of 3. First VGE detected at 81 minutes, Grade 0 from left arm, Grade 1 from left leg, Grade 
0 from right arm, and Grade 1 from right leg. Last VGE record at 192 minutes with Grade 0 from 
left arm, Grade 3 from left leg, Grade 0 from right arm, and Grade 2 from right leg. Symptoms in 
left knee resolved during descent at 7.65 psia. 
 
Diagnosis: Grade 2 Type I DCS 
Treatment: One-hr GLO, under medical monitoring for 12 hrs. Posttest GLO was extended 10 
minutes due to complaint of chest tightness after the fundus camera pictures of the eyes were 
completed. Follow-up consultation the next day was done. 
 
55. Summary: ID# 117-01, 26-year-old male, maximum Grade 4, first VGE at 49 minutes, 
first report at 169 minutes a symptom he noticed minutes earlier, study done on n = 11, crossover 
dependent sample statistical design. 
 
Procedure 14 
 
Narrative: At 169 minutes, subject reported a dull ache in left knee that was noticed during 
earlier exercise period and was intermittent while pushing on the joint during exercise. Did not 
report initial pain score on the 1–10 scale. Ache was not present at the time of the report at 169 
minutes. At 175 minutes, subject reported that there was a dull ache in left knee when he lifted 
his left leg off the floor. At 3rd-hr questioning, subject reported that left knee had a dull but clear 
low level of pain that did not interfere with any activities, and that knee felt like it was over-
extended. Pain score was not reported at 181 minutes into test. First VGE detected at 49 minutes, 
Grade 0 from left arm, Grade 2 from left leg, Grade 0 from right arm, and Grade 0 from right leg. 
Last VGE record at 193 minutes with Grade 0 from left arm, Grade 2 from left leg, Grade 0 from 
right arm, and Grade 0 from right leg. At 185 minutes, subject reported no symptoms in left knee 
using the row machine; but at 200 minutes on the row machine, there was a symptom, but not on 
standing. It is not clear why the test was extended by approximately 24 minutes, but 
recompression began at 204 minutes with no report of left knee symptoms then. Subject did not 
report if there was a change in left knee symptoms during descent. 
 
Diagnosis: Grade 2 Type I DCS 
Treatment: One-hr GLO with follow-up consultation. 
 
Bends 7b (low exercise): DCS Assigned at JSC 
 
56. Summary: ID# 121-02, 30-year-old male, maximum Grade 4, first VGE at 64 minutes, 
first report at 119 minutes a symptom he noticed at about 109 minutes, study done on n = 11, 
crossover dependent sample statistical design. 
 
Procedure 15 
 
Narrative: At 119 minutes, subject reported ache in left knee, left ankle, and right shoulder. 
Did not report initial pain score on the 1–10 scale. Subject reported that ache in left knee was 
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noticed about 10 minutes earlier, was hurting more during the row machine exercise, and was 
now continuous. Left ankle ache was noticed only on the row machine, with right shoulder ache 
occurring only once or twice during previous exercise. Pain score was not reported at 178 or 194 
minutes into test. First VGE detected at 64 minutes, Grade 2 from left arm, Grade 3 from left leg, 
Grade 2 from right arm, and Grade 0 from right leg. Last VGE record at 185 minutes with Grade 
2 from left arm, Grade 4 from left leg, Grade 1 from right arm, and Grade 4 from right leg. At 
3rd-hr questioning, subject reported a little discomfort in left knee; discomfort had not changed 
from previous reports. Left ankle and right shoulder pain had gone by the end of the test. Subject 
reported that he still felt something in his left knee during descent, but that knee was a lot better. 
During debrief, subject reported that there was still an awareness in left knee, but not pain. There 
was a discussion about pretest symptoms in the left knee that may have influenced the incom-
plete posttest response to recompression to site pressure. There were no symptoms in left 
knee at the conclusion of the posttest period of GLO. 
 
Diagnosis: Grade 2 Type I DCS 
Treatment: One-hr GLO with follow-up consultation. 
 
57. Summary: ID# 122-02, 45-year-old male, maximum Grade 3, first VGE at 25 minutes, first 
report at 84 minutes, study done on n = 11, crossover dependent sample statistical design. 
 
Procedure 15 
 
Narrative: At 84 minutes, subject reported a sharp pain in right elbow, like pain from the stick 
of a needle. Pain did not interfere with performance of formal exercise protocol. Did not report 
initial pain score on the 1–10 scale. Pain score was not reported at 120 minutes, but it was report-
ed as 0 at 179 minutes. At 96 minutes, subject reported that right elbow was still a little painful, 
but not like it was at report from the row machine. No VGE detected from left arm or right arm, 
but Grade 2 VGE were detected after 25 minutes in the right and left leg. First VGE detected at 
25 minutes, Grade 0 from left arm, Grade 2 from left leg, Grade 0 from right arm, and Grade 2 
from right leg. Last VGE record at 169 minutes with Grade 0 from left arm, Grade 0 from left 
leg, Grade 0 from right arm, and Grade 0 from right leg. Grade increased to 3, mostly in right 
leg. Test was terminated earlier than planned at just less than 3 hrs due to a Type II symptom in 
his chamber mate (121-01). There were no symptoms prior to descent; symptoms resolved at the 
test altitude of 6.5 psia. During debrief, pain in right elbow was described as having come on 
quickly, and as stabbing needles. Pain was continuous at lower levels but did not interfere with 
subject’s ability to perform the exercises. Subject said pain in right shoulder was over the 
scapula area, and only lasted 10 minutes. 
 
Diagnosis: Grade 2 Type I DCS 
Treatment: One-hr GLO with follow-up consultation. 
 
Bends 8a:(no prior treadmill exercise) DCS Assigned at JSC 
 
58. Summary: ID# 146-02, 35-year-old male, maximum Grade 1, first VGE at 37 minutes, 
first report at 54 minutes a symptom he noticed at 42 minutes, study done on n = 40, crossover 
dependent sample statistical design. 
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Procedure 16 
 
Narrative: At 54 minutes, subject reported pain in both right knee and left knee. Reported 
initial pain score of 6 on a 1–10 scale, but said right knee was more severe than left knee. During 
previous period at Doppler monitoring station, he said pain became more severe and standing did 
not help it. He first noticed symptoms in right knee at about 42 minutes; then about 3 minutes 
later, the left knee began to ache. Pain score increased to 8 at 60 minutes into test. Due to the 
intolerable nature and rapid onset of the knee pains, a decision was made to remove subject from 
the chamber. Initiated repressurization at 60 minutes. First VGE detected at 37 minutes, Grade 0 
from left arm, Grade 0 from left leg, Grade 0 from right arm, and Grade 1 from right leg. Last 
VGE record at 37 minutes with Grade 0 from left arm, Grade 0 from left leg, Grade 0 from right 
arm, and Grade 1 from right leg. Symptoms in both knees improved during descent such that at 
10.1 psia discomfort had decreased to a pain score of 3 while standing. Symptoms completely 
resolved during descent at 11.34 psia. During debrief, subject said right knee ache was first like 
a muscle “kink.” He said that both knees and thigh (first time mentioned in notes) had fairly 
severe pain in the joint. This last statement is as clear as debrief notes allow. 
 
Diagnosis: Grade 3 Type I DCS 
Treatment: Two-hr GLO with follow-up consultation. 
 
59. Summary: ID# 139-02, 23-year-old male, maximum Grade 0, first report at 80 minutes 
a symptom he noticed moments earlier, study done on n = 40, crossover dependent sample 
statistical design. 
 
Procedure 16 
 
Narrative: At 80 minutes, subject reported awareness in right ankle. Reported initial pain 
score of 2 on a 1–10 scale. Awareness did not interfere with exercise activities, and subject 
realized symptom moments earlier. Pain score remained constant at 2 at 120 minutes for right 
ankle. Subject also volunteered a pain score of 1 for a slight ache in middle of the back at 120 
minutes. At 3rd-hr questioning, there was still a pain score 2 in right ankle. Last VGE record 
at 174 minutes with Grade 0 from left arm, Grade 0 from left leg, Grade 0 from right arm, and 
Grade 0 from right leg. No VGE were detected in this subject. Symptoms in right ankle re-
solved during descent at 8.8 psia. 
 
Diagnosis: Grade 1 Type I DCS 
Treatment: One-hr GLO with follow-up consultation. 
 
60. Summary: ID# 147-01, 42-year-old male, maximum Grade 4, first VGE at 64 minutes, first 
report at 104 minutes, study done on n = 40, crossover dependent sample statistical design. 
 
Procedure 16 
 
Narrative: At 104 minutes, subject reported occasional pain in left knee. At 2nd-hr questioning, 
subject reported that left knee still hurt slightly, with steady pain. Reported pain score of 1 on a 
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1–10 scale. At 120 minutes, subject reported that left knee still hurt slightly; steady pain at 
patella. Pain does not interfere with movement. At 140 minutes, subject made his last report that 
left knee still hurt, and the test was terminated 3 minutes later since a second subject (149-01) 
had been removed earlier and was undergoing HBO treatment that could not be interrupted with 
a second case of DCS that might require HBO. First VGE detected at 64 minutes, Grade 2 from 
left arm, Grade 2 from left leg, Grade 0 from right arm, and Grade 3 from right leg. Last VGE 
record at 137 minutes with Grade 2 from left arm, Grade 4 from left leg, Grade 0 from right 
arm, and Grade 3 from right leg. Symptoms in left knee resolved during descent at 7.65 psia. 
 
Diagnosis: Grade 2 Type I DCS 
Treatment: One-hr GLO with follow-up consultation. 
 
61. Summary: ID# 138-01, 44-year-old male, maximum Grade 4, first VGE at 29 minutes, first 
report at 60 minutes, study done on n = 40, crossover dependent sample statistical design. 
 
Procedure 16 
 
Narrative: At 60 minutes, subject reported awareness in right knee. Did not report initial pain 
score on the 1–10 scale. Initially reported at 45 minutes mild pain in left upper arm that extended 
along bicep during the Pull Station exercise. At 51 minutes, there was no arm pain while working 
at the Crank Station exercise. At the time of the report about the right knee, there was no further 
pain in left upper arm. At 83, 95, and 120 minutes there was no pain in right knee. First VGE de-
tected at 29 minutes, Grade 0 from left arm, Grade 3 from left leg, Grade 0 from right arm, and 
Grade 2 from right leg. Last VGE record at 177 minutes with Grade 0 from left arm, Grade 4 
from left leg, Grade 0 from right arm, and Grade 4 from right leg. Subject completed test and 
reported no symptoms at 180 minutes. There were no symptoms prior to descent; symptoms 
resolved at the test altitude of 6.5 psia. Pain reoccurred in right knee at a more severe level 15 hrs 
after the test. He reported soreness in both knees. 
 
Diagnosis: Grade 2 Type I DCS 
Treatment: One-hr GLO and USN TT V HBO for reoccurrence of right knee symptom with 
symptom resolution. Follow-up consultation the next day was done. 
 
62. Summary: ID# 133-02, 31-year-old female, maximum Grade 4, first VGE at 41 minutes, 
first report at 105 minutes, study done on n = 40, crossover dependent sample statistical design. 
 
Procedure 16 
 
Narrative: At 105 minutes, subject reported sharp intermittent pain in right leg, from knee 
to ankle. Reported initial pain score of 1 on a 1–10 scale on movement of right leg. There was 
no pain score report at 120 minutes, but subject reported stiffness in right knee. At about 124 
minutes, subject reported pain in right leg; it was sharp and intermittent only on movement. At 
143 minutes, subject reported that she could not straighten her right leg, and the pain score had 
increased to 3.5–4.0. After 158 minutes, she reported severe pain on movement of both the right 
knee and right ankle and lesser continuous pain at both sites. Test was terminated for subject at 
this time. First VGE detected at 41 minutes, Grade 0 from left arm, Grade 0 from left leg, Grade 
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0 from right arm, and Grade 3 from right leg. Last VGE record at 138 minutes with Grade 0 from 
left arm, Grade 4 from left leg, Grade 0 from right arm, and Grade 4 from right leg. Symptoms in 
right knee were gone by 10.1 psia, with right ankle pain gone near site pressure at about 13.7 
psia. Posttest VGE monitoring 48 minutes after start of repressurization showed no VGE. 
Onset of fatigue reported 20 minutes after reaching site pressure, which subject attributed 
to a long day of exercise.  Limb pain reoccurred after 2.5 hrs on O2. 
 
Diagnosis: Grade 3 Type I DCS 
Treatment: A 2.5-hr GLO and USN TT V HBO with symptom resolution. Follow-up 
consultation the next day was done. 
 
63. Summary: ID# 127-01, 25-year-old male, maximum Grade 4, first VGE at 63 minutes, first 
report at 129 minutes, study done on n = 40, crossover dependent sample statistical design. 
 
Procedure 16 
 
Narrative: At 129 minutes, subject reported pain in right ankle. Reported initial pain score 
of 1 on a 1–10 scale. Pain was described as diffuse, and more in the right foot and towards the 
medial boarder. There was no tingling or numbness. The pain was on both sides of the right foot. 
At 145 minutes, symptom was reduced and described as a mild discomfort in right ankle. At 161 
minutes, subject mentioned that pain around the right ankle was more noticeable at the Doppler 
station when his weight was off his feet, and was not present during other exercise activities. At 
166 minutes, subject reported a new symptom of numbness under right knee, with discomfort 
still present on right ankle. At 175 minutes, a pain score of 8 was reported for top of right foot, 
with numbness still present under right knee, very slight and similar to the effects of Novocain 
(subject’s words). The 3-hr test was terminated at this time. First VGE detected at 63 minutes, 
Grade 0 from left arm, Grade 2 from left leg, Grade 2 from right arm, and Grade 3 from right leg. 
Last VGE record at 156 minutes with Grade 2 from left arm, Grade 3 from left leg, Grade 3 from 
right arm, and Grade 4 from right leg. Symptoms from right ankle and right knee resolved during 
descent between 8.3 and 9.0 psia. Debrief comments were that discomfort in right ankle was like 
a lightly twisted ankle on both sides, with later pain on top of right foot described as if something 
heavy had stepped on top of foot. Subject said he changed the way he did the exercise activities 
to avoid involving right foot. Subject mentioned that right foot really bothered him toward the 
end of the test. 
 
Diagnosis: Grade 3 Type I DCS 
Treatment: One-hr GLO with follow-up consultation. 
 
64. Summary: ID# 140-02, 24-year-old male, maximum Grade 4, first VGE at 40 minutes, first 
report at 60 minutes, study done on n = 40, crossover dependent sample statistical design. 
 
Procedure 16 
 
Narrative: At 60 minutes, subject reported aches in knuckles of right hand. Reported initial 
pain score of 1 on a 1–10 scale. At 72 minutes and 92 minutes, subject said that right hand did 
not hurt as much now. At 118 minutes, subject reported a pain score of 1 for right hip, a pain that 
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was present for the last 4–5 minutes. Described as a slight but steady ache in the front part of the 
right hip. Right hand discomfort was almost gone at this time. Pain score at 120 minutes was still 
1 in the hip. At 155 minutes, subject reported aches in right ankle and right knee, at same pain 
score as right hip, a value of 1. Just 2 minutes later, at 157 minutes, subject reported just the 
symptom in right hip; was not aware of any other symptoms. At 3rd-hr questioning, subject 
assigned a pain score of 1 to right hip and right ankle. First VGE detected at 40 minutes, Grade 0 
from left arm, Grade 0 from left leg, Grade 1 from right arm, and Grade 0 from right leg. Last 
VGE record at 169 minutes with Grade 1 from left arm, Grade 2 from left leg, Grade 2 from 
right arm, and Grade 4 from right leg. Symptoms in right hip and right ankle resolved dur-
ing descent at 7.65 psia. 
 
Diagnosis: Grade 1 Type I DCS 
Treatment: One-hr GLO with follow-up consultation. 
 
Bends 8b (prior treadmill exercise): DCS Assigned at JSC 
 
65. Summary: ID# 149-01, 40-year-old male, maximum Grade 4, first VGE at 45 minutes, first 
report at 108 minutes, study done on n = 41, crossover dependent sample statistical design. 
 
Procedure 17 
 
Narrative: At 108 minutes, subject reported irritation and itching on the chest. During 3rd VGE 
measurement period, at 45 minutes into exposure, Grade 3 VGE were detected when the left leg 
was flexed. Grade 4 VGE were detected from left leg and right leg at 77, 92, and 108 minutes. 
Bubble signals were more intense at 92 and 108 minutes and were assigned a Grade 4+. Last 
VGE record at 108 minutes with Grade 1 from left arm, Grade 4 from left leg, Grade 3 from 
right arm, and Grade 4 from right leg. Between 108 and 120 minutes, subject described irritation 
and itching on chest. There was blue and red marbling on the right side of chest. Skin mottling 
was diagnosed 120 minutes into the exposure. Subject was removed through a transfer airlock 
at 126 minutes. Rash and mottling reduced on descent, with mild redness at site pressure. 
 
Diagnosis: Type II DCS (at this time, CM by itself was also classified as Type II DCS at JSC) 
Treatment: One-hr GLO and USN HBO TT V, and the mottling resolved before treatment 
ended. Follow-up consultation the next day was done. 
 
A 40-year-old male, 80.9 kg, 174 cm, with 21% computed body fat and 26.7 BMI, participated in 
an altitude exposure at JSC. Subject had no previous altitude exposure as a research subject. 
Subject ascended to 6.5 psia for a 3 hr exposure while breathing 100% O2 through a mask. Prior 
to the ascent, there was a brief ear and sinus check done by depressurizing the chamber 
atmosphere to the equivalent of 6,000 feet altitude in about 1 minutes (5,000 feet/minute). 
Subject breathed air during this check, which took approximately 5 minutes for all subjects to be 
evaluated, primarily during the repressurization back to site pressure. The medical technician 
exited the chamber and an ascent on air to 10 psia at 6,500 feet/minute was begun 6 minutes 
from the start of the initial ascent. About 2 minutes later subject donned the O2 mask at 10 psia 
and the chamber continued the ascent to 6.5 psia at 6,500 feet/ minutes. The ascent time to 6.5 
psia was 12 minutes with subject breathing 100% O2 for 10 minutes. Exercise stressed the upper 
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body since 4 minutes were spent flexing the wrist, elbow, and shoulder joints while rhythmically 
rotating the wheel of a bicycle ergometer against a set resistance from a standing position, 4 
minutes torquing fixed bolts with either the left or right hand from a standing position, and 4 
minutes of rhythmically pulling against a set resistance from a seated position. The details of 
these exercises are available. Finally, there was a 4 minutes period of rest and a 4 minutes period 
of bubble monitoring with subject asked to flex each limb in turn while in a supine position. 
Subject ambulated to the three exercise stations within the chamber. During the third VGE 
measurement period, at 45 minutes into the exposure, Grade III VGE was detected when the left 
leg was flexed. Grade IV VGE was detected from the left and right legs at 77, 92, and 108 
minutes. The bubble signals were more intense during the 92 and 108 minutes times and were 
assigned a Grade IV+. Between 108 and 120 minutes subject described irritation and itching on 
the chest. There was blue and red marbling on the right side of the chest. Skin mottling was 
diagnosed 120 minutes into the exposure. Subject was removed through a transfer airlock at 126 
minutes. Rash and mottling reduced on descent, with mild redness at site pressure. Subject was 
treated with HBO on a USN TT V, and the mottling resolved before the treatment ended. 
 
66. Summary: ID# 157-01, 28-year-old female, maximum Grade 0, first report at 120 minutes 
a symptom she noticed at about 117 minutes, study done on n = 41, crossover dependent sample 
statistical design. 
 
Procedure 17 
 
Narrative: At 120 minutes, during 2nd-hr questioning, subject reported dull ache in right 
wrist that had started about 3 minutes earlier. Reported initial pain score of 3 on a 1–10 scale that 
was only present while exercising. No VGE were detected at this time. Pain score decreased to 1 
at 138 and 180 minutes. At 138 minutes, the dull ache was still present but reduced to pain score 
of 1. By end of the 3-hr test, the same dull ache in right wrist was just a little worse during the 
exercise. Last VGE record at 174 minutes with Grade 0 from left arm, Grade 0 from left leg, 
Grade 0 from right arm, and Grade 0 from right leg. No VGE were detected during the test. 
Mentioned she was hot, the chamber air conditioning was off. Said she was fatigued from 
the exercise profile. Symptoms in right wrist resolved during descent at 7.34 psia. 
 
Diagnosis: Grade 1 Type I DCS 
Treatment: Two-hr GLO with follow-up consultation. 
 
67. Summary: ID# 158-01, 26-year-old male, maximum Grade 4, first VGE at 56 minutes, 
first report at 111 minutes a symptom he noticed minutes earlier, study done on n = 41, crossover 
dependent sample statistical design. 
 
Procedure 17 
 
Narrative: At 111 minutes, subject reported that left ankle hurt. Reported initial pain score 
of 1 on a 1–10 scale. Discomfort was noticed at the Doppler station, and decreased on walking. 
Subject reported a dull ache in left shoulder and a cramp in left side during deep inspiration from 
between 90 to 100 minutes into the test. All of these symptoms were attributed to the exercise 
devices, and improved during the evolution of the left ankle symptom. Pain score for the left 
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ankle increased to 2 at 123 minutes, and was most noticeable at the Doppler station. Pain score 
reported to decrease to 1 by 138 minutes. Subject reported a slight pain in the left ankle at 152 
minutes on a pain score of 1–2, and a very slight awareness or dull pain just below the patella on 
right side of left knee at less than a 1 on pain score. At 180 minutes, during final interview about 
symptoms, subject reported the same slight pain in left ankle during flexion of joint, but didn’t 
notice symptom while walking. First VGE detected at 56 minutes, Grade 0 from left arm, Grade 
2 from left leg, Grade 0 from right arm, and Grade 0 from right leg. Last VGE record at 168 
minutes with Grade 0 from left arm, Grade 4 from left leg, Grade 0 from right arm, and Grade 
0 from right leg. Symptoms in left ankle and left knee resolved during descent at 10.1 psia. 
 
Diagnosis: Grade 1 Type I DCS 
Treatment: Two-hr GLO with follow-up consultation. 
 
68. Summary: ID# 164-01, 27-year-old male, maximum Grade 4, first VGE at 44 minutes, first 
report at 79 minutes, study done on n = 41, crossover dependent sample statistical design. 
 
Procedure 17 
 
Narrative: At 79 minutes, subject reported a mild transient dull ache in left knee. Reported 
initial pain score of 2 on a 1–10 scale. Pain score remained constant at 2 at 112 minutes, and then 
decreased to 1 at 146 minutes. At 3rd-hr questioning, subject mentioned that the left knee hurt 
during movement at the Doppler station; about a 2 on the pain score. Also detected mild pain in 
left ankle, at a pain score of 1. First VGE detected at 44 minutes, Grade 0 from left arm, Grade 4 
from left leg, no measurement from the right arm, and Grade 0 from right leg. Last VGE record 
at 178 minutes with Grade 0 from left arm, Grade 3 from left leg, Grade 0 from right arm, and 
Grade 0 from right leg. Symptoms in left knee and left ankle resolved during descent at 8.1 psia. 
 
Diagnosis: Grade 1 Type I DCS 
Treatment: Two-hr GLO with follow-up consultation. 
 
69. Summary: ID# 140-01, 24-year-old male, maximum Grade 4, first VGE at 20 minutes, first 
report at 97 minutes, study done on n = 41, crossover dependent sample statistical design. 
 
Procedure 17 
 
Narrative: At 97 minutes. subject reported mild or slight pain in right thumb. Reported initial 
pain score of 1–2 on a 1–10 scale. At 2nd-hr questioning, subject reported no change in right 
thumb symptom. At 163 minutes, subject reported slight pain in right knee, on a pain score of 1–
2. Pain was located beneath patella, with no change in symptom on flexion or extension of right 
leg. At 170 minutes, subject reported no pain in right thumb, no change in right knee. At 3rd-hr 
questioning, subject reported pain in right knee had almost gone. First VGE detected at 20 min-
utes, Grade 0 from left arm, Grade 0 from left leg, Grade 1 from right arm, and Grade 1 from 
right leg. Last VGE record at 168 minutes with Grade 0 from left arm, Grade 4 from left leg, 
Grade 0 from right arm, and Grade 4 from right leg. Symptoms in right knee resolved during 
descent at 7.65 psia. 
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Diagnosis: Grade 1 Type I DCS 
Treatment: One-hr GLO with follow-up consultation. 
 
70. Summary: ID# 139-01, 23-year-old male, maximum Grade 4, first VGE at 42 minutes, first 
report at 60 minutes, study done on n = 41, crossover dependent sample statistical design. 
 
Procedure 17 
 
Narrative: At 60 minutes, subject reported discomfort in outer fingers of left hand. Did not 
report initial pain score on a 1–10 scale. There was no numbness, or change in sensorium. At 
86 minutes, subject reported no change in discomfort of left hand. Mentioned that he became 
cold during ascent, but the sensation left. As it left, the first VGE began to appear and with them 
the discomfort in left hand began. Grade 2 VGE detected from left arm at 42 minutes, then Grade 
4 at 64 minutes. No other VGE were detected in left leg, right leg, or right arm. At 98 minutes, 
pain diminished and there was no further numbness or change in sensorial. Last Grade 4 VGE 
were recorded at 84 minutes, with lesser grades detected for the duration of the test. Last VGE 
record at 172 minutes with Grade 1 from left arm, Grade 0 from left leg, Grade 0 from right arm, 
and Grade 0 from right leg. At 126 minutes, there was no pain, but still an awareness. At 138 
minutes, there was no residual pain, the left hand did not hurt, but awareness was present. At 
146 minutes, there was still some awareness in left hand. He still had some pain in left hand 
prior to descent. On descent, all symptoms in left hand cleared at 7.43 psia. 
 
Diagnosis: Grade 1 Type I DCS 
Treatment: One-hr GLO with follow-up consultation. 
 
71. Summary: ID# 137-02, 24-year-old male, maximum Grade 4, first VGE at 59 minutes, first 
report at 120 minutes a symptom he noticed at about 105 to 110 minutes, study done on n = 41, 
crossover dependent sample statistical design. 
 
Procedure 17 
 
Narrative: At 120 minutes, during 2nd-hr questioning, subject reported slight pain in left 
knee. Reported initial pain score of 1 on a 1–10 scale, but only during extension of the left leg. 
Subject relayed that pain had started about 10–15 minutes earlier. Pain score remained constant 
at 1 at 120 and 128 minutes. At 140 minutes, subject reported a reduction in symptom in the left 
knee to a 0 on the 1–10 pain score. At 3rd-hr questioning, he reported no symptoms from left 
knee. First VGE detected at 59 minutes, Grade 0 from left arm, Grade 4 from left leg, Grade 0 
from right arm, and Grade 2 from right leg. Last VGE record at 168 minutes with Grade 0 from 
left arm, Grade 4 from left leg, Grade 0 from right arm, and Grade 0 from right leg. Logbook did 
not document whether or not subject reported if there was a change in left knee symptoms during 
descent. But during posttest debriefing, he mentioned that pain had disappeared on return to site 
pressure. He also volunteered that he experienced an extremely mild pain in his teeth, but no 
other details were available. 
 
Diagnosis: Grade 2 Type I DCS 
Treatment: One-hr GLO with follow-up consultation. 
165 
 
 
72. Summary: ID# 136-01, 26-year-old female, maximum Grade 4, first VGE at 37 minutes, 
first report at 60 minutes a symptom she noticed at 40 minutes, study done on n = 41, crossover 
dependent sample statistical design. 
 
Procedure 17 
 
Narrative: At 60 minutes, during 1st-hr questioning, subject reported mild discomfort 
in right elbow. Reported initial pain score of 3–4 on a 1–10 scale. Subject volunteered that 
discomfort was present for about 20 minutes. At 87 minutes, subject reported that pain in right 
elbow was less than previously reported, and still a little stiff. At 120 minutes, she reported slight 
uncomfortable pressure in left knee. She said knee pain was detected about 16 minutes earlier. 
Also, pain in the right elbow was gone. At 141 minutes, left knee pain score increased to 4–5. A 
new right knee pain also appeared and was given a pain score of 2. She mentioned that it would 
be “difficult to bend knee if had to.” A decision was made to terminate test for this subject, and 
at 146 minutes subject was returning to site pressure via the transfer lock. First VGE detected at 
37 minutes, Grade 2 from left arm, Grade 2 from left leg, Grade 2 from right arm, and Grade 4 
from right leg. Last VGE record at 132 minutes with Grade 0 from left arm, Grade 4 from left 
leg, Grade 0 from right arm, and Grade 4 from right leg. Subject reported symptoms in both 
knees had cleared by 10.5 psia. During debrief, subject described elbow pain as sharp, like a 
sprain. Knee symptoms were described as a deeper and more throbbing pain. Pain reoccurred 
after 18 hrs. It is not clear from the logbook it reoccurring pain was in one or both knees. 
 
Diagnosis: Grade 3 Type I DCS 
Treatment: One-hr GLO and TT VI HBO with symptom resolution. Follow-up consultation the 
next day was done. 
 
73. Summary: ID# 133-01, 31-year-old female, maximum Grade 4, first VGE at 25 minutes, 
first report at 137 minutes a symptom she noticed moments earlier, study done on n = 41, cross-
over dependent sample statistical design. 
 
Procedure 17 
 
Narrative: At 137 minutes, subject reported a sharp pain in right knee while bending right leg 
at the Doppler station. Reported initial pain score of 3–4 on a 1–10 scale. At 157 minutes, subject 
reported right knee was more tense when extending the leg. Symptom was scored as a 6 on pain 
score. Since extension of the leg was impaired, a decision was made to terminate the test. Initi-
ated repressurization at 166 minutes. First VGE detected at 25 minutes, Grade 0 from left arm, 
Grade 0 from left leg, Grade 0 from right arm, and Grade 2 from right leg. Last VGE record at 
156 minutes with Grade 0 from left arm, Grade 2 from left leg, Grade 0 from right arm, and 
Grade 4 from right leg. By 166 minutes during repressurization, pain in the right knee was 
still present at 7.9 psia. All right knee symptoms resolved during descent at 9.0 psia. 
 
Diagnosis: Grade 3 Type I DCS 
Treatment: Two-hr GLO with follow-up consultation. 
 
166 
 
74. Summary: ID# 31-06, 39-year-old male, maximum Grade 4, first VGE at 93 minutes, first 
report at 144 minutes a symptom he noticed moments earlier, study done on n = 41, crossover 
dependent sample statistical design. 
 
Procedure 17 
 
Narrative: At 144 minutes, subject reported mild pain in right ankle and right knee, just below 
joint in the right knee. Reported initial pain score of 1–2 on a 1–10 scale. Pain was noticed dur-
ing right leg motion at the Doppler station and was described as intermittent, not interfering with 
assigned exercises. Pain score remained at same low level of 1 at 180 minutes in the right knee. 
There was no further pain in the right ankle at the time of repressurization. First VGE detected at 
93 minutes, Grade 0 from left arm, Grade 0 from left leg, Grade 0 from right arm, and Grade 3 
from right leg. Last VGE record at 175 minutes with Grade 0 from left arm, Grade 1 from left 
leg, Grade 0 from right arm, and Grade 4 from right leg. Symptoms in right knee lessened dur-
ing descent at 7.2 psia, and there was only a slight awareness at 9.7 psia. No symptoms were 
present at site pressure. 
 
Diagnosis: Grade 1 Type I DCS 
Treatment: One-hr GLO with follow-up consultation. 
 
Bends 9a (ambulatory control): DCS Assigned at JSC 
 
75. Summary: ID# 170-01, 33-year-old female, maximum Grade 4, first VGE at 173 minutes, 
first report at 179 minutes, study done on n = 24, crossover dependent sample statistical design. 
 
Procedure 18 
 
Narrative: At 179 minutes, during 3rd-hr questioning, subject reported pain in left leg and 
left thigh, but no pain in left knee. Reported initial pain score of 5 on a 1–10 scale. Pain was 
described as not radiating. Pain score decreased to 4 at 190 minutes, and the test was over so 
descent began. First and last VGE detected at 173 minutes, Grade 0 from left arm, Grade 3 from 
left leg, Grade 0 from right arm, and Grade 4 from right leg. Symptom pain score intensity in left 
leg decreased to 1 at 10.1 psia; there were no symptoms in left leg at 12.2 psia, nor any residual 
symptoms at site pressure. VGE still detected after test at site pressure. VGE at 219 minutes was 
Grade 0 from left arm, Grade 1 from left leg, Grade 0 from right arm, and Grade 2 from right leg. 
During debrief, done with subject breathing 100% O2, symptoms were described as pain in left 
leg in the thigh and calf area, not radiating, not related to the knee joint, nor did it interfere with 
the exercise activity. Since the test was over and descent started approximately 12 minutes after 
the first report, it was not possible to follow the evolution of symptoms. 
 
Diagnosis: Grade 2 Type I DCS 
Treatment: Two-hr GLO, medical observation for 12 hrs with follow-up consultation. 
 
Bends 9b (adynamic): DCS Assigned at JSC 
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76. Summary: ID# 130-03, 28-year-old male, maximum Grade 3, first VGE at 52 minutes, 
first report after test, during the later part of the 3-hr altitude exposure, study done on n = 23, 
crossover dependent sample statistical design. 
 
Procedure 19 
 
Narrative: Subject did not report symptoms during test. During debrief, he mentioned mild pain 
in left knee during later part of altitude exposure. Pain resolved during return to site pressure. A 
review of his Questionnaire on Post-Exposure Symptoms also uncovered a comment that left hip 
joint also experienced pain along with left knee. He wrote that he experienced a cold sweat from 
10.1 psia on down to site pressure. He also experienced slight fatigue and weakness in the legs 
and lower back after standing up. Recall that this subject had been bed rested for the about 4 
days, which included the time at 6.5 psia. First VGE detected at 52 minutes, Grade 1 from left 
arm, Grade 3 from left leg, Grade 1 from right arm, and Grade 0 from right leg. Last VGE record 
at 181 minutes with Grade 0 from left arm, Grade 1 from left leg, Grade 1 from right arm, and 
Grade 2 from right leg. Subject did not report if there was a change in symptoms during descent. 
 
Diagnosis: Grade 1 Type I DCS 
Treatment: One-hr GLO with follow-up consultation. 
 
77. Summary: ID# 182-01, 52-year-old male, maximum Grade (see explanation below), first 
VGE at (see explanation below), first report at 113 minutes, study done on n = 23, crossover 
dependent sample statistical design. 
 
Procedure 19 
 
Narrative: At 113 minutes, subject reported itching and burning across the chest and axilla. 
Reported initial pain score of 2 on a 1–10 scale. Pain score was not reported at 136, 148, or 180 
minutes into the test. Last VGE record at 179 minutes with Grade 0 from left arm, Grade 0 from 
left leg, Grade 0 from right arm, and Grade 0 from right leg. The MO suspected contact dermati-
tis. At 2nd-hr questioning, subject reported no problems other than the mild skin irritation. At 136 
minutes, the DT reported an increased size of redness on the abdomen. Subject no longer re-
ported itching, but reported that areas felt hot. All agreed to monitor subject closely, but to con-
tinue the test. At 148 minutes, the DT reported that the sizes of the patches had increased on the 
abdomen, with whitening of certain areas. No bubbles were detected from a precordial position 
using a 2-mHz Doppler probe; and since symptoms were limited to slight burning, the decision 
was made to finish the test. Best diagnosis at the time was contact dermatitis. At 3rd- (and last) hr 
questioning, subject reported that skin irritation around stomach was no worse than earlier. 
Subject did not report if there was a change in skin symptoms during descent. At site pressure, 
189 minutes from start of exercise at 6.5 psia, the DT reported that there was no change in the 
skin colors. Subject was allowed to remove his O2 mask. Subject had minimal mottling on the 
return to site pressure. He also experienced postural hypotension and dizziness on standing, 
which persisted after he left the chamber area. 
 
Diagnosis: Type II DCS (at this time, CM by itself was also classified as Type II DCS at JSC) 
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Treatment: USN HBO TT V about 4.5 hrs after return to site pressure, at which time a rash was 
still evident. Treatment lasted 90 minutes, with no extensions since dizziness was judged to have 
diminished. Subject was held for observation through the night. At 21:00, the rash was still evi-
dent. At 06:30 the following day, the rash was reported as almost cleared on the lower abdomen, 
and greatly diminished in the left axilla. Postural hypotension confounds a proper characteriza-
tion of DCS since prolonged bed rest was part of the study design. Subject displayed a Doppler 
blood flow signal during the test that differed from that normally encountered in hypobaric/hy-
perbaric decompressions. Normally, the presence of individual gas bubbles can be heard in the 
flow signal; but here, individual bubble signals were absent. Instead, when limb movement ma-
neuvers occurred, the intensity of flow sound increased. Our opinion is that this is indicative of 
an increased number of scattering sites; the absence of individual, audible bubbles would indi-
cate that these were microbubbles. Subject did have a PFO, with positive indication at rest. 
 
A 52-year-old male, 80.6 kg, 179 cm, with 21% computed body fat and 25 BMI, participated in an altitude 
exposure at JSC. Subject had no previous altitude exposure as a research subject. Subject ascended to 6.5 psia for a 
3 hr exposure while breathing 100% O2 through a mask. Prior to the ascent, there was a brief ear and sinus check 
done by depressurizing the chamber atmosphere to the equivalent of 6,000 feet altitude in about 1 minutes (5,000 
feet/minutes). The ascent time to 6.5 psia was 12 minutes with subject breathing 100% O2 for 10 minutes. Subject 
was under strict bed rest conditions for three days prior to the ascent to simulate adaptation to microgravity. Subject 
stayed in a supine position during the altitude exposure. Exercise stressed the upper body, since 4 minutes were 
spent flexing the wrist, elbow, and shoulder joints while rhythmically rotating the wheel of an arm ergometer against 
a set resistance from a supine, 4 minutes torquing fixed bolts with either the left or right hand from a supine position, 
and 4 minutes of rhythmically pulling against a set resistance from a supine position. The details of these exercises 
are available. Finally, there was a 4 minutes period of rest and a 4 minutes period of bubble monitoring with subject 
asked to flex each limb in turn while in a supine position. Subject reported itching and burning across the chest (2 
out of 10 from a pain scale) and axilla at 113 minutes into the exposure. The MO suspected contact dermatitis. At 
the seconds hr questioning period subject reported no problems other than the mild skin irritation. At 136 minutes 
the DT reported an increased size of the redness on the abdomen. Subject no longer reported itching, but reported 
that the areas felt hot. All agreed to monitor subject closely, but to continue the test. At 148 minutes the DT reported 
that the sizes of the patches had increased on the abdomen, with whitening of certain areas. No bubbles were 
detected from a precordial position using a 2 mHz Doppler probe, and since the symptoms were limited to slight 
burning the decision was made to finish the test. However, subject displayed a Doppler blood flow signal during the 
test that was different from that normally encountered in hypo- or hyperbaric decompressions. Normally, the 
presence of individual gas bubbles can be heard in the flow signal, but in this case, individual bubble signals were 
absent. Instead, when the limb movement maneuvers occurred, the intensity of the flow sound increased. Our 
opinion is that this is indicative of an increased number of scattering sites; the absence of individual, audible bubbles 
would indicate that these were microbubbles. The best diagnosis at the time was still contact dermatitis. At the third 
(and last) hr questioning period subject reported that the skin irritation around the stomach was no worse than 
earlier. At site pressure, 189 minutes from start of exercise at 6.5 psia, the DT reported that there was no change in 
the skin colors. Subject was allowed to remove his O2 mask. A series of photographs were taken of the torso follow-
ing the return to site pressure (exact time is unavailable). The posttest comments in the logbook stated that subject 
had minimal mottling on the return to site pressure. Subject also experienced postural hypotension and dizziness on 
standing, and it persisted after he left the chamber area. A decision was made to treat subject on a USN TT V about 
4.5 hr after the return to site pressure, at which time a rash was still evident. The treatment lasted 90 minutes, with 
no extensions since the dizziness was judged to have diminished. Subject was held for observation through the night. 
At 9:00 p.m. the rash was still evident. At 6:30 a.m. the following day, the rash was reported as almost cleared on 
the lower abdomen, and greatly diminished in the left axilla. The postural hypotension confounds a proper 
characterization of DCS since prolonged bed rest was part of the study design.  
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Bends 9c (ambulatory control): DCS Assigned at JSC 
 
78. Summary: ID# 202-01, 40-year-old female, maximum Grade 4, first VGE at 38 minutes, 
first report at 114 minutes a symptom she noticed at about 94 minutes, study done on n = 11, 
crossover dependent sample statistical design. 
 
Procedure 20 
 
Narrative: At 114 minutes, subject reported persistent pain in left knee. Reported initial pain 
score of 3 on a 1–10 scale. Symptom had appeared about 20 minutes earlier and was now feeling 
better and never interfered with exercise activities. Pain score remained constant at 3 at 180 min-
utes, but became worse while standing. At 140 minutes, subject reported that pain in the left knee 
felt better while standing (2–3 score), and assigned it a score of 3 while sitting, but still not in-
terfering with exercise activities. At 152 minutes, subject reported pain in left knee was much 
reduced; a score of 1 or lower. During the 3rd-hr questioning, subject reported a pain score 1 for 
left knee, and a new pain or sensation at pain score 1 in left ankle. First VGE detected at 38 
minutes, Grade 2 from left arm, Grade 4 from left leg, Grade 2 from right arm, and Grade 4 from 
right leg. Last VGE record at 174 minutes with Grade 3 from left arm, Grade 4 from left leg, 
Grade 3 from right arm, and Grade 3 from right leg. Symptoms resolved during descent in 
left knee at 5.0 psia and in left ankle at 5.8 psia. 
 
Diagnosis: Grade 2 Type I DCS 
Treatment: One-hr GLO with follow-up consultation. 
 
79. Summary: ID# 204-01, 36-year-old male, maximum Grade 4, first VGE at 47 minutes, 
first report at 82 minutes a symptom he noticed at 80 minutes, study done on n = 11, crossover 
dependent sample statistical design. 
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Procedure 20 
 
Narrative: At 82 minutes, subject reported pain in right ankle. Reported initial pain score of 1 
on a 1–10 scale. He reported that pain started 2 minutes earlier, and was more noticeable during 
movement of ankle at the VGE monitoring station. At 87 minutes, subject reported pain in right 
ankle was gone. At 157 minutes, subject reported pain in right knee had started about 2 minutes 
earlier, but was not interfering with the exercise activities. Pain was constant, on a score of 2–3. 
No symptoms from right ankle. Pain score was constant at 2–3 just prior to descent at 180 min-
utes. First VGE detected at 47 minutes, Grade 0 from left arm, Grade 3 from left leg, Grade 3 
from right arm, and Grade 4 from right leg. Last VGE record at 173 minutes with Grade 3 
from left arm, Grade 3 from left leg, Grade 3 from right arm, and Grade 3 from right leg. 
Symptoms resolved in right knee during descent at 8.6 psia. 
 
Diagnosis: Grade 2 Type I DCS 
Treatment: Two-hr GLO with follow-up consultation. 
 
80. Summary: ID# 207-01, 31-year-old male, maximum Grade 4, first VGE at 62 minutes, first 
report at 165 minutes, study done on n = 11, crossover dependent sample statistical design. 
 
Procedure 20 
 
Narrative: At 165 minutes, subject reported minor pain in left knee. Did not provide initial 
pain score on a 1–10 scale. Pain was continuous, but did not interfere with exercise activities. 
First VGE detected at 62 minutes, Grade 1 from left arm, Grade 4 from left leg, Grade 1 from 
right arm, and Grade 4 from right leg. Last VGE record at 166 minutes with Grade 3 from left 
arm, Grade 4 from left leg, Grade 3 from right arm, and Grade 3 from right leg. Symptoms in 
left knee resolved during descent at 10.2 psia. During debrief, subject mentioned that he had 
a transient symptom in right knee that he did not report during the test. 
 
Diagnosis: Grade 1 Type I DCS 
Treatment: One-hr GLO with follow-up consultation. 
 
Bends 10: DCS Assigned at JSC 
 
81. Summary: ID# 192-01, 31-year-old male, maximum Grade 4, first VGE at 20 minutes, first 
report at 158 minutes a symptom he noticed moments earlier, study done on n = 19, independent 
sample statistical design. 
 
Procedure 21 
 
Narrative: At 158 minutes, subject reported mild joint awareness in left elbow. Reported initial 
pain score of 1 on a 1–10 scale. He noticed pain during the previous Doppler monitoring period. 
At 178 minutes, there was no pain. Bubbles first detected Grade 1 from right leg at 20 minutes, 
which increased in grade and stayed at Grade 3 during the last monitoring periods. At the same 
time, left arm, right arm, and left leg contributed Grade 1 and 2 from about 55 minutes for the 
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duration of the test. First VGE detected at 20 minutes, Grade 0 from left arm, Grade 0 from left 
leg, Grade 0 from right arm, and Grade 1 from right leg. Last VGE record at 165 minutes with 
Grade 2 from left arm, Grade 1 from left leg, Grade 2 from right arm, and Grade 3 from right leg. 
There were no symptoms prior to descent; symptoms resolved at the test altitude of 10.1 psia. 
 
Diagnosis: Grade 1 Type I DCS 
Treatment: One-hr GLO with follow-up consultation. 
 
Bends 11a: DCS Assigned at JSC 
 
82. Summary: ID# 215-01, 25-year-old male, maximum Grade 3, first VGE at 96 minutes, first 
report at 145 minutes a symptom he noticed at 144 minutes, study done on n = 28, independent 
sample statistical design. 
 
Procedure 22 
 
Narrative: At 145 minutes, subject reported mild pain under the patella and to the left of right 
knee. Reported initial pain score of 1 on a 1–10 scale. He noticed symptom 1 minute earlier. First 
VGE detected at 96 minutes, Grade 2 from left arm, Grade 2 from left leg, Grade 2 from right 
arm, and Grade 3 from right leg. Last VGE record at 133 minutes with Grade 2 from left arm, 
Grade 2 from left leg, Grade 2 from right arm, and Grade 3 from right leg. After 96 minutes, 
subject had Grade 3 VGE from right leg and Grades 1 and 2 assigned to the other 3 limbs. At the 
time of symptom report at 145 minutes, VGE grade was still 3 from right leg. Subject suggested, 
and the MO concurred, that he should stand and flex right leg to further evaluate this mild pain. 
Subject reported that mild pain had now abated and was not present once he returned to his seat. 
By this time, subject had been seated for 335 minutes. Decision was made by MO to abort the 
test. Entire test was terminated at 148 minutes into the 240 minutes test. There were no 
symptoms prior to descent; symptoms resolved at the test altitude of 4.3 psia. 
 
Diagnosis: Grade 1 Type I DCS 
Treatment: Two-hr GLO with follow-up consultation. 
 
83. Summary: ID# 228-01, 40-year-old female, maximum Grade 4, first VGE at 101 minutes, 
first report at 153 minutes, study done on n = 28, independent sample statistical design. 
 
Procedure 22 
 
Narrative: At 153 minutes, subject reported dull pain under and inside right patella. Pain did not 
increase on extension of right leg. At 101 minutes into test, Grade 2 VGE detected from left leg. 
First VGE detected at 101 minutes, Grade 0 from left arm, Grade 0 from left leg, Grade 0 from 
right arm, and Grade 2 from right leg. Last VGE record at 153 minutes with Grade 1 from left 
arm, Grade 3 from left leg, Grade 1 from right arm, and Grade 4 from right leg. At 117 minutes, 
VGE were Grade 2 from left leg and Grade 3 from right leg. At 137 minutes, VGE were Grade 4 
from left leg and Grade 4+ from right leg. Entire test was terminated at approximately 160 min-
utes into the 240-minute test. Pain in right knee resolved during descent at 6.75 psia. Grade 3 
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VGE detected from right leg at 175 minutes while at site pressure, and Grade 0 from all 
limbs by 194 minutes. 
 
Diagnosis: Grade 1 Type I DCS 
Treatment: Two-hr GLO with follow-up consultation. 
 
84. Summary: ID# 234-01, 31-year-old female, maximum Grade 4, first VGE at 32 minutes, 
first report at 48 minutes, study done on n = 28, independent sample statistical design. 
 
Procedure 22. Same as Procedure 22 except this subject had a problem with a right ear block 
after the 6000 ft ear and sinus check before the final ascent to 4.3 psia that effectively added 24  
minutes to the 3-hr PB. 
 
Narrative: At 48 minutes, subject reported a dull ache in right wrist that was noticeable 
without exercise. At 54 minutes, subject said it felt better after MO questioning, and MO 
continued test with instructions for subject to keep the MO informed of any changes in right 
wrist. At 32 minutes, Grade 2 VGE were detected from left leg and right leg and Grade 4 from 
right arm. At 51 minutes, Grade 3 VGE from left arm and right leg, with Grade 4 from left leg 
and right arm. At 68 minutes, all limbs showed Grade 4 VGE. Last VGE record at 68 minutes 
with Grade 4 from left arm, Grade 4 from left leg, Grade 4 from right arm, and Grade 4 from 
right leg. At 1st-hr questioning, subject said there was still discomfort in right wrist without 
activity, and it did not feel worse with exercise. She said this discomfort was not felt during the 
pre-test exercise practice in the Environmental Lab. At 72 minutes, during Doppler monitoring, 
subject reported pain in left wrist. It was same pain as in right wrist. The entire test was termi-
nated at 76 minutes into the 240-minute test. Pain in right wrist resolved during descent at 
4.56 psia and from left wrist at 4.99 psia. 
 
Diagnosis: Grade 1 Type I DCS 
Treatment: Two-hr GLO with follow-up consultation. 
 
Phase I PRP: DCS Assigned at Duke 
 
85. Summary: ID# D980113C, 23-year-old female, maximum Grade 3, first VGE at 75 minutes, 
first report at 76 minutes, study done on n = 47, independent sample statistical design. 
 
Procedure 23 
 
Narrative: At 76 minutes, subject reported soreness in right ankle, which progressed over 
ensuing 10 minutes to a constant deep ache. At 86 minutes, she reported pain score of 3 on a 1–
10 scale. She had no other problems, but could be observed to favor her right leg during the Pull 
Station exercises. At 94 minutes, she reported a persistent “weird aching feeling” in left ankle, 
joined by new complaint of pain in bottom of left foot, all on a 3 pain score. Preparations were 
made for subject lockout. Lockout preparations took about 15 minutes (about 110 minutes 
elapsed time from start of test), by which time subject noted onset of right knee pain. During 
move to chamber lock, subject experienced a bout of lightheadedness, probably orthostatic. First 
VGE detected at 75 minutes, Grade 2 from right arm, Grade 2 from left arm, Grade 3 from left 
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leg, and Grade 3 from right leg. Last VGE record at 104 minutes with Grade 0 from right arm, 
Grade 2 from left arm, Grade 2 from left leg, and Grade 3 from right leg. All symptoms 
in both ankles and right knee resolved on descent. 
 
Diagnosis: Type I DCS 
Treatment: Prophylactic USN HBO TT V was given. Follow-up consultation the next day was 
done. 
 
86. Summary: ID# D980120B, 46-year-old male, maximum Grade 4, first VGE at 16 minutes, 
first report at 113 minutes, study done on n = 47, independent sample statistical design. 
 
Procedure 23 
 
Narrative: At 113 minutes, subject reported pain or ache in left knee that differed from any 
he had before in his left knee. Reported initial pain score of 2 on a 1–10 scale. By 181 minutes, 
the pain was gone and the exposure had finished uneventfully. First VGE detected at 16 minutes, 
Grade 2 from right arm, Grade 2 from left arm, Grade 3 from left leg, and Grade 2 from right leg. 
VGE detected at time of the left knee report at 113 minutes was Grade 2 from right arm, Grade 1 
from left arm, Grade 4 from left leg, and Grade 2 from right leg. The last complete VGE record 
at 197 minutes with Grade 2 from right arm, Grade 3 from left arm, Grade 4 from left leg, and 
Grade 2 from right leg. Four days later, subject reported numbness in left foot at base of toes, 
which resolved spontaneously within a few hrs. Seven days postflight the numbness in left foot 
at base of toes returned. No objective abnormality was found on examination, but tissues deep to 
the skin at the base of toes on left foot felt numb. Hyperbaric treatment was initiated. 
 
Diagnosis: Type I DCS 
Treatment: USN HBO TT VI with full resolution of symptoms in last O2 period. Consulting 
MO “finds it difficult to believe these purely subjective features are due to the same (left knee) 
disorder, with onset 4 days after the trial. However, I cannot otherwise account for his com-
plaint.” Follow-up consultation the next day was done. 
 
87. Summary: ID# D980203B, 22-year-old female, maximum Grade 1, first VGE at 74 minutes, 
first report at 111 minutes, study done on n = 47, independent sample statistical design. 
 
Procedure 23 
 
Narrative: At 111 minutes, subject reported twitching on lateral surface of left calf. Pinprick 
sensation was evaluated during this time with no difference of sensation reported over involved 
area. First VGE detected at 74 minutes, Grade 0 from right arm, Grade 0 from left arm, Grade 1 
from left leg, and Grade 0 from right leg. Last VGE record at 242 minutes with Grade 0 from 
right arm, Grade 0 from left arm, Grade 0 from left leg, and Grade 0 from right leg. Symptom 
resolved by 180 minutes. There were no symptoms prior to descent; symptoms resolved at the 
test altitude of 4.3 psia. With return to surface, subject had no symptoms at rest; but upon rising 
from semi-supine position, she noticed a very mild discomfort in lateral, distal aspect of her right 
thigh, which she reported was apparent only while walking when right foot struck the floor. Sub-
ject was in mid-menstrual cycle and reported taking Loestrin. At 505 minutes, subject returned to 
174 
 
lab after having reported being awakened from a nap by pain in right wrist at 21:30. On inter-
view at 23:20, she noted that in addition to right wrist pain, she had also experienced transient 
numbness of the ends of fingers on right hand, which had resolved. Also noted that right hand 
felt colder than left hand, a sensation that persisted into the interview. Original discomfort in 
right thigh was unchanged. Hyperbaric treatment was initiated. 
 
Diagnosis: Type I DCS 
Treatment: USN HBO TT VI and both wrist and residual leg pain completely resolved within 
about 5 minutes of reaching depth. Compression was extremely slow (approximately 12 minutes) 
due to problems equalizing ears. Follow-up consultation the next day was done. 
 
88. Summary: ID# D980210A, 21-year-old female, maximum Grade 0, first report at 164 
minutes, study done on n = 47, independent sample statistical design. 
 
Procedure 23 
 
Narrative: At 164 minutes, subject reported a headache and feeling hot during exposure. 
Reported initial pain score of 2 on a 1–10 scale. No VGE were detected in this subject. Last VGE 
record at 228 minutes with Grade 0 from right arm, Grade 0 from left arm, Grade 0 from left leg, 
and Grade 0 from right leg. Subject completed exposure. At 1,649 minutes from start of altitude 
exposure (17:00 the day after the exposure), subject called FGHL (2/11/98) with complaint of 
intermittent pain in right elbow and right wrist throughout the day. Noted that on awakening in 
the morning (day immediately following the EVA day), she had some tingling in her right wrist 
and forearm, which quickly resolved. She remained unaware of any significant wrist or elbow 
pain until later in the day when, with the performance of manual tasks, she noted stiffness in both 
her right wrist and elbow that was worst immediately following use of her hands and improved 
with rest. Subject was symptom free and without complaint at 17:00, the time of the 2/11/98 call. 
Subject elected to wait until following morning to report to FGHL, when she was otherwise al-
ready scheduled to participate in another research study. On 2/12/98, subject reported to FGHL 
in morning. On physical examination, subject was found to be entirely within normal limits, 
specifically normal neurological to light touch, pinprick, normal reflexes and normal strength. 
However, subject complained of mild intermittent discomfort in right wrist and right elbow. She 
added that she would occasionally experience light twinges of tingling in her right hand, that her 
right hand did not feel normal (although no sensory deficit), and that she generally did not feel 
normal. Hyperbaric treatment was initiated. 
 
Diagnosis: Type I DCS 
Treatment: USN HBO TT VI and on arrival at 60 fsw [feet seawater] while breathing 100% O2 
subject reported full relief of joint pain, but still-persistent abnormal feeling in right hand. 
Follow-up consultation the next day was done. 
 
89. Summary: ID# D980303B, 27-year-old female, maximum Grade 3, first VGE at 49 minutes, 
first report at 134 minutes, study done on n = 47, independent sample statistical design. 
 
Procedure 23 
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Narrative: At 134 minutes, subject reported onset of pain in dorsum of left wrist. Reported 
initial pain score of 3 on a 1–10 scale. Pain worsened to a level 4 with distraction force (pulling) 
and improved to a level 2 with compressive force on wrist. Pain score improved spontaneously to 
2.5 after about 30 minutes of continued activity, but never completely resolved. Pain improved 
by 163 minutes but never completely resolved. Evaluation by inside tender demonstrated no 
abnormal pinprick sensation, and no visible cutaneous changes were evident. Subject was 
otherwise symptom-free. Persistence of symptoms in left wrist motivated a decision to remove 
subject from the chamber at 211 minutes. First VGE detected at 49 minutes, Grade 1 from right 
arm, Grade 1 from left arm, Grade 2 from left leg, and Grade 2 from right leg. Last VGE record 
at 186 minutes with Grade 0 from right arm, Grade 0 from left arm, Grade 0 from left leg, and 
Grade 0 from right leg. During descent at 10.11 psia, subject reported distal migration of pain to 
dorsum of left hand, still at a 2.5 pain score. At 12.69 psia, subject reported tingling in 4th and 5th 
digits of left hand. During evaluation at site pressure while subject on 100% O2, subject reported 
additional onset of left thumb pain, but improved digit tingling and resolution of left wrist and 
hand pain. Hyperbaric treatment initiated. 
 
Diagnosis: Type I DCS 
Treatment: Posttest O2 until USN HBO TT VI started. All remaining symptoms resolved. 
Subject returned for reevaluation 8-hr post USN TT VI reporting residual tenderness along ulnar 
aspect of left forearm, wrist, and 5th digit. On examination, tenderness was found to worsen with 
palpation and resisted motion at the wrist.  Otherwise subject without complaint of recurrent 
neurological symptoms in fingers, hand, or wrist.  New complaints consistent with mild 
tendonitis from EVA exercises. Subject instructed to begin course of nonsteroidal anti-
inflammatory medication for treatment. On follow-up 5 days later (3/9/98), mild residual 
tendonitis persisted but was improving. Subject, having returned to normal activity without 
residual deficit, reported being pleased with treatment course and recovery. 
 
Phase I PRP: DCS Assigned at Hermann 
 
90. Summary: ID# H980219A, 45-year-old male, maximum Grade 4, first VGE at 108 minutes, 
first report at 110 minutes, study done on n = 47, independent sample statistical design. 
 
Procedure 23 
 
Narrative: At 110 minutes, subject reported pain on left side of left knee. Reported initial pain 
score of 3 on a 1–10 scale, and pain was constant. Maximum VGE grades were 1 from right arm, 
1 from left arm, 4 from left leg, and 3 from right leg. First VGE detected at 108 minutes, Grade 1 
from right arm, Grade 1 from left arm, Grade 4 from left leg, and Grade 3 from right leg. Last 
VGE record at 228 minutes with Grade 0 from right arm, Grade 0 from left arm, Grade 2 from 
left leg, and Grade 3 from right leg. Pain report at 119 minutes into test was constant and mild at 
2 or 3 on 10-point scale. Subject reported that pain felt like it was in the joint and it did not inter-
fere with performance. Pain also continued at rest. At 128 minutes, pain was constant at a level 
of 2. At 196 minutes, subject described pain as awareness during the exercise and a 0.5 on pain 
score in left knee. Subject remained at 4.3 psia for the duration of the 4-hr test. Sometime during 
the descent to site pressure, awareness in left knee was completely gone. 
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Diagnosis: Type I DCS. MO diagnosed DCS at 119 minutes, but for unknown reasons allowed 
the test to continue to the end. 
Treatment: One-hr GLO with follow-up consultation. 
 
91. Summary: ID# H980226A, 28-year-old male, maximum Grade 3, first VGE at 76 minutes, 
first report at 144 minutes a symptom he noticed moments earlier, study done on n = 47, inde-
pendent sample statistical design. 
 
Procedure 23 
 
Narrative: At 144 minutes, subject reported pain on lateral-left ankle and under the patella of 
left knee. Reported initial pain score of 1 on a 1–10 scale. Pain was intermittent at the beginning 
but within 1 or 2 minutes became constant. Pain in left knee was described as intermittent at first 
and then became more constant under the patella. Pain seemed to have started shortly after the 
extension of left leg upon Doppler monitoring. First VGE detected at 76 minutes, Grade 0 from 
right arm, Grade 0 from left arm, Grade 3 from left leg, and Grade 2 from right leg. Last VGE 
record at 144 minutes with Grade 2 from right arm, Grade 2 from left arm, Grade 3 from left 
leg, and Grade 3 from right leg. Subject was locked out. Symptoms in left knee and left 
ankle cleared at 7.2 psi. 
 
Diagnosis: Type I DCS 
Treatment: One-hr GLO with follow-up consultation. 
 
92. Summary: ID# H980310A, 26-year-old male, maximum Grade 3, first VGE at 76 minutes, 
first report at 76 minutes, study done on n = 47, independent sample statistical design. 
 
Procedure 23 
 
Narrative: At 76 minutes, subject reported continuous pain on external side of left ankle. 
Reported initial pain score of 3 on a 1–10 scale. Subject had Grade 3 VGE from left leg at this 
time. First VGE detected at 77 minutes, Grade 0 from right arm, Grade 0 from left arm, Grade 1 
from left leg, and Grade 2 from right leg. Last VGE record at 92 minutes with Grade 1 from right 
arm, Grade 1 from left arm, Grade 3 from left leg, and Grade 3 from right leg. Subject wanted to 
continue exercises and, at 92 minutes, reported pain in right ankle. Subject was locked out. All 
symptoms in both ankles cleared at 5.2 psi. 
 
Diagnosis: Type I DCS. MO diagnosed DCS in left ankle after 76 minutes but subject wanted 
to continue test. The MO ended test after the second report of pain in right ankle at 92 minutes. 
Treatment: One-hr GLO with follow-up consultation. 
 
93. Summary: ID# H980324B, 29-year-old female, maximum Grade 3, first VGE at 76 minutes, 
first report at 76 minutes, study done on n = 47, independent sample statistical design. 
 
Procedure 23 
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Narrative: At 76 minutes, subject reported a feeling of tingling (like an itch) on both 
lower extremities. Subject had Grade 2 VGE from left leg at this time. First VGE detected at 77 
minutes, Grade 0 from right arm, Grade 0 from left arm, Grade 2 from left leg, and Grade 0 from 
right leg. Last VGE record at 160 minutes with Grade 1 from right arm, Grade 3 from left arm, 
Grade 3 from left leg, and Grade 3 from right leg. Subject wanted to continue the test and, at 108 
minutes, subject also reported tingling in left arm as well as original sensation in lower extremi-
ties. At 128 minutes, subject had Grade 3 VGE from left leg and the tingling sensation on both 
legs and left arm was becoming more intense. Sensation had expanded to both thighs. At 144 
minutes, sensation became more intense on outer thigh. At 160 minutes, subject had Grade 3 
VGE in both legs and said that tingling had expanded to the lower back area and the hips. Sub-
ject was locked out at 160 minutes, and all tingling symptoms resolved at 8.0 psi with some 
residual awareness on left thigh. During the MO interview after the test, subject reported that 
she had left knee and hip pain on a pain score of 3–4. At the end of postflight PB, subject was 
symptom free and was discharged by the on-call MO. NOTE: The 10-minute PB exercise was 
too hard for subject to keep up with her legs. Resistance was decreased from the prescribed 
133 to 83 for 4 minutes then back to 133. Target heart rate peaked at 189. 
 
Diagnosis: Type I DCS 
Treatment: One-hr GLO with follow-up consultation. 
 
Phase III PRP: DCS Assigned at Duke 
 
94. Summary: ID# D980630B, 29-year-old female, maximum Grade 0, first report at 52 
minutes, study done on n = 10, independent sample statistical design.  
 
Procedure 25 
 
Narrative: At 52 minutes, subject reported a headache on right anterior side of skull. Reported 
initial pain score of 1 on a 1–10 scale. Reported bilateral sinus pain at 67 minutes. At 101 min-
utes, subject reported right shoulder ache while exercising. At 142 minutes, right shoulder pain 
was reported to have increased with a pain score of 1 assigned to it, and was present during exer-
cise and rest. At 137 minutes, subject reported headache was at a pain score of 1.5 severity, and 
her eyes were dry. At 192 minutes, right shoulder pain had increased to a pain score of 2 and had 
become constant to persist throughout exercise and rest. Subject had no VGE. Last VGE record 
at 203 minutes with Grade 0 from right arm, Grade 0 from left arm, Grade 0 from left leg, and 
Grade 0 from right leg. Subject was locked out at 207 minutes with complete relief of shoulder 
symptoms. Subject experienced difficulty clearing her ears and sustained bilateral ear baro-
traumas. NOTE: Subject had a history of shoulder dislocation (side not specified) in child-
hood. Sacroiliac pain treated by chiropractor within 12 months preceding altitude test. 
 
Diagnosis: Type I DCS. Ear examination revealed moderately injected tympanic membranes 
with some hemorrhaging. 
Treatment: Two-hr GLO with follow-up consultation. 
 
95. Summary: ID# D980714C, 42-year-old male, maximum Grade 4, first VGE at 105 minutes, 
first report at 143 minutes, study done on n = 10, independent sample statistical design. 
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Procedure 25 
 
Narrative: At 143 minutes, subject reported itching on arms and legs (right side from an earlier 
e-mail). At 149 minutes, subject reported a “numb” feeling from heel to toe of right foot. At 169 
minutes, subject reported being “numb all over”.  Shortly after this report, subject reported right 
knee pain. First VGE detected at 105 minutes, Grade 0 from right arm, Grade 0 from left arm, 
Grade 1 from left leg, and Grade 0 from right leg.  Last VGE record at 156 minutes with Grade 
0 from right arm, Grade 1 from left arm, Grade 4 from left leg, and Grade 4 from right leg. 
Subject was returned to site pressure at this time, but symptoms persisted at site pressure. 
 
Diagnosis: Type II DCS 
Treatment: Multiple HBO treatments. Initial intermittent symptoms of right arm and right leg 
numbness progressed to include right-sided sensorimotor changes, right knee pain, unsteady gait, 
visual scotomata, disorientation, and confusion. These symptoms responded to a full USN TT 
VI, but recurred after surfacing. A second recompression treatment was performed, on a TT VI 
with Catalina Extensions (more 100% O2 than a standard TT VI). Following this, patient was 
admitted to hospital. His condition markedly improved, with minimal neurological findings 
remaining. Brain MRI [magnetic resonance imaging] was normal. Bubble contrast echocard-
iogram showed PFO at rest. Follow-up hyperbaric treatments were administered during 
next 2 days, and follow-up neurological examinations were normal. 
 
MO Consult Note, Time of Consult: 15:20 July 14, 1998 
Reason for Consult: Decompression Illness resulting from NASA Study. 
 
HISTORY OF PRESENT ILLNESS: The patient is a 42 year old white Caucasian male who was participating in a 
physiology experiment today in the Duke Hyperbaric Chamber on 14 July 1998. His first symptom was itching on 
the arms and legs that began 143 minutes (clock time 15:12) after arrival at 30,000 feet (4.3 psia). Prior to ascent he 
had breathed 100% O2 for 2 hr and continued breathing 100% O2 while at altitude. At altitude, the patient did 
intermittent mild arm and leg exercise according to the experimental protocol. 6 minutes after the onset of itching he 
noted a “numb” feeling from heel to toe. Over the course of the next 10 minutes the symptoms did not progress and 
became intermittent for a time. It was decided to observe closely but continue the protocol so long as symptoms 
continued to resolve. At this point the diagnosis of altitude DCS had not been made since transient sensory changes 
in extremities on this protocol are not uncommon. Approximately 26 minutes after the first symptom onset he re-
ported being “numb all over.” He said it came as a “flash” but did not persist. Shortly after that, right knee pain also 
developed. At this point (30 minutes after the initial itching) the diagnosis and DCS was made and preparations to 
return the patient to 1 ATA were begun immediately. As preparations were underway the leg numbness returned and 
he noted spots and lines in front of his eyes. Twelve minutes later he was at 1 ATA. Upon entering the transfer 
chamber for return to 1 ATA, he noted he was unsteady and actually fell down at one point. Upon reaching 1 ATA 
the patient was taken to the physiology laboratory where he was seated. The patient appeared dazed and did not 
respond to verbal queries as if he couldn’t hear. But after finally getting his attention, it was determined that his 
hearing was normal and that he was oriented to person, place, and time. 
 
PHYSICAL EXAMINATION: The patient appeared mildly confused and displayed a very flat affect but answered 
all questions correctly during examination. His speech seemed slow and deliberate. He was oriented to person, 
place, and time. Strength and cranial nerves were normal. There was decreased sensation to pinprick in the right arm 
compared to the left. He complained his right arm and leg felt numb. Finger-to-nose was slow and deliberate without 
past pointing. His normal Rhomberg showed significant unsteadiness. He could not perform tandem gait and his 
sharpened Rhomberg was less than 2 seconds. He was administered the same neurobehavioral cognitive exam that 
we used for evaluating CO patients and this was within normal limits. Proprioception was tested by moving the great 
toe up and down. He was consistently correct on the left but occasionally incorrect on the right.  He was at 1 ATA 
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approximately 50 minutes from the time he exited the altitude chamber until the time he was recompressed and 
during that time he said that he felt “less out of it” and was feeling a little better. During his time at 1 ATA while 
being examined he breathed air. 
 
IMPRESSION: Decompression sickness due to altitude exposure. 
 
DISPOSITION: Compressed to 60 feet, execute USN TT VI. 
 
TREATMENT PROGRESS: Treatment Table VI was started at 16:47 on 15 July 1998, 50 minutes after leaving the 
altitude chamber. After the 1st O2 period at 60 feet, there were no changes in his gait or his Rhomberg. The patient 
now noted some scintillating scotoma in both eyes. After the 2nd O2 breathing period at 60 feet, the patient noted 
that the right leg numbness was markedly decreased and his arm felt almost normal. His tandem gait had improved. 
After three O2 breathing periods at 60 feet and following the 30-minutes ascent to 30 feet, his tandem gait became 
completely normal and he was able to walk the length of the chamber heel to toe with his eyes closed. A sharpened 
Rhomberg was greater than 15 seconds. His speech and affect were normal as determined by the inside chamber 
tender. At this point complete resolution of symptoms had occurred. The patient surfaced from the TT VI at approx-
imately 21:34. Immediately upon exiting the chamber, the patient was noted to be speaking and walking normally 
and went off to the bathroom to urinate and change clothes. During my interview 10 minutes after surfacing, the 
patient again appeared dazed. He did not respond to all the questions appropriately and he kept saying that he had 
“lost his bearings”. He said that his right arm and leg began to go numb about 10 minutes just before arriving at the 
surface during the final ascent from 30 feet.  On physical examination his affect was flat and his speech is somewhat 
deliberate. He always paused before answering a question, but eventually got the right answer. The right arm is 
slightly weaker than left in flexors and extensors. Pinprick on the right arm and leg was decreased compared to the 
left. Pinprick on both sides of the abdomen and thorax was normal. He was unable to do a tandem gait or a sharp-
ened Rhomberg and kept falling to the right. His finger-to-nose was very slow and deliberate but there was no past 
pointing. Approximately 40 minutes after surfacing, he felt faint and began to collapse to the floor but was caught 
before he did so and immediately taken into the chamber and put in one of the treatment chairs. In the chamber the 
examination continued as preparations for recompression were begun. No nystagmus was noted but he did complain 
of feeling nauseated and eventually vomited his stomach contents that consisted mainly of pizza that he had eaten 
during the first treatment. The patient then became totally unresponsive to verbal commands for a few seconds but 
did not lose consciousness. He did respond to a loud voice but did not respond meaningfully to commands. He was 
not oriented at this time. Forty-5 minutes after surfacing from the first treatment, he was recompressed to 60 feet and 
began 100% O2 breathing periods. After arrival at 60 feet the patient was still dazed and was not responding mean-
ingfully to the tenders questions. The inside chamber tender would put his hands on parts of the patient’s body and 
ask him to identify them, but the patient was unable to do so. He had a completely flat affect and responded only 
slowly and deliberate to commands. An IV of D5W was started and run at approximately one liter. Additional 
hyperbaric treatments, a test for PFO, and a complete neurological work-up followed. Was found to have a 
resting PFO. 
 
Phase IV PRP: DCS Assigned at Hermann 
 
96. Summary: ID# H990511A, 29-year-old male, maximum Grade 0, first report at 92 minutes, 
study done on n = 57, independent sample statistical design. 
 
Procedure 26 
 
Narrative: At 92 minutes, subject reported mild pain just below right knee. Reported initial 
pain score of 1–2 on a 1–10 scale. Subject also described a prickly hot and cold sensation on 
skin on top of right foot first and then on top of left foot. Subject was asked to move around and 
remove his shoes. This was felt to be due to postural effects and not related to DCS. Subject had 
no VGE. Last VGE record at 84 minutes with Grade 0 from right arm, Grade 0 from left arm, 
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Grade 0 from left leg, and Grade 0 from right leg. Subject was locked out. Symptom in right 
knee resolved during descent to site pressure. 
 
Diagnosis: Type I DCS 
Treatment: Two-hr GLO with follow-up consultation. 
 
97. Summary: ID# H990527B, 24-year-old male, maximum Grade 3, first VGE at 64 minutes, 
first report at 84 minutes, study done on n = 57, independent sample statistical design. 
 
Procedure 26 
 
Narrative: At 84 minutes, subject reported only a mild aching pain on left knee. Some time 
later, subject reported a sharp, constant pain on left knee under patella. Reported pain score of 
7 on a 1–10 scale. Subject selected United States Air Force (USAF) Grade 2 pain as appropriate 
descriptive index. Subject said that pain started about 10 minutes earlier as a sensation of aware-
ness. First VGE detected at 64 minutes, Grade 0 from right arm, Grade 0 from left arm, Grade 3 
from left leg, and Grade 0 from right leg. Last VGE record at 80 minutes with Grade 0 from right 
arm, Grade 0 from left arm, Grade 3 from left leg, and Grade 0 from right leg. Subject was 
locked out. Symptoms in the left knee resolved during descent at 7.3 psia with no residual 
pain at site pressure. 
 
Diagnosis: Type I DCS 
Treatment: Two-hr GLO with follow-up consultation. 
 
98. Summary: ID# H990610A, 25-year-old male, maximum Grade 2, first VGE at 45 minutes, 
first report at 45 minutes, study done on n = 57, independent sample statistical design. 
 
Procedure 26 
 
Narrative: At 45 minutes, subject reported mild aching of right knee. Reported initial pain 
score of 2 on a 1–10 scale and then 3–4 a short time later. Subject first complained of hot spots 
at 12 minutes into the 4.3-psia exposure. VGE detected at 45 minutes, Grade 0 from right arm, 
Grade 0 from left arm, Grade 0 from left leg, and Grade 2 from right leg. Last VGE record was 
also at 45 minutes with Grade 0 from right arm, Grade 0 from left arm, Grade 0 from left leg, 
and Grade 2 from right leg. Decision was made to remove subject from test. Subject was 
locked out approximately 50 minutes into test. Symptoms in right knee resolved during 
descent at 12.7 psia with no residual pain at site pressure. 
 
Diagnosis: Type I DCS 
Treatment: Two-hr GLO with follow-up consultation. 
 
99. Summary: ID# H990615B, 28-year-old male, maximum Grade 3, first VGE at 169 minutes, 
first report at 183 minutes, study done on n = 57, independent sample statistical design. 
 
Procedure 26 
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Narrative: At 183 minutes, subject reported mild intermittent aching in left knee. Pain was 
intermittent but could be noticed when leg was extended. Reported initial pain score of 3 on a 1–
10 scale. Subject was asked to reposition himself to determine whether the sensation was due to 
positional/postural causes. Pain disappeared with repositioning, but then returned when left leg 
was stretched out. First VGE detected at 169 minutes, Grade 0 from right arm, Grade 0 from left 
arm, Grade 3 from left leg, and Grade 0 from right leg. Last VGE record at 247 minutes with 
Grade 0 from right arm, Grade 0 from left arm, Grade 3 from left leg, and Grade 0 from right 
leg. Decision was made to remove subject from test, but the scheduled end of test had arrived 
so no lockout was required. Symptoms in left knee resolved during descent with no residual 
pain at site pressure. 
 
Diagnosis: Type I DCS.  
Treatment: Two-hr GLO. Phoned next day with report of tenderness in left elbow. Given a 
USN HBO TT V treatment, with no relief. Was given anti-inflammatory medication.  Diagnosis 
was epicondylitis (tennis elbow) due to repeated arm and handwork the previous day.  Follow-up 
consultation the next day was done. 
 
Phase IV PRP: DCS Assigned at DCIEM 
 
100. Summary: ID# C990311B, 28-year-old male, maximum Grade 3, first VGE at 31 minutes, 
first report at 31 minutes, study done on n = 57, independent sample statistical design. 
 
Procedure 26 
 
Narrative: At 31 minutes, subject reported discomfort in left knee aggravated by exercise. 
First VGE detected at 31 minutes, Grade 0 from right arm, Grade 0 from left arm, Grade 3 from 
left leg, and Grade 0 from right leg. Last VGE record was also at 31 minutes with Grade 0 from 
right arm, Grade 0 from left arm, Grade 3 from left leg, and Grade 0 from right leg. Subject was 
locked out at 48 minutes. Symptoms in left knee cleared at 10.92 psia. 
 
Diagnosis: Type I DCS 
Treatment: Two-hr GLO with follow-up consultation. 
 
101. Summary: ID# C990315D, 45-year-old male, maximum Grade 4, first VGE at 40 minutes, 
first report at 56 minutes, study done on n = 57, independent sample statistical design. 
 
Procedure 26 
 
Narrative: At 56 minutes, subject reported discomfort in left knee, fading in and out. Reported 
initial pain score of 2 on a 1–10 scale. At 68 minutes, the report was still intermittent level 2 pain 
score in left knee. At 72 minutes, subject reported a slight improvement, and it was decided to 
remove subject from test. First VGE detected at 40 minutes, Grade 0 from right arm, Grade 0 
from left arm, Grade 3 from left leg, and Grade 0 from right leg. Last VGE record at 56 minutes 
with Grade 0 from right arm, Grade 1 from left arm, Grade 4 from left leg, and Grade 1 from 
right leg. Subject was locked out at 74 minutes. Symptoms in left knee cleared shortly after 
start of descent. 
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Diagnosis: Type I DCS 
Treatment: Two-hr GLO with follow-up consultation. 
 
102. Summary: ID# C990317D, 41-year-old male, maximum Grade 4, first VGE at 93 minutes, 
first report at 118 minutes, study done on n = 57, independent sample statistical design. 
 
Procedure 26 
 
Narrative: At 118 minutes, subject reported a sore left leg. At 121 minutes, reported steady 
discomfort. At this time, subject reported initial pain score of 2–3 on a 1–10 scale. At 124 min-
utes, reported left knee pain was 4–5 on the pain score. First VGE detected at 93 minutes, Grade 
0 from right arm, Grade 0 from left arm, Grade 3 from left leg, and Grade 0 from right leg. Last 
VGE record at 109 minutes with Grade 0 from right arm, Grade 2 from left arm, Grade 4 from 
left leg, and Grade 2 from right leg. Subject was locked out at 129 minutes. Symptoms in left 
knee cleared at 9.35 psia. 
 
Diagnosis: Type I DCS 
Treatment: Two-hr GLO with follow-up consultation. 
 
103. Summary: ID# C990324C, 35-year-old male, maximum Grade 4, first VGE at 40 minutes, 
first report at 92 minutes, study done on n = 57, independent sample statistical design. 
 
Procedure 26 
 
Narrative: At 92 minutes, subject reported awareness in right ankle and right knee. At 
108 minutes, he reported constant awareness in right ankle and right knee, not a pain. At 116 
minutes, he reported increased awareness in right knee at a 1–2 pain score on a 10-point pain 
scale with right ankle awareness less noticeable. First VGE detected at 40 minutes, Grade 0 from 
right arm, Grade 0 from left arm, Grade 0 from left leg, and Grade 2 from right leg. Last VGE 
record at 108 minutes with Grade 2 from right arm, Grade 3 from left arm, Grade 3 from left 
leg, and Grade 4 from right leg. Subject was locked out at 116 minutes. Symptoms were 
mostly gone at 6.75 psia with significant ear clearing problems below 7.34 psia. Subject 
had no symptoms in right ankle or right knee at 9.35 psia. 
 
Diagnosis: Type I DCS 
Treatment: Two-hr GLO with follow-up consultation. 
 
Phase V-1 PRP: DCS Assigned at Duke 
 
104. Summary: ID# D021219C, 27-year-old male, maximum Grade 4, first VGE at 96 minutes, 
first report at 110 minutes a symptom he noticed at 90 minutes, study done on n = 9, independent 
sample statistical design. 
 
Procedure 27 
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Narrative: At 110 minutes the subject reported a symptom that he first experienced at about 90 
minutes.  The subject noticed a very mild, but steady, right knee pain. This pain was slightly off 
the midline, on the medial side of the right knee, at the joint line. It is somewhat sharp, but deep. 
The pain did not subside, but grew slowly, but steadily worse. Subject has no history of knee 
pain, or previous knee injury. At 110 minutes into the 30,250 foot exposure, subject reported the 
pain to the tender. The pain was reported initially at a 2/10, and increased to a 3/10 just before 
descent.  At 115 minutes the subject was removed from the chamber.  The subject was noted to 
have a 4/4 Doppler score while moving his right lower extremity, and a large amount of bubbles 
were observed in the right heart on 2D echocardiography when he moved his lower extremity. 
First VGE were detected at 96 minutes, Grade 3 from the right leg, then at 122 minutes Grade 4 
from the right leg.  All other limb measurements had Grade 0 VGE.  The subject was returned to 
surface.  During the surface the pain rapidly improved, and was a 0.5/10 at the surface. After 
breathing oxygen on the surface for 5 minutes the pain was barely noticeable.       
 
Diagnosis: Type I DCS 
Treatment: Two-hr GLO with follow-up consultation. 
 
105. Summary: ID# D030122B, 30-year-old male, maximum Grade 4, first VGE at 43 minutes, 
first report at 80 minutes, study done on n = 9, independent sample statistical design. 
 
Procedure 27 
 
Narrative: At 80 minutes after reaching altitude and after the third exercise period the subject 
noticed and reported the onset of a sharp left ankle pain. This pain was constant but the severity 
waxed and waned between 2 to 4 out of 10. It was worse with movement. By 85 minutes the pain 
began to radiate to the left knee and thigh.  Subject did not develop other symptoms.  However, 
because this pain was constant in nature >5 minutes (did not completely resolve) he was 
removed from the exposure as per the NASA protocol. First VGE were detected at 43 minutes, 
Grade 3 from the left leg and again at 67 minutes, then at 78 minutes Grade 4 from the left leg.  
All other limb measurements had Grade 0 VGE.  Upon recompression to sea level the subject 
reported a gradual disappearance of his pain and was pain free within 5 minutes of arriving at sea 
level. 
 
Diagnosis: Type I DCS 
Treatment: Two-hr GLO with follow-up consultation. 
 
106. Summary: ID# D030122C, 48-year-old male, maximum Grade 2, first VGE at 33 minutes, 
first report at 62 minutes, study done on n = 9, independent sample statistical design. 
 
Procedure 27 
 
Narrative: At 62 minutes after reaching altitude and after the third exercise period the subject 
noticed and reported the onset of a sharp right shoulder pain. Note:  The case description in the 
PRP database indicates left shoulder pain initially, but goes on to describe right shoulder pain, 
which we accept as the correct location of the symptom.  This waxed and waned between 2 to 4 
out of 10 in severity. It was not worse with movement. The shoulder pain was also accompanied 
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by some transient right wrist and forearm pain. Subject did not develop other symptoms.  
However, because this pain was constant in nature >5 min (did not resolve completely) he was 
removed from the exposure as per the NASA protocol. First VGE were detected at 33 minutes, 
Grade 1 from the right arm.  At 50 minutes there was Grade 2 in right arm, then at 70 minutes 
there were Grade 2 in right arm, Grade 1 in left arm, and Grade 2 in left leg.  Finally, at 86 
minutes there was Grade 2 in right arm, Grade 1 in left arm, and Grade 2 in left leg. Upon 
recompression to 18,000 feet altitude (7.34 psia) the subject reported a gradual disappearance of 
his pain and was pain free at sea level. Note: While primary symptoms (as described in consult 
note) were reported in the right shoulder, the subject also described to investigators a dull and 
localized knee pain (2-3/10) that commenced suddenly at 85 minutes at altitude that also 
disappeared during repress.  But this additional information did not specify right or left knee. 
 
Diagnosis: Type I DCS 
Treatment: Two-hr GLO with follow-up consultation. 
 
Phase V-2 PRP: DCS Assigned at Duke 
 
107. Summary: ID# D030327A, 43-year-old female, maximum Grade 4, first VGE at 7 minutes, 
first report at 128 minutes, study done on n = 3, independent sample statistical design. 
 
Procedure 28 
 
Narrative: At 128 minutes subject developed the gradual onset of nausea without vomiting. 
Later questioning (after recompression to surface pressure) revealed that she also had developed 
some mild shortness of breath, throat fullness and cough around this time, but this was not 
communicated. The covering physician was called to evaluate her and remarked that at 129 
minutes she reported nausea, malaise and weakness which progressed to lightheadedness by 130 
minutes. The covering physician was not concerned that the reported degree of nausea was a 
severe enough symptom to remove her from the study at that time. However, at approximately 
131 minutes it became known to the covering physician that she had had Grade 4 venous gas 
emboli during the course of the study. At that time the covering physician requested a repeat left 
ventricular sided echo which was transmitted to the outside monitor. No left ventricular sided 
bubbles were observed, however; due to the rapid progression of the symptoms of increasing 
nausea combined with light headedness and the apparent anxiety and distress of the subject the 
covering physician elected to evacuate her from the altitude chamber. First VGE were detected at 
7 minutes, Grade 1 from right and left arms, with VGE grade increasing from all limbs over the 
next five sample intervals.  Final VGE collection at 128 minutes showed Grade 3 in right arm, 
Grade 4 in left arm, Grade 3 in left leg, and Grade 4 in right leg.  At 138 minutes the Delta 
chamber was depressurized with an attendant to lock out the subject. However, by the time the 
lock was able to be opened (145 min) the subject was in too much distress to be able to stand 
without assistance. At that point the covering physician began to suspect that the reported 
symptoms might represent the precursors to pulmonary decompression sickness and it was 
elected to abort the entire flight (146 min) to allow her to be extracted as soon as possible. By 
154 minutes the subject had been recompressed to surface pressure and while remaining on 
100% O2 she was removed from the chamber on a stretcher. She was taken to an adjacent room 
for an abbreviated history and physical exam by the covering physician.  
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Upon reaching the surface she reported mild but improving respiratory distress. On exam at that 
time she was diaphoretic, and flushed, however she did not have tachypnea and O2 saturation 
was 100%.  Her heart rate was 60.  Blood pressure was not immediately taken but she appeared 
well perfused.  She was oriented x 3, CN (cranial nerves?) were grossly normal. She had very 
soft rales at the bases but these were noted to clear within minutes (see second pulmonary exam 
in Alpha chamber below). There was no S3 or S4 on cardiac exam. Her neurological exam was 
normal with symmetrical motor strength, normal cognition and normal cranial nerves.  
 
Diagnosis: Type II DCS, pulmonary chokes 
Treatment: USN HBO TT VI with follow-up consultation.  A diagnosis of altitude DCS with 
pulmonary involvement was made and it was elected to treat her with hyperbaric O2. The subject 
was walked, with escorts on either side, to Alpha chamber so that the examining physician could 
continue to observe both her strength as well as her neurological status as reflected by her gait 
and balance. Her gait was “cautious” but otherwise normal and although she was able to stand on 
one foot she was weak. By the time she reached Alpha chamber she was able to stand without 
assistance, however; she still complained of feeling weak and tired. In Alpha, her lungs were also 
reexamined to note any interim improvement. No rales were heard on the second chest exam, 
however; the background noise level was high.  Although the issue was briefly discussed during 
the examination period, no chest x-ray or blood study was obtained in the interest of beginning 
treatment as rapidly as possible and because the patient seemed to be improving at ground level 
pressure. The examination and transport of the patient to Alpha chamber was totally completed 
at 173 minutes. The final preparations were made and the chamber was pressurized at 174 
minutes.  
 
By 176 minutes, she had been compressed to 60 feet sea water pressure and she reported 
improvement of her shortness of breath. At 195 minutes all symptoms were reported to be gone 
and she was joking with the chamber attendant in light hearted conversation. A brief 
neurological exam in the chamber revealed a normal gait, normal Romberg and normal heel to 
toe walking as observed by me over the video monitor.  The decision was made to complete a 
full USN TT VI in hopes of avoiding a recurrence of symptoms. 
 
Addendum: 3/28/03 10:00 a.m. 
After the treatment there were no recurrent symptoms and she felt subjectively much better. Vital 
signs were normal (blood pressure 114/78, heart rate 70) and her lungs were clear. Subject was 
sent to the Duke emergency room for a chest x-ray. The covering physician was called with the 
report at 21:50. No abnormalities were seen by the reading radiologist and the patient was 
discharged home.  The following morning (3/29/03, 9:59 am) the subject was called by the 
covering physician and reported that she had had no recurrence of her symptoms and the she was 
in her normal state of health. She was advised to call for any symptoms or questions that might 
arise. 
 
Phase V-3 PRP: DCS Assigned at DCIEM  
 
108. Summary: ID# C030612A, 27-year-old female, maximum Grade 3, first VGE at 144 
minutes, first report at 128 minutes, study done on n = 48, independent sample statistical design. 
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Procedure 29 
 
Narrative: At 128 minutes, subject stated that she felt some fullness in her left ankle.  Doppler 
scores at the time were all zero.  This was not described as pain at the time, so it was decided to 
monitor her.  Subject had no previous history of left ankle problems.  By 138 minutes, subject 
stated that the fullness was a discomfort that was 1-2/10 on rest and with movement.  It had 
progressed from an undulating feeling to a discomfort that was constant.  First VGE detected at 
144 minutes with Grade 2 in right leg and Grade 3 in left leg.  TTE also indicated bubbles on the 
right side of the heart.  By 153 minutes, the left ankle pain was 1-2/10 on rest and 3/10 with 
movement.  VGE grade at the next and last monitoring opportunity at 160 minutes was Grade 3 
in left and right legs. The reported symptoms met NASA criteria for protocol termination due to 
Type I DCS; the flight was terminated, subject was placed in the air lock and brought back down 
to ground level.  During descent her left ankle pain completely resolved by the time the lock 
reached 27,000 ft (4.99 psia).  She remained asymptomatic at ground level with VGE grades 
returning to 0. 
 
 Diagnosis: Type I DCS 
Treatment: Two-hr GLO with follow-up consultation. 
 
109. Summary: ID# C030626B, 46-year-old female, maximum Grade 3, first VGE at 96 
minutes, first report at 144 minutes, study done on n = 48, independent sample statistical design. 
 
Procedure 29 
 
Narrative: At 144 minutes, subject reported the development of a ‘feeling of fullness’ in her 
right ankle.  Moments later the subject reported that the feeling of fullness in the right ankle was 
still present, and that she occasionally got a very mild, deep, ‘shooting’ pain in her leg, like a 
‘shower of bubbles’ (she had no knowledge of her bubble scores).  Dr. Nishi elected to observe 
this probable DCS symptom for a few more minutes.  At 158 minutes the subject reported that 
the fullness and occasional pain was still present but less.  The pain in her ankle was now 
constant at 3/10 so the decision was made to lock her out.  The ‘fullness’ and pain were 
definitely better by 20,000 ft (6.75 psia) during the descent and completely resolved by 5,000 ft 
(12.23 psia).  First VGE detected at 96 minutes, Grade 3 from right leg.  At 112 minutes there 
was still Grade 3 VGE from the right leg.  At 132 minutes there was Grade 3 from right and left 
arms and right leg with Grade 2 from left leg.  At 148 minutes there was Grade 3 from the right 
leg.  The last VGE monitoring was at 164 minutes with Grade 1 from right and left arms and 
grade 2 from right and left legs.  Subject continued on 100% O2 on the surface for two hrs and 
encouraged to drink large amounts of fluids.  She was examined and found to have absolutely no 
residual signs or symptoms of the DCS and volunteered that she was in her menstrual period. 
Incidental note is made of a very mild headache that started the previous day and had continued 
unchanged during the run.  
 
 Diagnosis: Type I DCS 
Treatment: Two-hr GLO with follow-up consultation. 
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110. Summary: ID# C030916A, 59-year-old male, maximum Grade 3, first VGE at 40 minutes, 
first report at 170 minutes, study done on n = 48, independent sample statistical design. 
 
Procedure 29 
 
Narrative: At 170 minutes, subject reported 2-3/10 left knee discomfort.  The discomfort was 
constant at rest and with movement, and had been gradually getting worse for 7-8 minutes.  He 
had no previous history of left knee problems, was well hydrated and had no known risk factors 
for altitude DCS.  This met NASA criteria for protocol termination due to Type I pain only 
altitude DCS, and it was decided to terminate the flight.  By the time the airlock had reached 
altitude and he was transferred into it at 183 minutes, his left knee pain had increased to 5/10.  
First VGE detected at 40 minutes, grade 1 from left and right legs.  VGE grades increased from 
lower body over several sampling intervals.  Last VGE sample was at 176 minutes with Grade 3 
VGE from all four limb locations.  During descent, his knee pain gradually improved.  By 27,000 
ft (4.99 psia) it had decreased to 2/10, by 21,000 ft (6.48 psia) it was 1/10, and as the chamber 
broke through 18,000 ft (7.34 psia), he reported complete resolution of the knee pain.  He 
remained asymptomatic at ground level and did not require hyperbaric recompression.   
 
Diagnosis: Type I DCS 
Treatment: Two-hr GLO with follow-up consultation. 
 
111. Summary: ID# C030930C, 35-year-old female, maximum Grade 3, first VGE at 68 
minutes, first report at 104 minutes, study done on n = 48, independent sample statistical design. 
 
Procedure 29 
 
Narrative: At 104 minutes, subject reported a mild sensation in the muscle of her left thigh.  She 
did not describe it as a pain or discomfort, and it was not felt to be related to altitude DCS.  By 
116 minutes, subject noted that the sensation in her thigh had now migrated to her left knee.  At 
123 minutes, the sensation in her knee had definitely become a pain (Note: PRP database 
documents 116 minutes as the time to DCS).  It was constant, and slightly worse with movement.  
At 129 minutes, she stated the pain was 5/10 and worsening.  This met the NASA criteria for 
protocol termination due to Type I pain only altitude DCS, and it was decided to terminate the 
flight.  First VGE detected at 68 minutes, Grade 2 in left leg and Grade 1 in right leg.  At 82 
minutes there was Grade 2 from right and left arms and Grade 3 from left and right legs.  Last 
VGE monitoring at 114 minutes indicated Grade 3 from all four limbs.  By the time the airlock 
reached altitude, and she was transferred into it at 133 minutes, the left knee pain had increased 
to 6/10. During descent, her knee pain gradually improved.  By 27,000 ft (4.99 psia) it had 
decreased to 4/10, by 22,000 ft (6.21 psia) it was 3/10, and as the chamber broke through 16,000 
ft (7.96 psia), she reported complete resolution of the knee pain.  She remained asymptomatic at 
ground level and did not require recompression therapy.   
 
Diagnosis: Type I DCS 
Treatment: Two-hr GLO with follow-up consultation. 
 
Phase V-3 PRP: DCS Assigned at Duke  
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112. Summary: ID# D030825B, 47-year-old male, maximum Grade 3, first VGE at 59 minutes, 
first report at 195 minutes, study done on n = 48, independent sample statistical design. 
 
Procedure 29 
 
Narrative: At 195 minutes, subject experienced onset of left ankle and left knee pain.  
Symptoms were somewhat variable and improved with exertion.  Severity eventually reached 
3/10 over the next few minutes.  VGE first detected at 59 minutes, Grade 3 from right arm.  Low 
grade VGE (Grades 1 and 2) persisted from right arm up until 126 minutes.  At 179 minutes 
Grade 2 VGE were detected in left and right legs and at the last VGE monitoring opportunity at 
199 minutes there were also Grade 2 VGE from both legs.  The condition following completion 
of the last Doppler showed no further change in symptomatology with continued 3/10 deep dull 
ache in the left knee ankle and shin.  The subject was electively brought out of the chamber at 
204 minutes, reaching the surface at 211 minutes.  Severity of the constant leg/ankle ache during 
compression decreased to less than 1/10 over the left ankle.  He remained on GLO while 
undergoing physical examination. 
 
Diagnosis: Type I DCS 
Treatment: Some GLO in preparation for USN HBO TT V with follow-up consultation.  The 
patient was compressed on a USN TT V at 16:04 (229 min elapsed).  He experienced 100% 
relief of all symptoms at 16:07 (232 min elapsed) upon reaching 60 feet sea water.  He 
completed the remainder of the treatment without problem or difficulty.   
 
113. Summary: ID# D031009B, 25-year-old male, maximum Grade 3, first VGE at 43 minutes, 
first report at 61 minutes, study done on n = 48, independent sample statistical design. 
 
Procedure 29 
 
Narrative: At 61 minutes, subject complained of a 4/10 deep steady dull pain in his right 
shoulder that was present at rest and did not change with arm motion (Note: PRP database case 
description documents 76 minutes to report of symptom while elapsed time data in the same 
database confirms 61 minutes to report of first symptom.  Will use 61 minutes since a report of 
symptoms at 76 minutes is longer than the last VGE monitoring period at 65 minutes).  First 
VGE detected at 43 minutes, Grade 2 from right arm.  Next, and last, VGE monitoring at 65 
minutes had Grade 3 from right arm.  The shoulder pain decreased in severity to a 3/10 
immediately prior to recompression to surface and resolved during the descent.    
 
Diagnosis: Type I DCS 
Treatment: Some GLO in preparation for USN HBO TT V with follow-up consultation.  The 
subject tolerated compression for treatment of Type I DCS with USN TT V.  All symptoms 
(right shoulder pain) resolved during descent from altitude and did not recur at 1 ATA or during 
hyperbaric recompression and treatment.  On exam following treatment, the subject was without 
complaint and at his baseline level on physical examination without signs or symptom of DCS. 
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114. Summary: ID# D031106B, 45-year-old female, maximum Grade 0, first report at 106 
minutes, study done on n = 48, independent sample statistical design. 
 
Procedure 29 
 
Narrative: At 106 minutes, subject complained of “itchy dry skin” and a “prickly” sensation on 
both arms and legs of a 4/10 severity (Note: PRP database documents 162 minutes as the time to 
DCS).  She had no neurological deficit or complaint of pain.  At 162 minutes she complained of 
6/10 tingling in her left forearm during arm exercise which resolved during rest.  At 172 minutes 
she complained of 7/10 tingling and pain which decreased but did not resolve during rest.  VGE 
monitoring at approximately 15 minute intervals showed no detectable bubbles.  The subject was 
repressurized after a 172 minute exposure.  Symptom decreased in severity from 7/10 to 1.5/10 
upon reaching the surface.  She was examined and taken to Alpha Chamber for treatment of mild 
Type-1 DCS.  
 
Diagnosis: Type I DCS 
Treatment: Some GLO in preparation for USN HBO TT V with follow-up consultation.  
Subject noted decreased sensation/pain on compression to 60 feet sea water with complete 
resolution within 2 minutes of breathing O2 at 60 feet sea water.  She completed the USN TT V 
without problem or complication.   
 
Phase V-4 PRP: DCS Assigned at Duke  
 
115. Summary: ID# D040817B, 29-year-old male, maximum Grade 2, first VGE at 64 minutes, 
first report at 141 minutes, study done on n = 6, independent sample statistical design. 
 
Procedure 30 
 
Narrative: At 141 minutes, subject complained of a 5/10 deep steady dull pain in his right knee 
and 3/10 ankle pain that was present at rest and did not change with motion. The reported 
severity of the knee pain was increased to 6/10 and ankle pain to 5/10 at 143 minutes. The flight 
was aborted at this time. First VGE detected at 64 minutes, a Grade 2 from the right leg.  No 
VGE detected in the next three opportunities.  But at 130 minutes Grade 2 was once again 
coming from the right leg.  Both knee and ankle pain decreased in severity upon recompression 
to surface, the knee reaching 0/10 and the ankle 1/10.  The knee pain returned to a 2/10 level two 
minutes into the immediate post-flight period. There were no complaints of motor weakness, 
shortness of breath or cognitive disturbances reported. 
 
Diagnosis: Type I DCS 
Treatment: Some GLO in preparation for USN HBO TT V with follow-up consultation.  
Examination at the surface was at baseline and without neurological deficit.  Symptoms were 
completely resolved upon reaching the USN TT V treatment depth. The subject remained 
symptom free immediately following treatment and at 18 hr follows up. 
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116. Summary: ID# D040831A, 28-year-old female, maximum Grade 4, first VGE at 160 
minutes, first report at 199 minutes a symptom she noticed at 198 minutes, study done on n = 6, 
independent sample statistical design. 
 
Procedure 30 
 
Narrative: At 199 minutes, subject experienced onset of 2/10 left ankle pain.  She reported that 
she had been experiencing a sharp, constant pain in her left foot for the previous minute. The 
pain slowly progressed to her ankle then lower extremity over the next couple of minutes. The 
intensity and character did not change at rest or with exercise. The patient symptom report form 
was reviewed at 205 minutes and the decision was made to bring the subject back to ambient 
pressure.  First VGE detected at 160 minutes, Grade 2 from left leg and grade 3 from right leg.  
At 176 minutes there was Grade 2 from both arms, Grade 3 from left leg and grade 4 from right 
leg.  Final, and last, VGE monitoring was at 196 minutes with Grade 2 from right arm, Grade 1 
from left arm, Grade 2 from left leg, and Grade 4 from right leg.  The subject remained on O2 
and was repressurized to ambient pressure after 210 minutes at altitude. Symptoms resolved 
completely at 10,000 ft (10.11 psia) during descent.  
 
Diagnosis: Type I DCS 
Treatment: Some GLO in preparation for USN HBO TT V with follow-up consultation.  
Subject was without complaint and taken to Alpha chamber for prophylactic treatment with USN 
TT V following resolution of Type I DCS with descent from altitude. Subject tolerated 
compression without problem or complaint. She remained asymptomatic throughout the 
remainder of the treatment. 
 
117. Summary: ID# D040915A, 49-year-old female, maximum Grade 2, first VGE at 129 
minutes, first report at 31 minutes, study done on n = 6, independent sample statistical design. 
 
Procedure 30 
 
Narrative: At 31 minutes, subject had minimal brief left great toe pain (grade 2/10), which 
decreased after 40 minutes and became intermittent and was totally resolved 76 minutes into the 
exposure (Note: PRP database documents 127 minutes as the time to DCS).  Subject reported at 
127 minutes a slight (1/10), intermittent pain on the top inside of her left foot.  The pain 
progressed to the outside of the top of her left foot, increased to grade 3 intensity, and became 
constant at 139 minutes. The intensity and character did not change at rest or with exercise. The 
intensity increased to grade 4 after 142 minutes and the decision was made to bring the subject 
back to ambient pressure.  First and only VGE detected at 129 minutes, Grade 2 from the left leg.  
The subject remained on O2 and was repressurized to ambient pressure after 144 minutes at 
altitude. Symptoms decreased in intensity at 15,000 ft (8.29 psia) and resolved completely at 
5,500 ft (12.0 psia) during descent. 
 
Diagnosis: Type I DCS 
Treatment: Some GLO in preparation for USN HBO TT V with follow-up consultation. Subject 
was without complaint and taken to Alpha chamber for prophylactic treatment with USN TT V 
following resolution of Type I DCS with descent from altitude. Subject tolerated compression 
191 
 
without problem or complaint. She remained asymptomatic throughout the remainder of the 
treatment.   
 
Phase V-5 PRP: DCS Assigned at Duke  
 
118. Summary: ID# D070515A, 21-year-old female, maximum Grade 4, first VGE at 24 
minutes, first report at 58 minutes, study done on n = 48, independent sample statistical design. 
 
Procedure 31 
 
Narrative: At 58 minutes, subject experienced sudden onset of 5/10 right knee pain.  Pain was 
sharp, constant and circumferentially involved the entire right knee.  It was of a character similar 
to her usual knee pain following a very long and strenuous run.  It did not change in intensity or 
quality with position, palpation or pressure.  First VGE detected at 24 minutes, Grade 3 from 
right leg.  At 40 minutes there was Grade 1 from left leg and Grade 3 from right leg. Final 
monitoring period at 56 minutes revealed Grade 2 from left leg and Grade 4 from right leg.  
Initiated recompression to surface pressure within 5 minutes of symptom onset.  The intensity of 
pain decreased to 2/10 at 26,000 ft (5.22 psia), 1/10 at 20,000 ft (6.75 psia) and fully resolved at 
17,000 ft (7.65 psia) (three minutes after beginning recompression).  The subject was examined 
after return to ambient pressure and then immediately taken into Bravo chamber for treatment 
with a USN TT V. 
 
Diagnosis: Type I DCS 
Treatment: Some GLO prior to USN HBO TT V with follow-up consultation.  Prophylactically 
treated with USN TT V in order to avoid potential recurrence of pain.  Compression began 26 
minutes following onset of pain.  Administered 600 mg ibuprofen upon completion of treatment. 
Compression and decompression were without incident.  Physical findings remained unchanged 
and normal throughout.   
 
119. Summary: ID# D070821A, 39-year-old male, maximum Grade 4, first VGE at 76 minutes, 
first report at 93 minutes a symptom he noticed at 73 minutes, study done on n = 48, independent 
sample statistical design. 
 
Procedure 31 
 
Narrative: At 93 minutes, subject complained of a 3-6/10 constant, shooting pain in his right 
knee that quickly extended into his right thigh.  The decision by the subject to notify inside 
tenders was made after flexing the knee when the sharp pain became clearly apparent. The 
Medical Officer was notified at 94 minutes.  On questioning, it was noted that the pain did not 
change in character or intensity with motion. First VGE detected at 76 minutes, Grade 1 from left 
leg and Grade 2 from right leg.  Final monitoring period at 92 minutes revealed Grade 3 from left 
leg and Grade 4 from right leg.  The decision was made to bring the subject back to surface 
pressure at 95 minutes.  The subject left 30,250 ft (4.3 psia) at 104 minutes with full resolution of 
symptoms by 106 minutes while passing 8000 ft (10.92 psia).  He reached the surface at 108 
minutes, was transferred on O2 to Bravo chamber.  The subject had no complaints and the 
physical exam at this time was normal and non-focal for any deficits. On questioning the subject 
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mentioned that he experienced a mild non-specific right knee “ache” for 20 minutes prior to 
reporting the frank right knee pain. 
 
Diagnosis: Type I DCS 
Treatment: Some GLO prior to prophylactic USN HBO TT V with follow-up consultation.  
Exam following USN TT V was non-focal and unchanged from pre-flight physical.   
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Selected Narratives where DCS was not Diagnosed 
 
Bends 1c: Narratives but no DCS Assigned at JSC 
 
1. Summary: ID# 16-01, 21-year-old male, maximum Grade 1, first VGE at 26 minutes, first 
report after the end of the test during debrief, estimated at 120 minutes into the test, study done 
on n = 11, independent sample statistical design. 
 
Procedure 3 
 
Narrative: During debrief, subject mentioned that he felt some transient pain in middle of left 
foot, and tightening in left knee similar to what he experiences when running. He recalled that 
this appeared at the beginning of the second hr at 4.3 psia. Did not report initial pain score on the 
1–10 scale. First VGE detected at 26 minutes, Grade 0 from left arm, Grade 1 from left leg, 
Grade 0 from right arm, and Grade 0 from right leg. Last VGE record at 169 minutes with Grade 
0 from left arm, Grade 0 from left leg, Grade 0 from right arm, and Grade 0 from right leg. Sub-
ject did not report if there was a change in any symptoms during descent. During debrief, subject 
described symptoms he had during the test to the PI. Since symptoms in the left foot and left 
knee were still present at site pressure, a hyperbaric treatment was given. Symptoms did not 
respond to hyperbaric treatment. 
 
Diagnosis: No DCS 
Treatment: HBO provided to evaluate symptoms still present in left foot and left knee, but 
treatment table was not noted in the logbook. Treatment did not resolve the symptoms, so these 
were attributed to the exercise protocol used during the test. Follow-up consultation the next day 
was done. 
 
Bends 2a: Narratives but no DCS Assigned at JSC 
 
2. Summary: ID# 29-02, 43-year-old male, maximum Grade 0, first report at 72 minutes, study 
done on n = 23, independent sample statistical design.  
 
Procedure 5 
 
Narrative: At 72 minutes, during 1st-hr questioning, subject reported a little pain in left wrist 
that lasted about 30 seconds. Did not report initial pain score on the 1–10 scale. Subject had no 
VGE during the test. Last VGE record at 236 minutes with Grade 0 from left arm, Grade 0 from 
left leg, Grade 0 from right arm, and Grade 0 from right leg. It was out of normal protocol not to 
have a period of questioning for 2nd-, 3rd-, or 4th-hr questioning of this subject during test. Also 
During the test, 2 other chamber mates (37-02 and 21-02) were reporting symptoms that disrupt-
ed the normal flow of the experiment. There were no symptoms prior to descent; symptoms re-
solved at the test altitude of 4.3 psia. During debrief, subject described momentary symptom 
in left wrist as a pain or strain, which occurred during the ergometer cranking. It felt like a 
muscle strain, and did not occur for the duration of the test. 
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Diagnosis: No DCS 
Treatment: None, just self-monitoring most likely with follow-up consultation. 
 
Bends 3a: Narratives but no DCS Assigned at JSC 
 
3. Summary: ID# 48-02, 36-year-old male, maximum Grade 0, first report at 342 minutes a 
symptom he noticed at about 322 minutes, study done on n = 28, independent sample statistical 
design. 
 
Procedure 7 
 
Narrative: At 342 minutes, subject reported intermittent pain under right shoulder. Did not 
report initial pain score on the 1–10 scale. He mentioned that symptom was first noticed about 20 
minutes earlier (322 minutes). At 6th-hr questioning, he reported that for last 2 or 3 minutes the 
pain had become continuous and moved toward center of back. He had no VGE during the test. 
Last VGE record at 349 minutes with Grade 0 from left arm, Grade 0 from left leg, Grade 0 from 
right arm, and Grade 0 from right leg. Symptoms in back “pretty much gone” at 7.3 psia. During 
debrief at site pressure subject rated the intensity of pain in back a 1–2 pain score. It was ques-
tionable if symptoms in back cleared in a dramatic fashion, similar to what the PI had previ-
ously experienced. 
 
Diagnosis: None, Grade 1 Type I DCS was initially diagnosed; but after re-review 1 week 
later, the PI classified this as exercise-induced symptoms since a history of these symptoms was 
documented in records of the pre-test exercise training and the indefinite verification of symp-
toms during recompression to site pressure. 
Treatment: None, medical observation provided most likely for 12 hrs with follow-up 
consultation. 
 
Bends 3b: Narratives but no DCS Assigned at JSC 
 
4. Summary: ID# 10-05, 45-year-old male, maximum Grade 2, first VGE at 161 minutes, first 
report at 180 minutes, study done on n = 35, independent sample statistical design. 
 
Procedure 8 
 
Narrative: At 180 minutes, during 3rd-hr questioning, subject reported constant discomfort in 
right shoulder. Reported initial pain score of 1–2 on a 1–10 scale. At the 4th-hr questioning, he 
said symptoms were the same, still a 1–2 pain score. First VGE detected at 161 minutes, Grade 0 
from left arm, Grade 0 from left leg, Grade 2 from right arm, and Grade 0 from right leg. Next 
VGE monitoring was at 197 minutes, Grade 1 from left arm, Grade 2 from left leg, Grade 2 from 
right arm, and Grade 0 from right leg. Last VGE record at 360 minutes with Grade 0 from left 
arm, Grade 0 from left leg, Grade 0 from right arm, and Grade 0 from right leg. At 5th-hr ques-
tioning, he said discomfort was in right shoulder joint and muscle, on a 1–2 pain score, and was 
similar to how his shoulder felt after an injury he had about 1 year earlier. At 6th-hr questioning, 
subject reported symptoms in right shoulder were still on a 1–2 pain score. Symptoms in right 
shoulder did not resolve during repressurization to site pressure. During debrief, subject 
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mentioned he had constant discomfort from third hr on in right shoulder and right elbow. It still 
felt the same, on a 1–2 pain score. He was asked to crank the hand ergometer at 10.2 psia, the 
storage pressure prior to a second test the next day, and reported the same muscle soreness that 
he had previously reported. 
 
Diagnosis: No DCS 
Treatment: None, just self-monitoring most likely with follow-up consultation. 
 
Bends 3d: Narratives but no DCS Assigned at JSC 
 
5. Summary: ID# 43-05, 25-year-old male, maximum Grade 3, first VGE at 130 minutes, first 
report at 179 minutes, study done on n = 12, independent sample statistical design. 
 
Procedure 10 
 
Narrative: Subject had reported symptoms at first hr in left shoulder the day before while at 4.3 
psia. The PI was not convinced these were symptoms of DCS. Subject was clear to perform 
second test. At 3rd-hr questioning, subject reported slight discomfort in left shoulder. Reported 
initial pain score of 2–3 on a 1–10 scale. Awareness radiated from left shoulder to left elbow; 
subject had awareness while was lying down. At 4th-hr questioning, subject reported less pain in 
left shoulder compared to the previous report, with a pain score of 1. At 293 minutes, subject 
reported pressure on chest, a small pain in chest when he inhaled. Did not feel any symptoms 
when lying down, but felt symptom when he took a deep breath. At 5th-hr questioning, subject 
reported no symptoms from left shoulder. Pain in chest was at a pain score of 6 at its worst, but 
there was no coughing or need to cough. At 323 minutes, subject was asked about chest symp-
toms, and said no pain had reoccurred. At 6th-hr questioning, subject reported no symptoms 
in left shoulder. Symptoms in chest were just present for 5 minutes. First VGE detected at 130 
minutes, Grade 0 from left arm, Grade 1 from left leg, Grade 0 from right arm, and Grade 0 from 
right leg. Last VGE record at 356 minutes with Grade 0 from left arm, Grade 0 from left leg, 
Grade 0 from right arm, and Grade 0 from right leg. There were no symptoms prior to descent; 
symptoms resolved at the test altitude of 4.3 psia. During debrief at site pressure, subject men-
tioned that pain in left shoulder was worse today, and more constant, than he had experienced 
the day before on his first exposure to 4.3 psia. Chest pain was not diagnosed by the MO as 
chokes during the test. 
 
Diagnosis: No DCS 
Treatment: None, just self-monitoring most likely with follow-up consultation. 
 
Bends 5a: Narratives but no DCS Assigned at JSC 
 
6. Summary: ID# 94-01, 24-year-old female, maximum Grade 0, first report at 73 minutes, 
study done on n = 38, independent sample statistical design. 
 
Procedure 12 
 
Narrative: At 73 minutes, subject reported problem in right patella. Did not report initial pain 
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score on the 1–10 scale. At 84 minutes, reported discomfort in right wrist. At 93 minutes, subject 
reported that problem in right knee was worse, and he felt it when at the Doppler station but not 
at the exercise stations. At 110 minutes, subject reported discomfort in right wrist was present 
throughout previous exercise. At 2nd-hr questioning, a constant dull ache present at all times in 
the right wrist, but feeling in the right knee was only present at the Doppler monitoring station. 
At 3rd-hr questioning, subject reported symptom in right wrist had not bothered her over the last 
hr, and that she felt the right knee symptom when she bent down. At 4th- and 5th-hr questioning, 
subject reported being just fine, with no symptoms in right knee or right wrist. No VGE were 
detected during test. Last VGE record at 324 minutes with Grade 0 from left arm, Grade 0 from 
left leg, Grade 0 from right arm, and Grade 0 from right leg. There were no symptoms prior to 
descent; symptoms resolved at the test altitude of 4.3 psia. During debrief, subject mentioned she 
still felt something in right knee while squatting down, and recalled that she might have hurt 
right knee earlier in the week while playing with her children. 
 
Diagnosis: No DCS 
Treatment: None, just self-monitoring most likely with follow-up consultation. 
 
Bends 7 (high exercise): Narratives but no DCS Assigned at JSC 
 
7. Summary: ID# 116-01, 33-year-old male, maximum Grade 4, first VGE at 0 minutes, did 
not report a symptom until after the test during debriefing period, study done on n = 11, cross-
over dependent sample statistical design. 
 
Procedure 14 
 
Narrative: At about 30 minutes after the test, subject mentioned during the formal debriefing 
that he had “something” once during the test but it was exactly what he feels in some cramped 
positions, so he did not report anything. First VGE detected at 0 minutes, Grade 0 from left arm, 
Grade 0 from left leg, Grade 3 from right arm, and Grade 0 from right leg. It is very unusual to 
detect VGE early in the exposure, and even more unusual to detect VGE exclusively from the 
upper body. There was a rapid onset of VGE, with Grade 4 from the left and right legs at 96 
minutes into the test. Last VGE record at 189 minutes with Grade 0 from left arm, Grade 3 
from left leg, Grade 3 from right arm, and Grade 4 from right leg. Subject did not report 
if there was a change in symptoms during descent. 
 
Diagnosis: No DCS 
Treatment: One-hr GLO with follow-up consultation. 
 
Bends 7 (low exercise): Narratives but no DCS Assigned at JSC 
 
8. Summary: ID# 123-02, 28-year-old male, maximum Grade 4, first VGE at 76 minutes, first 
report at 120 minutes, study done on n = 11, crossover dependent sample statistical design. 
 
Procedure 15 
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Narrative: At 120 minutes, during 2nd-hr questioning, subject reported tingling on skin of face, 
shoulders, and wrists. He also mentioned being intermittently warm. Did not report initial pain 
score on the 1–10 scale. First VGE detected at 76 minutes, Grade 0 from left arm, Grade 1 from 
left leg, Grade 0 from right arm, and Grade 1 from right leg. Last VGE record at 185 minutes 
with Grade 0 from left arm, Grade 3 from left leg, Grade 0 from right arm, and Grade 2 from 
right leg. At 3rd-hr questioning, subject said all skin sensations had disappeared about 30 minutes 
earlier. There were no symptoms prior to descent; symptoms resolved at the test altitude of 6.5 
psia. Debrief notes indicate there was no rash on inspection of skin, and that symptoms could 
have been due to sweating early in the test. 
 
Diagnosis: No DCS 
Treatment: One-hr GLO with follow-up consultation . 
 
Bends 8a (no prior treadmill exercise): Narratives but no DCS  
Assigned at JSC 
 
9. Summary: ID# 122-03, 48-year-old male, maximum Grade 4, first VGE at 24 minutes, first 
report at 120 minutes, study done on n = 40, crossover dependent sample statistical design. 
 
Procedure 16 
 
Narrative: At 120 minutes, during 2nd-hr questioning, subject reported a warm head and forearm 
muscle stiffness during the Pull Station exercises. Did not provide initial pain score on a 1–10 
scale. Subject and DT had reported being warm about 20 minutes into the test. At 150 minutes, 
subject reported that stiffness in forearms was about the same, and that they felt a little sore. At 
160 minute,s subject reported a sinus headache localized to the ethmoid sinus. Headache was 
gradual in its onset, and subject felt it was related to O2 flow in the mask. At 174 minutes, 
sinuses still hurt, mostly around the eyes. No visual disturbances mentioned. First VGE detected 
at 24 minutes, Grade 2 from left arm, Grade 3 from left leg, Grade 0 from right arm, and Grade 0 
from right leg. Last VGE record at 168 minutes with Grade 2 from left arm, Grade 4 from left 
leg, Grade 2 from right arm, and Grade 4 from right leg. During repressurization, subject re-
ported that his sinuses hurt more than at 6.5 psia. Chamber descent was stopped at 2,000 feet 
returned to 3,000 feet, and a sinus spray was administered to help open the sinuses. During 
debrief, subject was asked to pull on the Pull Station ergometer; he noted that his forearms 
still hurt a little, but not as much as at altitude. It is noted in the logbook that the Pull Station 
ergometer resistance was higher than the training ergometer in the Environmental Physiology 
Laboratory. Sinusitis improved. 
 
Diagnosis: No DCS 
Treatment: One-hr GLO with follow-up consultation. 
 
Bends 8b (prior treadmill exercise): Narratives but no DCS  
Assigned at JSC 
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10. Summary: ID# 51-12, 32-year-old male, maximum Grade 1, first VGE at 175 minutes, first 
report at 60 minutes, study done on n = 41, crossover dependent sample statistical design. 
 
Procedure 17 
 
Narrative: At 60 minutes, during 1st-hr questioning, subject reported slight pain in right elbow. 
Reported initial pain score of 1 on a 1–10 scale. Pain was described as steady, and did not change 
with exercise. Subject mentioned that he had not experienced this sensation during ground 
training of the exercise activities. First VGE detected at 175 minutes, Grade 0 from left arm, 
Grade 1 from left leg, Grade 0 from right arm, and Grade 0 from right leg. Last VGE record was 
also at 175 minutes with Grade 0 from left arm, Grade 1 from left leg, Grade 0 from right arm, 
and Grade 0 from right leg. This was the only incident of a detected VGE. At 76 minutes, subject 
reported no change in right elbow symptoms, which were localized right on the elbow, were not 
sensitive to touch, and were described as a mild ache. At 91 minutes, in response to a query by 
the test investigator, subject said that sensation in right elbow had all but disappeared. At 2nd- 
and 3rd-hr questioning, subject had nothing to report about his right elbow. There were no 
symptoms prior to descent; symptoms resolved at the test altitude of 6.5 psia. 
 
Diagnosis: No DCS 
Treatment: One-hr GLO with follow-up consultation. 
 
Bends 9a (ambulatory control): Narratives but no DCS  
Assigned at JSC 
 
11. Summary: ID# 145-04, 43-year-old male, maximum Grade 4, first VGE at 32 minutes, first 
report at 60 minutes, study done on n = 24, crossover dependent sample statistical design. 
 
Procedure 18 
 
Narrative: At 60 minutes, during 1st-hr questioning, subject reported some lightheadedness and 
a slight headache. Did not report initial pain score on the 1–10 scale. At 2nd-hr questioning, 
subject reported that headache was gone, but still lightheaded. After this entry the logbook 
shows, in parentheses, “not as sharp as when first entered chamber.” It is not clear if this refers to 
lightheaded symptom. First VGE detected at 32 minutes, Grade 0 from left arm, Grade 1 from 
left leg, Grade 2 from right arm, and Grade 2 from right leg. Last VGE record at 175 minutes 
with Grade 0 from left arm, Grade 4 from left leg, Grade 1 from right arm, and Grade 4 from 
right leg. Subject experienced significant VGE from the start of test to the end of test. At 3rd-
hr questioning, subject only reported being a little lethargic. Except for the lethargy, there were 
no symptoms of headache or lightheadedness prior to descent. The logbook does not document if 
there were any improvements during the descent. The Questionnaire on Post-Exposure 
Symptoms indicated that subject experienced nausea halfway through the test. 
 
Diagnosis: No DCS 
Treatment: One-hr GLO with follow-up consultation. 
 
Phase I PRP: Narratives but no DCS Assigned at Duke 
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12. Summary: ID# D980331A, 29-year-old male, maximum Grade 0, first report at 58 minutes, 
study done on n = 47, independent sample statistical design. 
 
Procedure 23 
 
Narrative: At 58 minutes and 116 minutes, subject reported unusual muscle twitches or 
spasms in left elbow and left forearm during flexion of the limbs for VGE measurements. 
Subject had no VGE. Last VGE record at 229 minutes with Grade 0 from right arm, Grade 0 
from left arm, Grade 0 from left leg, and Grade 0 from right leg. There were no symptoms prior 
to descent; symptoms resolved at the test altitude of 4.3 psia. 
 
Diagnosis: No DCS 
Treatment: None, just self-monitoring with follow-up consultation. 
 
13. Summary: ID# D980331B, 24-year-old male, maximum Grade 3, first VGE at 28 minutes, 
first report at 59 minutes, study done on n = 47, independent sample statistical design. 
 
Procedure 23 
 
Narrative: At 59 minutes, subject reported bilateral pain in hands extending from base of 5th 
digit proximally along ulnar aspect to wrist and dorsally to base of thumb. Reported initial pain 
score of 3 on a 1–10 scale. Pain was sharp during exercise (tension-release portion of the PS/AS2 
station) and dull at a pain score of 1 during rest. Symptoms lasted for approximately 105 minutes 
before abating to a pain score of 0. The PS/AS2 exercise involved pulling and then holding 
pounds of force with isometric contraction in the arms, depending on your body weight, as well 
as flexing the lt and then rt arms across the chest against a resistance from bundge cord. First 
VGE detected at 28 minutes, Grade 0 from right arm, Grade 2 from left arm, Grade 0 from left 
leg, and Grade 2 from right leg. Last VGE record at 232 minutes with Grade 1 from right arm, 
Grade 0 from left arm, Grade 0 from left leg, and Grade 0 from right leg. There were no 
symptoms in the hands prior to descent; symptoms resolved at the test altitude of 4.3 psia. 
 
Diagnosis: No DCS, determined to be induced by exercise. 
Treatment: None, just self-monitoring with follow-up consultation. 
 
Phase II PRP: Narratives but no DCS Assigned at Duke 
 
14. Summary: ID# D980526B, 22-year-old male, maximum Grade 0, first report at 48 minutes, 
study done on n = 45, independent sample statistical design. 
 
Procedure 24 
 
Narrative: At 48 minutes, subject reported a dull, steady aching pain in right shin, lateral 
aspect. Reported initial pain score of 2 on a 1–10 scale. Subject had no VGE. Last VGE record 
at 233 minutes with Grade 0 from right arm, Grade 0 from left arm, Grade 0 from left leg, and 
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Grade 0 from right leg. All symptoms were gone by 232 minutes. There were no symptoms 
in right shin prior to descent; symptoms resolved at the test altitude of 4.3 psia. 
 
Diagnosis: No DCS, exercise-induced symptoms 
Treatment: None, just self-monitoring with follow-up consultation. 
 
15. Summary: ID# D980609A, 27-year-old male, maximum Grade 0, first report at 181 
minutes, study done on n = 45, independent sample statistical design. 
 
Procedure 24 
 
Narrative: At 181 minutes, subject reported a headache but did not mention this again during 
the exposure. Last VGE record at 241 minutes with Grade 0 from right arm, Grade 0 from left 
arm, Grade 0 from left leg, and Grade 0 from right leg. During evaluation at site pressure, subject 
volunteered an initial pain score of 4 on a 1–10 scale for the headache, and said that it had been a 
steady headache. He said that the headache decreased in severity during final descent, reaching 
approximately a 1–2 pain score after the test. 
 
Diagnosis: No DCS. Subject was diagnosed with idiopathic headache. 
Treatment: None, just self-monitoring with follow-up consultation. Instructed to take Motrin 
and to rehydrate. 
 
Phase II PRP: Narratives but no DCS Assigned at Hermann 
 
16. Summary: ID# H980707A, 36-year-old female, maximum Grade 3, first VGE at 160 
minutes, first report at 196 minutes, study done on n = 45, independent sample statistical design. 
 
Procedure 24 
 
Narrative: At 196 minutes, subject reported intermittent pain on antecubital side of right arm. 
Reported initial pain score of 2–3 on a 1–10 scale. At 212 minutes, subject reported fatigue and 
pain in right arm was reduced to a pain score of 1. First VGE detected at 160 minutes, Grade 0 
from right arm, Grade 0 from left arm, Grade 0 from left leg, and Grade 2 from right leg. Last 
VGE record at 228 minutes with Grade 0 from right arm, Grade 0 from left arm, Grade 0 from 
left leg, and Grade 3 from right leg. Subject finished the test, but reported that the pain did not 
resolve during descent. During a posttest interview by the MO, subject – while on 100% O2 – 
described pain in right arm as more like an itch or a bee sting. NOTE: Subject had a hard time 
during the 10-minutes exercise PB, and the resistance was reduced to almost half of the 
prescribed amount. 
 
Diagnosis: No DCS. The MO attributed all the symptoms to muscle strain. 
Treatment: One-hr GLO with follow-up consultation. 
 
Phase II PRP: Narratives but no DCS Assigned at DCIEM 
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17. Summary: ID# C980617A, 29-year-old male, maximum Grade 1, first VGE at 98 minutes, 
first report at 132 minutes, study done on n = 45, independent sample statistical design. 
 
Procedure 24 
 
Narrative: At 132 minutes, subject reported awareness in hips. Awareness persisted for the 
remainder of the exposure. First VGE detected at 98 minutes, Grade 0 from right arm, Grade 0 
from left arm, Grade 1 from left leg, and Grade 0 from right leg. Last VGE record at 234 minutes 
with Grade 0 from right arm, Grade 0 from left arm, Grade 0 from left leg, and Grade 0 from 
right leg. Subject finished test, but no details were provided about changing symptoms in 
hips during descent. 
 
Diagnosis: No DCS 
Treatment: None, just self-monitoring with follow-up consultation. 
 
18. Summary: ID# C980617C, 46-year-old male, maximum Grade 4, first VGE at 78 minutes, 
first report at 128 minutes, study done on n = 45, independent sample statistical design. 
 
Procedure 24 
 
Narrative: At 128 minutes, subject reported being suddenly tired. Fatigue was gone by 
196 minutes. First VGE detected at 78 minutes, Grade 0 from right arm, Grade 0 from left arm, 
Grade 3 from left leg, and Grade 0 from right leg. Last VGE record at 231 minutes with Grade 1 
from right arm, Grade 1 from left arm, Grade 4 from left leg, and Grade 2 from right leg. There 
were no symptoms prior to descent; symptoms resolved at the test altitude of 4.3 psia. NOTE: 
Subject had severely injured his left knee while skiing as a teenager. This was the limb with 
high VGE grades. 
 
Diagnosis: No DCS 
Treatment: None, just self-monitoring with follow-up consultation. 
 
19. Summary: ID# C980625C, 46-year-old male, maximum Grade 4, first VGE at 26 minutes, 
first report at 90 minutes, study done on n = 45, independent sample statistical design. 
 
Procedure 24 
 
Narrative: At 90 minutes, subject reported that left shoulder was a bit sore, had a dull ache, 
which was not pain, that did not interfere with activity. Reported initial pain score of 2 on a 1–
10 scale. No symptoms were present during rest but were present during activity for the rest of 
the exposure. First VGE detected at 26 minutes, Grade 0 from right arm, Grade 2 from left arm, 
Grade 1 from left leg, and Grade 2 from right leg. Last VGE record at 230 minutes with Grade 3 
from right arm, Grade 3 from left arm, Grade 3 from left leg, and Grade 2 from right leg. There 
was questionable improvement in left shoulder on descent and during a test-of-pressure at 60 fsw 
for 10 minutes. On descent, he felt subjective improvement at 10.5 psia; but on questioning at 
site pressure, he stated that he felt there was no change during the descent. 
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Diagnosis: No DCS. Musculo-skeletal symptom. Had history of multiple joint symptoms. 
Treatment: Trial of pressure to 60 fsw on O2 for 10 minutes, and no change in shoulder 
symptom reported. Follow-up consultation the next day was done. 
 
Phase III PRP: Narratives but no DCS Assigned at Duke 
 
20. Summary: ID# D980630A, 25-year-old female, maximum Grade 2, first VGE at 79 minutes, 
first report at 58 minutes, study done on n = 10, independent sample statistical design. 
 
Procedure 25 
 
Narrative: Subject reported lower dorsal and gluteal pain during surface interval prior to 
final ascent to 4.3 psia. Was given a pillow to improve lower body discomfort. At 59 minutes, 
subject reported lower back pain during exercise and while resting. Reported initial pain score of 
1 on a 1–10 scale. At 112 minutes, pain was described as pain score of 2 during sit-ups. At 162 
minutes, subject complained of pain score of 5 in same region and decision was made to return 
her to site pressure. First VGE detected at 79 minutes, Grade 0 from right arm, Grade 1 from left 
arm, Grade 1 from left leg, and Grade 2 from right leg. Last VGE record at 165 minutes with 
Grade 0 from right arm, Grade 0 from left arm, Grade 0 from left leg, and Grade 0 from right 
leg. She noted immediate relief of pain with standing in chamber during lockout preparation 
(before recompression), with resolution to pain score 1 by arrival at surface. Posttest exami-
nation uncovered no neurological signs or symptoms. 
 
Diagnosis: No DCS. Musculoskeletal symptom. 
Treatment: One-hr GLO with follow-up consultation. 
 
21. Summary: ID# D980707B, 29-year-old male, maximum Grade 0, first report at 108 minutes, 
study done on n = 10, independent sample statistical design. 
 
Procedure 25 
 
Narrative: At 108 minutes, subject reported dull transient pain above left eye in frontal sinus 
region. Reported initial pain score of 3 on a 1–10 scale. Given Afrin and monitored for remain-
der of flight. Pain score reduced to a value of 1 within 10 minutes (about 118 minutes elapsed 
time). Little pain (pain score of 2) was experienced during percussion test at 140 minutes. Mild 
sinus discomfort persisted throughout the test and during descent, with a reported pain score of 
0.5–1. Subject had no VGE. Last VGE record at 221 minutes with Grade 0 from right arm, 
Grade 0 from left arm, Grade 0 from left leg, and Grade 0 from right leg. Final descent was 
paused for 30 seconds at 6.65 psia to allow subject to clear ears. Posttest examination was 
unremarkable except for note of mild ear barotrauma. 
 
Diagnosis: No DCS 
Treatment: None, just self-monitoring with follow-up consultation. 
 
22. Summary: ID# D980714B, 40-year-old male, maximum Grade 0, first report at 21 minutes, 
study done on n = 10, independent sample statistical design. 
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Procedure 25 
 
Narrative: At 21 minutes, subject reported steady tingling in right toes at rest. Reported initial 
pain score of 2 on a 1–10 scale. This sensation persisted for about 1 minute before it completely 
subsided. Subject had no VGE. Last VGE record at end of test with Grade 0 from right arm, 
Grade 0 from left arm, Grade 0 from left leg, and Grade 0 from right leg. There were no 
symptoms prior to descent; symptoms resolved at the test altitude of 4.3 psia. 
 
Diagnosis: No DCS 
Treatment: None, just self-monitoring with follow-up consultation. 
 
Phase IV PRP: Narratives but no DCS Assigned at Duke 
 
23. Summary: ID# D990504C, 22-year-old male, maximum Grade 0, first report at 44 minutes, 
study done on n = 57, independent sample statistical design. 
 
Procedure 26 
 
Narrative: At 44 minutes, subject reported dull, steady tingling in both legs. Reported initial 
pain score of 1 on a 1–10 scale. At 59 minutes, tingling was barely noticeable; a pain score of 0.5 
was given, and a decision was made to remove subject due to persistence of symptom. Walking 
prior to lockout relieved symptoms. Subject had no VGE. Last VGE record at 40 minutes with 
Grade 0 from right arm, Grade 0 from left arm, Grade 0 from left leg, and Grade 0 from right leg. 
There were no symptoms prior to descent; symptoms resolved at the test altitude of 4.3 psia. 
 
Diagnosis: No DCS 
Treatment: None, just self-monitoring with follow-up consultation. 
 
24. Summary: ID# D990525A, 27-year-old male, maximum Grade 0, first report at 590 minutes 
(10 hrs from start of test), study done on n = 57, independent sample statistical design. 
 
Procedure 26 
 
Narrative: At 350 minutes (6 hrs) after the test, subject reported pain in lower back while 
seated. Reported initial pain score of 2 on a 1–10 scale with a sharp pain at a pain score of 6. 
Subject had no VGE. Last VGE record at 228 minutes with Grade 0 from right arm, Grade 0 
from left arm, Grade 0 from left leg, and Grade 0 from right leg. There were no symptoms prior 
to descent from 4.3 psia. 
 
Diagnosis: No DCS. Musculoskeletal pain. 
Treatment: None, just self-monitoring with follow-up consultation. 
 
Phase IV PRP: Narratives but no DCS Assigned at DCIEM 
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25. Summary: ID# C990121A, 55-year-old male, maximum Grade 4, first VGE at 81 minutes, 
first report at 136 minutes, study done on n = 57, independent sample statistical design. 
 
Procedure 26 
 
Narrative: At 136 minutes, subject reported mild ambiguous symptoms (awareness) in left 
proximal shin. First VGE detected at 81 minutes, Grade 0 from right arm, Grade 0 from left arm, 
Grade 3 from left leg, and Grade 0 from right leg. Last VGE record at 233 minutes with Grade 3 
from right arm, Grade 3 from left arm, Grade 4 from left leg, and Grade 4 from right leg. There 
were no respiratory or left and right knee symptoms prior to descent; symptoms resolved at the 
test altitude of 4.3 psia. NOTE: Subject had mild upper respiratory tract symptoms the following 
morning. This developed into a severe cold over the weekend, and he only started getting better 
on Wednesday. 
 
Diagnosis: No DCS 
Treatment: None, just self-monitoring with follow-up consultation. 
 
26. Summary: ID# C990121C, 40-year-old male, maximum Grade 4, first VGE at 93 minutes, 
first report at 136 minutes, study done on n = 57, independent sample statistical design. 
 
Procedure 26 
 
Narrative: At 136 minutes, subject reported mild irritation on inspiration; suspected dry O2. 
At 168 minutes, subject reported ambiguous symptoms (mild sensation) in both knees. First 
VGE detected at 93 minutes, Grade 0 from right arm, Grade 0 from left arm, Grade 2 from left 
leg, and Grade 0 from right leg. Last VGE record at 229 minutes with Grade 3 from right arm, 
Grade 3 from left arm, Grade 4 from left leg, and Grade 4 from right leg. There were no 
symptoms prior to descent; symptoms resolved at the test altitude of 4.3 psia. 
 
Diagnosis: No DCS 
Treatment: None, just self-monitoring with follow-up consultation. 
 
27. Summary: ID# C990303D, 37-year-old male, maximum Grade 4, first VGE at 130 minutes, 
first report was prior to ascent to 4.3 psia, study done on n = 57, independent sample statistical 
design. 
 
Procedure 26 
 
Narrative: Subject reported generalized numbness in legs at 9.6 psia, and was told to move 
legs on a regular basis during the test at 4.3 psia. Numbness was attributed to the exercise cot. 
At 42 minutes, subject reported a sore right bicep; and at 94 minutes, he had cramps in both leg 
muscles. At 210 minutes, subject reported stiff legs. First VGE detected at 130 minutes, Grade 0 
from right arm, Grade 0 from left arm, Grade 3 from left leg, and Grade 0 from right leg. Last 
VGE record at 230 minutes with Grade 2 from right arm, Grade 1 from left arm, Grade 4 from 
left leg, and Grade 3 from right leg. No information was provided about change in symptoms 
during descent to site pressure. NOTE: Subject complained of minor backache and sore leg in 
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the morning before the PB started, but the database narrative was not specific on which leg was 
sore. 
 
Diagnosis: No DCS 
Treatment: None, just self-monitoring with follow-up consultation. 
 
28. Summary: ID# C990324A, 53-year-old male, maximum Grade 4, first VGE at 44 minutes, 
first report at 112 minutes, study done on n = 57, independent sample statistical design. 
 
Procedure 26 
 
Narrative: At 112 minutes, subject reported slight awareness in both knees. This sensation 
had gone by the next Doppler measurement period (about 12 minutes). First VGE detected at 44 
minutes, Grade 2 from right arm, Grade 1 from left arm, Grade 2 from left leg, and Grade 1 from 
right leg. Last VGE record at 232 minutes with Grade 0 from right arm, Grade 0 from left arm, 
Grade 3 from left leg, and Grade 3 from right leg. There were no symptoms in both knees 
prior to descent; symptoms resolved at the test altitude of 4.3 psia. 
 
Diagnosis: No DCS 
Treatment: None, just self-monitoring with follow-up consultation. 
 
29. Summary: ID# C990331A, 37-year-old male, maximum Grade 4, first VGE at 82 minutes, 
first report at 114 minutes, study done on n = 57, independent sample statistical design. 
 
Procedure 26 
 
Narrative: At 114 minutes, subject reported some discomfort in right knee, possibly from 
sitting. At 124 minutes, subject reported a pain score of 1 on the 1–10 pain scale and definite 
steady discomfort for right knee. At 138 minutes, there was still steady discomfort in right knee 
at a 1 on the pain score. At 154 minutes, subject reported no discomfort; symptom had com-
pletely resolved. First VGE detected at 82 minutes, Grade 0 from right arm, Grade 2 from left 
arm, Grade 0 from left leg, and Grade 2 from right leg. Last VGE record at 234 minutes with 
Grade 0 from right arm, Grade 0 from left arm, Grade 3 from left leg, and Grade 3 from right 
leg. There were no symptoms in right knee prior to descent; symptoms resolved at the test 
altitude of 4.3 psia. 
 
Diagnosis: No DCS 
Treatment: None, just self-monitoring with follow-up consultation. 
 
30. Summary: ID# C990331C, 25-year-old female, maximum Grade 3, first VGE at 146 
minutes, first report at 14 minutes, study done on n = 57, independent sample statistical design. 
 
Procedure 26 
 
Narrative: At 14 minutes, subject reported some tingling, but disappearing. At 130 minutes, 
subject reported slight tingling in back only when doing sit-ups. By 146 minutes, the tingling 
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sensations were subsiding. First VGE detected at 146 minutes, Grade 0 from right arm, Grade 0 
from left arm, Grade 2 from left leg, and Grade 0 from right leg. Last VGE record at 230 minutes 
with Grade 0 from right arm, Grade 0 from left arm, Grade 3 from left leg, and Grade 0 from 
right leg. There were no symptoms of tingling in back prior to descent; symptoms resolved 
at the test altitude of 4.3 psia. 
 
Diagnosis: No DCS 
Treatment: None, just self-monitoring with follow-up consultation. 
 
31. Summary: ID# C990331D, 28-year-old female, maximum Grade 0, first report at 214 
minutes, study done on n = 57, independent sample statistical design. 
 
Procedure 26 
 
Narrative: At 214 minutes, subject reported momentary tingling in left foot. Subject had 
no VGE. Last VGE record at 230 minutes with Grade 0 from right arm, Grade 0 from left arm, 
Grade 0 from left leg, and Grade 0 from right leg. No VGE during the run. There were no symp-
toms of tingling in left foot prior to descent; symptoms resolved at the test altitude of 4.3 psia. 
 
Diagnosis: No DCS 
Treatment: None, just self-monitoring with follow-up consultation. 
 
Phase IV PRP: Narratives but no DCS Assigned at Hermann 
 
32. Summary: ID# H990615A, 22-year-old male, maximum Grade 0, first report at 157 
minutes, study done on n = 57, independent sample statistical design. 
 
Procedure 26 
 
Narrative: At 157 minutes, subject reported forearm numbness. Sensation improved but with 
a decreased sensation of an area of 2 in.  6 in. described. Subject did not have decreased grip 
strength and felt fine after interview with MO. At approximately 210 minutes, subject reported 
bilateral forearm numbness that extended to wrists bilaterally. A decision was made to remove 
subject from the test. Subject had no VGE. Last VGE record at 145 minutes with Grade 0 from 
right arm, Grade 0 from left arm, Grade 0 from left leg, and Grade 0 from right leg. Symptoms 
did not resolve on return to site pressure, but numbness may have improved. On pinprick testing, 
bilateral forearms had decreased pinprick, as well as thenar eminence bilaterally. Soft touch was 
also reduced. However, muscle strength was 5/5 in all groups, and reflexes were completely nor-
mal, both upper and lower. After 15 minutes (on sea level O2, as per protocol), subject still com-
plained of tingling of bilateral forearms, although decreased pinprick was completely resolved. 
Due to persistent subjective numbness, it was decided to provide a hyperbaric treatment. 
 
Diagnosis: No DCS. A mild case of bilateral median nerve irritation due to repetitive muscle 
activity was diagnosed. Due to the fact that there symptoms were bilateral, did not appear to im-
prove in direct relation to recompression (either to sea level or at 60 fsw), and were all referable 
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to the median nerve, it was the opinion of the MO that this was not DCS, but was bilateral 
median nerve irritation. 
 
Treatment: USN HBO TT VI for possible neurological DCS, with no relief with compression to 
60 fsw. After the first O2 cycle, all subjective symptoms of tingling had resolved. This treatment 
was complicated by the fact that symptoms were improving when subject first entered the treat-
ment chamber. He had no problems with TT VI, and had neither subjective nor objective 
neurological complaints after treatment. Follow-up consultation the next day was done. 
 
   
208 
 
Appendix V:  Prebreathe and Test Details 
 
Procedure 1 (Test 1a): A 3.5-hr O2 PB at 14.7 psia prior to 3-hr exposure to 4.3 psia in the 
ETA, an altitude chamber conFig.d to resemble the Shuttle crew compartment. Decompression 
required 6 minutes at 5,000 feet/minute. Exercise stressed lower body. Exercise was 4 minutes 
of flexing elbow and shoulder joints by rhythmically lifting a 1.36-kg weight alternately every 
5 seconds from left to right hand, 4 minutes flexing hip and knee joints by rhythmically stepping 
on an 18.4-cm step once every 10 seconds, 4 minutes sitting or standing with no physical activ-
ity, and 4 minutes in a supine position while flexing arms and legs sequentially to improve bub-
ble detection by DT. Each limb was flexed 3 times along with wrist and ankle rotation. Subjects 
used these devices from a standing or seated (non-adynamic) position and were allowed to walk 
during PB or altitude exposure. Test termination for DCS was after any performance was 
affected; but during Bends 1, the MO always stopped the test once DCS was diagnosed. 
 
Procedure 2 (Test 1b): Twelve hrs at 10.2 psia plus a 40-minutes O2 PB prior to a 3-hr exposure 
to 4.3 psia in the ETA, an altitude chamber conFig.d to resemble the Shuttle crew compartment.  
Decompression required 2 minutes on air to 10.2 psia and 4 minutes to 4.3 psia after the final 
PB, all at 5,000 feet/minute.  Exercise stressed lower body.  Gas composition at 10.2 psia was 
nominal 26.5% O2 - 73.5% N2, but protocol records indicated 27% O2 was the goal.  Exercise 
was 4 minutes flexing elbow and shoulder joints by rhythmically lifting a 1.36-kg weight 
alternately every 5 seconds from left to right hand, 4 minutes flexing hip and knee joints by 
rhythmically stepping on an 18.4-cm step once every 10 seconds, 4 minutes sitting or standing 
with no physical activity, and 4 minutes in a supine position while flexing arms and legs 
sequentially to improve bubble detection by DT. Each limb was flexed 3 times along with wrist 
and ankle rotation. Subjects used these devices from a standing or seated (non-adynamic) 
position and were allowed to walk during PB or altitude exposure. Test termination for DCS was 
after any performance was affected; but during Bends 1, the MO always stopped the test once 
DCS was diagnosed. 
 
Procedure 3 (Test 1c): Twelve hrs at 10.2 plus a 90-minute O2 PB prior to a 3-hr exposure to 
4.3 psia in the ETA, an altitude chamber conFig.d to resemble the Shuttle crew compartment. 
Decompression required 2 minutes on air to 10.2 psia and 4 minutes to 4.3 psia after the final 
PB, all at 5,000 feet/minute.  Gas composition at 10.2 psia was nominal 26.5% O2 - 73.5% N2, 
but protocol records indicated 27% O2 was the goal.  The exercise was 4 minutes flexing elbow 
and shoulder joints by rhythmically lifting a 1.36 kg-weight alternately every 5 seconds from left 
to right hand, 4 minutes flexing hip and knee joints by rhythmically stepping on an 18.4-cm step 
once every 10 seconds, 4 minutes sitting or standing with no physical activity, and 4 minutes in a 
supine position while flexing arms and legs sequentially to improve bubble detection by DT. 
Each limb was flexed 3 times along with wrist and ankle rotation. Subjects used these devices 
from a standing or seated (non-adynamic) position and were allowed to walk during PB or 
altitude exposure. Test termination for DCS was after any performance was affected; but during 
Bends 1. The MO always stopped the test once DCS was diagnosed. 
 
Procedure 4 (Test 1d): Eighteen hrs at 10.2 psia plus a 40-minute O2 PB prior to a 3-hr 
exposure to 4.3 psia in the ETA, an altitude chamber conFig.d to resemble the Shuttle crew 
compartment. Decompression required 2 minutes on air to 10.2 psia and 4 minutes to 4.3 psia 
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after the final PB, all at 5,000 feet/minute. Exercise stressed lower body.  Gas composition at 
10.2 psia was nominal 26.5% O2 - 73.5% N2, but protocol records indicated 27% O2 was the 
goal.  The exercise was 4 minutes flexing elbow and shoulder joints by rhythmically lifting a 
1.36-kg weight alternately every 5 seconds from left to right hand, 4 minutes flexing hip and 
knee joints by rhythmically stepping on an 18.4-cm step once every 10 seconds, 4 minutes sitting 
or standing with no physical activity, and 4 minutes in a supine position while flexing arms and 
legs sequentially to improve bubble detection by DT. Each limb was flexed 3 times along with 
wrist and ankle rotation. Subjects used these devices from a standing or seated (non-adynamic) 
position and were allowed to walk during PB or altitude exposure. Test termination for DCS was 
after any performance was affected; but during Bends 1, the MO always stopped the test once 
DCS was diagnosed. 
 
Procedure 5 (Test 2a): A 3.5-hr O2 PB at 14.7 psia prior to a 4-hr exposure to 4.3 psia in the 
ETA, an altitude chamber conFig.d to resemble the Shuttle crew compartment. Decompression 
was gradual and allowed 30 minutes of additional O2 PB prior to reaching 4.3 psia. The detailed 
ascent profile is: 6 minutes to travel from 14.7 psia to 9.2 psia, a hold at 9.2 psia for 10 minutes, 
4 minutes to travel from 9.2 psia to 5.2 psia, and finally 10 minutes to travel from 5.2 psia to 4.3 
psia.  Simulated EVA work activity and VGE monitoring began at 5.2 psia during the final 10-
min pressure decrease to 4.3 psia.  Since this defines the beginning of the simulated EVA, the 
additional 10 min of prebreathe during the final ascent is not considered as prebreathe time.  The 
exercise stressed the upper body. “A” cycle exercise included 4 minutes seated at mini-gym set 
to 16.7 kg of resistance and pulling once in 5 seconds with right arm then pulling once in 5 
seconds with the left arm, 4 minutes standing at ergometer set to 5-N resistance and cranking 3 
times in 5 seconds with right hand going clockwise. A 5-second rest was taken, then 3 cranks 
repeated, 4 minutes standing at torque station 107 cm above floor where ten 3/8-in. fixed studs 
were torqued to 400 cm-kg. Torque was held for 5 seconds in both directions. A total of 24 
separate isotonic torques were done in the 2- to 3-minute periods. Remaining time was spent 
stressing the wrist with a ball ratchet placed on several studs and maintaining an isotonic torque 
for 5 seconds. “A” cycle was to use the right hand with the ball ratchet, and finally 4 minutes in a 
supine position while flexing arms and legs sequentially to improve bubble detection by DT. 
Each limb was flexed 3 times along with wrist and ankle rotation. “B” cycle exercise included 4 
minutes at mini-gym set to the same resistance as “A” cycle and pulling twice in a 5-second 
period, 4 minutes at ergometer using same rate except using left hand and cranking 
counterclockwise, 4 minutes at torque station using same torque pattern except with left hand, 4 
minutes rest after completing “B” cycle, and finally 4 minutes in a supine position while flexing 
arms and legs sequentially to improve bubble detection by DT. Subjects used these devices from 
a standing or seated (non-adynamic) position and were allowed to walk during PB or altitude 
exposure. Test termination for DCS was after any performance was affected. 
 
Procedure 6 (Test 2b): Twelve hrs at 10.2 psia plus a 40-minute O2 PB prior to a 4-hr exposure 
to 4.3 psia in the ETA, an altitude chamber conFig.d to resemble the Shuttle crew compartment. 
Decompression was gradual and allowed 25 minutes of additional O2 PB prior to reaching 4.3 
psia after the stay at 10.2 psia.   The detailed ascent profile is: 5 minutes to travel from 14.7 psia 
to 10.2 psia on air, then the 12 hr stay at 10.2 psia, plus the 40-minute O2 PB.  There was a 1 
minute travel from 10.2 psia to 9.2 psia, a hold at 9.2 psia for 10 minutes, 4 minutes to travel 
from 9.2 psia to 5.2 psia, and finally 10 minutes to travel from 5.2 psia to 4.3 psia, all on 100% 
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O2.  Simulated EVA work activity and VGE monitoring began at 5.2 psia during the final 10-
min pressure decrease to 4.3 psia.  Since this defines the beginning of the simulated EVA, the 
additional 10 min of prebreathe during the final ascent is not considered as prebreathe time.  
Exercise stressed the upper body.  Gas composition at 10.2 psia was nominal 26.5% O2 - 73.5% 
N2, but protocol records indicated 27% O2 was the goal.  “A” cycle exercise included 4 minutes 
seated at mini-gym set to 16.7 kg of resistance and pulling once in 5 seconds with right arm then 
pulling once in 5 seconds with the left arm, 4 minutes standing at ergometer set to 5-N resistance 
and cranking 3 times in 5 seconds with right hand going clockwise. A 5-second rest was taken, 
then 3 cranks repeated, 4 minutes standing at torque station 107 cm above floor where ten 3/8-in. 
fixed studs were torqued to 400 cm-kg. Torque was held for 5 seconds in both directions. A total 
of 24 separate isotonic torques were done in the 2- to 3-minute periods. Remaining time was 
spent stressing the wrist with a ball ratchet placed on several studs and maintaining an isotonic 
torque for 5 seconds. “A” cycle was to use the right hand with the ball ratchet, and finally 4 
minutes in a supine position while flexing arms and legs sequentially to improve bubble 
detection by DT. Each limb was flexed 3 times along with wrist and ankle rotation. “B” cycle 
exercise included 4 minutes at mini-gym set to the same resistance as “A” cycle and pulling 
twice in a 5-second period, 4 minutes at ergometer using same rate except using left hand and 
cranking counterclockwise, 4 minutes at torque station using same torque pattern except with left 
hand, 4 minutes rest after completing “B” cycle, and finally 4 minutes in a supine position while 
flexing arms and legs sequentially to improve bubble detection by DT. Subjects used these 
devices from a standing or seated (non-adynamic) position and were allowed to walk during PB 
or altitude exposure. Test termination for DCS was after any performance was affected. 
 
Procedure 7 (Test 3a): Subject was sequestered in a trailer at JSC for about 13 hrs, 
starting at 17:00 the day prior to the start of the test. A 4-hr O2 PB at 14.7 psia prior to a 6-hr 
exposure to 4.3 psia in the ETA, an altitude chamber conFig.d to resemble the Shuttle crew 
compartment.  Decompression was gradual and allowed 30 minutes of additional O2 PB prior to 
reaching 4.3 psia. The detailed ascent profile is: 6 minutes to travel from 14.7 psia to 9.2 psia, a 
hold at 9.2 psia for 10 minutes, 4 minutes to travel from 9.2 psia to 5.2 psia, and finally 10 
minutes to travel from 5.2 psia to 4.3 psia.  Simulated EVA work activity and VGE monitoring 
began at 5.2 psia during the final 10-min pressure decrease to 4.3 psia.  Since this defines the 
beginning of the simulated EVA, the additional 10 min of prebreathe during the final ascent is 
not considered as prebreathe time.  Exercise stressed the upper body. “A” cycle exercise included 
4 minutes seated at mini-gym set to 16.7 kg of resistance and pulling once in 5 seconds with 
right arm then pulling once in 5 seconds with the left arm, 4 minutes standing at ergometer set to 
5-N resistance and cranking 3 times in 5 seconds with right hand going clockwise. A 5-second 
rest was taken, then 3 cranks repeated, 4 minutes standing at torque station 107 cm above floor 
where ten 3/8-in. fixed studs were torqued to 400 cm-kg. Torque was held for 5 seconds in both 
directions. A total of 24 separate isotonic torques were done in the 2- to 3-minute periods. 
Remaining time was spent stressing the wrist with a ball ratchet placed on several studs and 
maintaining an isotonic torque for 5 seconds. “A” cycle was to use the right hand with the ball 
ratchet, and finally 4 minutes in a supine position while flexing arms and legs sequentially to 
improve bubble detection by DT. Each limb was flexed 3 times along with wrist and ankle 
rotation. “B” cycle exercise included 4 minutes at mini-gym set to the same resistance as “A” 
cycle and pulling twice in a 5-second period, 4 minutes at ergometer using same rate except 
using left hand and cranking counterclockwise, 4 minutes at torque station using same torque 
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pattern except with left hand, 4 minutes rest after completing “B” cycle, and finally 4 minutes in 
a supine position while flexing arms and legs sequentially to improve bubble detection by DT. 
An additional 16 minutes of rest after 3 hrs of exercise was given to exercising subjects and DT 
due to altitude duration. Water was available only during the 6-hr chamber exposures. Subjects 
used these devices from a standing or seated (non-adynamic) position and were allowed to walk 
during PB or altitude exposure. Test termination for DCS was after any performance was 
affected. 
 
Procedure 8 (Test 3b): Subject was sequestered in a trailer at JSC for about 24 hrs, starting 
at 17:00 the day prior to the start of the test. A 60-minute O2 PB at 14.7 psia was followed by 12 
hrs at 10.2 psia plus an additional 40-minute O2 PB prior to a 6-hr exposure to 4.3 psia in the 
ETA, an altitude chamber conFig.d to resemble the Shuttle crew compartment. Decompression 
was gradual and allowed 25 minutes of additional O2 PB prior to reaching 4.3 psia. The detailed 
ascent profile is: 45 minutes of the 60 minute initial PB was completed prior to a 15 minute 
travel from 14.7 psia to 10.2 psia on O2, then the 12 hr stay at 10.2 psia, plus the 40-minute O2 
PB.  There was a 1 minute travel from 10.2 psia to 9.2 psia, a hold at 9.2 psia for 10 minutes, 4 
minutes to travel from 9.2 psia to 5.2 psia, and finally 10 minutes to travel from 5.2 psia to 4.3 
psia, all on 100% O2.  Simulated EVA work activity and VGE monitoring began at 5.2 psia 
during the final 10-min pressure decrease to 4.3 psia.  Since this defines the beginning of the 
simulated EVA, the additional 10 min of prebreathe during the final ascent is not considered as 
prebreathe time.  Exercise stressed the upper body.  Gas composition at 10.2 psia was nominal 
26.5% O2 - 73.5% N2, but protocol records indicated 27% O2 was the goal.  “A” cycle exercise 
included 4 minutes seated at mini-gym set to 16.7 kg of resistance and pulling once in 5 seconds 
with right arm then pulling once in 5 seconds with the left arm, 4 minutes standing at ergometer 
set to 5-N resistance and cranking 3 times in 5 seconds with right hand going clockwise. A 5-
second rest was taken, then 3 cranks repeated, 4 minutes standing at torque station 107 cm above 
floor where ten 3/8-in. fixed studs were torqued to 400 cm-kg. Torque was held for 5 seconds in 
both directions. A total of 24 separate isotonic torques were done in the 2- to 3-minute periods. 
Remaining time was spent stressing the wrist with a ball ratchet placed on several studs and 
maintaining an isotonic torque for 5 seconds. “A” cycle was to use the right hand with the ball 
ratchet, and finally 4 minutes in a supine position while flexing arms and legs sequentially to 
improve bubble detection by DT. Each limb was flexed 3 times along with wrist and ankle 
rotation. “B” cycle exercise included 4 minutes at mini-gym set to the same resistance as “A” 
cycle and pulling twice in a 5-second period, 4 minutes at ergometer using same rate except 
using left hand and cranking counterclockwise, 4 minutes at torque station using same torque 
pattern except with left hand, 4 minutes rest after completing “B” cycle, and finally 4 minutes in 
a supine position while flexing arms and legs sequentially to improve bubble detection by DT. 
An additional 16 minutes of rest after 3 hrs of exercise was given to exercising subjects and DT 
due to altitude duration. Water was available only during the 6-hr chamber exposures. Subjects 
used these devices from a standing or seated (non-adynamic) position and were allowed to walk 
during PB or altitude exposure.  Test termination for DCS was after any performance was 
affected. 
 
Procedure 9 (Test 3c): This was the second of 2 decompressions, the first being Test 3a.   
Subjects returned to 14.7 psia for 13 hrs, a period of time spent sequestered in a trailer at JSC.  
Fourteen of 28 subjects from Test 3a repeated the protocol after a 13-hr interval on air at 14.7 
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psia.  The total time on 100% O2 from Test 3a, including 6 hrs simulated EVA and 6 minutes 
repressurization to 14.7 psia, and the intervening 13 hrs on air is carried over as part of the PB 
for this test since there is some benefit from the initial PB.  After 13 hrs on air the subjects 
performed a 4-hr O2 PB at 14.7 psia prior to a 6-hr exposure to 4.3 psia in the ETA, an altitude 
chamber conFig.d to resemble the Shuttle crew compartment. Decompression was gradual and 
allowed 30 minutes of additional O2 PB prior to reaching 4.3 psia.  The detailed ascent profile is: 
6 minutes to travel from 14.7 psia to 9.2 psia, a hold at 9.2 psia for 10 minutes, 4 minutes to 
travel from 9.2 psia to 5.2 psia, and finally 10 minutes to travel from 5.2 psia to 4.3 psia.  
Simulated EVA work activity and VGE monitoring began at 5.2 psia during the final 10-min 
pressure decrease to 4.3 psia.  Since this defines the beginning of the simulated EVA, the 
additional 10 min of prebreathe during the final ascent is not considered as prebreathe time.  
Exercise stressed the upper body. “A” cycle exercise included 4 minutes seated at mini-gym set 
to 16.7 kg of resistance and pulling once in 5 seconds with right arm then pulling once in 5 
seconds with the left arm, 4 minutes standing at ergometer set to 5-N resistance and cranking 3 
times in 5 seconds with right hand going clockwise. A 5-second rest was taken, then 3 cranks 
repeated, 4 minutes standing at torque station 107 cm above floor where ten 3/8-in. fixed studs 
were torqued to 400 cm-kg. Torque was held for 5 seconds in both directions. A total of 24 
separate isotonic torques were done in the 2- to 3-minute periods. Remaining time was spent 
stressing the wrist with a ball ratchet placed on several studs and maintaining an isotonic torque 
for 5 seconds. “A” cycle was to use the right hand with the ball ratchet, and finally 4 minutes in a 
supine position while flexing arms and legs sequentially to improve bubble detection by DT. 
Each limb was flexed 3 times along with wrist and ankle rotation. “B” cycle exercise included 4 
minutes at mini-gym set to the same resistance as “A” cycle and pulling twice in a 5-second 
period, 4 minutes at ergometer using same rate except using left hand and cranking 
counterclockwise, 4 minutes at torque station using same torque pattern except with left hand, 4 
minutes rest after completing “B” cycle, and finally 4 minutes in a supine position while flexing 
arms and legs sequentially to improve bubble detection by DT. An additional 16 minutes of rest 
after 3 hrs of exercise was given to exercising subjects and DT due to the altitude duration. 
Water was available only during the 6-hr chamber exposures. Subjects used these devices from a 
standing or seated (non-adynamic) position and were allowed to walk during PB or altitude 
exposure. Test termination for DCS was after any performance was affected. 
 
Procedure 10 (Test 3d): This was the second of 2 decompressions, the first being Test 3b.   
Subjects returned to 10.2 psia in the ETA, an altitude chamber conFig.d to resemble the Shuttle 
crew compartment, for 16 hrs and 20 minutes.  Twelve of 35 subjects from Test 3b repeated the 
protocol after 16 hrs and 20 minutes at 10.2 psia.  The total time on 100% O2 from Test 3b, 
including 6 hrs simulated EVA and 6 minutes repressurization to 10.2 psia, and the intervening 
16 hrs and 20 minutes at 10.2 psia is carried over as part of the PB for this test since there is 
some benefit from the initial PB.  After 16 hrs and 20 minutes at 10.2 psia the subjects performed 
a 40 min O2 PB.  Decompression was gradual and allowed 25 minutes of additional O2 PB prior 
to reaching 4.3 psia. The detailed ascent profile is: a 1 minute travel from 10.2 psia to 9.2 psia, a 
hold at 9.2 psia for 10 minutes, 4 minutes to travel from 9.2 psia to 5.2 psia, and finally 10 
minutes to travel from 5.2 psia to 4.3 psia, all on 100% O2.  Simulated EVA work activity and 
VGE monitoring began at 5.2 psia during the final 10-min pressure decrease to 4.3 psia.  Since 
this defines the beginning of the simulated EVA, the additional 10 min of prebreathe during the 
final ascent is not considered as prebreathe time.  Exercise stressed the upper body.  Gas 
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composition at 10.2 psia was nominal 26.5% O2 - 73.5% N2, but protocol records indicated 27% 
O2 was the goal.  “A” cycle exercise included 4 minutes seated at mini-gym set to 16.7 kg of 
resistance and pulling once in 5 seconds with right arm then pulling once in 5 seconds with the 
left arm, 4 minutes standing at ergometer set to 5-N resistance and cranking 3 times in 5 seconds 
with right hand going clockwise. A 5-second rest was taken, then 3 cranks repeated, 4 minutes 
standing at torque station 107 cm above floor where ten 3/8-in. fixed studs were torqued to 400 
cm-kg. Torque was held for 5 seconds in both directions. A total of 24 separate isotonic torques 
were done in the 2- to 3-minute periods. Remaining time was spent stressing the wrist with a ball 
ratchet placed on several studs and maintaining an isotonic torque for 5 seconds. “A” cycle was 
to use the right hand with the ball ratchet, and finally 4 minutes in a supine position while flexing 
arms and legs sequentially to improve bubble detection by DT. Each limb was flexed 3 times 
along with wrist and ankle rotation. “B” cycle exercise included 4 minutes at mini-gym set to 
the same resistance as “A” cycle and pulling twice in a 5-second period, 4 minutes at ergometer 
using same rate except using left hand and cranking counterclockwise, 4 minutes at torque sta-
tion using same torque pattern except with left hand, 4 minutes rest after completing “B” cycle, 
and finally 4 minutes in a supine position while flexing arms and legs sequentially to improve 
bubble detection by DT. An additional 16 minutes of rest after 3 hrs of exercise was given to 
exercising subjects and DT due to the altitude duration. Water was available only during the 6-hr 
chamber exposures. Subjects used these devices from a standing or seated (non-adynamic) 
position and were allowed to walk during PB or altitude exposure. Test termination for DCS 
was after any performance was affected. 
 
Procedure 11 (Test 4a): A 60-minute O2 PB at 14.7 psia was followed by 12 hrs at 10.2 psia 
plus an additional 40-minute O2 PB prior to a 3-hr exposure to 4.3 psia in the ETA, an altitude 
chamber conFig.d to resemble the Shuttle crew compartment. This was the first of 2 exposures in 
the same day. Decompression was gradual and allowed 25 minutes of additional O2 PB prior to 
reaching 4.3 psia.  Gas composition at 10.2 psia was nominal 26.5% O2 - 73.5% N2, but protocol 
records indicated 27% O2 was the goal.  The detailed ascent profile is: 45 minutes of the 60 
minute initial PB was completed prior to a 15 minute travel from 14.7 psia to 10.2 psia on O2, 
then the 12 hr stay at 10.2 psia, plus the 40-minute O2 PB.  There was a 1 minute travel from 
10.2 psia to 9.2 psia, a hold at 9.2 psia for 10 minutes, 4 minutes to travel from 9.2 psia to 5.2 
psia, and finally 10 minutes to travel from 5.2 psia to 4.3 psia, all on 100% O2.  Subjects 
returned to 10.2 psia in the ETA in 6 minutes.  Simulated EVA work activity and VGE 
monitoring began at 5.2 psia during the final 10-min pressure decrease to 4.3 psia.  Since this 
defines the beginning of the simulated EVA, the additional 10 min of prebreathe during the final 
ascent is not considered as prebreathe time.  Exercise stressed the upper body. “A” cycle exercise 
included 4 minutes seated at mini-gym set to 16.7 kg of resistance and pulling once in 5 seconds 
with right arm then pulling once in 5 seconds with the left arm, 4 minutes standing at ergometer 
set to 5-N resistance and cranking 3 times in 5 seconds with right hand going clockwise. A 5-
second rest was taken, then 3 cranks repeated, 4 minutes standing at torque station 107 cm above 
floor where ten 3/8-in. fixed studs were torqued to 400 cm-kg. Torque was held for 5 seconds in 
both directions. A total of 24 separate isotonic torques were done in the 2- to 3-minute periods. 
Remaining time was spent stressing the wrist with a ball ratchet placed on several studs and 
maintaining an isotonic torque for 5 seconds. “A” cycle was to use the right hand with the ball 
ratchet, and finally 4 minutes in a supine position while flexing arms and legs sequentially to 
improve bubble detection by DT. Each limb was flexed 3 times along with wrist and ankle ro-
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tation. “B” cycle exercise included 4 minutes at mini-gym set to the same resistance as “A” 
cycle and pulling twice in a 5-second period, 4 minutes at ergometer using same rate except 
using left hand and cranking counterclockwise, 4 minutes at torque station using same torque 
pattern except with left hand, 4 minutes rest after completing “B” cycle, and finally 4 minutes in 
a supine position while flexing arms and legs sequentially to improve bubble detection by DT. 
Subjects used these devices from a standing or seated (non-adynamic) position and were 
allowed to walk during PB or altitude exposure. Test termination for DCS was after any 
performance was affected. 
 
Procedure 11a (Test 4b): This was the second of 6 decompressions, the first being Test 4a.  All 
previous PB and pressure-change history from Test 4a is carried forward plus the PB for this test.   
Subjects returned to 10.2 psia in the ETA in 6 minutes, an altitude chamber conFig.d to resemble 
the Shuttle crew compartment, for 120 minutes.  This was the second of 2 exposures on day 1 of 
3.  The twelve subjects repeated the ascent after 120 minutes at 10.2 psia.  This was a scheduled 
lunch and bathroom break.  The total time on 100% O2 from Test 4a, including 3 hrs simulated 
EVA and 6 minutes repressurization to 10.2 psia, and the intervening 120 minutes at 10.2 psia is 
carried over as part of the PB for this test since there is some benefit from the initial PB.  After 
80 minutes at 10.2 psia the subjects performed a 40 min O2 PB.  Decompression was gradual 
and allowed 25 minutes of additional O2 PB prior to reaching 4.3 psia. The detailed ascent 
profile is: a 1 minute travel from 10.2 psia to 9.2 psia, a hold at 9.2 psia for 10 minutes, 4 
minutes to travel from 9.2 psia to 5.2 psia, and finally 10 minutes to travel from 5.2 psia to 4.3 
psia, all on 100% O2.  Simulated EVA work activity and VGE monitoring began at 5.2 psia 
during the final 10-min pressure decrease to 4.3 psia.  Since this defines the beginning of the 
simulated EVA, the additional 10 min of prebreathe during the final ascent is not considered as 
prebreathe time.  Exercise stressed the upper body.  Gas composition at 10.2 psia was nominal 
26.5% O2 - 73.5% N2, but protocol records indicated 27% O2 was the goal.  “A” cycle exercise 
included 4 minutes seated at mini-gym set to 16.7 kg of resistance and pulling once in 5 seconds 
with right arm then pulling once in 5 seconds with the left arm, 4 minutes standing at ergometer 
set to 5-N resistance and cranking 3 times in 5 seconds with right hand going clockwise. A 5-
second rest was taken, then 3 cranks repeated, 4 minutes standing at torque station 107 cm above 
floor where ten 3/8-in. fixed studs were torqued to 400 cm-kg. Torque was held for 5 seconds in 
both directions. A total of 24 separate isotonic torques were done in the 2- to 3-minute periods. 
Remaining time was spent stressing the wrist with a ball ratchet placed on several studs and 
maintaining an isotonic torque for 5 seconds. “A” cycle was to use the right hand with the ball 
ratchet, and finally 4 minutes in a supine position while flexing arms and legs sequentially to 
improve bubble detection by DT. Each limb was flexed 3 times along with wrist and ankle 
rotation. “B” cycle exercise included 4 minutes at mini-gym set to the same resistance as “A” 
cycle and pulling twice in a 5-second period, 4 minutes at ergometer using same rate except 
using left hand and cranking counterclockwise, 4 minutes at torque station using same torque 
pattern except with left hand, 4 minutes rest after completing “B” cycle, and finally 4 minutes in 
a supine position while flexing arms and legs sequentially to improve bubble detection by DT. 
An additional 16 minutes of rest after 3 hrs of exercise was given to exercising subjects and DT 
due to the altitude duration. Water was available only during the 6-hr chamber exposures. 
Subjects used these devices from a standing or seated (non-adynamic) position and were allowed 
to walk during PB or altitude exposure. Test termination for DCS was after any performance was 
affected. 
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Procedure 11b (Test 4c): This was the third of 6 decompressions.  All previous PB and 
pressure-change history from Test 4a and 4b is carried forward plus the PB for this test.  Subjects 
returned to 10.2 psia in the ETA in 6 minutes, an altitude chamber conFig.d to resemble the 
Shuttle crew compartment, for 14 hrs.  This was the first of 2 exposures on day 2 of 3.   The 
twelve subjects repeated the ascent after 40 minutes of PB at 10.2 psia.  Decompression was 
gradual and allowed 25 minutes of additional O2 PB prior to reaching 4.3 psia. The detailed 
ascent profile is: a 1 minute travel from 10.2 psia to 9.2 psia, a hold at 9.2 psia for 10 minutes, 4 
minutes to travel from 9.2 psia to 5.2 psia, and finally 10 minutes to travel from 5.2 psia to 4.3 
psia, all on 100% O2.  Simulated EVA work activity and VGE monitoring began at 5.2 psia 
during the final 10-min pressure decrease to 4.3 psia.  Since this defines the beginning of the 
simulated EVA, the additional 10 min of prebreathe during the final ascent is not considered as 
prebreathe time.  Exercise stressed the upper body.  Gas composition at 10.2 psia was nominal 
26.5% O2 - 73.5% N2, but protocol records indicated 27% O2 was the goal. “A” cycle exercise 
included 4 minutes seated at mini-gym set to 16.7 kg of resistance and pulling once in 5 seconds 
with right arm then pulling once in 5 seconds with the left arm, 4 minutes standing at ergometer 
set to 5-N resistance and cranking 3 times in 5 seconds with right hand going clockwise. A 5-
second rest was taken, then 3 cranks repeated, 4 minutes standing at torque station 107 cm above 
floor where ten 3/8-in. fixed studs were torqued to 400 cm-kg. Torque was held for 5 seconds in 
both directions. A total of 24 separate isotonic torques were done in the 2- to 3-minute periods. 
Remaining time was spent stressing the wrist with a ball ratchet placed on several studs and 
maintaining an isotonic torque for 5 seconds. “A” cycle was to use the right hand with the ball 
ratchet, and finally 4 minutes in a supine position while flexing arms and legs sequentially to 
improve bubble detection by DT. Each limb was flexed 3 times along with wrist and ankle 
rotation. “B” cycle exercise included 4 minutes at mini-gym set to the same resistance as “A” 
cycle and pulling twice in a 5-second period, 4 minutes at ergometer using same rate except 
using left hand and cranking counterclockwise, 4 minutes at torque station using same torque 
pattern except with left hand, 4 minutes rest after completing “B” cycle, and finally 4 minutes in 
a supine position while flexing arms and legs sequentially to improve bubble detection by DT. 
An additional 16 minutes of rest after 3 hrs of exercise was given to exercising subjects and DT 
due to the altitude duration. Water was available only during the 6-hr chamber exposures. 
Subjects used these devices from a standing or seated (non-adynamic) position and were allowed 
to walk during PB or altitude exposure. Test termination for DCS was after any performance was 
affected. 
 
Procedure 11c (Test 4d): This was the fourth of 6 decompressions.  All previous PB and 
pressure-change history from Test 4a, 4b, and 4c is carried forward plus the PB for this test.    
Subjects returned to 10.2 psia in the ETA in 6 minutes, an altitude chamber conFig.d to resemble 
the Shuttle crew compartment, for 120 minutes.  This was the second of 2 exposures on day 2 of 
3.  The twelve subjects repeated the ascent after 120 minutes at 10.2 psia.  This was a scheduled 
lunch and bathroom break.  After 80 minutes at 10.2 psia the subjects performed a 40 min O2 
PB.  Decompression was gradual and allowed 25 minutes of additional O2 PB prior to reaching 
4.3 psia. The detailed ascent profile is: a 1 minute travel from 10.2 psia to 9.2 psia, a hold at 9.2 
psia for 10 minutes, 4 minutes to travel from 9.2 psia to 5.2 psia, and finally 10 minutes to travel 
from 5.2 psia to 4.3 psia, all on 100% O2.  Simulated EVA work activity and VGE monitoring 
began at 5.2 psia during the final 10-min pressure decrease to 4.3 psia.  Since this defines the 
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beginning of the simulated EVA, the additional 10 min of prebreathe during the final ascent is 
not considered as prebreathe time.  Exercise stressed the upper body.  Gas composition at 10.2 
psia was nominal 26.5% O2 - 73.5% N2, but protocol records indicated 27% O2 was the goal.  
“A” cycle exercise included 4 minutes seated at mini-gym set to 16.7 kg of resistance and pulling 
once in 5 seconds with right arm then pulling once in 5 seconds with the left arm, 4 minutes 
standing at ergometer set to 5-N resistance and cranking 3 times in 5 seconds with right hand 
going clockwise. A 5-second rest was taken, then 3 cranks repeated, 4 minutes standing at torque 
station 107 cm above floor where ten 3/8-in. fixed studs were torqued to 400 cm-kg. Torque was 
held for 5 seconds in both directions. A total of 24 separate isotonic torques were done in the 2- 
to 3-minute periods. Remaining time was spent stressing the wrist with a ball ratchet placed on 
several studs and maintaining an isotonic torque for 5 seconds. “A” cycle was to use the right 
hand with the ball ratchet, and finally 4 minutes in a supine position while flexing arms and legs 
sequentially to improve bubble detection by DT. Each limb was flexed 3 times along with wrist 
and ankle rotation. “B” cycle exercise included 4 minutes at mini-gym set to the same resistance 
as “A” cycle and pulling twice in a 5-second period, 4 minutes at ergometer using same rate 
except using left hand and cranking counterclockwise, 4 minutes at torque station using same 
torque pattern except with left hand, 4 minutes rest after completing “B” cycle, and finally 4 
minutes in a supine position while flexing arms and legs sequentially to improve bubble 
detection by DT. An additional 16 minutes of rest after 3 hrs of exercise was given to exercising 
subjects and DT due to the altitude duration. Water was available only during the 6-hr chamber 
exposures. Subjects used these devices from a standing or seated (non-adynamic) position and 
were allowed to walk during PB or altitude exposure. Test termination for DCS was after any 
performance was affected. 
 
Procedure 11d (Test 4e): This was the fifth of 6 decompressions.  All previous PB and 
pressure-change history from Test 4a, 4b, 4c, and 4d is carried forward plus the PB for this test.     
Subjects returned to 10.2 psia in the ETA in 6 minutes, an altitude chamber conFig.d to resemble 
the Shuttle crew compartment, for 14 hrs.  This was the first of 2 exposures on day 3 of 3.  The 
twelve subjects repeated the ascent after 40 minutes of PB at 10.2 psia.  Decompression was 
gradual and allowed 25 minutes of additional O2 PB prior to reaching 4.3 psia. The detailed 
ascent profile is: a 1 minute travel from 10.2 psia to 9.2 psia, a hold at 9.2 psia for 10 minutes, 4 
minutes to travel from 9.2 psia to 5.2 psia, and finally 10 minutes to travel from 5.2 psia to 4.3 
psia, all on 100% O2.  Simulated EVA work activity and VGE monitoring began at 5.2 psia 
during the final 10-min pressure decrease to 4.3 psia.  Since this defines the beginning of the 
simulated EVA, the additional 10 min of prebreathe during the final ascent is not considered as 
prebreathe time.  Exercise stressed the upper body.  Gas composition at 10.2 psia was nominal 
26.5% O2 - 73.5% N2, but protocol records indicated 27% O2 was the goal.  “A” cycle exercise 
included 4 minutes seated at mini-gym set to 16.7 kg of resistance and pulling once in 5 seconds 
with right arm then pulling once in 5 seconds with the left arm, 4 minutes standing at ergometer 
set to 5-N resistance and cranking 3 times in 5 seconds with right hand going clockwise. A 5-
second rest was taken, then 3 cranks repeated, 4 minutes standing at torque station 107 cm above 
floor where ten 3/8-in. fixed studs were torqued to 400 cm-kg. Torque was held for 5 seconds in 
both directions. A total of 24 separate isotonic torques were done in the 2- to 3-minute periods. 
Remaining time was spent stressing the wrist with a ball ratchet placed on several studs and 
maintaining an isotonic torque for 5 seconds. “A” cycle was to use the right hand with the ball 
ratchet, and finally 4 minutes in a supine position while flexing arms and legs sequentially to 
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improve bubble detection by DT. Each limb was flexed 3 times along with wrist and ankle 
rotation. “B” cycle exercise included 4 minutes at mini-gym set to the same resistance as “A” 
cycle and pulling twice in a 5-second period, 4 minutes at ergometer using same rate except 
using left hand and cranking counterclockwise, 4 minutes at torque station using same torque 
pattern except with left hand, 4 minutes rest after completing “B” cycle, and finally 4 minutes in 
a supine position while flexing arms and legs sequentially to improve bubble detection by DT. 
An additional 16 minutes of rest after 3 hrs of exercise was given to exercising subjects and DT 
due to the altitude duration. Water was available only during the 6-hr chamber exposures. 
Subjects used these devices from a standing or seated (non-adynamic) position and were allowed 
to walk during PB or altitude exposure. Test termination for DCS was after any performance was 
affected. 
 
Procedure 11e (Test 4f): This was the sixth of 6 decompressions.  All previous PB and 
pressure-change history from Test 4a, 4b, 4c, 4d, and 4e is carried forward plus the PB for this 
test.  Subjects returned to 10.2 psia in the ETA in 6 minutes, an altitude chamber conFig.d to 
resemble the Shuttle crew compartment, for 120 minutes.  This was the second of 2 exposures on 
day 3 of 3.  The twelve subjects repeated the ascent after 120 minutes at 10.2 psia.  This was a 
scheduled lunch and bathroom break.  After 80 minutes at 10.2 psia the subjects performed a 40 
min O2 PB.  Decompression was gradual and allowed 25 minutes of additional O2 PB prior to 
reaching 4.3 psia.  The detailed ascent profile is: a 1 minute travel from 10.2 psia to 9.2 psia, a 
hold at 9.2 psia for 10 minutes, 4 minutes to travel from 9.2 psia to 5.2 psia, and finally 10 
minutes to travel from 5.2 psia to 4.3 psia, all on 100% O2.  Simulated EVA work activity and 
VGE monitoring began at 5.2 psia during the final 10-min pressure decrease to 4.3 psia.  Since 
this defines the beginning of the simulated EVA, the additional 10 min of prebreathe during the 
final ascent is not considered as prebreathe time.  Exercise stressed the upper body.  Gas 
composition at 10.2 psia was nominal 26.5% O2 - 73.5% N2, but protocol records indicated 27% 
O2 was the goal.  “A” cycle exercise included 4 minutes seated at mini-gym set to 16.7 kg of 
resistance and pulling once in 5 seconds with right arm then pulling once in 5 seconds with the 
left arm, 4 minutes standing at ergometer set to 5-N resistance and cranking 3 times in 5 seconds 
with right hand going clockwise. A 5-second rest was taken, then 3 cranks repeated, 4 minutes 
standing at torque station 107 cm above floor where ten 3/8-in. fixed studs were torqued to 400 
cm-kg. Torque was held for 5 seconds in both directions. A total of 24 separate isotonic torques 
were done in the 2- to 3-minute periods. Remaining time was spent stressing the wrist with a ball 
ratchet placed on several studs and maintaining an isotonic torque for 5 seconds. “A” cycle was 
to use the right hand with the ball ratchet, and finally 4 minutes in a supine position while flexing 
arms and legs sequentially to improve bubble detection by DT. Each limb was flexed 3 times 
along with wrist and ankle rotation. “B” cycle exercise included 4 minutes at mini-gym set to 
the same resistance as “A” cycle and pulling twice in a 5-second period, 4 minutes at ergometer 
using same rate except using left hand and cranking counterclockwise, 4 minutes at torque sta-
tion using same torque pattern except with left hand, 4 minutes rest after completing “B” cycle, 
and finally 4 minutes in a supine position while flexing arms and legs sequentially to improve 
bubble detection by DT. An additional 16 minutes of rest after 3 hrs of exercise was given to 
exercising subjects and DT due to the altitude duration. Water was available only during the 6-hr 
chamber exposures. Subjects used these devices from a standing or seated (non-adynamic) 
position and were allowed to walk during PB or altitude exposure. Test termination for DCS 
was after any performance was affected. 
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Procedure 12 (Test 5a): A 6-hr O2 PB at 14.7 psia prior to a 6-hr exposure to 4.3 psia in the 
PTC.  This was the first test to include females.  Prior to ascent, a brief ear and sinus check was 
done by depressurizing the chamber atmosphere to the equivalent of 6,000 feet altitude in 
approximately 1 minute (5,000 feet/minute). Subject continued to breathe O2 by mask during this 
check, which took about 5 minutes for subjects and DT to be evaluated, primarily during the 
repressurization back to site pressure. The medical technician exited the chamber, and ascent to 
the test altitude was initiated at 3,000 feet/min.  Decompression required 10 minutes. Exercise 
stressed upper body. “A” cycle exercise included 4 minutes seated at mini-gym set to 16.7 kg of 
resistance and pulling once in 5 seconds with right arm then pulling once in 5 seconds with the 
left arm, 4 minutes standing at ergometer set to 5-N resistance and cranking 3 times in 5 seconds 
with right hand going clockwise. A 5-second rest was taken, then 3 cranks repeated, 4 minutes 
standing at torque station 107 cm above floor where ten 3/8-in. fixed studs were torqued to 400 
cm-kg. Torque was held for 5 seconds in both directions. A total of 24 separate isotonic torques 
were done in the 2- to 3-minute periods. Remaining time was spent stressing the wrist with a ball 
ratchet placed on several studs and maintaining an isotonic torque for 5 seconds. “A” cycle was 
to use the right hand with the ball ratchet, and finally 4 minutes in a supine position while flexing 
arms and legs sequentially to improve bubble detection by DT. Each limb was flexed 3 times 
along with wrist and ankle rotation. “B” cycle exercise included 4 minutes at mini-gym set to the 
same resistance as “A” cycle and pulling twice in a 5-second period, 4 minutes at ergometer 
using same rate except using left hand and cranking counterclockwise, 4 minutes at torque 
station using same torque pattern except with left hand, 4 minutes rest after completing “B” 
cycle, and finally 4 minutes in a supine position while flexing arms and legs sequentially to 
improve bubble detection by DT. An additional 16 minutes of rest after 3 hrs of exercise was 
given to exercising subjects and DT due to altitude duration. Water was available only during the 
6-hr chamber exposures. Subjects used these devices from a standing or seated (non-adynamic) 
position and were allowed to walk during PB or altitude exposure. Test termination for DCS was 
after any performance was affected. 
 
Procedure 12a (Test 5b): A 8-hr O2 PB at 14.7 psia prior to a 6-hr exposure to 4.3 psia in the 
PTC. Prior to ascent, a brief ear and sinus check was done by depressurizing the cham-
ber atmosphere to the equivalent of 6,000 feet altitude in approximately 1 minute (5,000 
feet/minute). Subject continued to breathe O2 by mask during this check, which took about 5 
minutes for subjects and DT to be evaluated, primarily during the repressurization back to site 
pressure. The medical technician exited the chamber, and ascent to the test altitude was initiated 
at 3,000 feet/min. Decompression required 10 minutes. Exercise stressed upper body. “A” cycle 
exercise included 4 minutes seated at mini-gym set to 16.7 kg of resistance and pulling once in 5 
seconds with right arm then pulling once in 5 seconds with the left arm, 4 minutes standing at 
ergometer set to 5-N resistance and cranking 3 times in 5 seconds with right hand going 
clockwise. A 5-second rest was taken, then 3 cranks repeated, 4 minutes standing at torque 
station 107 cm above floor where ten 3/8-in. fixed studs were torqued to 400 cm-kg. Torque was 
held for 5 seconds in both directions. A total of 24 separate isotonic torques were done in the 2- 
to 3-minute periods. Remaining time was spent stressing the wrist with a ball ratchet placed on 
several studs and maintaining an isotonic torque for 5 seconds. “A” cycle was to use the right 
hand with the ball ratchet, and finally 4 minutes in a supine position while flexing arms and legs 
sequentially to improve bubble detection by DT. Each limb was flexed 3 times along with wrist 
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and ankle rotation. “B” cycle exercise included 4 minutes at mini-gym set to the same resistance 
as “A” cycle and pulling twice in a 5-second period, 4 minutes at ergometer using same rate 
except using left hand and cranking counterclockwise, 4 minutes at torque station using same 
torque pattern except with left hand, 4 minutes rest after completing “B” cycle, and finally 4 
minutes in a supine position while flexing arms and legs sequentially to improve bubble 
detection by DT. An additional 16 minutes of rest after 3 hrs of exercise was given to exercising 
subjects and DT due to altitude duration. Water was available only during the 6-hr chamber 
exposures. Subjects used these devices from a standing or seated (non-adynamic) position and 
were allowed to walk during PB or altitude exposure. Test termination for DCS was after any 
performance was affected. 
 
Procedure 13 (Test 6): A 2-hr O2 PB at 14.7 psia prior to 24 hrs at 10.2 psia in the 
ETA, an altitude chamber conFig.d to resemble the Shuttle crew compartment.  After 24 hrs at 
10.2 psia the subjects donned masks and ascended to 6.0 psia.  A review of the protocol 
suggested a nominal 10-minute decompression from 14.7 psia to 10.2 psia and a nominal 10-min 
decompression from 10.2 psia to 6.0 psia.  But a review of the logbook shows an average 8 min 
ascent from 14.7 psia to 10.2 psia and an average 7 min ascent from 10.2 psia to 6.0 psia.  
Subjects exercised 6 hrs while breathing a 60% O2-40% N2 mixture.  Gas composition at 10.2 
psia was 28% O2-72% N2.  Exercise stressed upper body.   “A” cycle exercise included 4 
minutes seated at mini-gym set to 16.7 kg of resistance and pulling once in 5 seconds with right 
arm then pulling once in 5 seconds with the left arm, 4 minutes standing at ergometer set to 5-N 
resistance and cranking 3 times in 5 seconds with right hand going clockwise. A 5-second rest 
was taken, then 3 cranks repeated, 4 minutes standing at torque station 107 cm above floor where 
ten 3/8-in. fixed studs were torqued to 400 cm-kg. Torque was held for 5 seconds in both 
directions. A total of 24 separate isotonic torques were done in the 2- to 3-minute periods. 
Remaining time was spent stressing the wrist with a ball ratchet placed on several studs and 
maintaining an isotonic torque for 5 seconds. “A” cycle was to use the right hand with the ball 
ratchet, and finally 4 minutes in a supine position while flexing arms and legs sequentially to 
improve bubble detection by DT. Each limb was flexed 3 times along with wrist and ankle 
rotation. “B” cycle exercise included 4 minutes at mini-gym set to the same resistance as “A” 
cycle and pulling twice in a 5-second period, 4 minutes at ergometer using same rate except 
using left hand and cranking counterclockwise, 4 minutes at torque station using same torque 
pattern except with left hand, 4 minutes rest after completing “B” cycle, and finally 4 minutes in 
a supine position while flexing arms and legs sequentially to improve bubble detection by DT. 
An additional 16 minutes of rest after 3 hrs of exercise was given to exercising subjects and DT 
due to altitude duration. Water was available only during the 6-hr chamber exposures. Subjects 
used these devices from a standing or seated (non-adynamic) position and were allowed to walk 
during PB or altitude exposure. Test termination for DCS was after any performance was 
affected. 
 
Procedure 14 (Test 7a with high exercise): Exposure to 6.5 psia in the PTC for 3 hrs after 
no PB. Decompression to 6.5 psia required 3.2 minutes (6,500 feet/minute). Row machine 
replaced the standard mini-gym and was used to achieve peak exercise of 2,000 Btu/hr for 15 
minutes at about 1.5 hrs into the test. Prior to ascent, a brief ear and sinus check was done by 
depressurizing the chamber atmosphere to the equivalent of 6,000 feet altitude in approximately 
1 minute (5,000 feet/minute). Subject breathed air during this check, which took approximately 5 
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minutes for 2 subjects and the DT to be evaluated, primarily during the repressurization back to 
site pressure. The medical technician exited the chamber and an ascent on air to 10 psia at 6,500 
feet/minute was begun 6 minutes from the start of initial ascent. About 2 minutes later, subject 
donned the O2 mask at 10 psia and the chamber continued ascent to 6.5 psia at 6,500 feet/minute. 
For the first hr, “A” cycle exercise included 4 minutes standing at ergometer set to 5-N resistance 
and cranking 3 times in 5 seconds with right hand going clockwise. A 5-second rest was taken, 
and then 3 cranks repeated. There were 4 minutes standing at torque station above the floor 
where ten 3/8-in. fixed studs were torqued to 400 cm-kg with the right hand. Torque was held for 
5 seconds in both directions. There were 4 minutes in a supine position while flexing arms and 
legs sequentially to improve bubble detection by DT. Each limb was flexed 3 times along with 
wrist and ankle rotation. There were 4 minutes in a semi-recumbent position on a row machine 
where upper and lower body was exercised. Cycle “B” exercise was the same as cycle “A” 
except the left hand was used with the torque and crank stations. At 64 minutes into the test, 
subject exercised for three 16-minute periods on the row machine, with a 4-minute Doppler 
monitoring at the end of each 16-minute cycle. The middle row exercise achieved about 2,000 
Btu/hr while the previous and later 16-minute intervals achieved about 1,600 Btu/hr. For the last 
hr, the same cycle “A” and “B” exercises resumed. Subjects used these devices from a standing 
or seated (non-adynamic) position and were allowed to walk prior to ascent or during altitude 
exposure. Test termination for DCS was after any performance was affected. 
 
Procedure 15 (Test 7b with low exercise): Exposure to 6.5 psia in the PTC for 3 hrs after 
no PB. Decompression to 6.5 psia required 3.2 minutes (6,500 feet/minute). Row machine used 
in place of the standard mini-gym to achieve an average energy expenditure of 800 Btu/hr. Prior 
to ascent, a brief ear and sinus check was done by depressurizing the chamber atmosphere to the 
equivalent of 6,000 feet altitude in about 1 minute (5,000 feet/minute). Subject breathed air dur-
ing this check, which took approximately 5 minutes for 2 subjects and the DT to be evaluated, 
primarily during the repressurization back to site pressure. The medical technician exited the 
chamber and an ascent on air to 10 psia at 6,500 feet/minute was begun 6 minutes from the start 
of initial ascent. About 2 minutes later, subject donned the O2 mask at 10 psia and the chamber 
continued the ascent to 6.5 psia at 6,500 feet/minute. “A” cycle exercise included 4 minutes 
standing at ergometer set to 5-N resistance and cranking 3 times in 5 seconds with right hand 
going clockwise. A 5-second rest was taken, and then 3 cranks repeated. There were 4 minutes 
standing at torque station above the floor where ten 3/8-in. fixed studs were torqued to 400 cm-
kg with the right hand. Torque was held for 5 seconds in both directions. There were 4 minutes 
in a supine position while flexing arms and legs sequentially to improve bubble detection by DT. 
Each limb was flexed 3 times along with wrist and ankle rotation. There were 4 minutes in a 
semi-recumbent position on a row machine where upper and lower body was exercised. Cycle 
“B” exercise was the same as cycle “A” except the left hand was used with the torque and crank 
stations. Subjects used these devices from a standing or seated (non-adynamic) position and 
were allowed to walk prior to ascent or during altitude exposure. Test termination for DCS 
was after any performance was affected. 
 
Procedure 16 (Test 8a): Exposure to 6.5 psia in the PTC for 3 hrs after no PB. Decompression 
to 6.5 psia required 3.2 minutes (6,500 feet/minute). Prior to ascent, a brief ear and sinus check 
was done by depressurizing the chamber atmosphere to the equivalent of 6,000 feet altitude in 
about 1 minute (5,000 feet/minute). Subject breathed air during this check, which took 
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approximately 5 minutes for subjects and the DT to be evaluated, primarily during the repressur-
ization back to site pressure. The medical technician exited the chamber and an ascent on air to 
10 psia at 6,500 feet/minute was begun 6 minutes from the start of initial ascent. Approximately 
2 minutes later, subject donned the O2 mask at 10 psia and the chamber continued the ascent to 
6.5 psia at 6,500 feet/minute. Exercise stressed the upper body. “A” cycle exercise included 4 
minutes seated at mini-gym set to 16.7 kg of resistance and pulling once in 5 seconds with right 
arm then pulling once in 5 seconds with the left arm, 4 minutes standing at ergometer set to 5-N 
resistance and cranking 3 times in 5 seconds with right hand going clockwise. A 5-second rest 
was taken, then 3 cranks repeated, 4 minutes standing at torque station where ten 3/8-in. fixed 
studs were torqued to 400 cm-kg. Torque was held for 5 seconds in both directions. A total of 
24 separate isotonic torques were done in the 2- to 3-minute periods. Remaining time was spent 
stressing the wrist with a ball ratchet placed on several studs and maintaining an isotonic torque 
for 5 seconds. “A” cycle was to use the right hand with the ball ratchet, and finally 4 minutes in 
a supine position while flexing arms and legs sequentially to improve bubble detection by DT. 
Each limb was flexed 3 times along with wrist and ankle rotation. “B” cycle exercise included 
4 minutes at mini-gym set to the same resistance as “A” cycle and pulling twice in a 5-second 
period, 4 minutes at ergometer using same rate except using left hand and cranking counterclock-
wise, 4 minutes at torque station using same torque pattern except with left hand, 4 minutes rest 
after completing “B” cycle, and finally 4 minutes in a supine position while flexing arms and 
legs sequentially to improve bubble detection by DT. Subjects used these devices from a stand-
ing or seated (non-adynamic) position and were allowed to walk during PB or altitude exposure. 
Test termination for DCS was after any performance was affected. A 1-hr posttest period 
breathing 100% O2 for all subjects was observed, with longer periods as warranted at the 
direction of the attending MO. 
 
Procedure 17 (Test 8b): Exposure to 6.5 psia in the PTC for 3 hrs after no PB. Decompression 
to 6.5 psia required 3.2 minutes (6,500 feet/minute). Prior to ascent, a brief ear and sinus check 
was done by depressurizing the chamber atmosphere to the equivalent of 6,000 feet altitude in 
approximately 1 minute (5,000 feet/minute). Subject breathed air during this check, which took 
about 5 minutes for subjects and the DT to be evaluated, primarily during the repressurization 
back to site pressure. The medical technician exited the chamber and an ascent on air to 10 psia 
at 6,500 feet/minute was begun 6 minutes from the start of the initial ascent. About 2 minutes 
later, subject donned the O2 mask at 10 psia and the chamber continued the ascent to 6.5 psia at 
6,500 feet/minute. Prior to exposure, subject performed 3 days of treadmill exercise at anaerobic 
threshold for 30 minutes. A minimum of 16 hrs elapsed from the last treadmill exercise to the 
start of ascent. Exercise at 6.5 psia stressed the upper body. “A” cycle exercise included 4 
minutes seated at mini-gym set to 16.7 kg of resistance and pulling once in 5 seconds with right 
arm then pulling once in 5 seconds with the left arm, 4 minutes standing at ergometer set to 5-N 
resistance and cranking 3 times in 5 seconds with right hand going clockwise. A 5-second rest 
was taken, then 3 cranks repeated, 4 minutes standing at torque station where ten 3/8-in. fixed 
studs were torqued to 400 cm-kg. Torque was held for 5 seconds in both directions. A total of 24 
separate isotonic torques were done in the 2- to 3-minute periods. Remaining time was spent 
stressing the wrist with a ball ratchet placed on several studs and maintaining an isotonic torque 
for 5 seconds. “A” cycle was to use the right hand with the ball ratchet, and finally 4 minutes in a 
supine position while flexing arms and legs sequentially to improve bubble detection by DT. 
Each limb was flexed 3 times along with wrist and ankle rotation. “B” cycle exercise included 4 
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minutes at mini-gym set to the same resistance as “A” cycle and pulling twice in a 5-second 
period, 4 minutes at ergometer using same rate except using left hand and cranking 
counterclockwise, 4 minutes at torque station using same torque pattern except with left hand, 4 
minutes rest after completing “B” cycle, and finally 4 minutes in a supine position while flexing 
arms and legs sequentially to improve bubble detection by DT. Subjects used these devices from 
a standing or seated (non-adynamic) position and were allowed to walk during PB or altitude 
exposure. Test termination for DCS was after any performance was affected. A 1-hr posttest 
period breathing 100% O2 for all subjects was observed, with longer periods as warranted at the 
direction of the attending MO. 
 
Procedure 18 (Test 9a): Exposure to 6.5 psia in the PTC for 3 hrs after no PB. Decompression 
to 6.5 psia required 3.2 minutes (6,500 feet/minute). Prior to ascent, a brief ear and sinus check 
was done by depressurizing the chamber atmosphere to the equivalent of 6,000 feet altitude in 
about 1 minute (5,000 feet/minute). Subject breathed air during this check, which took 
approximately 5 minutes for subjects and the DT to be evaluated, primarily during the repressuri-
zation back to site pressure. The medical technician exited the chamber and an ascent on air to 10 
psia at 6,500 feet/minute was begun 6 minutes from the start of initial ascent. About 2 minutes 
later, subject donned the O2 mask at 10 psia and the chamber continued the ascent to 6.5 psia 
at 6,500 feet/minute. Exercise stressed the upper body. “A” cycle exercise included 4 minutes 
seated at mini-gym set to 16.7 kg of resistance and pulling once in 5 seconds with right arm then 
pulling once in 5 seconds with the left arm, 4 minutes standing at ergometer set to 5-N resistance 
and cranking 3 times in 5 seconds with right hand going clockwise. A 5-second rest was taken, 
then 3 cranks repeated, 4 minutes standing at torque station where ten 3/8-in. fixed studs were 
torqued to 400 cm-kg. Torque was held for 5 seconds in both directions. A total of 24 separate 
isotonic torques were done in the 2- to 3-minute periods. The remaining time was spent stressing 
the wrist with a ball ratchet placed on several studs and maintaining an isotonic torque for 5 
seconds. “A” cycle was to use the right hand with the ball ratchet, and finally 4 minutes in a 
supine position while flexing arms and legs sequentially to improve bubble detection by DT. 
Each limb was flexed 3 times along with wrist and ankle rotation. “B” cycle exercise included 
4 minutes at mini-gym set to the same resistance as “A” cycle and pulling twice in a 5-second 
period, 4 minutes at ergometer using same rate except using left hand and cranking counterclock-
wise, 4 minutes at torque station using same torque pattern except with left hand, 4 minutes rest 
after completing “B” cycle, and finally 4 minutes in a supine position while flexing arms and 
legs sequentially to improve bubble detection by DT. Subjects used these devices from a stand-
ing or seated (non-adynamic) position and were allowed to walk prior to and during altitude 
exposure. Test termination for DCS was after any performance was affected. 
 
Procedure 19 (Test 9b): Three days prior to ascent, subject was maintained in strict bed rest in a 
6-degree head-down tilt. Exposure to 6.5 psia in the PTC for 3 hrs after no PB. Decompression to 
6.5 psia required 3.2 minutes (6,500 feet/minute). Prior to ascent, a brief ear and sinus check was 
done by depressurizing the chamber atmosphere to the equivalent of 6,000 feet altitude in about 
1 minute (5,000 feet/minute). Subject breathed air during this check, which took approximately 5 
minutes for subjects and the DT to be evaluated, primarily during the repressurization back to 
site pressure. The medical technician exited the chamber and an ascent on air to 10 psia at 6,500 
feet/minute was begun 6 minutes from the start of initial ascent. About 2 minutes later, subject 
donned the O2 mask at 10 psia and the chamber continued the ascent to 6.5 psia at 6,500 
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feet/minute. Exercise stressed upper body and was performed while still in a 6-degree head-down 
tilt. “A” cycle exercise included 4 minutes at mini-gym set to 16.7 kg of resistance and pulling 
once in 5 seconds with right arm then pulling once in 5 seconds with the left arm, 4 minutes at 
ergometer set to 5-N resistance and cranking 3 times in 5 seconds with right hand going clock-
wise. A 5-second rest was taken, then 3 cranks repeated, 4 minutes at torque station where ten 
3/8-in. fixed studs were torqued to 400 cm-kg. Torque was held for 5 seconds in both directions. 
A total of 24 separate isotonic torques were done in the 2- to 3-minute periods. Remaining time 
was spent stressing the wrist with a ball ratchet placed on several studs and maintaining an iso-
tonic torque for 5 seconds. “A” cycle was to use the right hand with the ball ratchet, and finally 4 
minutes in a 6-degree head-down position while flexing arms and legs sequentially to improve 
bubble detection by DT. Each limb was flexed 3 times along with wrist and ankle rotation. “B” 
cycle exercise included 4 minutes at mini-gym set to the same resistance as “A” cycle and pull-
ing twice in a 5-second period, 4 minutes at ergometer using same rate except using left hand and 
cranking counterclockwise, 4 minutes at torque station using same torque pattern except with left 
hand, 4 minutes rest after completing “B” cycle, and finally 4 minutes in a supine position while 
flexing arms and legs sequentially to improve bubble detection by DT. Subjects used these de-
vices from a recumbent (adynamic) position and were not allowed to walk prior to or during 
altitude exposure. Test termination for DCS was after any performance was affected. 
 
Procedure 20 (Test 9c): A 4-hr O2 PB at 14.7 psia prior to a 3-hr exposure to 4.3 psia in the 
PTC. Prior to ascent, a brief ear and sinus check was done by depressurizing the chamber 
atmosphere to the equivalent of 6,000 feet altitude in about 1 minute (5,000 feet/minute).  
Subject breathed O2 during this check, which took approximately 5 minutes for subjects and the 
DT to be evaluated, primarily during the repressurization back to site pressure.  The medical 
technician exited the chamber before the ascent to 4.3 psia at 5,000 feet/minute.  Ascent was 6 
minutes to 4.3 psia.  Exercise stressed the upper body. “A” cycle exercise included 4 minutes 
seated at mini-gym set to 16.7 kg of resistance and pulling once in 5 seconds with right arm then 
pulling once in 5 seconds with the left arm, 4 minutes standing at ergometer set to 5-N resistance 
and cranking 3 times in 5 seconds with right hand going clockwise. A 5-second rest was taken, 
then 3 cranks repeated, 4 minutes standing at torque station where ten 3/8-in. fixed studs were 
torqued to 400 cm-kg. Torque was held for 5 seconds in both directions. A total of 24 separate 
isotonic torques were done in the 2- to 3-minute periods. Remaining time was spent stressing the 
wrist with a ball ratchet placed on several studs and maintaining an isotonic torque for 5 seconds. 
“A” cycle was to use the right hand with the ball ratchet, and finally 4 minutes in a supine 
position while flexing arms and legs sequentially to improve bubble detection by DT. Each limb 
was flexed 3 times along with wrist and ankle rotation. “B” cycle exercise included 4 minutes at 
mini-gym set to the same resistance as “A” cycle and pulling twice in a 5-second period, 4 
minutes at ergometer using the same rate except using left hand and cranking counterclockwise, 
4 minutes at torque station using the same torque pattern except with left hand, 4 minutes rest 
after completing “B” cycle, and finally 4 minutes in a supine position while flexing arms and 
legs sequentially to improve bubble detection by DT. Subjects used these devices from a 
standing or seated (non-adynamic) position and were allowed to walk prior to and during altitude 
exposure. Test termination for DCS was after any performance was affected. 
 
Procedure 20a (Test 9d):  Subjects were adynamic for 6 hrs by sitting in a chair prior to the 
start of ascent.  During this period of adynamia a 4-hr O2 PB at 14.7 psia was done prior to a 3-hr 
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exposure to 4.3 psia in the PTC.  Prior to ascent, a brief ear and sinus check was done by 
depressurizing the chamber atmosphere to the equivalent of 6,000 feet altitude in about 1 minute 
(5,000 feet/minute).  Subject breathed O2 during this check, which took approximately 5 minutes 
for subjects and the DT to be evaluated, primarily during the repressurization back to site 
pressure.  The medical technician exited the chamber before the ascent to 4.3 psia at 5,000 
feet/minute.  Ascent was 6 minutes to 4.3 psia.  Exercise stressed the upper body. “A” cycle 
exercise included 4 minutes seated at mini-gym set to 16.7 kg of resistance and pulling once in 5 
seconds with right arm then pulling once in 5 seconds with the left arm, 4 minutes standing at 
ergometer set to 5-N resistance and cranking 3 times in 5 seconds with right hand going 
clockwise. A 5-second rest was taken, then 3 cranks repeated, 4 minutes standing at torque 
station where ten 3/8-in. fixed studs were torqued to 400 cm-kg. Torque was held for 5 seconds 
in both directions. A total of 24 separate isotonic torques were done in the 2- to 3-minute 
periods. Remaining time was spent stressing the wrist with a ball ratchet placed on several studs 
and maintaining an isotonic torque for 5 seconds. “A” cycle was to use the right hand with the 
ball ratchet, and finally 4 minutes in a supine position while flexing arms and legs sequentially to 
improve bubble detection by DT. Each limb was flexed 3 times along with wrist and ankle 
rotation. “B” cycle exercise included 4 minutes at mini-gym set to the same resistance as “A” 
cycle and pulling twice in a 5-second period, 4 minutes at ergometer using the same rate except 
using left hand and cranking counterclockwise, 4 minutes at torque station using the same torque 
pattern except with left hand, 4 minutes rest after completing “B” cycle, and finally 4 minutes in 
a supine position while flexing arms and legs sequentially to improve bubble detection by DT. 
Subjects used these devices from a recumbent (adynamic) position and were not allowed to walk 
prior to or during altitude exposure. Test termination for DCS was after any performance was 
affected. 
 
Procedure 20b (Test 9e):  Subjects were adynamic for 6 hrs by sitting in a chair prior to the 
start of ascent.  During this period of adynamia a 4-hr O2 PB at 14.7 psia was done prior to a 3-hr 
exposure to 4.3 psia in the PTC.  Starting 3.5 hrs before ascent very light upper and lower body 
exercise was done during the PB.  The goal was to achieve about 140 kcal/hr, but measured 
metabolic rate in the laboratory was closer to 188 + 15 kcal/hr.  The exercise consisted of lower 
body bicycle ergometry from the chair at 50 revolutions/minute at 25 watts for 10 seconds 
followed by 5 seconds of upper body exercise by lifting two three-pound weights, one for each 
arm.  This sequence was continuous for the last 3.5 hrs of a 4-hr PB.  Prior to ascent, a brief ear 
and sinus check was done by depressurizing the chamber atmosphere to the equivalent of 6,000 
feet altitude in about 1 minute (5,000 feet/minute).  Subject breathed O2 during this check, which 
took approximately 5 minutes for subjects and the DT to be evaluated, primarily during the 
repressurization back to site pressure.  The medical technician exited the chamber before the 
ascent to 4.3 psia at 5,000 feet/minute.  Ascent was 6 minutes to 4.3 psia.  Exercise stressed the 
upper body. “A” cycle exercise included 4 minutes seated at mini-gym set to 16.7 kg of 
resistance and pulling once in 5 seconds with right arm then pulling once in 5 seconds with the 
left arm, 4 minutes standing at ergometer set to 5-N resistance and cranking 3 times in 5 seconds 
with right hand going clockwise. A 5-second rest was taken, then 3 cranks repeated, 4 minutes 
standing at torque station where ten 3/8-in. fixed studs were torqued to 400 cm-kg. Torque was 
held for 5 seconds in both directions. A total of 24 separate isotonic torques were done in the 2- 
to 3-minute periods. Remaining time was spent stressing the wrist with a ball ratchet placed on 
several studs and maintaining an isotonic torque for 5 seconds. “A” cycle was to use the right 
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hand with the ball ratchet, and finally 4 minutes in a supine position while flexing arms and legs 
sequentially to improve bubble detection by DT. Each limb was flexed 3 times along with wrist 
and ankle rotation. “B” cycle exercise included 4 minutes at mini-gym set to the same resistance 
as “A” cycle and pulling twice in a 5-second period, 4 minutes at ergometer using the same rate 
except using left hand and cranking counterclockwise, 4 minutes at torque station using the same 
torque pattern except with left hand, 4 minutes rest after completing “B” cycle, and finally 4 
minutes in a supine position while flexing arms and legs sequentially to improve bubble 
detection by DT.  Subjects used these devices from a recumbent (adynamic) position and were 
not allowed to walk prior to or during altitude exposure. Test termination for DCS was after any 
performance was affected.   
 
Procedure 21 (Test 10): Subjects exercised while breathing air at a simulated depth of 20 
feet in a hyperbaric chamber. A 0.33-minute compression (1 fsw/sec) to 1.59 ATA in the 
Hyperbaric Treatment Chamber (20 feet fresh water depth), 400-minute exposed to air while 
performing three 4-minute exercises with a 4-minutes period of rest. The exercise consisted of 
right arm ergometry from a standing position at a rate of 10 rev clockwise per 5 seconds against 
a weight of 6 lbs with a rest period of 5 seconds before starting left arm ergometry with a 
counterclockwise rotation, lifting a 3-lb weight in each hand while performing a step test, and 4 
minutes standing at torque station where ten 3/8-in. fixed studs were torqued to 400 cm-kg. 
Torque was held for 5 seconds in both directions. A total of 24 separate isotonic torques were 
done in the 2- to 3-minute periods. Remaining time was spent stressing the wrist with a ball 
ratchet placed on several studs and maintaining an isotonic torque for 5 seconds. “A” cycle was 
to use the right hand and “B” cycle was to use the left hand. Cycles are repeated for 400 minutes 
with a 4-minute rest every 30 minutes and an 8-minute rest every hr. Ascent to site pressure was 
made in 0.33 minutes; 14 hrs elapsed before a 2-minute ascent to 10.1 psia (10,000 feet altitude) 
in the PTC.  Subject breathed air at 10,000 feet and did no exercise during the 3-hr exposure. 
Doppler monitoring performed for 4 minutes after 16 minutes of exercise for the duration of 
exposure. Subjects used the exercise devices at 1.59 ATA from a standing (non-adynamic) 
position and were allowed to walk during the surface interval and altitude exposure. Test 
termination for DCS was after any performance was affected. 
 
Procedure 22 (Test 11a): A 3-hr O2 PB at 14.7 psia prior to a 4-hr exposure to 4.3 psia in the 
PTC. Prior to ascent, a brief ear and sinus check was done by depressurizing the chamber 
atmosphere to the equivalent of 6,000 feet altitude in about 1 minute (5,000 feet/minute). Subject 
breathed O2 during this check, which took approximately 5 minutes for subjects and the DT to be 
evaluated, primarily during repressurization back to site pressure. The medical technician exited 
the chamber before the ascent to 4.3 psia at 5,000 feet/minute. Ascent was 6 minutes to 4.3 psia. 
The average PB time to the start of exercise at 4.3 psia was 195 + 3 minutes, with a range from 
190 to 204 minutes.  Exercise stressed the upper body. “A” cycle exercise included 4 minutes 
seated at mini-gym set to 16.7 kg of resistance and pulling once in 5 seconds with right arm then 
pulling once in 5 seconds with the left arm, 4 minutes seated at ergometer set to 5-N resistance 
and cranking 3 times in 5 seconds with right hand going clockwise. A 5-second rest was taken, 
then 3 cranks repeated, 4 minutes seated at torque station where ten 3/8-in. fixed studs were 
torqued to 400 cm-kg. Torque was held for 5 seconds in both directions. A total of 24 separate 
isotonic torques were done in the 2- to 3-minute periods. Remaining time was spent stressing the 
wrist with a ball ratchet placed on several studs and maintaining an isotonic torque for 5 seconds. 
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“A” cycle was to use the right hand with the ball ratchet, and finally 4 minutes in a supine 
position while flexing arms and legs sequentially to improve bubble detection by DT. Each limb 
was flexed 3 times along with wrist and ankle rotation. “B” cycle exercise included 4 minutes at 
mini-gym set to the same resistance as “A” cycle and pulling twice in a 5-second period, 4 
minutes at ergometer using same rate except using left hand and cranking counterclockwise, 4 
minutes at torque station using same torque pattern except with left hand, 4 minutes rest after 
completing “B” cycle, and finally 4 minutes in a seated position while flexing arms and legs 
sequentially to improve bubble detection by DT. Subjects used these devices from a seated 
(adynamic) position and were not allowed to walk during PB or altitude exposure. Test 
termination for DCS was at first indication of DCS. 
 
Procedure 22a (11b):  The intent of this brief study was to compare the quality of blood flow 
and bubble detection with a prototype in-suit Doppler ultrasound bubble detector with our 
standard medical-grade Doppler ultrasound unit (Neuroguard).  The goal was to create 
decompression stress to elicit VGE, but not to have symptoms of DCS.  There was no O2 PB at 
14.7 psia prior to a 2-hr exposure to 6.5 psia in the PTC.  Prior to ascent, a brief ear and sinus 
check was done by depressurizing the chamber atmosphere to the equivalent of 6,000 feet 
altitude in about 1 minute (5,000 feet/minute).  Subject breathed O2 during this check, which 
took approximately 5 minutes for subjects and the DT to be evaluated, primarily during the 
repressurization back to site pressure.  The medical technician exited the chamber before the 
ascent to 6.5 psia at 5,000 feet/minute.  Ascent was 4.2 minutes to 6.5 psia.  Exercise stressed the 
lower body.  The subjects walked within the chamber to encourage VGE from the lower body.  
They walked for 2 minutes, and sat on a bench for 6 minutes, then started the cycle again.  Every 
12 minutes they would be monitored for 2 minutes with the Neuroguard Doppler ultrasound from 
the precordial position, then 2 minutes of monitoring with the prototype in-suit Doppler bubble 
detector with the probe held in place over the pulmonary artery by the DT.  During this 
monitoring period the subjects flexed arms and legs sequentially to improve bubble detection by 
the DT.  Test termination for DCS was after any performance was affected. 
 
Procedure 23 (Phase I PRP): PB exercise was 10 minutes of dual-cycle arm and leg 
ergometery initiated at the start of PB, and done at 75% of peak O2 consumption for the last 7 
minutes.  The subject first performed a peak O2 consumption test (VO2 peak test) using leg 
ergometry several days before the experiment, and a linear regression of O2 consumption 
vs. watts (workload) was created.  An exercise prescription based on watts was produced that 
distributes the appropriate workload between the upper body (12%) and the lower body (88%).  
One the day of the test the first 3 minutes of the dual-cycle arm and leg ergometry was warm-up, 
at about 75 rpm using a prescription that increased work from 37.5%, to 50.0% and then to 
62.5% of the VO2 peak. The ergometry was completed after 7 min at 75% of VO2 peak.  No 
additional exercise was allowed for the balance of the 150-minute O2 PB. After 50 minutes of 
100% O2 PB at site pressure, subject ascended to 9.6 psia in 20 minutes followed by a 10-minute 
descent to 10.2 psia, still breathing 100% O2. The gas supply was switched in the mask, and 
subject breathed 73.5% N2 and 26.5% O2 for 30 minutes while at 10.2 psia. A 100% O2 PB was 
reestablished and, after 5 minutes, a descent to site pressure was performed. Subject remained on 
100% O2 for 35 minutes at site pressure and during the 30-minute ascent to 4.3 psia. Subject 
breathed 100% O2 for the duration of the 4-hr test. Five exercise devices simulated intense hand 
and upper body activity plus postural contractions in the lower body that occur during EVA. Two 
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bungee cord devices simulated the resistance to move a flexible spacesuit from an otherwise 
neutral position. Subjects pulled bungee cord with left and right arm across the chest, and flexed 
the upper body forward against the bungee cord connected to the back of a harness. Three other 
devices simulated assembly tasks done while in a spacesuit. Subjects torqued fixed studs to 25 ft-
lb with the right and left arm, contracted the right and left hand with 5-lb of force using a hand 
exercise device, and pulled against a plate at their feet with leg muscles contracted to resist the 
pull to a force in lbs normalized to their body weight. Subjects used these devices from a 
recumbent (adynamic) position and were not allowed to walk during PB or altitude exposure. 
Each activity was 4 minutes in duration and performed at a 5- or 10-second cadence with brief 
periods of rest during some activities. There were also 4-minute periods with no physical 
activity, and 4 minutes in a supine position while flexing arms and legs sequentially to improve 
bubble detection by DT. Each limb was flexed 3 times along with wrist and ankle rotation. Test 
termination for DCS was at first indication of DCS. 
 
Procedure 24 (Phase II PRP): PB exercise was 10 minutes of dual-cycle arm and leg 
ergometery initiated at the start of PB, and done at 75% of peak O2 consumption for the last 7 
minutes. The subject first performed a peak O2 consumption test (VO2 peak test) using leg 
ergometry several days before the experiment, and a linear regression of O2 consumption 
vs. watts (workload) was created.  An exercise prescription based on watts was produced that 
distributes the appropriate workload between the upper body (12%) and the lower body (88%).  
One the day of the test the first 3 minutes of the dual-cycle arm and leg ergometry was warm-up, 
at about 75 rpm using a prescription that increased work from 37.5%, to 50.0% and then to 
62.5% of the VO2 peak. The ergometry was completed after 7 min at 75% of VO2 peak plus 24 
minutes of additional intermittent light arm and leg exercise starting 55 minutes into the PB and 
ending 95 minutes after the start of PB. Here, heavy short-duration ergometry exercise was 
combined with light intermittent short-duration exercise during the later part of the PB. After 50 
minutes of 100% O2 PB at site pressure, subject ascended to 9.6 psia in 20 minutes followed by a 
10-minute descent to 10.2 psia, still breathing 100% O2. After the gas supply was switched in the 
mask, the subject breathed 73.5% N2 and 26.5% O2 for 30 minutes while at 10.2 psia. A 100% 
O2 PB was reestablished and, after 5 minutes, a descent to site pressure was performed. Subject 
remained on 100% O2 for 35 minutes at site pressure and during the 30-minute ascent to 4.3 psia. 
Subject breathed 100% O2 for the duration of the 4-hr test. Five exercise devices simulated 
intense hand and upper body activity plus postural contractions in the lower body that occur 
during EVA. Two bungee cord devices simulated the resistance to move a flexible spacesuit 
from an otherwise neutral position. Subjects pulled bungee cord with left and right arm across 
the chest, and flexed the upper body forward against the bungee cord connected to the back of a 
harness. Three other devices simulated assembly tasks done while in a spacesuit. Subjects 
torqued fixed studs to 25 ft-lb with the right and left arm, contracted the right and left hand with 
5-lb of force using a hand exercise device, and pulled against a plate at their feet with leg 
muscles contracted to resist the pull to a force in lbs normalized to their body weight. Subjects 
used these devices from a recumbent (adynamic) position and were not allowed to walk during 
PB or altitude exposure. Each activity was 4 minutes in duration and performed at a 5- or 10-
second cadence with brief periods of rest during some activities. There were also 4-minute 
periods with no physical activity, and 4 minutes in a supine position while flexing arms and 
legs sequentially to improve bubble detection by DT. Each limb was flexed 3 times along 
with wrist and ankle rotation. Test termination for DCS was at first indication of DCS. 
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Procedure 25 (Phase III PRP): PB exercise was 24 minutes of intermittent light arm and leg 
exercise starting 55 minutes into the PB and ending 95 minutes after the start of PB. After 50 
minutes of 100% O2 PB at site pressure, subject ascended to 9.6 psia in 20 minutes followed by 
a 10-minute descent to 10.2 psia, still breathing 100% O2. The gas supply was switched in the 
mask, and subject breathed 73.5% N2 and 26.5% O2 for 30 minutes while at 10.2 psia. A 100% 
O2 PB was reestablished and, after 5 minutes, a descent to site pressure was performed. Subject 
remained on 100% O2 for 35 minutes at site pressure and during the 30-minute ascent to 4.3 psia. 
Subject breathed 100% O2 for the duration of the 4-hr test. Five exercise devices simulated in-
tense hand and upper body activity plus postural contractions in the lower body that occur during 
EVA. Two bungee cord devices simulated the resistance to move a flexible spacesuit from an 
otherwise neutral position. Subjects pulled bungee cord with left and right arm across the chest, 
and flexed the upper body forward against the bungee cord connected to the back of a harness. 
Three other devices simulated assembly tasks done while in a spacesuit. Subjects torqued fixed 
studs to 25 ft-lb with the right and left arm, contracted the right and left hand with 5-lb of force 
using a hand exercise device, and pulled against a plate at their feet with leg muscles contracted 
to resist the pull to a force in lbs normalized to their body weight. Subjects used these devices 
from a recumbent (adynamic) position and were not allowed to walk during PB or altitude 
exposure. Each activity was 4 minutes in duration and performed at a 5- or 10-second cadence 
with brief periods of rest during some activities. There were also 4-minute periods with no 
physical activity, and 4 minutes in a supine position while flexing arms and legs sequentially 
to improve bubble detection by DT. Each limb was flexed 3 times along with wrist and ankle 
rotation. Test termination for DCS was at first indication of DCS. 
 
Procedure 26 (Phase IV PRP): PB exercise was 56 minutes of intermittent light long-
duration arm and leg exercise that started 4 minutes into the PB and ended 95 minutes from the 
start of the PB. After 50 minutes of 100% O2 PB at site pressure, subject ascended to 9.6 psia in 
20 minutes followed by a 10-minute descent to 10.2 psia, still breathing 100% O2. The gas sup-
ply was switched in the mask, and subject breathed 73.5% N2 and 26.5% O2 for 30 minutes while 
at 10.2 psia. A 100% O2 PB was reestablished and, after 5 minutes, a descent to site pressure was 
performed. Subject remained on 100% O2 for 35 minutes at site pressure and during a 30-minute 
ascent to 4.3 psia. Subject breathed 100% O2 for the duration of the 4-hr test. Five exercise 
devices simulated intense hand and upper body activity plus postural contractions in the lower 
body that occur during EVA. Two bungee cord devices simulated the resistance to move a flex-
ible spacesuit from an otherwise neutral position. Subjects pulled bungee cord with left and right 
arm across the chest, and flexed the upper body forward against the bungee cord connected to the 
back of a harness. Three other devices simulated assembly tasks done while in a spacesuit. Sub-
jects torqued fixed studs to 25 ft-lb with the right and left arm, contracted the right and left hand 
with 5-lb of force using a hand exercise device, and pulled against a plate at their feet with leg 
muscles contracted to resist the pull to a force in lbs normalized to their body weight. Subjects 
used these devices from a recumbent (adynamic) position and were not allowed to walk during 
PB or altitude exposure. Each activity was 4 minutes in duration and performed at a 5- or 10-
second cadence with brief periods of rest during some activities. There were also 4-minute 
periods with no physical activity, and 4 minutes in a supine position while flexing arms and 
legs sequentially to improve bubble detection by DT. Each limb was flexed 3 times along 
with wrist and ankle rotation. Test termination for DCS was at first indication of DCS. 
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Procedure 27 (Phase V-1 PRP):  PB exercise was 20 minutes of intermittent exercise (two 
minutes of exercise followed by two minutes of rest) at an intensity targeting 60% VO2 peak. The 
dual-cycle arm and leg ergometry exercise was conducted in the first 44 minutes of the PB 
period.  Subjects remained at rest for the duration of the PB period.  Details appear in Fig. 1. 
 
 
 
 
 
 
 
 
 
Fig. 1. Timeline of PRP Phase V-1. 
 
The subject first performed a peak O2 consumption test (VO2 peak test) using leg ergometry 
several days before the experiment, and a linear regression of O2 consumption vs. watts 
(workload) was created.  An exercise prescription based on watts was produced that distributes 
the appropriate workload between the upper body (12%) and the lower body (88%), with 
ergometry at about 75 rpm.  After 90 minutes of 100% O2 PB at site pressure, the subject 
ascended to 4.3 psia in 30 minutes, still breathing 100% O2. Subject breathed 100% O2 for the 
duration of the 4-hr test. Five exercise devices simulated intense hand and upper body activity 
plus postural contractions in the lower body that occur during EVA. Two bungee cord devices 
simulated the resistance to move a flexible spacesuit from an otherwise neutral position. Subjects 
pulled bungee cord with left and right arm across the chest, and flexed the upper body forward 
against the bungee cord connected to the back of a harness. Three other devices simulated 
assembly tasks done while in a spacesuit.  Subjects torqued fixed studs to 25 ft-lb with the right 
and left arm, contracted the right and left hand with 5-lb of force using a hand exercise device, 
and pulled against a plate at their feet with leg muscles contracted to resist the pull to a force in 
lbs normalized to their body weight. Subjects used these devices from a recumbent (adynamic) 
position and were not allowed to walk during PB or altitude exposure. Each activity was 4 
minutes in duration and performed at a 5- or 10-second cadence with brief periods of rest during 
some activities. There were also 4-minute periods with no physical activity, and 4 minutes in a 
supine position while flexing arms and legs sequentially to improve bubble detection by DT. 
Each limb was flexed 3 times along with wrist and ankle rotation. Test termination for DCS was 
at first indication of DCS. 
 
Procedure 28 (Phase V-2 PRP):  PB exercise was 20 minutes of intermittent exercise (an initial 
two minute warm up targeting 50% VO2 peak followed by two minutes of rest, then six, three 
minute periods targeting 60% VO2 peak exercise, each followed by two minutes of rest). The dual-
cycle arm and leg ergometry exercise was conducted in the first 34 minutes of the PB period. 
Subjects remained at rest for the duration of the 90 minute PB period. Details appear in Fig. 2. 
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Fig. 2. Timeline of PRP Phase V-2. 
 
The subject first performed a peak O2 consumption test (VO2 peak test) using leg ergometry 
several days before the experiment, and a linear regression of O2 consumption vs. watts 
(workload) was created.  An exercise prescription based on watts was produced that distributes 
the appropriate workload between the upper body (12%) and the lower body (88%), with 
ergometry at about 75 rpm.  After 90 minutes of 100% O2 PB at site pressure, the subject 
ascended to 4.3 psia in 30 minutes, still breathing 100% O2. Subject breathed 100% O2 for the 
duration of the 4-hr test. Five exercise devices simulated intense hand and upper body activity 
plus postural contractions in the lower body that occur during EVA. Two bungee cord devices 
simulated the resistance to move a flexible spacesuit from an otherwise neutral position. Subjects 
pulled bungee cord with left and right arm across the chest, and flexed the upper body forward 
against the bungee cord connected to the back of a harness. Three other devices simulated 
assembly tasks done while in a spacesuit.  Subjects torqued fixed studs to 25 ft-lb with the right 
and left arm, contracted the right and left hand with 5-lb of force using a hand exercise device, 
and pulled against a plate at their feet with leg muscles contracted to resist the pull to a force in 
lbs normalized to their body weight. Subjects used these devices from a recumbent (adynamic) 
position and were not allowed to walk during PB or altitude exposure. Each activity was 4 
minutes in duration and performed at a 5- or 10-second cadence with brief periods of rest during 
some activities. There were also 4-minute periods with no physical activity, and 4 minutes in a 
supine position while flexing arms and legs sequentially to improve bubble detection by DT. 
Each limb was flexed 3 times along with wrist and ankle rotation. Test termination for DCS was 
at first indication of DCS. 
 
Procedure 29 (Phase V-3 PRP):  PB exercise combined moderate intensity intermittent exercise 
and low intensity exercise periods. The PB began with 20 minutes of intermittent dual-cycle arm 
and leg ergometry conducted in the first 36 minutes of the PB (an initial two minute rest period 
was followed by a two minute warm up exercise targeting 50%, the subjects then repeated a 
pattern of 3 minutes exercise at 60% VO2 followed by two minutes rest).  Subjects remained at 
rest for 14 minutes following the intermittent exercise. Forty minutes of light exercise in the suit 
exercise simulator was then conducted, and the remaining 30 minutes of the PB period was spent 
at rest.  Details appear in Fig. 3. 
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Fig. 3. Timeline of PRP Phase V-3. 
 
The subject first performed a peak O2 consumption test (VO2 peak test) using leg ergometry 
several days before the experiment, and a linear regression of O2 consumption vs. watts 
(workload) was created.  An exercise prescription based on watts was produced that distributes 
the appropriate workload between the upper body (12%) and the lower body (88%), with 
ergometry at about 75 rpm.  After 120 minutes of 100% O2 PB at site pressure, the subject 
ascended to 4.3 psia in 30 minutes, still breathing 100% O2. Subject breathed 100% O2 for the 
duration of the 4-hr test. Five exercise devices simulated intense hand and upper body activity 
plus postural contractions in the lower body that occur during EVA. Two bungee cord devices 
simulated the resistance to move a flexible spacesuit from an otherwise neutral position. Subjects 
pulled bungee cord with left and right arm across the chest, and flexed the upper body forward 
against the bungee cord connected to the back of a harness. Three other devices simulated 
assembly tasks done while in a spacesuit.  Subjects torqued fixed studs to 25 ft-lb with the right 
and left arm, contracted the right and left hand with 5-lb of force using a hand exercise device, 
and pulled against a plate at their feet with leg muscles contracted to resist the pull to a force in 
lbs normalized to their body weight. Subjects used these devices from a recumbent (adynamic) 
position and were not allowed to walk during PB or altitude exposure. Each activity was 4 
minutes in duration and performed at a 5- or 10-second cadence with brief periods of rest during 
some activities. There were also 4-minute periods with no physical activity, and 4 minutes in a 
supine position while flexing arms and legs sequentially to improve bubble detection by DT. 
Each limb was flexed 3 times along with wrist and ankle rotation. Test termination for DCS was 
at first indication of DCS. 
 
Procedure 30 (Phase V-4 PRP):  PB exercise moved away from the effort to employ high 
intensity and short duration intermittent dual-cycle ergometry exercise.  Instead, it incorporated 
150 minutes of intermittent light activity (5.8 ml/kg-min) in a 160 minute O2 PB conducted at 
site pressure.  Details appear in Fig. 4. 
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Fig. 4. Timeline of PRP Phase V-4. 
 
 
After 160 minutes of 100% O2 PB at site pressure, the subject ascended to 4.3 psia in 30 minutes, 
still breathing 100% O2. Subject breathed 100% O2 for the duration of the 4-hr test. Five exercise 
devices simulated intense hand and upper body activity plus postural contractions in the lower 
body that occur during EVA. Two bungee cord devices simulated the resistance to move a flex-
ible spacesuit from an otherwise neutral position. Subjects pulled bungee cord with left and right 
arm across the chest, and flexed the upper body forward against the bungee cord connected to the 
back of a harness. Three other devices simulated assembly tasks done while in a spacesuit.  Sub-
jects torqued fixed studs to 25 ft-lb with the right and left arm, contracted the right and left hand 
with 5-lb of force using a hand exercise device, and pulled against a plate at their feet with leg 
muscles contracted to resist the pull to a force in lbs normalized to their body weight. Subjects 
used these devices from a recumbent (adynamic) position and were not allowed to walk during 
PB or altitude exposure. Each activity was 4 minutes in duration and performed at a 5- or 10-
second cadence with brief periods of rest during some activities. There were also 4-minute 
periods with no physical activity, and 4 minutes in a supine position while flexing arms and 
legs sequentially to improve bubble detection by DT. Each limb was flexed 3 times along 
with wrist and ankle rotation. Test termination for DCS was at first indication of DCS. 
 
Procedure 31 (Phase V-5 PRP):  PB exercise was low intensity for longer duration spaced over 
190 minutes, which included 30 minutes for suit donning at 10.2 psia while breathing 26.5% O2.  
There was 90 minutes of upper body light exercise (mean 5.8 mL·kg-1·min-1) using the suit 
exercise simulator, followed by 50 minutes of light leg ergometer exercise at approximately 6.8 
mL·kg-1·min-1 using a leg ergometer mounted on the suit exercise simulator, followed by 50 
minutes of rest before depress to 4.3 psia.  Details appear in Fig. 5. 
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Fig. 5. Timeline of Proposed PRP Phase V-5. 
 
After the 190 minute staged exercise PB protocol, the subject ascended to 4.3 psia in 30 minutes, 
still breathing 100% O2. Subject breathed 100% O2 for the duration of the 4-hr test. Five exercise 
devices simulated intense hand and upper body activity plus postural contractions in the lower 
body that occur during EVA. Two bungee cord devices simulated the resistance to move a flex-
ible spacesuit from an otherwise neutral position. Subjects pulled bungee cord with left and right 
arm across the chest, and flexed the upper body forward against the bungee cord connected to the 
back of a harness. Three other devices simulated assembly tasks done while in a spacesuit.  Sub-
jects torqued fixed studs to 25 ft-lb with the right and left arm, contracted the right and left hand 
with 5-lb of force using a hand exercise device, and pulled against a plate at their feet with leg 
muscles contracted to resist the pull to a force in lbs normalized to their body weight. Subjects 
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used these devices from a recumbent (adynamic) position and were not allowed to walk during 
PB or altitude exposure. Each activity was 4 minutes in duration and performed at a 5- or 10-
second cadence with brief periods of rest during some activities. There were also 4-minute 
periods with no physical activity, and 4 minutes in a supine position while flexing arms and 
legs sequentially to improve bubble detection by DT. Each limb was flexed 3 times along 
with wrist and ankle rotation. Test termination for DCS was at first indication of DCS. 
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Appendix VI:  Summary of Protocols from 1982 - 2009 
Test  P2 
(psia) 
duration 
(hr) 
sample 
m       f 
mean 
age 
DCS 
cases 
DCS 
(%) 
mean
BGI 
VGE 
(any Grade) 
VGE  
(Grade IV) 
1a  4.3  3  11      0  34.5  4  36.3  29.7  7  4 
1b  4.3  3  13      0  32.3  3  23.0  56.3  11  7 
1b10.2  10.2  12  13      0    32.3  0  0  19.7  n/a  n/a 
1c  4.3  3  12      0  32.0  4  33.3  53.7  7  6 
1c10.2  10.2  12  12      0  32.0  0  0  19.7  n/a  n/a 
1d  4.3  3  3        0  39.6  2  66.6  58.6  3  2 
1d10.2  10.2  18  3        0  39.6  0  0  21.9  n/a  n/a 
2a  4.3  4  23      0  31.6  7  30.4  35.7  15  8 
2b  4.3  4  22      0  31.5  6!  27.3  64.7  10  7 
2b10.2  10.2  12  22      0  31.5  0  0  19.5  n/a  n/a 
3a  4.3  6  28      0  31.0  6  21.4  41.9  13  11 
3b  4.3  6  35      0  30.1  8  22.8  45.2  20  8 
3b10.2  10.2  12  35      0  30.1  0  0  1.0  n/a  n/a 
3c  4.3  6  14      0  32.5  3  21.4  29.7  5  1 
3d  4.3  6  12      0  28.5  2  16.6  32.5  5  2 
4a  4.3  3  12      0  30.1  1  8.3  28.0  7  3 
4a10.2  10.2  12  12      0  30.1  0  0  1.0  n/a  n/a 
4b  4.3  3  12      0  30.1  0  0  36.4  2  1 
4c  4.3  3  12      0  30.1  0  0  18.7  4  1 
4d  4.3  3  12      0  30.1  0  0  19.0  0  0 
4e  4.3  3  12      0  30.1  0  0  18.0  4  1 
4f  4.3  3  12      0  30.1  0  0  17.7  0  0 
5a  4.3  6  19    19  31.5  4  10.5  28.5  11  4 
5b  4.3  6  11      0  32.0  0  0  1.0  0  0 
6  6.0  6  15    14  32.9  1  3.4  21.1  3  0 
610.2  10.2  24  15    14  32.9  0  0  1.0  n/a  n/a 
7a  6.5  3  11      0  28.2  4!!  36.3  25.6  8  6 
7b  6.5  3  11      0  28.2  2  18.2  25.6  8  4 
8a  6.5  3  29    11  32.4  7  17.5  25.6  20  13 
8b  6.5  3  30    11  32.6  10!  24.4  25.5  22  17 
9a  6.5  3  15      9  32.1  1  4.1  25.6  12  7 
9b  6.5  3  14      9  33.8  2!  8.7  25.6  6  1 
9c  4.3  3  9        2  34.8  3  27.3  25.6  5  4 
9d  4.3  3  6         1  36.4  0  0  24.7  2  0 
9e  4.3  3  7         0  34.5  0  0  21.4*  2  0 
10  10.11  3  14      5  31.7  1  5.2  17.0  6  3 
11a  4.3  4  16    12  33.2  3  10.7  38.5  9  4 
11b  6.5  2  1        3  39.5  0  0  18.2  1  0 
Phase I  4.3  4  35    14  29.4  9  18.3  41.7*  24  2 
Phase II  4.3  4  38    12  32.2  0  0  40.8*  15  3 
Phase III  4.3  4  8        2  29.4  2!  20.0  43.4*  2  1 
Phase IV  4.3  4  50    15  30.4  8  12.3  42.8*  26  9 
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P2 is the ambient pressure in the altitude chamber, ! one case was classified as Type II DCS; !! 2 were classified as 
Type II DCS. n/a is not applicable since monitoring for VGE was not performed. *PB included prescribed exercise; 
all others were resting during PB. 
 
Phase V‐1  4.3  4  7        3  31.2  3  30.0  43.9*  6  2 
Phase V‐2  4.3  4  2       2  42.0  1!  25.0  42.7*  4  2 
Phase V‐3  4.3  4  39     11  36.9  7  14.0  41.3*  25  5 
Phase V‐4  4.3  4  4        3  31.1  3  42.8  35.8*  3  1 
Phase V‐5  4.3  4  38      11  32.1  2  4.1  36.3*  14  8 
